Role of MIR-29B-1 and MIR-29A in endocrine-resistant breast cancer. by Muluhngwi, Penn
University of Louisville 
ThinkIR: The University of Louisville's Institutional Repository 
Electronic Theses and Dissertations 
5-2017 
Role of MIR-29B-1 and MIR-29A in endocrine-resistant breast 
cancer. 
Penn Muluhngwi 
University of Louisville 
Follow this and additional works at: https://ir.library.louisville.edu/etd 
 Part of the Biochemistry Commons 
Recommended Citation 
Muluhngwi, Penn, "Role of MIR-29B-1 and MIR-29A in endocrine-resistant breast cancer." (2017). 
Electronic Theses and Dissertations. Paper 2714. 
https://doi.org/10.18297/etd/2714 
This Doctoral Dissertation is brought to you for free and open access by ThinkIR: The University of Louisville's 
Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized 
administrator of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of the 
author, who has retained all other copyrights. For more information, please contact thinkir@louisville.edu. 






B.Sc., University of Buea, 2007 
M.S., New Mexico Highland University, 2012  




Submitted to the Faculty of the 
University of Louisville School of Medicine 
in Partial Fulfillment of the Requirements 
for the Degree of  
 
 
Doctor of Philosophy  
in Biochemistry and Molecular Biology 
 
 
Department of Biochemistry and Molecular Genetics 






















B.Sc., University of Buea, 2007 
M.S., New Mexico Highland University, 2012  
M.S., University of Louisville, 2015 
 
A Dissertation Approved on 
 
April 12, 2017 
 




























This dissertation is dedicated to my parents for their constant love, encouragement and 
support over the course of my life and my Ph.D. program.  Also, I would like to dedicate 
this to my siblings Ateh, Lum, Francine, Ambe, Bernard, Benise, Rose-Mary and 
Abongwa for their constant love and prayers.  Finally I will want to also dedicate this to 








I am sincerely grateful to my mentor, Dr. Carolyn M. Klinge for her encouragement and 
support in my scientific growth.  Her guidance was invaluable for my doctoral work.  I 
would also like to thank my committee members Dr. Alan Cheng, Dr. Ted S. Kalbfleisch, 
Dr. Robert C. Mitchell, Dr. David J. Samuelson and Dr. Christine E. Schaner-Tooley for 
their comments and advice towards my project.  I am sincerely grateful to members of the 








ROLE OF MIR-29B-1 AND MIR-29A IN ENDOCRINE-RESISTANT BREAST 
CANCER 
Penn Muluhngwi 
April 12, 2017 
Therapies targeting estrogen receptor α (ERα) including selective estrogen 
receptor modulators (SERMs), e.g., tamoxifen (TAM); selective estrogen receptor 
downregulators (SERDs), e.g., fulvestrant (ICI 182,780); and aromatase inhibitors (AI), 
e.g., letrozole, are successfully used in treating breast cancer patients whose initial tumor 
expresses ERα.  Unfortunately, the effectiveness of endocrine therapies is limited as ~ 
40% of breast cancer patients will eventually acquire resistance to them.  The role of 
miRNAs in the progression of endocrine-resistant breast cancer is of keen interest in 
developing biomarkers and therapies to counter metastatic disease.  This dissertation 
begins with a review on miRNAs implicated in breast cancer, their bona fide gene targets, 
and associated pathways promoting endocrine resistance. 
Although microRNAs are dysregulated in breast cancer, their contribution to 
endocrine-resistance is not yet fully understood.  Previous microarray analysis identified 
miR-29a and miR-29b-1 as repressed by TAM in MCF-7 endocrine-sensitive breast 
cancer cells but stimulated by TAM in LY2 endocrine-resistant breast cancer cells.  Here 
we examined the mechanism for the differential regulation of these miRs by TAM in 




of these microRNAs in these cells.  Knockdown studies revealed that ERα is responsible 
for TAM regulation of miR-29b-1/a transcription.  Transient overexpression of miR-29b-
1/a decreased MCF-7, LCC9, and LY2 proliferation and inhibited LY2 cell migration and 
colony formation but did not sensitize LCC9 or LY2 cells to TAM.  Furthermore, TAM 
reduced DICER1 mRNA and protein in LY2 cells, a known target of miR-29.  
Supporting this observation, anti-miR-29b-1 or anti-miR-29a inhibited the suppression of 
DICER by 4-OHT.  These results suggest that miR-29b-1/a have tumor suppressor 
activity in TAM-resistant cells and do not appear to play a role in mediating TAM 
resistance.   
The target genes mediating miR-29b-1/a tumor suppressor activity were 
unknown.  Here, using RNA sequencing, we identify miR-29b-1 and miR-29a target 
transcripts in both MCF-7 and LCC9 cells.  We find that miR-29b-1 and miR-29a 
regulate common and unique transcripts in each cell line.  The cell-specific and common 
downregulated genes were characterized using the MetaCore Gene Ontology (GO) 
enrichment analysis algorithm.  LCC9-sepecific miR-29b-1/a-regulated GO processes 
include oxidative phosphorylation, ATP metabolism, and apoptosis. Extracellular flux 
analysis of cells transfected with anti- or pre- miR-29a confirmed that miR-29a inhibits 
mitochondrial bioenergetics in LCC9 cells.  qPCR and luciferase reporter assays also 
verified the ATP synthase subunit genes ATP5G1 and ATPIF1 as bona fide miR29b-1/a 
targets. Our results suggest that miR-29 repression of TAM-resistant breast cancer cell 





There is a critical need to develop sensitive circulating biomarkers that accurately 
identify signaling pathways altered in breast cancer patients resistant to endocrine 
therapies.  Serum miRNAs have the potential to serve as biomarkers of the progression of 
endocrine-resistant breast cancer due to their cancer-specific expression and stability.  
Exosomal transfer of miRNAs has been implicated in metastasis and endocrine-
resistance.  This dissertation ends with a review on miRNAs in breast tumors and in 
serum, including exosomes, from breast cancer patients that are associated with 
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CHAPTER I: INTRODUCTION1 
 
BREAST CANCER SUBTYPES 
Breast cancer (BC) is the most common malignant disease among women 
worldwide [1] with an estimated 1.7 million new cases diagnosed in 2012 according to 
GLOBOCAN statistics. In 2017 about 255,180 new cases will be diagnosed in the US 
and approximately 41,070 women are projected to die from the disease [2].  These data 
underscore the need to improve and/or develop better preventive, diagnostic, and 
therapeutic strategies addressing BC. Mortality from BC is decreasing in part due to early 
diagnosis and implementation of advanced therapies including adjuvant chemo- and 
hormone-therapies [3].   
BC is a heterogeneous disease characterized by distinct molecular and 
morphological traits that inform prognosis and therapy.  BC is classified into five 
subtypes based on distinct gene expression profiles: luminal A, luminal B, basal, human 
epidermal growth factor receptor 2 (HER2/ERBB2)-positive (+), and normal breast-like 
tumors [4-8].  Most tumors are classified as luminal [7] and express estrogen receptor α 
(ERα), progesterone receptor (PR), and the luminal cytokeratins (CK) 8 and 18.  Luminal 
B tumors have higher Ki67 expression than luminal A [9].  Ki67 is a nuclear protein 
                                                 
1The text and figures of this chapter and Chapter II were published in: 1) Mol Cell Endocrinol. 2017 Feb 2. 
pii: S0303-7207(17)30080-1. doi: 10.1016/j.mce.2017.02.004 and 2) Endocr Relat Cancer. 2015 Oct; 22 




associated with cellular proliferation, disease recurrence, relapse, and poor survival in BC 
patients [10-12].  ERα+ tumors are associated with smaller, low grade tumors and are 
often lymph node negative [13, 14].  HER2+, basal and ‘normal breast-like’ tumors are 
ERα/PR negative (ERα-/PR-).  HER2 is constitutively active and predicts reduced 
disease-free survival [15].  Triple negative breast cancer (TNBC, i.e., ER-/PR-, and 
HER2-) is a highly diverse group of breast cancers with poor prognosis [16]. The origins 
of TNBC are debated.  One model from murine mammary tumors suggests that in vivo 
tumor heterogeneity of luminal A tumors gives rise to claudin-low tumors, basal-like 
tumors and HER2+ tumors [17].  The expression profiles of ‘normal breast-like’ tumors 
are more varied and are similar to adipose tissue, basal epithelial cells, and other non-
epithelial components of the breast [4, 5].  The HER2+, basal-like, and TNBC tumors are 
associated with more advanced stage at presentation [18] and patients have reduced 
disease-free survival [19].  In this chapter, I will focus on luminal A and B tumors and 
resistance to endocrine therapy  
 
ER PATHWAYS IN BREAST TUMORS 
Estrogens are steroid hormones whose effects mediate cellular processes 
including cell proliferation, cell survival and apoptosis [20]. In addition to their roles in 
breast and reproductive tract development and homeostasis, estrogens are involved in a 
variety of physiological processes including skeletal homeostasis, maintenance of the 
cardiovascular and central nervous systems, lipid and carbohydrate metabolism, and 




female physiology, reproduction, and behavior [21, 22]. The most potent estrogen is 17β-
estradiol (E2). The biological effects of estrogens, including E2, are mediated by binding 
to nuclear receptors ERα and ERβ and their splice variants, e.g., ERα36 (reviewed in [23] 
and ERα46 [24], and to G-protein coupled ER (GPER) [25].  The ERα activation initiated 
by E2 binding and consequent conformational changes results in “nuclear/genomic” or 
“non-genomic/membrane-initiated” responses [26, 27].  ERα is upregulated in breast 
tumors [28].  It is the target for therapeutic agents originally termed antiestrogens because 
they compete with E2 for ERα binding, but now termed SERMs and SERDs because of 
our greater understanding of their molecular actions [29].  Because the role of ERβ in 
breast cancer remains to be clearly established (reviewed in [30]) and because ERα 
expression is higher than ERβ in breast tumors and is thus the target of therapeutic 
intervention, this dissertation will focus primarily on ERα activities related to miRNA 
expression and activity in endocrine-resistance.   
The ERα activation initiated by E2 binding and consequent conformational 
changes results in ‘nuclear/genomic’ or ‘non-genomic/membrane-initiated responses [26, 
27]. In the nuclear/genomic response, ERα serves as ligand-activated transcription factor 
that dimerizes either within the nucleus or translocates to the nucleus where, in 
combination with coregulators/coactivators which remodel chromatin, it binds to estrogen 
response elements (EREs) in promoter regions of estrogen-regulated genes [31]. 
Genome-wide chromatin immunoprecipitation (ChIP) for ERα binding sites revealed 
ERα binding sites in the 3’ UTR of target genes as well as in interchromatin regions [32, 
33]. The ERE is a short palindromic inverted repeat 5’-AGGTCAnnnTGACCT-3’ where 




richness, number of nucleotides separating the inverted repeat, and nucleotide changes in 
each half-site (5'-AGGTCA-3') determines the affinity for ERα binding to ERE [35, 36]. 
ERα also binds imperfect, non-palindromic EREs in E2-regulated genes, usually in 
collaboration with other transcription factors [37]. The transcriptional activity of ERα is 
also mediated by ‘tethering’ involving protein:protein interaction of ERα with other 
transcription factors including activator protein-1 (AP-1) and specificity protein (Sp1) at 
cognate DNA-responsive sites [38]. Coactivators including AIB1 (SRC-3), which is 
overexpressed in TAM-resistant tumors and cell lines [39], enhance ERα transcriptional 
activity [40]. The end result is an increase or decrease in gene transcription resulting in 
the physiological outputs associated with estrogen signaling, including tissue- and cell- 
specific changes in cell cycle, proliferation, apoptosis, invasion, angiogenesis, and 
survival [41].  
In the non-nuclear/membrane-initiated ER pathways, E2 rapidly alters 
intracellular signaling pathways culminating in changes in gene transcription by a 
processes mediated by plasma membrane-associated ERα, ERβ, or GPER/GPR30 
(reviewed in [26, 27, 42-44]).  These rapid responses include E2 activation of PI3K and 
Src in the plasma membrane (PM) which then activate mTOR through PI3K-mediated 
AKT phosphorylation.  Membrane ER and GPER activate epidermal growth factor 
receptor (EGFR) with downstream signaling through Ras/Raf and mitogen-activated 
protein kinase (MAPK) [45].  E2 activation of EGFR can increase ERα phosphorylation 
(reviewed in [44, 46, 47]).  These signaling pathways subsequently regulate ER 
transcriptional activity.  Despite the numerous studies on ERα, the events and overall 





MECHANISMS OF ENDOCRINE THERAPY IN BREAST CANCER 
Antiestrogen therapies function by two main mechanisms: targeting ERα activity 
and/or stability.  SERMs, e.g., TAM, raloxifene (RAL), and toremifene, compete with E2 
for binding the ligand binding domain (LBD) of ERα and inhibit ERα transcriptional 
activity in a gene- and cell-specific manner.  SERMs can be agonists or antagonists 
depending on the tissue and gene.  For example, SERMs are agonists for ERα in the 
endometrium and increase endometrial tumor incidence [48, 49]. As antagonists, SERMs 
are used in the treatment of breast cancer patients with ERα+ breast tumors [50].  SERDs, 
e.g., fulvestrant (ICI 182,780, Faslodex), not only alters the ERα conformation, but 
stimulate ER protein degradation [51-53].  Aromatase inhibitors (AIs) inhibit the activity 
of aromatase (CYP19A1), thus reducing estrogen synthesis in peripheral adipose tissues 
and within the tumor [51].  Examples of AIs include letrozole and anastrozole, which are 
steroidal/irreversible inhibitors, and exemestane, a non-steroidal/reversible inhibitor [51]. 
For postmenopausal women with ERα+ primary tumors, ASCO guidelines 
recommend AI therapy, and for premenopausal women, TAM for 10 years is 
recommended [54].  Adjuvant therapy with TAM for postmenopausal women with 
endocrine responsive breast tumors effectively reduced the odds of recurrence by 40% 
and death from breast cancer after 5 years by 20% [55].  Unfortunately, 40-50% of 
patients initially responsive to TAM develop TAM resistance [56].  Likewise, a similar 




mechanisms evolve to promote breast cancer progression in the absence of estrogen 
signaling. 
 
MECHANISMS OF ENDOCRINE RESISTANCE 
A number of molecular mechanisms have been implicated in promoting endocrine 
resistance (Fig. 1) [56, 59, 60].  For example, ERα expression is silenced by DNA 
methylation, resulting in reduced ERα protein [61].  Mutations in ERα [62] or increased 
expression of truncated forms of ERα, including ERα36 [63], are potential mechanisms in 
acquired resistance.  Alterations in ERα coregulators, e.g., increased expression of AP1 
and nuclear factor-κB (NF-κB) are associated with endocrine resistance [64, 65].  
Crosstalk between ERα and amplification or activation of receptor tyrosine kinases 
(RTKs), including EGFR and insulin-like growth factor receptor (IGFR), have also been 
implicated in endocrine resistance [44].  Overexpression of HER2 (ERBB2) can elicit 
TAM resistance [44], although HER2+ tumors are of a distinct molecular genotype from 
luminal A/ERα + breast tumors [66].  Apoptotic and cell survival signals are also 
dysregulated in TAM-resistant cells [42].  A more extensive review of mechanisms 












Receptor tyrosine kinases (RTKs)






↑MYC, Cyclin D1 & E1
↓p21, p27 & RB
↓ Apoptosis















Figure 1. Summary of the molecular mechanisms promoting acquired endocrine 
resistance. 
Activation and/or amplification of receptor tyrosine kinases (RTKs) including insulin-
like growth factor receptor (IGFR), epidermal growth factor receptor (EGFR), and HER2 
have been detected in tamoxifen-resistant breast cancer cells and endocrine-resistant 
patient tumors.  Plasma membrane-associated GPER and ERα, including splice variants 
ERα36 ERα46, are increased in endocrine-resistant breast cancer cells and tumors.  
Activation of these receptors activate intracellular signaling cascades including MAPK 
and PI3K/AKT pathways that ultimately increase transcription of genes that promote 
growth and survival, and resistance to apoptosis.  Additionally, these pathways increase 
ligand-independent ERα activation by phosphorylation.  Alternatively, MAPK and 
PI3K/AKT can directly promote expression of non-ERE responsive genes by activating 
other transcription factors, e.g., AP-1, not shown here.  Promoter methylation of CpG 
islands and histone deacetylation have been shown to repress ERα expression and 
promote endocrine resistance.  Abbreviations: Estrogen receptor α (ERα), estrogen 
response element (ERE), G protein-coupled estrogen receptor (GPER), plasma membrane 
(PM), retinoblastoma (RB), V-Myc Avian Myelocytomatosis Viral (MYC), B-cell 
lymphoma (BCL), homologous antagonist killer (BAK), BCL-2-interacting killer (BIK)  
 






CHAPTER II: SIGNIFICANCE OF MICRORNA EXPRESISON IN 
ENDOCRINE/TAMOXIFEN-RESISTANT BREAST CANCERS 
 
MICRORNA BIOGENESIS 
miRNAs are evolutionarily conserved, small, non-coding, 22 nt RNAs that post-
transcriptionally regulate gene expression by binding to the 3’ untranslated region 
(3’UTR) of mRNAs to repress translation or promote degradation [68].  There are an 
estimated 2,588 miRNAs arising from intragenic or intergenic regions of the human 
genome (June 2014; http://www.mirbase.org/) [69].  Intragenic, i.e., intronic or exonic, 
miRNAs, which constitute about half of all miRNAs [70], originate from within protein 
coding genes and can therefore have a shared promoter (and/or transcriptional start site 
(TSS)) and are expressed simultaneously with their host protein-coding transcript [71, 
72].  However, later findings suggest this may not be the case and regulation of intronic 
miRNA transcription can occur independent from the host gene [73, 74].  Intergenic 
miRNAs tend to have their own promoters [74].  Determining these TSSs will be 
essential in understanding the regulation of miRNA expression.  Sixty percent of all 
human protein coding genes are regulated by miRNAs [75] and because miRNAs 
regulate multiple mRNAs, they are implicated as key regulators in a variety of cellular 





miRNA biogenesis occurs through canonical and non-canonical pathways.  In the 
canonical pathway of miRNA biogenesis, the primary RNA transcript (pri-miRNA) is 
transcribed from DNA by RNA polymerase II.  Pri-miRNA is further processed to a 
hairpin precursor transcript (pre-miRNA; ~70 nt) by a microprocessor complex 
comprised of Drosha (RNase III enzyme) and associated DiGeorge syndrome critical 
region gene 8 (DGR8) [77].  DGR8 anchors and recognizes the miRNA region for 
endonuclease cleavage by Drosha [78, 79].  The Drosha microprocessor complex is also 
implicated in miRNA-independent functions including regulation of heteronuclear 
ribonucleoproteins (hnRNPs) and alternative splicing [80].  Pre-miRNA is exported from 
the nucleus by Exportin 5 (a RanGTP-dependent dsRNA-binding protein [81]) to the 
cytoplasm where it is further processed by another RNase III enzyme, DICER, in 
conjugation with trans-activation response (TAR) RNA binding protein (TRBP) and 
protein activator of the interferon-induced protein kinase (PACT; also known as PRKRA) 
results in a small dsRNA duplex (~22 nt) [78, 82].  One of the duplex strands is included 
in the RNA-induced silencing (RISC) complex where it recognizes and binds mRNA 
resulting in mRNA degradation or translational repression depending on the extent of 
complementarity [83].  The core RISC complex is composed of four Argonaute (Ago) 
proteins with AGO2 endonuclease activated upon recruitment of target mRNAs [84]. 
In the non-canonical pathway, miRNAs (miRtrons) are processed by 
spliceosomes in an RNase III (Drosha)-independent manner (reviewed in [85]).  The 
intermediate generated is further processed by lariat debranching enzyme resulting in 
products that appear as pre-miRNA mimics.  These mimics then enter the canonical 




miRNAs are considered to be key players in cellular transformation and in the 
initiation and progression of cancer [86].  Selected miRNA signatures have been 
recognized in categorizing developmental lineages and differentiation states of different 
tumors [87, 88].  In these roles miRNAs may function as oncomiRs (oncogenic miRNAs) 
or oncosuppressor miRNAs, although there is an overall downregulation of miRNAs in 
tumors compared to normal tissues [87].  Substantial effort is currently underway to 
understand the molecular mechanisms associated with miRNA dysregulation to assist in 
early diagnosis and management of breast cancer patients. 
 
MICRORNA AND BREAST CANCER 
Since 2005, when miRNA deregulation was first reported in breast cancer [89], 
over 1000 studies have been published identifying and examining the role of miRNAs in 
this disease.  Some of these miRNAs are regulated by E2 and/or influence expression of 
estrogen-responsive genes [90-92].  miRNAs have been implicated in regulating 
hallmarks of breast cancer (reviewed in [93]) including cell proliferation, cell death, 
apoptosis, immune response, cell cycle energetics, metabolism, replicative immortality, 
senescence, invasion, metastasis (reviewed in [94-97], and angiogenesis (reviewed in [93, 





MODELS FOR MICRORNA INVESTIGATION 
The process of investigating miRNAs involved in endocrine resistance usually 
begins with an initial profiling of miRNA differences between endocrine-sensitive versus 
endocrine-resistant breast cancer cell lines or between breast tumors from patients 
responsive and non-responsive to endocrine therapies.  Methods used in these studies 
have included microarrays, RNA sequencing (RNA-seq), and the relatively recent high-
throughput sequencing of RNA isolated by crosslinking immunoprecipitation (HITS-
CLIP) method with confirmation by qPCR.  These methods result in the acquisition of 
huge amounts of data that require integrative analysis and further confirmation.  
Computational approaches are then utilized to predict possible targets and signaling 
pathways that are aberrantly regulated by the identified miRNAs.  Functional analysis 
utilizing ectopic expression and forced repression of miRNA expression are performed to 
validate the role of deregulated miRNAs in tumorigenesis and/or endocrine resistance in 
vivo and in vitro.  The targets of miRNAs are further confirmed by cloning the target 3’-
UTR downstream of a luciferase reporter, transfecting a cell line with this reporter 
plasmid to validate direct inhibition; western blots and qPCR.  Target validation in 
clinical samples provide human significance to the study.  These models have identified 
miRNAs involved in endocrine resistance that are summarized in Tables 1 and 2.   
There are limitations to these approaches.  For example, integrative analysis for 
identifying aberrantly expressed miRNAs is limited by the set of computational 
parameters used in the study, and rarely are these parameters applied to other studies.  
Functional investigations need to be performed for each miRNA and its target.  The 




translate to physiological significance.  This necessitates further studies within clinical 
settings.  HITS-CLIP is technically challenging and complex. It requires great skill but 
has the advantage of capturing interactions ‘frozen’ by UV-crosslinking under 
physiological conditions without the use of exogenous crosslinking agents which can lead 
to artificial interactions [99]. 
 
MICRORNAs REGULATING ERα PROTEIN AND SIGNALING 
The role of miRNAs in promoting endocrine resistance is exemplified by, but not 
limited to, their involvement in regulating ERα (Fig. 2).  Decreased ERα expression is 
involved in endocrine-resistant breast cancer progression.  miRNAs including miR-
221/222 [100], miR-342-3 p [101], miR-873 [102] and Let7b/Let-7i [103] downregulate 
ERα protein expression (Table 1).  miR-221 and miR-222 are overexpressed in TAM-
resistant and ERα-negative breast cancer cell lines and tumors [100, 104, 105].  miR-
221/222 directly target the 3’UTR of ERα. This results in a decrease ERα protein but not 
mRNA [100].  Transient overexpression of miR-221/222 in TAM-sensitive MCF-7 and 
T47D cells resulted in TAM resistance whereas downregulation of miR-221/222 in ERα 
negative/TAM-resistant MDA-MB-468 cells restored ERα expression and sensitized cells 
to TAM-induced cell cycle arrest and apoptosis [100].  ERα is not a direct target of miR-
342-3p, but loss miR-342-3p was associated with a concomitant loss in ERα expression 
and resulted in TAM resistance [101].  Conversely, forced overexpression of miR-342-3p 




promoting loss of ERα expression upon downregulation of miR-342-3p is yet to be 
determined [106]. 
Increased expression of ERα splice variants have also been reported to be 
associated with poor prognosis and contribute to endocrine resistance [107, 108].  ERα36 
is an N-terminal truncated 36 kDa variant of full-length ERα (ERα66) [109].  ERα36 
lacks AF-1 and AF-2 of ERα66, retains DNA binding and dimerization domains, binds 
E2, but is not inhibited by TAM or fulvestrant [109].  ERα36 is expressed in ERα-
negative breast cancer cells and tumors [110] and overexpressed in TAM-resistant breast 
cancer cells [108].  Increased ERα36 protein expression is proposed to be mediated by 
decreased let-7 levels, since transfection of let-7b and let-7i mimics repressed ERα36 
expression and sensitizes TAM-resistant MCF-7 cells to TAM growth inhibition [103].  
Let-7 family members are downregulated in breast cancer tissues and TAM-resistant 
MCF-7 cells [103, 111]. 
ERα is regulated by post-translational modifications including phosphorylation, 
methylation, sumoylation, and palmitoylation [112-116].  These modifications influence 
ERα interaction with other molecules, including transcriptional coregulators, hence 
regulating gene transcription (Fig. 1).  These post-translational events also contribute to 
endocrine resistance [117].  miRNAs are implicated in altering post-translational ERα 
modifications to promote TAM resistance [114].  For example, miR-873 targets CDK3, 
which phosphorylates ERα at Ser104/116 and Ser118 [114].  miR-873 expression was 
downregulated in TAMR/MCF-7 breast cancer cells, and forced overexpression of miR-




authors postulated that the decrease in miR-873 resulted in enhanced ERα 








Table 1: miRNA associated with antiestrogen-resistance in breast cancer 
Experimentally proven bona fide targets and method used in confirming target are indicated.  Proposed pathways associated with 
endocrine-resistance are included.  Method of identification of targets: 3’-UTR luciferase reporter assay (L), downregulation of 
protein shown by western blot (W), and downregulation of target in quantitative real-time PCR assay (Q).   
miRNA Treatment/Human Cell line/ 
tissue 
Comments Targets (method 
of identification) 
Pathway 
Putative oncomiRs based on experimental data 
miR-101 0, 1, 2, 3, 4 µM 4-OHT 4 d in 
MCF-7 cells  
miR-101 infected cells promote 
growth stimulatory activity in 
medium lacking E2 and TAM 
resistant.  miR-101 has growth 
inhibitory activity in E2-containing 










miR125b-5p 0.001- 10 µM anastrozole or 
letrozole in LET-R MCF-7 ANA-R 
MCF-7 vs MCF-7aro cells; 
Primary breast tumors  
Upregulated in LET-R MCF-7 cells, 
ANA-R MCF-7 compared to MCF-
7aro; high miR-125b-5p correlated 
with earlier relapse in ER+/PR+ 
patients [119]  
  
miR-128a TAM+LET-R MCF-7 cells, MCF-
7aro cells  
Upregulated in TAM+LET-R MCF-7 
cells vs MCF-7aro cells [120] 










MiR-181b Human breast samples;  
1 µM 4-OHT, for 0, 24, 48 and 72 
h,  
50 nM 4-OHT, 0, 3, 5 min 
T47D, TAM-R MCF-7 vs TAM-S 
MCF-7 
Enhanced expression in TAM-R 
MCF-7 cells [121] 
Anti-miR-181b suppressed TAM-R 
xenograft tumor growth in TAM 
treated mice.   





miR-205-5p 1, 10, 100 nM, 1, 10 µM 
anastrozole, 1, 10, 100 nM, 1, 10 
µM letrozole; LET-R MCF-7 cells, 
ANA-R MCF-7 vs MCF-7aro 
Primary breast tumors  
Upregulated in LET-R MCF-7 cells, 
ANA-R MCF-7 compared to MCF-
7aro cells; High miR-125b-5p 
correlated with earlier relapse in 
ER+/PR+ patients [119] 
  
miR-210 Patient samples,  
100 nM 4-OHT, 0, 1, 2, 3, 4 d, 
MCF-7, MDA-MB-231  
Increased miR-210 with breast tumor 
histological grade.   
Higher in MDA-MB-231 compared 
to MCF-7 cells [102] 
  
miR-222 Human breast samples  
1 µM 4-OHT, for 0, 24, 48 and 72 
h; 50 nM 4-OHT, 0, 3, 5 min 
Anti-miR-222 suppressed TAM-
resistant xenograft tumor growth in 
TAM treated mice [121]  
 


























0-65 µM 4-OHT, 6 d MCF-7/TAM-
R vs MCF-7 measured in 
conditioned media [122] 
Six-fold increase in exosomes in 
MCF-7/ TAM-S vs MCF-7/TAM-R 
cells [122] 




0, 15, and 20 μM TAM, 16 h TAM-
S vs TAM-R MCF-7 cells, 
HER2/neu (+) vs HER2/neu (-) 
human breast tissue  
TAM increased miR-221/222 in 
TAM-R cells and HER2/neu (+) 
breast tumors compared to TAM-S 











0, 5, 10, 20 µM 4-OHT, 12, 24, 48 
h, MCF-7 and MDA-MB-231  




10 µM 4-OHT, -/+1 nM E2, 48 h 
MCF-7 mammosphere transformed 
vs MCF-7 cells as xenografts in 
SCID mice 
Higher in MCF-7 mammospheres 










100 nM fulvestrant;  Overexpressed in Ful-R MCF-7 cells.  


























TAM-R MCF-7, Ful-R MCF-7, 
MCF-7, MCF-7-Mek5, MCF-7 
TNR  
Repression of TGF-β mediated 
growth inhibition [125] 
 
 
0, 5, 10, 20 µM, 10, 20, nM 4-
OHT, 72 h MCF-7, T47D vs MDA-
MB-468 cells 
Breast tumor tissue  
Higher in ERα negative MDA-MB-
468 breast cancer cells and primary 
breast tumors vs ERα positive MCF-7 
and T47D cells [100] 






100 nM 4-OHT, 100 nM 
fulvestrant, 6 h, 2 d, TAM-sensitive 
MCF-7 vs TAM-resistant LY2 cells  
4-OHT upregulates miR-221/222 in 
LY2 TAM-resistant cells and down 
regulates miR-221/222 in MCF-7 
cells [105] 
 











miR-301 300 nM 4-OHT, 24, 48, 72 h MCF-
7, MDA-MB-231  
Higher in MCF-7, T47D, MDA-MB-
231, and MDA-MB-231 compared to 
MCF-7 10A.  Higher expression in 
lymph node negative (LNN) invasive 
ductal breast cancer [126] 
FOXF2, BBC3, 





miR-519a 0, 5, 10 µM 4-OHT, 3 h , 72 h 
TAM-R MCF-7 vs MCF-7, HEK 
293FT, breast cancer patient 
datasets 
Upregulated in TAM-resistant MCF-
7 cells compared to TAM-sensitive 
MCF-7 cells [127] 
CDKNIA, RB1 
and PTEN (L, W, 
Q) [127] 
Cell cycle 
miR-1280 Patient blood samples  Higher in blood from patients with 
metastatic breast cancer after 
cytotoxic chemotherapy or undefined 
endocrine therapy [128] 
  
Putative oncosuppressor miRNAs based on experimental data 
Let-7b/Let-7i TAM-R MCF-7, MCF-7, MDA-
MB-231 
Breast cancer tissues 
Overexpression of Let-7b/Let-7i 
enhanced sensitivity of TAM-R 
MCF-7 cells to TAM only in 
hormonal withdrawal medium and 
not in normal growth medium [103] 
ERα36 (L, W, Q) 
[103] 
ERα signaling 
Let-7i 5, 10, 15 and 20 μM 4-OHT, 48 h, 
ZR-75-1 cells  
Overexpression of Let-71 increased 









Inverse correlation of Let-7i and TNF 
receptor associated factor (TRAF)1 
[129] 
miR-10a Primary breast tumors Higher expression in patient tumors 
was associated with longer relapse-
free time. Increased expression 
predicted tumor relapse in TAM-
treated ER+ postmenopausal breast 
cancer patients [130] 
  
miR-15a/16 100 pM E2, 1 µM 4-OHT, 100 nM 
fulvestrant, E2+4-OHT, E2+ICI, 
for 24 h, 24 h, 72 h  
TAM-R MCF-7/HER2Δ16 vs 
MCF-7/HER2 cells [131] 
Suppressed expression of miR-15a 
and miR-16 in HER2Δ16 mutant 
cells associated with inverse 
expression of BCL-2 protein and 
mRNA and decreased sensitivity to 
TAM and ICI [131] 
 Apoptosis/cell 
survival signaling 
miR-30a-3p Patient samples [132] Increased expression in 
ER+  primary breast tumors of 
patients who received TAM and 
showed longer progression-free 
survival; Inverse correlation with 
HER2 and RAC1 cell motility 
signaling pathways [132]  
  
miR-126 Primary breast tumors Higher expression in patient tumors 
was associated with longer relapse-








predicted tumor relapse in TAM-
treated ER+ postmenopausal breast 
cancer patients [130] 
miR-
200b/200c 
100 nM 4-OHT, 100 nM 
fulvestrant, 6 h, 2 d, 
TAM-S MCF-7 vs TAM-R LY2 
[133]  
Decreases in TAM-resistant LCC1, 
LCC2, LCC9 and LY2 cells vs MCF-
7 cells [133] 
 





100 nM 4-OHT, 100 nM ICI, 6 h, 2 
d, TAM- sensitive MCF-7 vs TAM-
resistant LY2  
Increased in TAM-sensitive MCF-7 





miR-342-3p 24h 100 pM E2, 1µM 4-OHT, 
E2+4-OHT in TAM-R MCF-
7/HER2Δ16, MCF-7/HER2, 
TAMR1, LCC2 cells, Breast 
tumors [134] 
Downregulated in TAM-R MCF-
7/HER2Δ16 cell, TAMR1, LCC2 
cells and TAM refractory 
human breast tumors vs MCF-7 cells 
and TAM-S tumors. TXNIP is an 











Primary breast tumors 
10 nM E2, 20 µM 4-OHT, 72 h, 
MCF-7 vs SKBR-3 & MDA-MB-
231 cells 
Decreased in ERα (-) SKBR-3 and 
MDA-MB-231 cells vs MCF-7 cells. 
Direct correlation between miRNA-
342 expression and ERα expression 
[101] 







miR-375 5 µM 4-OHT TAM- resistant MCF-
7 cells vs TAM-sensitive MCF-7 
cells  
Lower in TAM-R MCF-7 vs MCF-7 
cells [135] 
MTDH (L, W, Q) 
[135] 
EMT 
miR-424-3p 0.001-10 µM anastrozole or 
letrozole; LET-R MCF-7 cells, 
ANA-R MCF-7 vs MCF-7aro 
Primary breast tumors  
Downregulated in LET-RMCF-7 




miR-451  1 µM 4-OHT for 0 h, 4 h, 8 h 24h  
TAM-R MCF-7 vs TAM-S MCF-7 
cells 
 Reduced levels in TAM-R vs TAM-
S MCF-7 cells [136] 




miR-574-3p 1µM 4-OHT, MCF-7 cells/ tissue 
sample 
Lower in TAM-R MCF-7 cells and 
clinical breast cancer tissues 
compared to TAM-S MCF-7cells and 
adjacent normal control, respectively 
[137] 
Clathrin heavy 
chain (CLTC) ( L, 
W, Q) [137] 
GFR Cytoplasmic 
signaling 
miR-873 1, 10, 100 nM, 1, 5 µM 4-OHT, 7 d 
MCF-7/TAM-R vs MCF-7 cells 
and xenograft tumors  
Downregulated in TAM-R MCF-7 
and breast tumors compared to TAM-
S and normal tissues, respectively. 
 
cyclin-dependent 
kinase 3 (CDK3) 




Abbreviations: 4-hydroxytamoxifen (4-OHT); TAM-sensitive (TAM-S); TAM-resistant (TAM-R); letrozole-resistant (LET-R), 




MICRORNA REGULATION OF ERα PATHWAYS IN BREAST CANCER 
ERα interacts with other transcription factors, e.g., AP-1, Sp-1, NF-κB, and 
forkhead transcription factor (FOXM1), to regulate gene expression [138-140].  Increased 
activity of these transcription factors is associated with endocrine resistance [64, 65, 141, 
142].  FOXM1 is overexpressed in many cancers, including breast cancer, and its ectopic 
expression promotes cell invasiveness [142].  Repression of FOXM1 was associated with 
increased miR-211 [143] and miR-23a [144], and repressed breast cancer cell growth, 
migration and invasion in animal models.   
Activation of NF-κB contributes to endocrine-resistance in breast cancer [145].  A 
genome-wide miRNA screen in HEK-293T cells identified 13 miRNAs regulating NF-κB 
transcriptional activity [145].  Subsequent studies in MDA-MB-231 TNBC cells 
demonstrated that miR-570 and miR-373 inhibited TGFα-activation of NF-κB-induced 
transcription of pro-inflammatory cytokines, e.g., IL-6, IL-8, CXCL1 and ICAM-1, and 
TGF-β signaling by direct targeting of RELA and TGFBR2.  The authors reported that 
transient overexpression of miR-520 or miR-373 inhibited TGF-β induced MDA-MB-
231 cell invasion.  While they did not detect miR-373 in human breast tumors, a 
correlation of higher miR-520c expression in ERα- tumors and lower TGFBR2 transcript 
expression was observed, allowing the authors to suggest loss of miR-520 expression 
may play a role in ERα-tumor progression via altered NF-κB signaling [145].  
The nuclear receptor coactivator proline glutamic acid leucine rich protein 
(PELP1) interacts with ERα [146] to modulate genomic [147] and nongenomic functions 




metastasis and promotes human breast tumor xenograft growth in nude mice [149-151].  
In MCF-7 cells, cytoplasmic localization of PELP1 conferred resistance to TAM [149].  
Although the mechanisms of PELP1 promotion of TAM resistance is not fully known, 
the binding of PELP to the proximal promoters of the oncosuppressors miR-200a and 
miR-141 recruited histone-deacetylase 2 (HDAC2) and repressed their transcription 
[152].  The attendant decrease in miR-200a and miR-141 was suggested to stimulate 
metastatic growth [153].   
ERα coactivator nuclear receptor co-activator 3 (NCOA3, also known as SRC-3 
[154] and AIB1 [155]) is overexpressed in 50% breast tumors [156]. Targeting SRC-3 is 
of clear clinical interest [157]. SRC-3 overexpression results in constitutive activation of 
ERα-mediated transcription, breast tumor growth, and resistance to TAM in vivo and in 
xenograft models [56, 158].  SRC-3 translation is repressed by miR-17-5p. 
Overexpression of miR-17-5p in MCF-7 cells repressed E2-induced proliferation and 
endogenous cyclin D1 transcription [159].  MiR-195 negatively regulates SRC-3 in 
human hepatoma cells [160], but whether it does so in breast cancer is unknown. 
ERα corepressors including nuclear receptor co-repressor 1 (NCoR1) influence 
gene transcription by recruiting HDAC complexes to promote chromatin condensation 
and repression of gene transcription [56, 161].  NCoR1 is reduced in TAM-resistant 
MCF-7 xenograft tumors grown in nude mice [161].  However, both NCoR and the 
corepressor SMRT stimulated 4-OHT-ERα agonist activity on an ERE-driven luciferase 
reporter in transiently transfected Rat-1 cells.  Blockage of NCoR1 promoted the 
agonistic activity of TAM [161].  To our knowledge, there are no reports of miRNA 




DICER in LNCaP prostate cancer cells increased NCoR1 transcription and likewise, 
NCoR1 increased in the prostate of DICER-/- mice [162].  Conversely ectopic expression 
of DICER mediates metastasis and TAM resistance in breast cancer cells [163]. 
 
MICRORNA ACTIVATION OF GROWTH FACTOR RECEPTOR SIGNALING 
Endocrine resistant breast cancer cells and tumors show increased EGFR 
signaling [164].  Although trastuzimab is a targeted therapy widely used in patients 
whose breast tumors overexpress HER2, these patients also benefit from TAM [165].  
Unfortunately, overexpression of an isoform of HER2, HER2Δ16, which is associated 
with metastasis [166], also promotes TAM resistance [131, 134].  Decreased expression 
of miR-15a, miR-16, and miR-342-3p contribute to endocrine resistance in TAM-
resistant MCF-7/HER2Δ16 breast cancer cells [131, 134].  miR-342 was also 
downregulated in TAM-non-responsive breast tumors and HER2 negative, TAM-
resistant TAMR1 and LCC2 cells [134].  Transient overexpression of miR-342 
resensitized TAM-resistant MCF-7/HER2Δ16 and TAMR1 cells to TAM-induced 
apoptosis; decreased BMP7, GEMIN4, and SEMAD are proposed as direct miR-342 
targets mediating this response.  However, the role of these targets in directly promoting 
TAM resistance was not examined.   
Decreased miR-451 also regulates mitogenic signaling to promote TAM 
resistance [136].  TAM, but not raloxifene or fulvestrant, downregulates miR-451 in 
TAM- resistant cells [136].  Downregulation of miR-451 was associated with 




correlated with early time to disease recurrence in patients treated with TAM.  
Overexpression of miR-451 in MCF-7 cells decreased 14-3-3ζ and reduced activation of 
HER2, EFGR, and MAPK signaling, resulting in decreased cell proliferation and 
migration and increased apoptosis.  In addition, overexpression of miR-451 restored the 
inhibitory effectiveness of SERMs in TAM-resistant cells.   
Ujihira, et al. used a miRNA library screen to identify miRNAs associated with 
TAM sensitivity in MCF-7 cells [137].  The authors identified miR-105-2, miR-877, let-
7f, miR-125a and miR-574-3p as “dropout” miRNAs that were downregulated in 4-OHT-
treated compared to vehicle control-treated MCF-7 cells.  Of these miRNAs, miR-574-3p 
was found to be downregulated in breast cancer tissue samples compared to adjacent 
normal tissue samples.  Luciferase reporter assays and knockdown or overexpression of 
miR-574-3p identified clathrin heavy chain (CLTC) as a bona fide miR-574-3p target.  
Low CLTC transcript levels were correlated with better survival in breast cancer patients.  
This study outlines a new role of miR-574-3p in mediating TAM responses: however, 
whether upregulation of miR-574-3p will sensitize TAM-resistant cells to TAM remains 
to be determined. 
Earlier, we discussed downregulation of ERα protein by increased miR-221/222 
in endocrine-resistant breast cancer.  Dysregulation of miR-221/222 was also reported to 
regulate multiple stages of RTK pathways to promote anti-endocrine resistance.  In vitro 
analysis confirmed miR-221/222 was increased in endocrine resistant HER2 positive 
primary human breast cancer tissues compared to HER-2 negative tissue samples [104].  
Overexpression of miR-221/222 made TAM-sensitive MCF-7 cells resistant to TAM and 




TAM-induced cell death in TAM-resistant MCF-7 cells [104].  The same lab reported 
that repression of miR-222 and miR-181b suppressed growth of TAM-resistant MCF-7 
tumor xenografts in mice [121].  Reduced expression of tissue metalloproteinase inhibitor 
3 (TIMP3), a common target of miR-221 /222/181b, in primary breast carcinomas was 
also reported to mediate TAM resistance by relieving repression of ADAM10 and 
AMAM17.  ADAM10 and AMAM17 are critical for growth of TAM-resistant cells 
[121].  Ectopic expression of TIMP3 repressed growth of TAM-resistant cells and 
reduced phosphoMAPK- and EGF- induced phosphoAKT levels.  Conversely, repression 
of TIMP3 in TAM-sensitive MCF-7 promoted phosphorylation of MAPK and AKT, and 
desensitized the cells to growth inhibition by TAM in vitro and in vivo.  In another study, 
the same group showed that sensitivity to TAM upon inhibition of miR-221/222 was 
unique to ERα positive MCF-7 cells and not ERα-negative MDA-MB-231 cells, although 
TIMP3 was a miR-221/222 target in both cells [123].   
By promoting cell growth, miR-221/222 also promotes resistance to fulvestrant 
[125].  Ectopic expression of miR-221/222 in TAM-resistant MCF7 and TAM-resistant 
BT474 cells increased β-catenin and relieved TGF-β-mediated growth inhibition.  
Inhibition of β-catenin decreased estrogen-independent growth in pre-miR-221/222-
transfected MCF-7 cells [125].  The TGF-β signaling pathway was inhibited in letrozole-
resistant, aromatase-stably transfected MCF-7 (T+LET R) breast cancer cells and miR-
128a was upregulated in these cells [120].  miR-128a targeted and repressed TGF-βR1 
(TGF-β receptor 1) protein expression in T+LET R cells compared to the parental MCF-7 
cells stably transfected with aromatase (MCF-7aro).  Repression of miR-128a re-




Loss of PTEN is associated with poor outcome in HER2+ breast tumors [167].  
PTEN is downregulated by miR-101 [118].  Overexpression of miR-101 promotes MCF-
7 cell growth and TAM resistance in estrogen-free growth medium but suppressed cell 
growth in E2-containing medium [118].  TAM resistance was mediated by AKT 
activation and was independent of ERα expression.  miR-101 repressed its target MAGI-
2 (membrane associated guanylate kinase), a scaffolding protein required for PTEN 
activity, thus reducing PTEN activity leading to activation of AKT.  PTEN is also a bona 
fide target of the oncomiR miR-301 [126].  Transient repression of miR-301 in MCF-7 
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Figure 2. Established targets of miRNAs in endocrine resistant breast cancer. 
miRNAs associated with ERα signaling, growth factor/RTK signaling, EMT, 
dysregulation of cell cycle kinetics, and apoptosis and their targets in these pathways 
involved in endocrine resistance are shown.  The miRNAs and their targets are described 
in the text and summarized in Tables 1 and 2.  The bona fide targets are indicated with 





MICRORNAs AS CELL CYCLE REGULATORS 
SERMs can be cytostatic and cytotoxic by promoting G1-phase cell cycle arrest 
[168].  miR-221/222 [104] and miR-519a [127] have been implicated in altering 
expression of molecular regulators of the cell cycle to promote endocrine resistance.  
miR-221/222 represses p27 to promote TAM resistance in breast cancer cells [104, 122].   
Recently, miR-519a was reported as a novel oncomiR by increasing cell viability 
and cell cycle progression [127].  miR-519a was upregulated in TAM- resistant MCF-7 
cells compared with TAM-sensitive MCF-7 cells.  Elevated levels of miR-519a in 
primary breast tumors were associated with reduced disease-free survival in ERα+ breast 
cancer patients and miR-519a was suggested to contribute to TAM resistance.  
Knockdown of miR-519a in TAM-resistant MCF-7 cells sensitized the cells to TAM 
growth inhibition.  Concordantly, overexpression of miR-519a in TAM-sensitive MCF-7 
cells desensitized the cells to TAM by preventing growth inhibition while promoting 
caspase activity and apoptosis.  Tumor suppressor genes (TSGs) involved in PI3K 
signaling CDKNIA (which encodes p21), RB1, and PTEN, were reported to be bona fide 
targets of miR-519a, although the role of these targets in mediating TAM-resistance have 
not been explored. 
 
MICRORNAs IN EPITHELIAL-TO-MESENCHYMAL TRANSITION (EMT) 
Changes involved in tumor progression include acquisition of migration/invasion, 
gain of front-rear polarity, resistance to anoikis, and mesenchymal transition [169].  
Genetic changes that occur during EMT include but are not limited to activation of 
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SNAIL, increased Zinc-finger E-box-binding 1 (ZEB1), reduced E-cadherin, and 
increased vimentin and N-cadherin [170].  EMT is also implicated as a mechanism by 
which tumors enact resistance to TAM [171].   
To identify miRNAs that mediate TAM resistance, we used a microarray to 
identify miRNAs differentially regulated between endocrine-sensitive MCF-7 cells and 
an endocrine-resistant MCF-7 variant LY2 cells, with selected results confirmed by 
qPCR [105].  Among these, miR-200a, miR-200b, and miR-200c were found to be 
downregulated in LY2 cells and other TAM-resistant breast cancer cell lines (LCC9) 
compared with parental TAM-sensitive MCF-7 cells [105, 133].  The decrease in miR-
200 family expression was associated with increase in ZEB1.  ZEB1 is an EMT-inducing 
transcription factor that represses E-cadherin [172].  Ectopic expression of miR-200b 
and/or miR-200c altered LY2 morphology to a more epithelial-like phenotype and 
inhibited cell migration.  These phenotypic changes were associated with repression of 
the mesenchymal markers N-cadherin, vimentin, and ZEB1 and an increase in the 
epithelial marker E-cadherin.  Further, upregulation of miR-200b/200c or ZEB1 
knockdown sensitized LY2 cells to TAM- and fulvestrant-induced growth inhibition.  
However, overexpression of miR-200b/200c in MCF-7 cells did not promote resistance to 
TAM or fulvestrant, indicating that cellular changes in addition to downregulation of 
miR-200 family members are involved in TAM resistance in LY2 cells.   
In another miRNA microarray study, miR-375 was found to be downregulated in 
a mesenchymal TAM-resistant MCF-7 cell line model [135].  Re-expression of this miR-
375 sensitized TAM-resistant cells to TAM and reduced invasiveness by decreasing 
expression of mesenchymal markers fibronectin, ZEB1, and SNAI2 while increasing the 
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epithelial markers E-cadherin and ZO-1.  This resulted in partial reversal of EMT called 
MET (mesenchymal-to-epithelial transformation).  Metadherin (MTDH), a cell surface 
protein upregulated in breast tumors that mediates metastasis [173], was identified as a 
direct, bona fide miR-375 target mediating this response.  TAM- treated patients whose 
primary tumor presented with high MTDH showed shorter-disease-free survival and a 
higher risk of relapse.  This study exemplifies the role of miRNAs in mediating cellular 
transformations that foster tumor progression and TAM resistance. 
EMT allows the emergence of cancer stem cells (CSCs) that have properties 
including self-renewal potential and tumorigenicity [135, 174].  Mammosphere culture is 
widely utilized to enrich the population of mammary epithelial stem cells and breast 
CSCs in vitro [175, 176].  Mammosphere culture of MCF-7 cells (MCF-7M cells) resulted 
in permanent EMT with increased miR-221/222 and loss of their target ERα mRNA 
expression [124].  MCF-7M cells were also characterized by downregulation of epithelial-
associated tumor suppressor miRNAs including miR-200c, miR-203 and miR-205.  
MCF-7M cells were resistant to TAM-induced cell death.  These data reinforce other 
studies discussed above demonstrating a role for increased expression of miR-221/222 in 
driving TAM-resistance.   
 
MICRORNAs AS REGULATORS OF APOPTOSIS/CELL SURVIVAL 
SIGNALING  
Tumor growth reflects a balance between cell growth and cell death.  Endocrine 
inhibitors activate apoptotic and stress signals to inhibit breast cancer cell growth [42, 60, 
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177].  However, the molecular mechanisms behind these observations are yet to be fully 
defined.  Activation of antiapoptotic proteins such as BCL-2, crosstalk between apoptotic 
effects of antiestrogens and the TNF-α pathway, and promotion of survival signals 
including PI3K-AKT and NF-κB have been documented to promote resistance endocrine 
therapy [42].  MiRNAs can directly target antiapoptotic transcripts or regulate mediators 
of the survival signaling pathways.  For example, low miR-15a/16 expression correlated 
with upregulation of BCL-2 in TAM- and fulvestrant- treated TAM-resistant MCF-
7/HER2Δ16 cells and xenograft tumor promotion in vivo [131].  RNAi targeting of BCL-
2 or reintroduction of miR-15a/16 decreased TAM-induced BCL-2 expression in TAM- 
resistant MCF-7/HER2Δ16 cells resulting in TAM-induced decrease in cell growth and 
promotion of apoptosis.  Conversely, repression of miR-15a/16 in TAM-sensitive MCF-
7/vector or MCF-7/HER2 increased BCL-2 expression and promoted resistance to TAM 
by inhibiting apoptosis and preventing growth inhibition. 
To identify potentially ethnic group-specific TAM sensitivity biomarkers, Weng 
et al. performed an integrative genomic analysis on 58 African-derived HapMap YRI 
lymphoblastoid cell lines (YRI LCLs; breast cancer cells) [178].  Genetic variants 
(including 50 SNPs with effects on 34 genes and 30 miRNAs) were identified to be 
sensitive to endoxifen, an active metabolite of TAM.  Among the genes identified, 
increased TNF receptor-associated factor 1 (TRAF1) and decreased let-7i expression 
correlated with endoxifen resistance in 44 YRI LCLs.  TRAFs are intracellular signal 
transducers for death receptor superfamily TNF receptor (TNFR) [178].  TRAF1 
associates with TRAF2 to form a protein complex that interacts with inhibitor-of-
apoptosis protein (IAP) to mediate anti-apoptotic signals (MAPK8/JNK and NF-κB) from 
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the TNF receptor [179, 180].  Repression of TRAF1 or overexpression of let-7i in ZR-75-
1 luminal breast cancer cells enhanced sensitivity to TAM and decreased the number of 
viable cells.  These data show that by regulating death signals, miRNAs can also mediate 
response to antiestrogens.   
 
EXTRACELLULAR VESICULAR (EXOSOME) TRANSPORT OF MICRORNAs 
Extracellular vesicles (EVs), produced by outward budding of the PM, contain 
proteins and nucleic acids that can be transported in blood between tissues and cells [181, 
182].  The contents of EVs can facilitate tumor growth including angiogenesis, invasion, 
metastasis, and immune suppression.  They also play a role in reducing effectiveness of 
drugs [183].  Exosomes are smaller EVs of endosomal origin and formed by the fusion of 
multivesicular bodies with PMs [184, 185].  Exosomes transport miRNAs in circulation.  
Mechanisms of exosomal formation and delivery are cell-specific and display proteins 
from their tissue of origin and are specific to the target cells [186-188].  It was initially 
reported that miRNAs were randomly packaged into exosomes with no specific miRNA 
preferentially incorporated [189, 190].  Studies now indicate different miRNAs are 
associated with specific customized exosomes [191].  However, the selection mechanism 
for incorporating miRNAs into exosomes is yet to be elucidated. 
EVs or exosomal delivery of miRNAs is thought to play roles in breast 
tumorigenesis and metastasis (Table 2).  Cell culture studies showed that exosomes 
secreted by TAM-sensitive MCF-7 cells were larger in size and number compared to 
TAM-resistant MCF-7 cells [122].  This study showed that miR-221/222 released in 
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TAM-resistant exosomes were taken up by TAM-sensitive MCF-7 cells resulting in 
reduction of their target genes p27 and ERα, and enhanced TAM resistance.  Transfection 
of a miR-221/222 inhibitor in MCF-7 cells treated with TAM-resistant MCF-7 exosomes 
reduced TAM-resistance.  These data again support the importance of miR-221/222 in 
TAM resistance in MCF-7 cells.  The potential use of exosomal miRNAs as candidate 
biomarkers for cancer diagnosis and prognosis remains to be definitively proven.  The 
manipulation of exosomal miRNAs suggest a new therapeutic approach for drug delivery, 







Table 2: Exosomal miRNAs described in breast cancer 
↑ Increased expression; ↓ Reduced expression.  Method of identification of targets: 3’-UTR luciferase reporter assay (L), 
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Abbreviations: Adriamycin (Adr), Docetaxel (Doc), Mesenchymal stem cells (MSCs), Mouse breast cancer cell line (4T1), mouse 
endothelial cell line (SVEC), nontumorigenic mouse mammary epithelial cells (NMuMG), human mammary epithelial 




MICRORNAs OF UNKNOWN FUNCTION IN ENDOCRINE-RESISTANT 
BREAST CANCER 
Other microRNAs identified by microarray or library screen and confirmed by 
qPCR to promote antiestrogen resistance in breast cancers, but having undetermined 
functional roles include: miR-10a, miR-21, miR-22, miR-29a, miR-181a, miR-125b, 
miR-205 which mediate resistance to TAM [105]; and miR-125a and miR-877 which 
also mediate TAM resistance [137]  Other miRNAs identified by integrative analysis to 
make up network clusters that contribute to antiestrogen resistance include: miR-146a, 
miR-27a, miR-145, miR-21, miR-155, miR-125b, and let-7s [204]. 
 
ROLES OF DROSHA, DICER, AND AGO2 IN ENDOCRINE-RESISTANT 
BREAST CANCER 
As described earlier in this review, Drosha and DICER function in miRNA 
processing.  The role of Drosha in endocrine resistance has not been ascertained, despite 
the observation that reduced cytoplasmic Drosha is predictive of better endocrine therapy 
response [205].  Loss of DICER is predictive of a better response to endocrine therapy 
[206].  Elevated DICER was associated with TAM resistance in metastatic breast tumors 
and tumor xenografts [163].  DICER-overexpressing cells were enriched with the breast 
cancer resistance protein (BCRP), a member of the ATP-binding cassette (ABC) 
transporter superfamily that causes resistance to several chemotherapeutic agents [207].  
Increased BCRP resulted in a more efficient efflux of TAM in DICER-overexpressing 
cells compared to control cells.  Inhibition of BCRP inhibited TAM efflux and restored 
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TAM sensitivity in DICER-overexpressing cells.  In ERα negative breast cancer cells, 
DICER is targeted by oncogenic miRNAs including miR-103/107 [208], let-7, miR-
222/221, and miR-29a [209].  Whether repression of DICER by these miRNAs mediates 
endocrine resistance is yet to be determined.   
AGO2 recruits mRNA and miRNA into the RISC complex and is the catalytic 
component of the RISC complex.  AGO2 is elevated in ERα negative compared to ERα 
positive breast cancer cell lines and tumors [210].  Expression of AGO2 is mediated by 
ERα/estrogen signaling and epidermal growth factor (EGFR)/ mitogen-activated protein 
kinase (MAPK) signaling pathways [210].  Ectopic expression of full length AGO2 in 
MCF-7 cells promoted cell proliferation, reduced cell-cell adhesion, and increased cell 
migration [210].  Whether AGO2 plays a role in endocrine resistance is yet to be 
determined.   
We examined the association of AGO2 expression and overall survival rate in 
breast cancer patients using the online survival analysis tool, Kaplan–Meier Plotter 
(http://kmplot.com/backup/breast) [211].  It assesses the association of gene expression 
on breast cancer prognosis using microarray data from 3554 patients.  The patient data 
are from GEO.  Higher AGO2 expression correlates with reduced relapse-free survival in 







Figure 3. Higher expression of AGO2 is statistically associated with decreased 
relapse-free survival in all breast cancer and in patients whose primary tumors are 
ERα+/PR+.   
The Kaplan-Meier plots of AGO2 expression in breast tumors with breast cancer survival 
were generated using http://kmplot.com/analysis/index.php?p=service [212]. A) All 
breast tumors, n = 3557; B) ERα+/PR+, n = 701. 






miRNAs are dysregulated in endocrine-resistant breast cancer and these miRNAs 
regulate specific genes in growth-promoting, apoptosis-resistant, and EMT pathways that 
result in TAM- and AI- resistance (Tables 1 and 2).  The involvement of exosomes 
containing miRNAs in mediating endocrine resistance provides a new target for 
biomarker identification and therapeutic intervention to block metastatic spread.  
Although identifying new miRNAs mediating endocrine resistance is important, research 
effort is needed to determine the mechanisms and functional roles of already identified 
miRNAs with unknown roles in endocrine resistance and to develop “targeted” 





DISSERTATION HYPOTHESIS AND SPECIFIC AIMS 
Despite initial sensitivity to TAM and other antiestrogens, ~40-50% of patients 
develop acquired endocrine resistance, relapse, and eventually die from their disease [56, 
213].  These observations underscore a need to identify and target mechanisms promoting 
endocrine-resistance of ERα+ breast cancers. 
Previous microarray analysis identified [105] and quantitative real time PCR (qPCR) 
confirmed microRNAs (miR) miR-29b-1 and miR-29a to be downregulated in 
estrogen/tamoxifen sensitive (TAM-S) MCF-7 and upregulated in estrogen-
independent/TAM resistant (TAM-R) LCC2, LCC9, and LY2 human breast cancer cells 
treated with 4-hydoxytamoxifen (4-OHT, a bioactive TAM metabolite).  miR-29b-1/a are 
encoded by a single primary miR (pri-miR) transcript and share a promoter.  Depending 
on the cell type, miR-29b-1/a serve as oncosuppressor miRNAs or oncomiRs.  For 
example, miR-29b-1 upregulation in a triple negative breast cancer (TNBC) cell line 
increased cell migration and invasion [214].  However, the role of miR-29b-1/a in 
endocrine-resistant breast cancer is unknown.  The research performed here tested the 
hypothesis that miR- 29b-1/a promotes TAM-resistance by recruiting ERα to its promoter 
to stimulate its transcription, consequently resulting in downregulation of miR-29b-1/a 




SPECIFIC AIM 1: Determine the role of ERα in modulating miR-29b-1/a 
expression in response to tamoxifen in TAM-S MCF-7 cells and TAM-R LCC9 cells. 
ERα regulates cell proliferation and survival by binding estrogen response elements 
(EREs) in the promoter or enhancer regions of target genes [92].  I hypothesized that ERα 
normally regulates miR-29b-1/a expression and that 4-OHT treatment alters ERα 
occupancy at the miR-29b-1/a promoter.  Experiments examined whether ERα 
knockdown and/or overexpression modulate miR-29b-1/a transcription in 4-OHT- treated 
cells.   
 
SPECIFIC AIM 2: Determine if upregulation of miR-29b-1/a in endocrine sensitive 
and knockdown of miR-29b-1/a in endocrine-resistant breast cancer cells alters 
cellular responses to antiestrogens in vitro.  The role of miRNAs, including miR-29b-
1/a, in acquired endocrine resistant breast cancer was unknown.  I hypothesized that the 
opposite regulation of miR-29b-1/a in TAM-S MCF-7 and TAM-R LCC9 and LY2 cells 
in response to 4-OHT corresponds to functional outcomes that promote TAM-resistance 
and cell migration, invasion, and hence disease dissemination.  Experiments examined 
whether overexpression of miR-29b-1/a in MCF-7 cells or knockdown of miR-29b-1/a in 
LCC9 and LY2 cells have functional outcomes on cell  proliferation, migration  and 
colony formation, and whether blocking 4-OHT-induced miR-29b-1/a upregulation in 




SPECIFIC AIM 3: Identify miR-29b-1/a targets differentially regulated in response 
to tamoxifen in TAM-S MCF-7 and TAM-R LCC9 cells. Differential regulation of 
miRNAs and concomitant inverse expression of their target genes are reported in several 
cancers [215, 216]. However, the identity of miR-29b-1/a target genes specifically found 
in TAM-resistant breast cancer were unknown.  I hypothesized that changes in miR-29b-
1/a expression were associated with inverse changes in target gene expression.  To 
identify miR-29b-1/a targets specific to TAM-R breast cancer cells, RNA sequencing 
(RNA-Seq) was performed in MCF-7 and LCC9 cells transfected with pre-miR-b-1/a and 
anti-miR-29a.  Selected targets were verified by qPCR.  Luciferase reporter assays was 
used to ascertain the authenticity of mRNAs directly regulated by miR29b-1/a while 








CHAPTER III: TAMOXIFEN DIFFERENTIALLY REGULATES MIR-29B-1 AND 
MIR-29A EXPESSION DEPENDING ON ENDOCRINE-SENSITIVITY IN BREAST 
CANCER2 
INTRODUCTION 
Breast cancer is the second leading cause of cancer-related deaths in women in 
the US [3].  Seventy percent of breast tumors express estrogen receptor α (ERα) [56, 
217], making these patients eligible for endocrine therapies including aromatase 
inhibitors (AIs), e.g., letrozole, and selective estrogen receptor modulators (SERMs), e.g., 
tamoxifen (TAM).  Unfortunately ~40% of patients initially responsive to endocrine 
therapies acquire resistance to TAM or AI therapy [55].  The selective estrogen receptor 
down regulator (SERD) fulvestrant (ICI 182 780) is used for the treatment of patients 
who relapse on AIs or TAM [50, 51, 53, 218].  New clinical studies show that patients 
treated with AIs who have metastatic tumors with ERα ligand binding domain mutations 
show increased disease-free and overall survival with fulvestrant treatment [219].  These 
and other data implicate ERα as an important target in endocrine resistance.  While still 
not completely understood, a variety of mechanisms play a role in endocrine resistance 
including increases in coactivators SRC-1 (NCOA1) and/or SRC-3 (NCOA3), activation 
of receptor tyrosine kinases (TRKs, e.g., epidermal growth factor receptor (EGFR)) that 
crosstalk with ERα, and deregulation of apoptotic or cell survival signals [56, 59, 220].  
                                                 
2The text of this chapter was published in Can. Lett. 2017 388: 230-238. doi: 10.1016/j.canlet.2016.12.007  
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MicroRNAs are 22 nucleotide (nt) noncoding RNA molecules that bind to the 3’-
UTR region of target mRNAs to cause mRNA degradation or translational repression 
[221, 222].  microRNAs are dysregulated in breast tumors resulting in aberrant 
expression of target proteins involved in cellular processes including proliferation, 
apoptosis, and migration.  A number of microRNAs play a role in mediating endocrine 
resistance (reviewed in [218, 220]); however, it is likely that additional microRNAs 
contribute to the emergence of endocrine-resistance.  Previously we used microarray 
analysis to identify microRNAs that are differentially regulated between estradiol (E2)- 
and TAM-sensitive MCF-7 and endocrine-resistant LY2 human breast cells that were 
derived by long-term incubation of MCF-7 cells with a precursor to raloxifene and which 
are cross-resistant resistant to TAM and fulvestrant [223, 224].  Several microRNAs, 
including miR-29b-1 and miR-29a, were identified to be differentially regulated by 4-
hydroxytamoxifen (4-OHT, the active metabolite of TAM) between MCF-7 and LY2 
cells.  However, the role of miR-29b-1/a in breast cancer remains unclear and the 
relationship between increased miR-29b-1 and miR-29a in 4-OHT-treated LY2 cells and 
TAM resistance is unknown.  
The miR-29 family includes 4 members encoded at two genomic sites.  miR-29b-
2 and miR-29c are encoded on chromosome 1q32.2 separated by 502 base pairs (bp) with 
miR-29b-2 upstream of miR-29c [225, 226].  miR-29b-1 and miR-29a are located on 
chromosome 7q32.3, separated by 652 bp, with miR-29b-1 upstream of miR-29a [227-
229].  Each pair (miR-29b-2/c and miR-29b-1/a) is postulated to share a promoter and be 
transcribed as a single primary-microRNA, i.e., pri-miR-29b-2/c and pri-miR-29b-1/a.  
All four miR-29s have the same seed sequence [226].  Interestingly, miR-29 family 
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members have higher expression in Luminal A and B breast tumors compared with basal 
and HER2+ tumors [230].   
Both oncogenic and tumor suppressive roles have been ascribed to miR-29 in 
breast cancer progression (summarized in SupplementaryTable1) [231-233].  Forced 
overexpression of miR-29b and miR-29a promoted an epithelial-to-mesenchymal 
transition (EMT) in MCF-7 and T47D cells while miR-29a repression reduced 
invasiveness of MDA-MB-231 triple negative breast cancer (TNBC) cells [234].  
However, other studies indicate that miR-29a and miR-29b act as oncosuppressors in 
breast cancer cells by repressing cell proliferation, differentiation, and metastasis [230, 
235, 236].  These conflicting studies underscore the need to further elucidate the role of 
miR-29b-1/a in breast cancer.   
In the current study, we confirmed the opposing regulation of miR-29b-1 and 
miR-29a transcription by 4-OHT seen in the original microarray studies in MCF-7 and 
LY2 cells [223] using quantitative realtime PCR (qPCR).  We examined the mechanism 
for this opposite regulation by 4-OHT in these cells and in additional TAM- and 
fulvestrant-resistant cell lines derived from MCF-7 cells: LCC2 and LCC9.  Transient 
overexpression of miR-29b-1 and miR-29a decreased cell proliferation in all 3 cell lines 
and inhibited migration and colony formation of LY2 cells.  Inhibition of miR-29b-1/a 
did not sensitize TAM-resistant LCC9 or LY2 cells to TAM.  The increase in miR-29b-
1/a in LY2 cells was associated with decreased protein expression of DICER, a bone fide 
target of miR-29b-1/a.  Knockdown of miR-29b-1/a blocked 4-OHT mediated repression 
of DICER.  Our results suggest that miR-29b-1/a do not appear to play a role in acquired 




MATERIALS AND METHODS 
Cell culture/treatments 
MCF-7 (purchased from American Type Culture Collection (ATTC, Manassas, 
VA, USA), LCC2, LCC9 and LY2 (provided by Robert Clarke, Georgetown University) 
[224, 237, 238] cells were grown in phenol red IMEM supplemented with 5% fetal 
bovine serum (FBS, Atlanta Biologicals, Lawrenceville, GA, USA) and 1% 
penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA).  These cells represent a model 
of progression to endocrine/TAM- resistance [239].  For the experiments described here, 
cells were grown in hormone depleted medium: phenol red-free IMEM supplemented 
with 5% dextran-coated charcoal-stripped fetal bovine serum(DCC-FBS, Atlanta 
Biologicals, Lawrenceville, GA, USA) for 48 h prior to experiments to reduce basal 
hormone-related activities [240]. Where indicated, cells were pretreated with 10 μg/ml 
actinomycin D (ACTD, a transcriptional inhibitor, Sigma, St. Louis, MO, USA) or 100 
nM fulvestrant (ICI 182,780; Tocris, Ellisville, MO, USA) for 6 h prior to treatment. 
Treatments included vehicle control (ethanol (EtOH) or DMSO) or 100 nM 4-
hydroxytamoxifen, (4-OHT; Sigma St Louis, MO, USA).  
 
Transfection 
MCF-7, LCC9, and LY2 cells were transiently transfected for 48 h with miR-29b-
1/a inhibitor (Anti-miRTMs, Ambion, Austin, TX, USA), siERα (Silencer®, Ambion), pre-
miR-29b-1/a precursor (Pre-miRTMs, Ambion), using Lipofectamine RNAiMAX 
(Invitrogen, Carlsbad, CA, USA) and Opti-MEM® Reduced Serum Medium (Invitrogen, 
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Carlsbad, CA).  Negative controls were Anti-miR ™ negative control #1 (Ambion), Pre-
miR™ negative control #1 (Ambion), or Negative Control #1 (Silencer®, Ambion). 
Treatments were performed following transfections.   
 
Quantitative real-time PCR (qRT-PCR)  
RNA was isolated using the miRCURY RNA isolation kit (Exiqon, Vedbaek, 
Denmark) according to manufacturer’s instructions. RNA concentration and quality was 
assessed using a NanoDrop spectrophotometer (Thermo Scientific, Rockford, IL, USA).  
The TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems) and the High 
Capacity cDNA Reverse Transcription kit for RNA (PE Applied Biosystems, Carlsbad, 
CA, USA) were used to make cDNA for microRNA and mRNA respectively. 
Quantitative real-time PCR (qPCR) for pri-miR-29b-1/a, miR-29b-1/a, (Applied 
Biosystems) and DICER1 [241] (IDT), was performed using TaqMan (Applied 
Biosystems/Life Technologies) or SYBR green (QIAGEN). Normalizers included 
RNU6B, RNU48 or RNU38, PPIA, 18S rRNA (Applied Biosystems) or GAPDH (SYBR 
green).  qPCR was performed in the ABI Viia 7 (LifeTechnologies) with each reaction 
run in triplicate.  Fold change was determined using the comparative threshold cycle (Ct) 






To examine ERα regulation of miR-29b-1/a promoter, CHO-K1 cells were 
transiently transfected in triplicate in 24 well plates with pGL3 -1530/+165 miR-29b-
1/miR-29a promoter fragment [227] and pGL4-hRluc-TK (Renilla, Promega, Madison, 
WI, USA ) using FuGENE HD (Roche, Indianapolis, IN, USA) for 48 h as per the 
manufacturer’s protocol. 18 h post transfection, cells were either not pre-treated or pre-
treated for 6 h and then treated for 24 h prior to performing dual luciferase assay 
(Promega). Relative expression was determined by dividing averaged values from DMSO 
treated values. 
 
Cell proliferation (BrdU), colony formation, and migration (wound healing) assays 
MCF-7, LCC9 and LY2 cells were placed in hormone-depleted medium and 
transfected with precursor microRNA or anti-miR transcripts or 48 h and the following 
assays performed: For BrdU assays, cells were treated with 100 nM 4-OHT for 48 h and 
cell proliferation quantified using BrdU ELISA assay (Roche).  For colony formation, 
following transfection, LY2 cells were counted and transferred to agarose plates and 
allowed to grow for 14 days to form colonies.  Colonies were stained with crystal violet 
(0.005% w/v, Sigma) and counted using an inverted Nikon microscope (x10 objective).  
For cell migration assays, LY2 cells grown in hormonally depleted medium and 
transfected in six well plates for 24 h. Cells were wounded by scratching with a p20 
pipette tip, and treated with 100 nM 4-OHT for up to 8 h.  Images were captured at each 
time point at 4X magnification using an EVOS microscope (Thermo Fisher 
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Scientific Waltham, MA, USA).  NIH Image J software (http://imagej.nih.gov/ij/) was 
used to analyze percent wound area.     
 
Western blot 
Whole cell extracts (WCE) were prepared in RIPA buffer (Sigma) with added 
phosphatase and complete protease inhibitors (Roche). Protein concentration was 
determined using the Bio-Rad DC protein assay (Bio-Rad). Where indicated, 10 or 15 µg 
of protein was boiled for 5 min,  electrophoresed on 10% SDS-PAGE gels and 
electroblotted on PVDF membranes (Bio-Rad) for western blotting with the following 
antibodies: ERα (G-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA), DICER1, 
PTEN  (Cell Signaling, Danvers, MA, USA) and β-actin (loading control; Sigma).  Bands 
were visualized using Carestream Image Station 4000R PRO with Carestream Molecular 
Imaging Software Version 5.0.2.30 (Carestream Health, Inc., New Haven, CT, USA) and 
quantified by UN-SCAN-IT Graph Digitizer Software 7.1 (Silk Scientific, Orem, UT, 
USA).  The values were normalized to loading control and the normalized values for 




Statistical evaluations were performed using Student’s t-test or one-way ANOVA 





4-OHT reduces expression of miR-29b-1/a in TAM-sensitive (TAM-S) MCF-7 cell and 
increases miR-29b-1/a expression in TAM-resistant (TAM-R) LCC2, LCC9 and LY2 
human breast cancer cells 
Our previous microarray analysis of microRNA expression revealed that 4-OHT 
reduced expression of miR-29b-1 and miR-29a in endocrine sensitive MCF-7 breast 
cancer cells and increased expression in endocrine resistant LY2 cells [223].  As a follow 
up on these initial observations, qPCR was performed to examine the effect of 4-OHT on 
miR-29b-1 and miR-29a expression in MCF-7 cells and a panel of MCF-7-derived cells 
lines showing progressive resistance to TAM and fulvestrant: LCC2, LCC9 and LY2 
cells [224, 237].  For these experiments, cells were grown in hormone-depleted medium 
i.e., incubated with phenol-red free IMEM + 5% DCC-stripped FBS + 1% P/S, for 48 h 
to reduce basal hormone-related activities [240] and then treated with 100 nM 4-OHT for 
6 h.  Confirming the microarray data [223], 4-OHT decreased the expression of miR-29b-
1 and miR-29a in MCF-7 cells, but increased miR-29b-1 and miR-29a expression in the 
three endocrine-resistant cell lines: LCC2, LCC9 and LY2 cells (Fig. 4A).  miR-29b-1/a-
3p expression levels were higher than miR-29b-1/a-5p expression levels (Supplementary 
Fig. 1).  Thus, we examined miR-29b-1-3p and miR-29a-3p in all subsequent 
experiments.   
miR-29b-1 and miR-29a are transcribed from a common promoter as a single 
primary transcript [227].  Pri-miR-29b-1 and pri-miR-29a expression was reduced by 4-
OHT in MCF-7 cells and increased by 4-OHT in LCC2 and LCC9 cells (Fig. 4B).  These 
data suggest 4-OHT regulates pri-miR-29b-1/a transcription.   
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To examine if the 4-OHT regulation of miR-29b-1/a expression was mediated at 
the level of transcription, cells were preincubated with the transcriptional inhibitor 
actinomycin D (ACT D; Fig. 4C and D).  While ACT D inhibited basal expression of 
miR-29b-1 and miR-29a in all cells (data not shown), ACT D further inhibited miR-29b-
1 and miR-29a expression in 4-OHT-treated MCF-7 cells.  Also, ACT D inhibited the 4-
OHT-induced miR-29b-1 (Fig. 4C) and miR-29a (Fig. 4D) expression in LCC9 and LY2 







Figure 4. Differential regulation of miR-29b-1/a expression by 4-OHT in MCF-7, 
LCC2, LCC9, and LY2 breast cancer cells. 
Cells were grown in hormonally depleted medium for 48 h and treated with vehicle 
control (DMSO) or 100 nM 4-OHT for 6 h.  A, C, and D) miR-29b-1 and miR-29a 
expression was normalized to RNU38 or RNU48. B) pri-miR-29b-1 and pri-miR-29a 
expression was normalized to GAPDH.  C and D) Cells were pre-incubated with 10 
µg/ml actinomycin D (ActD) for 1 h prior to 6 h treatment.  Values are the average of 4-
20 (A), 3-9 (B), and 3 (C, D) separate experiments ± SEM. *p < 0.05 versus control; 







































































































































































































































































































ERα mediates 4-OHT regulation of miR-29b-1/a transcription 
The observed 4-OHT regulation of miR-29b-1/a transcription in these ERα+ 
breast cancer cells suggests a possible role of ERα, and/or ERβ, in mediating these 
effects.  MCF-7 and LCC9 cells have higher ERα than ERβ and higher ERα protein 
levels than LY2 [239].  To evaluate ERα’s role in mediating 4-OHT-regulation of miR-
29b-1/a expression, MCF-7 and LCC9 cells were transfected with siERα or siControl.  
siERα reduced ERα protein levels by ~ 70% in MCF-7 and ~90% in LCC9 cells, 
respectively (Fig. 5A).  ESR1 mRNA levels were decreased by siERα in both cell lines 
(Fig. 5B).  ERα knockdown had no significant effect on basal pri-miR-29b-1/a expression 
in MCF-7 or LCC9 cells (Fig. 5C).  ERα knockdown inhibited the decrease in pri-miR-
29b-1/a (Fig. 5C), as well as the reduction in miR-29b-1 and miR-29a seen with 4-OHT 
treatment in MCF-7 cells (Fig. 5D).   
Although ERα knockdown did not affect basal pri-miR-29b/1a expression in 
LCC9 cells (Fig. 5C), there was a significant increase in miR-29a (Fig. 5D).  Knockdown 
of ERα blocked 4-OHT stimulation of pri-miR-29b-1/a (Fig. 5C) and mature miR-29b-1 
and miR-29a expression (Fig. 5D).  Comparable results were seen with ERα knockdown 
in LY2 cells (Supplementary Fig. 2).  Together, these data suggest that ERα plays a role 
in mediating 4-OHT suppression of miR-29b-1/a expression in MCF-7 cells and 4-OHT 
stimulation of miR-29b-1/a expression in LCC9 and LY2 cells.   
 
4-OHT regulates miR-29b-1/a promoter activity  
 To examine the direct effect of 4-OHT on the 5’ promoter of miR-29b-1/a, CHO-
K1 cells were transiently transfected with an ERα expression vector [243] and a 
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luciferase reporter containing  –1530  to +165 of the human miR-29b-1/a promoter [227]. 
4-OHT reduced luciferase activity and this was inhibited by fulvestrant (Supplementary 
Fig. 3).  These data support the model that 4-OHT inhibits miR-29b-1/a promoter activity 







Figure 5. ERα regulates miR-29b-1/a expression in MCF-7 and LCC9 cells. 
Cells were grown in hormonally depleted medium and transfected with siControl or 
siERα. 48 h post transfection, cells were treated for 6 h with EtOH or 100 nM4-OHT. (A) 
ERα protein was examined in WCE and the blot was stripped and re-probed for β-actin 
for normalization.  Values are the ERα/β-actin with siControl set to one for each cell line. 
Q-PCR for ESR1 (B); pri-miR-29b-a and pri-miR-29a (C); and mR-29b-1 and miR-29a 
(D). Values are the average of 4-6 separate experiments ± SEM. *p < 0.05 versus control-
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miR-29b-1/a inhibit cell proliferation but do not sensitize cells to 4-OHT inhibition 
To examine the functional roles of miR-29b-1 and miR-29a in sensitivity to 
TAM, we evaluated how overexpression or inhibition of miR-29b-1 and miR-29a 
affected MCF-7, LCC9, and LY2 cell proliferation.  Successful repression or 
overexpression of miR-29b-1 and miR-29a was confirmed by qPCR up to 6 d post 
transfection (Supplementary Fig. 9).  Anti-miR-29b-1 or anti-miR-29a transfection had 
no effect on basal cell proliferation (Fig. 6A-C).  However, inhibition of miR-29a 
blocked 4-OHT inhibition of MCF-7 proliferation (Fig. 6A).  Further, the combined 
inhibition of miR-29b-1 and miR-29a resulted in 4-OHT stimulating MCF-7 cell 
proliferation, effectively reversing the normal antiestrogenic pharmacology of 4-OHT in 
MCF-7 cells (Fig. 6A).  These data are commensurate with the inhibition of miR-29b-1/a 
expression by 4-OHT in MCF-7 cells (Fig. 4), suggesting a possible role for miR-29b-1 
and miR-29a in 4-OHT’s antiproliferative activity in MCF-7 cells.   
Since 4-OHT stimulated miR-29b-1/a in TAM-resistant LCC9 and LY2, cells, we 
anticipated that inhibiting miR-29b-1 and/or miR-29a might sensitize these cells to 4-
OHT inhibition.  However, inhibition of miR-29b-1/a did not result in 4-OHT inhibiting 
cell proliferation (Fig. 6B, 6C).  In contrast, inhibiting miR-29b-1 and/or miR-29a 
resulted in a stimulation of LCC9 cell proliferation with 4-OHT treatment (Fig. 6B).  
There was no significant effect of anti- mR-29b-1 or miR-29a on 4-OHT-stimulated LY2 
cell proliferation (Fig. 6C).  
Transfection of pre-miR-29b-1 and/or pre-miR-29a inhibited basal MCF-7 and 
LCC9 cell proliferation (Fig. 6A, 6B).  In LCC9 cells, the inhibition by pre-miR-29b-1/a 
transfection was reduced by 4-OHT, although the effect was not statistically significant 
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for miR-29a (Fig. 6B).  Transfection of pre-miR-29a, alone or in combination with pre-
miR-29b-1, inhibited LY2 cell proliferation, but did not sensitize the cells to further 









Figure 6. Overexpression of miR-29b-1 /a decreases cell proliferation. 
Cells were grown in hormonally depleted medium and transfected with anti-miR-control, 
anti-miR-29b-1/a, pre-miR control, or pre-miR-29b-1/a for 48 h prior to treatment with 
DMSO (vehicle control) or 100 nM 4-OHT for 48 h prior to BrdU assay.  Values are the 
± SEM of 3 separate experiments *p < 0.05 versus vehicle control-transfected cells; #p < 
0.05 versus 4-OHT-treated control transfected cells, ^p < 0.05 versus DMSO-treated 





























































Transfected    - -
Pre-miRAnti-miR






























miR-29b-1/a inhibit LY2 cell migration and colony formation 
Transfection of MDA-MB-231 triple negative breast cancer (TNBC) cells with 
pre-miR-29b increased invasion, whereas anti-miR-29b inhibited invasion [214].  To 
further elucidate the possible functional role of miR-29b-1/a in ER-positive breast cancer 
cells, cell migration and colony formation experiments were performed with LY2 cells. 
We chose LY2 cells because they are invasive whereas MCF-7 and LCC9 cells are not 
[244, 245].  In accordance with our observation for an antiproliferative role for miR-29b-
1 and miR-29a in LY2 cells, transfection of LY2 cells with pre-miR-29b-1 and pre-miR-
29a inhibited cell migration (Fig. 7A, 7B).  4-OHT inhibited LY2 cell migration by ~ 5% 
after 8 h; however, this inhibition was not detected in cells transfected with pre-miR-29b-
1 or pre-miR-29a.   
4-OHT inhibited LY2 colony formation.  Transfection of LY2 cells with pre-miR-
29b-1 and pre-miR-29a inhibited colony formation and these transfections enhanced 4-
OHT inhibition of colony formation (Fig. 7C).  Together, these data suggest that miR-
29b-1 and miR-29a stimulate anti-migratory and anti-colony-forming activity in LY2 
cells.  It appears that overexpression of miR-29b-1 and miR-29a enhance LY2 cell 








Figure 7. Overexpression of miR-29b-1 /a decreases LY2 cell migration. 
LY2 cells were grown in hormonally depleted medium and transfected with pre-miR 
control or pre-miR-29b-1/a .(A-B) Twenty-four h post transfection cells were treated with 
DMSO (vehicle) or 4-OHT for up to 8 h and images taken at indicated time points.  (C) 
Two d post transfection, colony formation assay was performed for 14 d.  (B) Values are 
the ± SEM of 3 separate measurements within an experiment.  (C) Values are the ± SEM 
of 6 replicates. *p < 0.05 versus vehicle control-transfected cells; #p < 0.05 versus 
control transfected + 4-OHT-treated cells 
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miR-29b-1/a decrease DICER in LY2 cells. 
Next it was important to examine how 4-OHT’s regulation of miR-29b-1/a 
transcription affected a bona fide target of miR-29b-1/a in these cells.  To address the 
identity of such miR-29b-1/a targets, we searched online databases (mirdb.org[246]; 
microrna.org [247])) and identified DICER1 as one such candidate [209].  There are no 
previous reports of TAM-regulation of DICER1 transcription.  Although DICER1 
expression is upregulated in TAM-R MCF-7 cells [163], the mechanism was not 
examined.  Transfection of LY2 cells with pre-miR-29b-1 or pre-miR-29a, individually 
or together, reduced DICER1 protein (Fig. 8A).  Conversely, transfection with either anti-
miR-29b-1 or anti-miR-29a, alone or in combination, increased DICER1 protein 
expression (Fig. 8A), suggesting that DICER1 is a target of miR-29b-1/a in LY2 cells.  
Similar results were observed for another bona fide target of miR-29b-1/a: tumor 
suppressor PTEN [248] (Supplementary Fig. 5).  RNA-seq data (GSE81620) show lower 
transcript levels of PTEN in LCC9 versus MCF-7 cells (Supplementary Fig. 6A).  
However, qPCR for PTEN reveal no difference in basal PTEN transcript levels in MCF-7 
and LCC9 cells grown in hormonally depleted medium (5% DCC-FBS, phenol-red free 
IMEM) for 48 h and treated with DMSO (vehicle control) or 100 nM 4-OHT 
(Supplementary Fig. 6B).  Significantly higher PTEN transcript levels were found in LY2 
cells under these experimental conditions.  We note that while ‘serum starvation’ in 0.5% 
FBS had no effect on PTEN in MCF-7 cells, PTEN was increased in more aggressive 
adenocarcinoma cell lines including MDA-MB-468 TNBC cells [249]. Our data indicate 
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that 4-OHT increased PTEN in MCF-7 cells but not in LCC9 or LY2 cells, 
commensurate with the TAM-resistant phenotype of these cells.   
To determine whether 4-OHT would decrease DICER1 by increasing miR-29b-
1/a in LY2 cells, cells were treated with 100 nM 4-OHT for 24 h following 48 h growth 
in hormone-depleted medium.  Indeed, 4-OHT decreased DICER1 mRNA (Fig. 8B) and 
protein (Fig. 10C).  Next, we examined if anti-miR-29b-1 and anti-miR-29a would block 
4-OHT downregulation of DICER1 expression.  Anti-miR-29b-1/a transfection blocked 
4-OHT downregulation of DICER protein (Fig. 10C) and transcript (Supplementary Fig. 
7).  We also show that 4-OHT downregulation of DICER1 mRNA expression is mediated 
through ERα since knockdown of ERα blocked 4-OHT inhibition of DICER1 mRNA 
(Supplementary Fig. 8).  These results suggest that the 4-OHT-stimluated increase in 
miR-29b-1/a in LY2 cells results in decreased DICER1 expression.  
4-OHT-increased miR-29b-1/a in LY2 suppresses DICER1, we would anticipate 
lower overall miRNA expression in 4-OHT-treated LY2 cells relative to 4-OHT-treated 
MCF-7 cells in which miR-29b-1/a is repressed.  We examined data from the miRNA 
microarray study and note that indeed, we detected lower expression overall of miRNAs 







Figure 8. miR-29b-1/a downregulate DICER in LY2 cells and 4-OHT decreases DICER1 
mRNA and protein in LY2 cells. 
A) LY2 cells were transfected with Anti-miR-control, Anti-mIR-29b-1, AS-miR-29a, or 
the combination for 48 h.  B and C) LY2 cells were grown in hormonally depleted 
medium for 48 h and treated for 24 h with vehicle control (DMSO) or 100 nM 4-OHT. B) 
qPCR for DICER1 relative to 18S.  Values are the average of triplicate determinations ± 
SEM in one experiment.  For A and C, the blots were striped and reprobed for β-actin. 
Values are the ratio of DICER/β-actin from the experiment shown.  All experiments were 
repeated 3-4 times and representative data is shown.  D) Model of suggested pathway for 

























































































In this study, we demonstrated that ERα-mediates the 4-OHT-induced decrease in 
miR-29b-1 and miR-29a expression in endocrine-sensitive MCF-7 cells and the 4-OHT-
induced increase in the transcription of these microRNAs in LCC2, LCC9 and LY2 cells. 
This supports our findings in a microarray analysis of 4-OHT-regulated microRNAs in 
MCF-7 and LY2 cells [223].  These 4-OHT-induced changes in mature miR-29b-1/a 
expression were initiated at the level of ERα-regulated transcription of pri-miR-29b-1/a.  
However, knockdown of ERα had no effect on basal pri-miR-29b-1/a transcription, or 
mature miR-29b-1 or miR-29a levels, suggesting the importance of the ligand 4-OHT in 
the ERα transcriptional response.  A recent study identified a positive roles for Oct-4 
(POU5F1 gene) and the E3 ubiquitin ligase SKP2 and a negative role for NKX3-1 in 
TAM-ERα stimulated gene transcription in MCF-7 cells [250]. This study did not 
examine regulation of miRNAs.  The authors provided evidence for a 4-OHT-ERα/SKP2 
complex and postulate this complex collaborates with Oct-4 to increase transcription of 
TAM-stimulated genes.  To our knowledge, there are no reports of Oct-4 regulation of 
miR-29 family members.  Oct-4 was increased and NKX3-1 decreased in TAM-R MCF-
7 cells compared to parental MCF-7 cells [250].  We found no difference in Oct-4 
(POU5F1) transcript levels between MCF-7 and LCC9 cells whereas SKP2 was 
increased and NKX3-1 decreased in LCC9 compared to MCF-7 cells (Supplementary Fig. 
9).  Future studies will be required to elucidate the role of these factors in 4-OHT-ERα 
stimulated miR-29b-1/a transcription in LCC9 cells.   
We observed that transfection of both TAM-S MCF-7 and its TAM-R cell line 
derivatives with miR-29b-1 or miR-29a repressed cell proliferation.  Transient 
overexpression of miR-29a also inhibited the growth of MDA-MB-453 TNBC cells 
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[236], implying repression of cell growth by miR-29a is not dependent on ERα.  If the 4-
OHT-induced increase in miR-29b-1/a in TAM-R cells is involved in resistance, then we 
would expect that inhibiting miR-29-b-1/a should enhance 4-OHT inhibition of cell 
proliferation.  However, inhibition of miR-29b-1 or miR-29a did not enhance the 
sensitivity of the TAM-R cells to 4-OHT.   
Likewise, transient overexpression of either miR-29b-1 or miR-29a in TAM-R 
LY2 cells decreased cell migration and colony formation.  Interestingly, overexpression 
of miR-29a alone or in combination with miR-29b-1 enhanced 4-OHT inhibition of LY2 
colony formation.  These data suggest that the 4-OHT-induced increase in miR-29b-1/a 
in LY2 may be involved in TAM-sensitivity, not resistance.  Future studies will address if 
a combination of miR-29a and 4-OHT may lead to mesenchymal-to-epithelial transition 
(MET) in LY2 cells, although other gene expression changes are likely to contribute.  
The inhibitory effect of miR-29b-1 and miR-29a on LY2 cell migration and colony 
formation are the opposite of the effect of overexpression of these miRs in MDA-MB-
231 TNBC cells.  Overexpression of miR-29b enhanced the mesenchymal-like phenotype 
in MDA-MB-231 whereas transient transfection of antisense miR-29b decreased MDA-
MB-231 cell migration [214].  The expression of ERα and other genes in LY2 cells may 
mediate the observed phenotypic difference in cellular responses to manipulation of miR-
29b-1/a expression as TNBCs, by definition, lack ERα.   
miR-29 family members contribute to resistance of chemotherapeutic agents 
[251-254].  For example, miR-29a contributes to resistance to Adriamycin and Docetaxel 
in breast cancer by repressing the tumor suppressor PTEN [251], fostering cell 
proliferation and inhibiting apoptosis.  Transient overexpression of miR-29b increased 
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MCF-7 cell migration and invasion by repressing the PTEN [214].  Upregulation of miR-
29b was recently reported to enhance sensitivity of gastric cancer cells to cisplatin, while 
knockdown enhanced cisplatin resistance [252].  Likewise, loss of miR-29 inhibits 
cisplatin-induced cell death in ovarian cancer through upregulation of collagen type I 
alpha 1 (COL1A1) and inactivation of glycogen synthase kinase beta (GSKβ) [253].  In 
pancreatic cancer, miR-29a contributes to resistance of gemcitabine through upregulation 
of the Wnt/β-catenin signaling pathway [254].  These studies implicate the miR-29 
family as mediators of drug resistance and sensitivity in several cancers through 
mechanisms that may be drug and cancer-type-specific.  It is therefore essential to 
identify the deregulated pathways mediating responses to miR-29 in each disease type. 
Although miR-29b-1 and miR-29a originate from the same primary transcript, 
sharing the same promoter and seed sequence [226, 227], they had similar but not 
identical functional outcomes in our study.  This difference can be explained in part by 
nucleotide differences adjacent to the seed sequence which contribute to target specificity 
and posttranscriptional processing, including subcellular localization and stability [232, 
255].  Specifically, a hexanucleotide terminal localization motif present in miR-29b-1 
and not in miR-29a targets miR-29b-1 for nuclear enrichment, while miR-29a and other 
vertebrate microRNAs are predominantly cytoplasmic [255, 256].  The nuclear 
localization of miR-29b appears to depend on the cell type, suggesting cell-specific 
expression of the machinery involved in miR-29b nuclear import [257].  We speculate 
this difference in subcellular localization may cause differential gene regulation and 
hence, differences in the functional outcomes between miR-29b-1 and miR-29a.  Further 
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studies are needed to examine the subcellular distribution of miR-29a and miR-29b-1 in 
breast cancer cells.   
miR-29b-1 and miR-29a downregulate DICER1 protein levels in LY2 breast 
cancer cells.  Because of its role in microRNA processing from pre-miRs to mature 
microRNAs, DICER1 regulates cellular processes including cell differentiation, 
programmed cell death, senescence, DNA repair, and chromatin remodeling [258-262].  
DICER1 expression was reported to be downregulated in breast cancer cells exhibiting 
mesenchymal phenotypes and in primary breast tumors of patients with lower disease 
free survival [263].  However, a larger study of primary breast tumors reported that 
DICER1 staining was associated with ER negativity, HER2+, high Ki67, and expression 
of basal-like biomarkers [264].  Our observation that 4-OHT reduced DICER1 by 
increasing miR-29b-1/a and the reported increase in DICER1 in ERα-negative breast 
tumors suggest a possible role for ERα in DICER1 regulation, although further 
experiments are needed to validate this suggestion. Further DICER1 expression was 
associated with reduced overall survival, except in HER2+ patients where moderate or 
strong DICER1 expression was associated with improved disease free survival [264] .   
DICER1 mRNA expression was decreased in breast cancer tissues [265] and in 
invasive ductal breast carcinomas [258].  In ERα negative breast cancer cells, DICER1 is 
repressed by tumor promoting microRNAs including miR-103/107 [208], miR-222/221 
[209], and miR-18a [266].  The differing reports on the role of DICER1 deregulation 
underscore the limited current knowledge of its role in cellular processes and mechanism 
of action.  These discrepancies can, in part, be explained by heterogeneity and genetic 
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diversity of cancers and cell types [267], target expression status, the cell type and the 
microenvironment of each cell [234].  
We observed that TAM decreased DICER1 protein expression in the TAM-R 
breast cancer cells by upregulating miR-29b-1/a, suggesting a decrease in DICER1 may 
play a role in promoting TAM resistance.  This is contrary to a previous report that stable 
DICER1-overexpression in MCF-7 breast cancer cells conferred TAM resistance by 
increasing breast cancer resistance protein (BCRP) [163].  However, miR-29b-1/a 
regulation of DICER1 was not examined.  In prostate tumors, DICER1 mRNA levels 
were negatively correlated with miR-29b-1 [268].  Further studies are needed on the 
impact of DICER1 in TAM resistance.  Increased expression of miR-29b-1 and miR-29a 
in 4-OHT-treated TAM-R cells also suggest that this microRNA family could target 
transcripts of tumor suppressor proteins. Indeed, we observed downregulation of the 
tumor suppressor PTEN, another bona fide target of miR-29 regulation [248].  Certainly 
additional miR-29 targets may contribute to the response of TAM-R cells to TAM. 
 
CONCLUSIONS 
Mechanisms for endocrine resistance in breast cancer are multifactorial (reviewed in 
[269]).  Here we identified miR-29b-1/a as regulated in opposite direction by 4-OHT in 
TAM-S MCF-7 cells versus TAM-R LCC2, LCC9, and LY2 cells.  We show that the 
TAM regulation of miR-29b-1/a is mediated by ERα in opposite direction, i.e., 
stimulation in LCC9 and LY2 versus inhibition in MCF-7 cells.  We found that inhibiting 
miR-29b-1/a in TAM-R LCC9 and LY2 cells did not increases their sensitivity to 4-OHT 
inhibition.  Further studies to identify other targets of these microRNAs are needed.  It is 
perhaps not surprising that miR-29b1/a has a complicated set of effects, given that there 
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are 632 predicted gene targets for has-miR-29a-3p and has-miR-29b-3p in the microRNA 
data base (http://mirdb.org/miRDB/). Examining the role of microRNAs in mediating 
endocrine resistance will provide new insights in elucidating defective cellular pathways 






CHAPTER IV: THE MIR-29 TRANSCRIPTOME IN ENDOCRINE-SENSITIVE AND 
RESISTANT BREAST CANCER CELLS  
 
INTRODUCTION 
microRNAs (miRNA, miRs) are 22 nt non-coding RNAs that recognize and bind 
complementary seed sequences in the 3’-UTR region of a target messenger RNA 
(mRNA) [221, 222] . This results in translational repression and/or transcriptional 
degradation of the target gene. By targeting several mRNAs, miRNAs regulate several 
cellular and biological processes including cell cycle, cell proliferation and cell 
differentiation, apoptosis, cellular respiration and glycolysis (reviewed in [94-97]). 
Aberrant miRNA expression mediates disease initiation and progression in breast and 
other cancers [86]. 
Seventy percent of breast tumors express estrogen receptor alpha (ERα) implying 
eligibility for endocrine therapies including selective estrogen receptor modulators 
(SERMs), e.g., Tamoxifen (TAM), and aromatase inhibitors (AI), e.g., letrozole.  The 
efficacy of endocrine therapy is limited by relapse in ~40% of patients [56, 270].  
Endocrine resistance is mediated by multiple mechanisms depending on the type of 
therapy used (reviewed in [40, 156, 271-273]). Alterations in miRNA expression are also 
implicated in endocrine-resistance (reviewed in [220, 274]).   
Previously, we reported miR-29b-1 and miR-29a were downregulated by TAM in 
TAM- sensitive (TAM-S) MCF-7 BC cells and upregulated in TAM-resistant (TAM-R) 
 
 78 
LCC2, LCC9, and LY2 BC cells [275]. There are four miR-29 family members in the 
human genome: miR-29b-2 and miR-29c (chromosome 1q32.2) and miR-29b-1 and miR-
29a (chromosome 7q32.3). miR-29b-1 and miR-29a are separated by ~652 bp on the 
same pri-miRNA transcript [226-229].  Upon processing, mature miR-29b-1 
preferentially localizes to the nucleus, while mature miR-29a localizes to the cytoplasm 
[255].  miR-29 family members have been reported to exhibit both tumor suppressive and 
oncogenic roles in breast cancer [231-233, 275]. 
We recently reported that ERα mediates 4-hydroxyTAM (4-OHT) repression of 
miR-29b-1/a in MCF-7 and upregulation in TAM-R LCC9 and LY2 BC cells. However, 
inhibition of miR-29b-1 and miR-29a did not sensitize LCC9 or LY2 cells to TAM [275]. 
Ectopic expression of miR-29b-1/a did not drive TAM resistance in MCF-7 cells, but it 
did significantly repress proliferation of TAM-R LCC9 and LY2 cells as compared to 
TAM-S MCF-7 cells. This suggests that miR-29b-1/a may regulate different transcripts, 
and thus pathways, in TAM-R cells and TAM-S cells.  To identify and quantitate mRNA 
targets regulated by miR-29, we performed RNA-sequencing (RNA-seq) in MCF-7 and 
LCC9 BC cells transiently transfected with anti-miR-29a, pre-miR-29b-1 or pre-miR-
29a. MetaCore™ functional analysis of the RNA-seq data identified several metabolic 
processes including oxidative phosphorylation (OXPHOS) uniquely regulated by both 
miR-29b-1 and miR-29a in LCC9 cells.  We observed that miR-29a overexpression 
inhibited mitochondrial bioenergetic function in LCC9 cells, thus correlating function 
with identified Gene Ontology (GO) processes. We used qPCR and a luciferase reporter 
assay to validate that two subunits of ATP synthase (Complex V in the oxidative 
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phosphorylation respiratory chain), ATP5G1 and ATPIF1, are bona fide miR-29b-1/a 
targets. 
 
MATERIALS AND METHODS 
Cell lines and reagents 
The following cells and reagents were used: HEK-293 (ATCC® CRL-1573™) and MCF-7 
cells were purchased from ATCC. LCC9 cells are ERα+/progesterone receptor (PR)+ 
cells resistant to antiestrogens (tamoxifen and fulvestrant) and were kindly provided by 
Dr. Robert Clarke, Georgetown University [238]. Transfection reagents included anti-
miR-29a (Anti-miRTMs, Ambion), pre-miR-29b-1-3p or pre-miR-29a-3p precursor (Pre-
miRTMs, Ambion), miR-29a mimic or miR-29b-1 mimic (miR-Vana™, Ambion),  
Lipofectamine RNAiMAX (Invitrogen), FuGENE® HD (Promega), Pre-miR™ negative 
control #1 (Ambion), Anti-miR™ negative control #1(Ambion), miR-Vana™ negative 
control (Ambion), pEZX-MT06_ATP5G1 wild type (WT), pEZX-MT06_ATPIF1 (WT), 
pEZX-MT06_negative control (miTarget™ miRNA 3’ UTR, GeneCopoeia).  
 
Transient transfection of miRNAs and anti-miRNAs 
Cells were grown as previously described in [275]. Briefly, MCF-7  and LCC9 cells were 
grown in hormone-depleted medium: phenol-red free IMEM (Gibco, Thermo Fisher) 
supplemented with 5% dextran-coated charcoal-stripped fetal bovine serum (DCC-FBS, 
Atlanta Biologicals) [275] and concomitantly transfected with either anti-miR-29a, pre-
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miR-29b-1-3p, pre-miR-29a-3p, pre-miR™ negative control #1 or anti-miR ™ negative 
control #1 for a 48 h, as indicated. 
 
RNA-sequencing 
RNA-sequencing was previously described in [276]. In brief, MCF-7 and LCC9 breast 
cancer cells were plated in 100 mm plates, hormone-depleted and transfected in triplicate 
with either pre-miR-29b-1, pre-mir-29a and anti-miR-29a using Lipofectamine (Ambion) 
and OPTI-MEM® I (Gibco: Life technologies). Twenty-four h post transfection, RNA 
was isolated using miRCURY RNA isolation kit (Exiqon) according to manufacturer’s 
instructions and RNA concentration and quality assessed with a NanoDrop 
spectrophotometer. Using TruSeq Stranded mRNA kit (Illumina, San Diego, CA, USA), 
mRNA libraries were made using 2 μg of RNA and validated with an Agilent 2100 
Bioanalyzer (Santa Clara (CA). After further library quantification with the Illumina 
Library Quantification Kit, RT-PCR was performed using the ABI Prism qPCR Mix 
(Kapa Biosystems) on an ABI17900HT real-time PCR instrument. Single read 
sequencing (75-76 cycles) was then performed using the 500 High-output v2 (75cycle) 
sequencing kit on an Illumina NextSeq500 instrument. Obtained read sequences were 
mapped to the human reference genome version GRCh37.1 using the mapping algorithm 
tophat [277] version 2.0.2. Using cufflinks version 2.2.1 and annotations found at 
ENSEMBL, Homo_sapiens GRCh37.73.gtf expression levels at loci were quantified. 
Raw sequencing data files obtained from our analysis are available at Gene Expression 
Omnibus (GEO) database: accession number GSE81620. Entrez gene identifiers for 
significantly expressed genes had a q-value cutoff of 0.05. Samples were then divided 
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into fastq single end sequencing files representing comparisons of pre-miR-29b-1 vs anti-
miR-29a and anti-miR-29a vs pre-miR-29a in MCF-7 and LCC9 cells. 
 
In silico network analysis 
Data from RNA-seq was analyzed such that transcripts selected had a log2 fold-change 
greater than 0.34 (or -0.34 for repressed transcripts) and a statistical significant threshold 
q value less than 0.05. Pathway and network analysis of differentially expressed genes 
was determined using the web-based software MetaCore™ version 6.27 (GeneGO, 
Thomson Reuters, New York, N.Y).  MetaCore™ is a manually curated data base of over 
6 million experimental findings interactions including protein-protein, protein-DNA, 
protein-RNA, and protein-compounds; metabolic and signaling pathways; and other 
additional information [278]. 
 
Metabolic analysis with the Seahorse XF24 extracellular flux analyzer 
Metabolic profiles were performed as previously described in [276, 279]. Briefly, LCC9 
cells were plated at 25,000 cells/well in XF24 plates. Twenty-four h post plating, cells 
were transfected with either anti-miR-29a or pre-miR-29a for 48 h. One hour prior to 
running the Seahorse Mito Stress Test assay, the media was replaced with DMEM assay 
media containing 1 mM sodium pyruvate, 25 mM glucose, and 1.85 g/L NaCl (all from 
Sigma), 2 mM Glutamax (Thermo Fisher), pH 7.4, and maintained at 37oC in an non-CO2 
incubator. Sensor cartridges were incubated in XF24 calibrant solution (Agilent 
Technologies) at least 6 h prior to running assay. Initial measurement of basal ECAR 
 
 82 
(mpH/min) and OCR (pmol O2/min) were taken prior to determining mitochondrial 
function using sequential injections of oligomycin A (1.5 μM), FCCP (0.5 μM) and 
combination of antimycin A (10 μM) and rotenone (2 μM) [276]. The protein 
concentration in each well was determined using the BioRad DC™ Protein Assay 
(BioRad, Hercules, CA, USA). OCR and ECAR values were normalized to protein 
concentration/well.  Each experimental condition was run in quadruplicate within one 
experiment and separate experiments were run 3-4 times for statistical evaluation.   
 
quantitative real-time PCR (qRT-PCR) 
RNA isolation, RT-PCR and qPCR were performed as previously described in [275]. 
TaqMan (Thermo Fisher Scientific) master mix was used for miR-29b-1/a primers 
(Thermo Fisher Scientific) and SYBR green (QIAGEN) master mix was used for LDHA 
[280], ENO1 [281], CYCS [282], ATP5G1 [283], ATP5C1 [284], ATPIF1 [285], ATP5G3 
[283], NDUFS6 [286], NDUFC2 [287].  Normalizers included RNU6B or U48 (Thermo 
Fisher Scientific) for miRNA and GAPDH (SYBR green) [288] and 18S (TaqMan; 
Thermo Fisher) for mRNA. 
 
Site-directed mutagenesis, transient transfection of HEK-293 cells, and Dual luciferase 
assay 
Mutation of the predicted 3’UTR binding site of miR-29b-1/a on pEZX-MT06 miRNA 3' 
UTR target dual luciferase expression vectors was performed using the GeneArt® Site-
Directed Mutagenesis PLUS Kit (Thermo Fisher Scientific) according to manufacturer’s 
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instructions. Where indicated, HEK-293 cells were plated in 24 well plates and co-
transfected with 200 ng of wild type (wt) or mutant (mut) vectors plus a 20 nM final 
concentration of miR-29b-1/a mimic, anti-miR-29a or negative control mimic using 
FuGENE HD (Promega) according to manufacturer’s protocol. Twenty-four h post 
transfection, a dual luciferase assay (Promega) was performed. Luciferase expression was 
determined relative to negative control mimic and statistical evaluation performed using 
GraphPad Prism Software (Graph Pad Software, San Diego, CA). 
 
Statistics 
Data are represented as mean ± standard error of the mean (SEM) of at least three 
independent experiments. Statistical analyses were performed using GraphPad Prism 5 
(Graph Pad Software, Inc.).  One-way analysis of variance (ANOVA) was followed by 
Tukey’s or Newman-Keuls multiple comparison post hoc tests where indicated [275].   
 
RESULTS 
Identification and characterization of the miR-29b-1 and miR-29a transcriptome in 
MCF-7 and LCC9 cells 
To identify potential miR-29b-1 and miR-29a targets in breast cancer cells and 
their possible role in tumor suppression, TAM-S MCF-7 and TAM-R LCC9 cells were 
grown in hormonally depleted medium and transfected with anti-miR-29a (that inhibits 
both miR-29b-1 and miR-29a expression) and pre-miR-29b-1 or pre-miR-29a 
(Supplementary Fig. 10). The strategy of comparing the transcriptome of cells transfected 
with anti-miR-29a versus pre-miR-29b-1 and anti-miR-29a versus pre-miR-29a was 
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selected to enrich for direct miR-29b-1 and miR-29a targets. As miRNAs historically 
repress target transcript translation and/or mRNA expression, we focused on genes 
downregulated with pre-miRNA treatment and upregulated with anti-miR treatment for 
transcriptome analysis.  
miR-29b-1 and miR-29a downregulated 447 and 139 genes in MCF-7 cells 
respectively (Fig. 9A) and 1,751 and 1959 genes in LCC9 cells (Fig. 9B; p < 0.05), 
respectively.  The identity of these genes with MetaCore pathway analysis is provided in 
Supplementary Tables 2 and 3.  These data suggest that miR-29b-1 and miR-29a regulate 




























Common miR-29b-1 and miR-29a targets
Uniquely downregulated genes 
in MCF-7 cells
Uniquely downregulated genes in 
LCC9 cells
Commonly DOWNREGULATED  top 10 pathways
1. Neurophysiological Process
2. Immune response:IL-6 signaling
3. Development: Role if CNTF and LIF in regulation of oligodendrocyte
4. Development: EGFR signaling via small GTPases
5. Cell adhesion: Plasmin signaling
6. Cell adhesion: Tight junctions
7. Glycine, serine, cysteine and threonine metabolism
8. Main growth factor signaling cascades in multiple myeloma cells
9. Development: Neurotrophin family signaling
10. Development: EPO-induced MAPK pathway
1. Cell cycle: Chromosome condensation in 
prometaphase
2. Translation: Non-genomic (rapid) action 
of Androgen Receptor
3. Regulation of metabolism: Triidothronine
and Thyroxine signaling
4. Aberrant lipid trafficking and metabolism 






4. Apoptosis and survival role: 
Role of IAP-proteins in 
apoptosis








Figure 9. Enrichment analysis of RNA-seq data.  
Differentially expressed genes were identified in pairwise comparisons: Pre-miR-29b-1 
vs. Anti-miR-29a and Anti-miR-29a vs. Pre-miR-29a using tophat and cufflink-cuff 
diff2. The Venn diagrams show the number of differentially and commonly regulated 
genes identified.  GeneGo Pathways Software (MetaCore™) was then used to identify 
genes significantly downregulated by miR-29b-1 and miR-29a in A) MCF-7 and B) 
LCC9 cells. C) Pathway analysis of the downregulated genes was performed using 
MetaCore™.  The order of the pathways identified for each comparison are listed in the 





In MCF-7 cells, 132 genes were identified as common targets of both miR-29b-1 
and miR-29a (Fig. 9A). In LCC9 cells, 1,508 genes were common targets to both miR-
29b-1 and miR-29a (Fig.  9B). MetaCore™ pathway analysis of the common and 
uniquely regulated genes is provided in Supplementary Fig. 11 and Supplementary Fig. 
12. Of the common targets, 60 were unique to MCF-7 and 1,436 were unique to LCC9 
(Fig. 9A, Supplementary Tables 4). Seventy-two targets were common to both MCF-7 
and LCC9 cells (Fig. 9C). Together, these data confirm that miR-29b-1 and miR-29a 
regulate common and unique targets in MCF-7 and LCC9 cells.  MetaCore™ pathway 
enrichment analysis was performed for each dataset and the top pathways identified are 
listed in Fig. 9C.  
Gene ontology (GO) analysis of the uniquely downregulated transcripts by both 
miR-29b-1 and miR-29a in LCC9 cells (Fig. 9C) identified organonitrogen compound 
metabolic and biosynthetic processes and cotranslational protein targeting to the 
membrane as the top three regulated processes (Supplementary Fig. 13A). The top five 
regulated process networks included translation initiation, elongation, termination, and 
cell cycle S phase (Supplementary Fig. 13B).  
Pathway enrichment analysis of the uniquely downregulated miR-29b-1/a target 
genes in LCC9 cells identified pathways including oxidative phosphorylation, ATP 
metabolism, apoptosis, and cell survival.  MetaCore™ network analysis on mitochondrial 
respiratory complex genes downregulated by miR-29b-1/a is shown in Supplementary 
Fig. 13C. Several genes including components of respiratory Complex II and III, 
Cytochrome c oxidase, and ATP synthase (Complex IV) were uniquely downregulated by 
miR-29b-1/a in LCC9 cells (Supplementary Fig. 13C).  We previously reported that six 
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genes encoding subunits of ATP synthase that are not regulated by miR-29 were more 
highly expressed in LCC9 than MCF-7 cells [276].  The role of these genes in endocrine 
resistance will require further evaluation.  
 
miR-29a regulates mitochondrial bioenergetics in tamoxifen-resistant LCC9 cells 
Because OXPHOS was identified as the top enrichment pathway modulated by 
miR-29b-1/a in LCC9 cells, and not in MCF-7 cells (Fig. 9C), we postulated that miR-
29a regulates mitochondrial bioenergetics activity in LCC9 cells. We focused on miR-
29a because its basal expression is higher in LCC9 and other breast cancer cells 
compared to miR-29b-1 [275]. To examine the impact of miR-29a on mitochondrial 
respiration, MCF-7 and LCC9 cells were transfected with either anti-miR-29a or pre-
miR-29a, versus control, and grown in hormonally depleted phenol red-free medium for 
48 h prior to determining oxygen consumption rate (OCR) and extracellular acidification 
rate (ECAR; reflects glycolytic rate) [279] using the Seahorse extracellular flux assay 
[276, 279] (Supplementary Fig. 14).  
In agreement with our previous work [276], TAM-R LCC9 cells grown in 
hormonally depleted medium have increased basal OCR versus MCF-7 cells (Fig. 10A). 
Transfection of LCC9 cells with anti-miR-29b-1 increased while pre-miR-29a repressed 
basal OCR, ATP-linked OCR (which measures the rate of mitochondrial ATP synthesis) 
and mitochondrial reserve (also known as reserve respiratory capacity) [289] (Fig. 10A).  
Similar results were seen in pre-miR-29a-transfected MCF-7 cells except that growth in 
hormonally depleted medium ablates reserve capacity, and thus, no effect of miR-29a on 
reserve capacity was detected (Fig. 10A). The changes in basal OCR suggest that miR-
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29a modulates metabolic rate in part through electron flow. The regulation of reserve 
capacity, which is a measurement of the ability to respond to increased energy demand 
after injection of the uncoupler FCCP, suggests that miR-29-regulated genes adversely 
impact LCC9’s mitochondrial ability to mitigate cellular stress. Inverse changes, albeit of 
lesser magnitude, were seen in LCC9 cells transfected with anti-miR-29a.   
Compared to MCF-7 cells, LCC9 cells have higher basal proton leak. Proton leak 
is required for protecting against cellular oxidative damage through lowering ROS 
produced by the electron transport chain (ETC) [290]. Pre-miR-29a transfection 
repressed proton leak in LCC9 cells (Fig. 10A). Non-mitochondrial activity, which is 
attributed to cytoplasmic oxidases, was lower in LCC9 cells transfected with pre-miR-
29a (Fig. 10A).  Transfection of LCC9 cells with anti-miR-29a increased while pre-miR-
29a transfection decreased maximal mitochondrial (mt) capacity (Fig. 10B). The maximal 
mitochondrial capacity is the OCR measured after injection of the uncoupler FCCP and is 








Figure 10. Upregulation of miR-29a represses mitochondrial function in MCF-7 and 
LCC9 cells.  
MCF7 and LCC9 cells were plated in XF-24 plates in hormonally-depleted medium and 
transfected with control, anti-miR-29a, or pre-miR-29a for 28 h prior to running the 
Seahorse extracellular flux assay to determine mitochondrial activity. A and B) OCR 
parameters; C and D) ECAR parameters. Each bar is an average of 4 separate wells 
±SEM in one experiment. *p <0.05 versus LCC9 or MCF-7 control for the indicated 
parameter. For LCC9, data were analyzed by one-way ANOVA followed by Tukey’s 






















































































































































































































































We previously reported that ECAR measurements agree with conversion of radio-
labelled glucose to H2O in MCF-7 and T47D breast cancer cells, demonstrating that 
ECAR is a reliable measure of glycolysis [279]. LCC9 cells alone or upon transfection 
with anti-miR-29a had increased basal ECAR than MCF-7 cells (Fig. 10C).  The 
glycolytic response to oligomycin, considered as the glycolytic reserve [292], was 
increased by miR-29a repression and reduced by miR-29a overexpression in LCC9 cells 
(Fig. 10D).  These data suggest that miR-29a regulates genes with roles in glycolysis in 
LCC9 cells.  Examination of the RNA-seq data identified TPI1, PGAM1, ENO1, and 
LDHA as possible targets of miR-29b-1/a (Supplementary Fig. 15A).  qPCR analysis 
confirmed that overexpression of miR-29b-1/a inhibited ENO1 and LDHA transcript 
expression in MCF-7 and LCC9 cells (Supplementary Fig. 15B).  Future studies will 
further evaluate these observations.   
 
Validation of ATP5G1 and ATPIF1 as bona fide targets of miR-29b-1 and miR-29a.  
miR-29a regulation of mitochondrial activity is suggestive of direct regulation of 
mitochondrial complex genes. Analysis of our RNA-seq data revealed miR-29 regulation 
of mitochondrial genes including ATP5G1, ATP5C1, ATPIF1, ATP5G3, NDUFS6 and 
NDUFC2 (Supplementary Fig. 16). To confirm miR-29 regulation of the putative target 
transcripts, qPCR was performed for these genes in MCF-7 and LCC9 cells transfected 
with either anti-miR-29a, pre-miR-29b-1, pre-miR-29a or their negative controls (Fig. 11, 
Supplementary Fig. 17). Anti-miR-29a transfection increased ATP5G1 and ATPIF1 
mRNA expression in MCF-7 and LCC9 cells (Fig. 11A & 11B). Conversely, pre-miR-
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29b-1 and pre-miR-29a transfection repressed ATP5G1 in LCC9 cells alone and ATPIF1 
mRNA expression in both MCF-7 and LCC9 cells (Fig. 11A & 11B).  
In LCC9 cells, anti-miR-29a transfection increased ATP5C1 and NDUFC2 while 
pre-miR-29b-1 and pre-miR-29a transfection repressed ATP5C1, ATP5G3, NDUFS6 and 
NDUFC2 transcript expression (Fig. 11C-11F). In MCF-7 cells anti-miR-29a transfection 
increased NDUFC2 mRNA expressions while pre-miR-29b-1 and pre-miR-29a 
transfection repressed expression of ATP5G3 and NDUFC2 transcripts (Fig 11D & 11F). 
Taken together, these data suggest cell line specific differential regulation of miR-29 
targets between MCF-7 and LCC9 cells. Notably, ATP5G1 and ATP1F1 were 
downregulated by miR-29b-1/a in both LCC9 and MCF-7 cells (Fig. 11A & 11B). 
Further, basal mRNA expression of ATP5G1, ATP5IF1 and ATP5G3 were higher (lower 
CT) relative to ATP5IC1, NDUFS6, and NDUFC2 in both MCF-7 and LCC9 BC cells, 











































































































































































































































































































































































Figure 11. miR-29b-1/a regulates mRNA expression of putative targets in MCF-7 
and LCC9 cells. 
MCF-7 and LCC9 cells were grown in hormone-depleted media and transfected with 
anti-miR-control, anti-miR-29a (3p), pre-miR control or pre-miR-29b-1/a (3p), as 
indicated. Twenty-four h post transfection, RNA was isolated and qPCR performed. 
Values were normalized to 18S. Values are the mean ± SEM of 3 independent 
experiments. Within each experiment, each sample was run in triplicates. Statistical 
evaluation was performed using one-way ANOVA followed by Tukey’s test. *p<0.05 





To determine whether ATP5G1 and ATPIF1 are bona fide miR-29 targets, we 
tested the ability of miR-29 to repress the luciferase activity from reporter vectors 
containing wild type (WT) or mutant (mut) 3’ UTRs of these genes. The miR-29 binding 
region at the 3’UTR region of ATP5G1 and ATPIF1 are conserved across species (Fig. 
12A). We created mutations in the miR-29 recognition sequence in ATP5G1 (Fig. 12A). 
Cotransfection of miR-29b or miR-29a mimics with the luciferase reporter containing 
ATP5G1 3’ UTR WT sequence repressed luciferase activity (Fig. 12B). Mutation of the 
ATP5G1 3’ UTR (Mut) abrogated repression by the miR-29b and miR-29a mimics (Fig. 
12B).  These data demonstrate that ATP5G1 is a bona fide direct target of miR-29b and 
miR-29a.  Additionally, miR-29b and miR-29a mimics repressed luciferase activity from 
the ATPIF1 3’ UTR WT luciferase vector and repression was abrogated when cells were 
cotransfected with anti-miR-29a (Fig. 12C). These data suggest that ATPIF1 is also a 







Figure 12. miR-29b-1/a regulate ATP5G1 and ATPIF1 3’-UTRs luciferase reporter 
activity. 
A) Alignment of miR-29b-1 and miR-29a, their seed elements (in bold) and the 3’-UTRs 
of ATP5G1 and ATPIF1. The mutated seed element in ATP5G1 used in luciferase assay 
is indicated in red. miR-29 family members have the same seed sequence and their 
binding sites in the 3’UTRs of ATP5G1 and ATPIF1 are conserved across several 
species. B and C) HEK-293 cells grown in hormonally depleted medium were transiently 
transfected with pEZ-MT10 dual luciferase reporter containing the 3’UTR of ATP5G1 
wildtype (WT), ATPIF1 WT, miR-29 seed element mutated (Mut) constructs and an 
RNA mimic negative control or miR-29b or miR-29a mimics +/- Anti-miR-29a for 24 h 
prior to dual luciferase assay.  Data are the avg. of three replicate wells ± SEM. *p <0.05 
versus negative control. Statistical analysis used one-way ANOVA followed by 
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Dysregulation of the miR-29 family members plays a role in breast cancer 
progression, metastasis, and endocrine resistance [160, 275]. However, the precise 
mechanism(s) and targets of miR-29 in breast cancer are not fully elucidated. Here we 
identified the miR-29b-1 and miR-29a transcriptomes in MCF-7 TAM-S and LCC9 
TAM-R breast cancer cells.  Although miR-29b-1 and miR-29a have commonly 
regulated transcripts, they also have uniquely regulated transcripts. We observed that 
miR-29 regulates more transcripts in LCC9 than MCF-7 cells, and MetaCore™ 
enrichment analysis of unique miR-29 target transcripts in LCC9 cells identified GO 
pathways involved in oxidative phosphorylation, ATP metabolism, apoptosis and 
survival. In agreement with this literature-based association, ectopic miR-29a expression 
resulted in an inhibition of mitochondrial bioenergetics in LCC9 cells.  Further, we 
demonstrate for the first time that ATP5G1 and ATPIF1 are bona fide miR-29b-1/a 
targets. 
Dysregulation of mitochondrial bioenergetics is common in cancer cells [290]. 
Thus, identifying impaired mitochondrial pathways is of pathological and therapeutic 
relevance [293]. Mitochondria dysregulation results from alterations in mitochondrial 
function and ultrastructure [294], overproduction of reactive oxygen species (ROS) [295], 
and mitochondrial DNA (mtDNA) mutations and deletions [295, 296]. miRNA regulation 
of mitochondria has previously been reported (reviewed in [297, 298]). However, this is 
the first report that miR-29b-1/a regulate genes in ATP synthase (Complex V). 
In agreement with the MetaCore pathway enrichment identification of OXPHOS 
as the top enriched pathway among miR-29b-1/a regulated genes in LCC9 cells, we 
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observed that pre-miR-29a decreased basal OCR, ATP-linked OCR, and mt reserve.  
Concordantly, anti-miR-29a increased OCR and mt reserve, suggesting that repression of 
miR-29a may serve as an adaptive response to meet the increased energy demand of 
cancer cells and promote survival. Basal-like human breast tumors have lower levels of 
miR-29a, miR-29b, and miR-29c compared with Luminal A and B tumors [230].  
Repression of miR-29a increased basal ECAR (glycolysis) in LCC9 cells (Fig. 10C), a 
finding in agreement with the Warburg effect of increased glycolysis seen in basal-like 
tumors [299, 300].  Overall changes in OCR and ECAR suggest overexpression of miR-
29a has a greater impact on OXPHOS while repression of miR-29a increases both 
glycolytic activity and mitochondrial activity (OXPHOS) in LCC9 cells. Pre-miR-29a 
transfection repressed proton leak in LCC9 cells to levels below those seen in MCF-7 
cells with hormone deprivation, suggesting miR-29a overexpression depletes 
mitochondrial OXPHOS, which could lead to activation of apoptosis or other cell death 
pathways.  
LCC9 cells alone or when transfected with anti-miR-29a had a higher maximum 
mitochondrial capacity than the hormonally depleted MCF-7 cells, suggesting increased 
bioenergetics reserve. Indeed repression of miR-29a in LCC9 cells increased the 
glycolytic reserve. This may be attributable in part to the higher non-mitochondrial 
activity in LCC9 cells. Further metabolomics studies will be required to further assess 
changes in cellular metabolism with changes in miR-29b/a expression.   
We identify several ETC proteins including ATP synthase genes ATP5G1 and 
ATPIF1 as targets of miR-29b-1/a.  We experimentally validated that ATP5G1 and 
ATPIF1 are bona fide targets of miR-29b and miR-29a. Inhibition of ATP synthase in 
 
 99 
MCF7, T47D and MDA-MB-231 BC cells induced cell cycle arrest, decreased colony 
formation, and inhibited cell proliferation [301]. The targeting of ATP synthase complex 
subunits may account for miR-29’s repression of OCR and of BC cell proliferation [275]. 
Additional studies are warranted to confirm this suggestion.  
 
CONCLUSIONS 
Our RNA-seq transcriptome analysis revealed that miR-29b-1 and miR-29a 
regulate common and unique gene targets in TAM-S MCF-7 and TAM-R LCC9 BC 
cells.  We focused on common miR-29b-1 and miR-29a targets downregulated uniquely 
or in common in MCF-7 and LCC9 cells.  We report that miR-29b-1 and miR-29a 
regulate more transcripts in LCC9 than MCF-7 cells.  MetaCore™ pathway enrichment 
analysis identified OXPHOS as the top GO pathway regulated by miR-29b-1/a target 
transcripts in LCC9 cells and cell cycle: chromosome condensation in prometaphase as 
the top GO pathway in MCF-7 cells. Seahorse extracellular flux analyses of LCC9 and 
MCF-7 cells confirmed regulation of cellular bioenergetics by miR-29a including 
repression of OXPHOS by ectopic miR-29a expression. We experimentally validated 
ATP5G1 and ATPIF1 as new miR-29 bona fide targets suggesting that these targets play 







CHAPTER V: FUTURE PERSPECTIVE-MICRORNAS AS POTENTIAL 
BIOMARKERS FOR ACQUIRED ENDOCRINE RESISTANCE IN BREAST 
CANCER3 
 
miRNAs from metastases and in the serum of BC patients resistant to endocrine 
therapies has the potential to serve as selective biomarkers. These miRNA biomarkers 
can help identify patients with endocrine-resistant disease who could benefit from early 
intervention using an alternative therapeutic modality.  Here, we will summarize what is 
known about miRNAs with predictive and prognostic potential in endocrine-resistant BC. 
 
DYSREGULATED MICRORNAs THAT REGULATE ERα SIGNALING 
ERα signaling is critical for response to endocrine therapy.  miRNAs serve as 
predictive signatures for ER status [302] and regulate ERα protein expression to mediate 
endocrine resistance [91, 218, 220].  For example, miR-221/222 [100], miR-342-3 p 
[101], miR-873 [114] and Let7b/Let-7i [103] downregulate ERα protein expression (Fig. 
13; Table 3).  Lower ERα provides less target for endocrine therapies and thus, in 
combination with other deregulated miRNAs, serves as a mechanism for resistance.   
  
                                                 







Figure 13. miRNAs that regulate ERα signaling that have been identified in human 
breast tumors and serum as potential biomarkers. 
As described in the text, breast tumors have higher let-7a, 7b, and 7i [303], higher miR-
221 [100, 304] and miR-222 [100, 304] compared to normal breast tissue.  Each targets 
ERα. E2-ERα represses miR-222 [100] and miR-222 [100].  As summarized in Table 3, 
elevated miR-10a was reported in breast tumors but its predictive role remains unclear.  
The corepressor SMRT (NCOR2) is a bona fide target of miR-10 [305].  As indicated in 










Table 3. miRNA associated with endocrine-resistance in human breast tumors or patient samples 
Experimentally proven bona fide targets and the method used to confirm the target are indicated.  Methods of identification of the 
miRNA gene targets: 3’-UTR luciferase reporter assay (L), downregulation of protein shown by western blot (W), and downregulation 
of target in quantitative real-time PCR assay (Q) or Northern blot (N).  Proposed pathways associated with endocrine-resistance are 
included.  LET-R: letrozole-resistant; ANA-R: anastrozole-resistant. TAM-R: tamoxifen-resistant 




miRNAs with increased expression (Putative oncomiRs) and their suggested targets in endocrine-resistance.   
miR125b-5p Human breast tumors [119] Upregulated in LET-R MCF-7 
cells, ANA-R MCF-7 compared to 
MCF-7aro (aromatase-
overexpressing MCF-7 cells). 
High miR-125b-5p correlated with 
earlier relapse in ER+/PR+ patients 
[119].  




prognostic for  
lower relapse-free 
survival 
miR-205-5p Human breast tumors [119] Upregulated in LET-R MCF-7 and 
ANA-R MCF-7 cells. [119]. 
ERBB2 (L,W, Q) [307]  Increased 
expression is a 
biomarker of poor 
prognosis and 








miR-210 Human breast tumors [102] Increased miR-210 with breast 
tumor histological grade [102] 
ISCU (iron-sulfur 
cluster scaffold 
homolog) and COX10 
(cytochrome c oxidase 








Human breast tumors [104] TAM increased miR-221/222 in 
TAM-R cells and HER2+ breast 
tumors compared to TAM-S MCF-
7 and HER2-tumors, respectively 
[104]. 











Human breast tumors [100] Higher in ERα negative MDA-MB-
468 BC cells and primary breast 
tumors vs ERα positive MCF-7 and 
T47D cells [100]. 
ESR1/ERα (L, W) 
[100] 
 
miR-301 Human breast tumors  [126] Higher expression in lymph node 
negative (LNN) invasive ductal BC 
[126]. 
FOXF2, BBC3, PTEN, 






relapse to TAM 
miR-375 Patient whole blood [309] Increased circulating levels are 
associated with disease recurrence 
[309]. 










miR-519a BC patient datasets [127] High expression correlated with 
decreased disease-free survival in 
ERα-positive BCs. Upregulated in 
TAM-resistant MCF-7 cells and in 
ERα-negative breast tumors 
compared to TAM-sensitive MCF-
7 cells and ERα-positive tumors, 
respectively [127]. 
CDKNIA, RB1 and 
PTEN (L, W, Q) [127] 
Increased 
expression is 
prognostic for  
lower disease-free 
survival 
miR-1266 Human breast tumors  Upregulation was indicative of 
lower disease-free survival and 
prognostic for recurrence. 
IL17BR (Q)[311]  Increased 
expression is 
indicative of poor 
prognosis 
miR-1280 BC patient blood samples [128] Higher in blood from patients with 
metastatic BC after cytotoxic 
chemotherapy or undefined 
endocrine therapy [128]. 





miRNAs with decreased expression (putative tumor suppressor) and their suggested targets in endocrine-resistance. 
Let-7b/Let-7i Human breast tumors [103] Overexpression of Let-7b/Let-7i 
enhanced sensitivity of TAM-R 
MCF-7 cells to TAM only in 
ERα36 (L, W, Q) [103] 
ERα (L, W, Q) [303] 









hormone-depleted medium and not 
in normal growth medium [103].  
oncomiRs in targeting  
ERα) 
indicative of poor 
prognosis 
miR-10a Human breast tumors [130] Higher expression in tumors was 
associated with longer relapse-free 
survival. Increased expression 
predicted tumor relapse in TAM-
treated ER-positive 
postmenopausal BC patients [130] 








Human breast tumors [132] Increased expression in ER-
positive primary breast tumors of 
patients who received TAM and 
showed longer progression-free 
survival; Inverse correlation with 
HER2 and RAC1 cell motility 
signaling pathways [132].  







miR-126 Human breast tumors [130] Higher tumor expression was 
associated with longer relapse-free 
time.  Increased expression 
predicted tumor relapse in TAM-
treated ER+ postmenopausal BC 
patients [130] 





miR-342-3p Human breast tumor samples 
[134] 
Downregulated in TAM-R MCF-
7/HER2Δ16 cell, TAMR1, LCC2 
cells and TAM refractory 
BMP7, GEMIN4 









human breast tumors vs MCF-7 
cells and TAM-responsive tumors. 









Human breast tumors [101] Decreased in ERα (-) SKBR-3 and 
MDA-MB-231 cells vs MCF-7 
cells. 
Direct correlation between 
miRNA-342 expression and ERα 
expression [101] 
 
miR-574-3p Human breast tumors [137] Downregulation in TAM-resistant 
MCF-7 cells and clinical breast 
tumors compared to TAM- 
sensitive MCF-7cells and adjacent 
normal control respectively [137] 
Clathrin heavy chain 
(CLTC) ( L, W, Q) 
[137] 
Lower expression 







Low let-7a, b, and c family members were associated with high recurrence scores 
(RS) score in human breast tumors [315].  One validated target of let-7b-5p and let-7i-5p 
is ERa36 [103]ERα36 is an ERα splice variant that is associated with poor prognosis and 
contributes to endocrine resistance [107, 108].  Let-7 family members are downregulated 
in breast tumors and TAM-resistant MCF-7 cells [103, 111].  However, meta-analysis 
identified let-7b-5p as upregulated in ductal carcinoma in situ (DCIS) [316], indicating 
the need for further study on let-7’s function in BC.   
miR-221 and miR-222 are overexpressed in TAM-resistant and ERα- BC cell 
lines and tumors [100, 104, 105].  Inhibition of miR-221/222 restored TAM inhibition 
only to ERα positive MCF-7 cells and not ERα-negative MDA-MB-231 TNBC cells 
[123].  Higher miR-222 was associated with ERα+, high Ki67 proliferation index, and 
tumor grade but was not associated with EMT expression markers (increased vimentin, 
smooth muscle actin (SMA), osteonectin and N-cadherin; loss of E-cadherin) in breast 
tumors suggesting increased miR-222 as a marker related to aggressiveness and 
endocrine resistance in ERα+ primary tumors [317].  Identification of increased 
expression of ERα targeting miRNAs, e.g., miR-222, may predict unfavorable outcomes 
to endocrine and other therapies [318]. Interestingly E2-ERα inhibits miR-221 [319] and 
miR-222 [125, 319] expression in ERα positive MCF-7 cells (Fig 13). 
miRNAs may also affect ERα-regulated gene transcription in breast tumors by 
targeting coregulators, i.e., coactivators and corpressors (reviewed in [91]).  For this 
review, we will summarize only those miRNAs that regulate ERα and have been reported 
to be associated with endocrine-resistance in breast tumors or blood samples (Table 3). 
For example, miR-10a and miR-10b repress SMRT/NCOR2 [305].  As summarized in 
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Table 3, the precise role of miR-10a in breast tumors remains to be defined since it has 
been reported to correlate with both longer relapse-free survival and tumor relapse in 
TAM-treated patients [130].  Serum levels of miR-10a-5p were reported to be associated 
with poorer overall survival in acute myeloid leukemia (AML) [320].  miR-10b is 
considered a metastasis-regulating miRNA in breast and other cancers [321]. Of course 
since each miRNA regulates hundreds of targets, these miRNAs regulate targets in 
addition to ERα that are involved in breast tumorigenesis and metastasis.   
 
MICRORNA REGULATION OF ERα COACTIVATOR SRC-3 IN BREAST 
CANCER 
ERα interacts with coactivators and corepressors in a ligand-dependent manner.  
These coregulators regulate ERα’s transcriptional activity by promoting changes in 
chromatin.  ERα coactivator nuclear receptor co-activator 3 (NCOA3), also referred to as 
SRC-3 [154] and AIB1 [155], is overexpressed in ~ 50% breast tumors [156].  SRC-3 
overexpression activates ligand-independent ERα transcription, breast tumor growth, and 
resistance to TAM [56, 158].  SRC-3 is a direct target of miR-17-5p and overexpression 
of miR-17-5p in MCF-7 cells repressed E2-induced proliferation [159].  This suggests 
that miR-17-5p would be a biomarker of endocrine-sensitivity and a meta-analysis 




MICRORNAs AS BIOMARKERS 
MammaPrint, Oncotype DX and PAM50 gene arrays are used in ERα+ BC 
diagnostics, but are limited by cost and inability to predict recurrence beyond 5 years 
[322-324].  None of these tests currently includes miRNAs.  To date, there is one study 
correlating miRNA expression with RS from Oncotype DX on 23 human BC tumors 
[315].  That study reported reduced expression of Let-7 family members in cases with 
high RS and high expression of miR-377-5p, miR-663b and miR 3648 were associated 
with high RS scores.  
Circulating miRNAs as signatures for distinguishing histopathological features 
and molecular BC subtypes have been reviewed in [8].  Important for biomarker 
measurement, circulating miRNAs are usually very stable [325].  Moreover, as a 
potential tool for personalized BC management, serum miRNAs are easily accessible [8].  
These features suggest miRNAs as practical for clinical applications.  However, 
discrepancies in miRNA signatures resulting from clinicopathological variables and 
intrinsic heterogeneity of BC are challenges remaining to be resolved [8]. 
 
MICRORNAs AS BIOMARKERS TO TAM RESPONSE AND RESISTANCE 
Ideally, miRNA biomarkers would be used to track BC patient response to 
adjuvant endocrine therapy and thus be predictive of relapse.  Endocrine resistant BC 
cells and tumors show increased epidermal growth factor receptor (EGFR) signaling 
[164].  TAM, but not raloxifene or fulvestrant, downregulates miR-451 in TAM-R cells 
[136].  Downregulation of miR-451 upregulates its target protein 14-3-3ζ, a scaffolding 
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protein correlated with early disease recurrence in patients treated with TAM.  
Overexpression of miR-451 in MCF-7 TAM-resistant BC cells decreased 14-3-3ζ and 
reduced activation of HER2, EFGR and MAPK signaling, resulting in decreased cell 
proliferation and migration and increased apoptosis [136].  In addition, overexpression of 
miR-451 restored the inhibitory effectiveness of SERMs in TAM-resistant cells. In 
another study, lower circulating miR-451 levels was a predictor to resistance in BC 
patients who underwent neoadjuvant chemotherapy [326].  These findings suggest that 
miR-451 may be a biomarker of resistance to both endocrine and chemotherapy.  
Importantly, higher serum miR-341 levels in patients with locally advanced BC receiving 
neo-adjuvant chemotherapy were associated with improved clinical and pathological 
responses and disease-free survival [327].  
miR-105-2, miR-877, let-7f, miR-125a and miR-574-3p were associated with a 
loss of inhibition by TAM in MCF-7 cells [137].  Of these miRNAs, miR-574-3p was 
also reduced in BC tissue samples compared to adjacent normal breast tissue.  This report 
suggests that miR-574-3p may serve both as a diagnostic biomarker of BC and a 
predictive biomarker of endocrine-resistance. Increased miR-125b was associated with 
lower relapse-free survival, poor prognosis and their repression was suggestive as 
therapeutic targets to overcome letrozole resistance [119]. Indeed we reported higher 
miR-125b expression  in TAM-R LY2 compared to TAM-S MCF-7 cells [223].  Thus 
reduced expression of miR-125 family members may serve as biomarkers of endocrine 
response.  
To identify miRNAs that promote TAM resistance, Miller et al. used microarray 
analysis to show increased expression of miR-221, miR-222, and miR-181 and decreased  
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expression of miR-21, miR-342, and miR-489 in TAM-resistant versus TAM-sensitive 
MCF-7 cells [104]. miR-221/222 was higher in endocrine resistant, HER2+ primary BC 
tumors [104]. Overexpression of miR-221/222 made TAM-sensitive MCF-7 cells 
resistant to TAM.  This finding makes sense because, as reviewed above, miR-221 and 
miR-222 target ERα [100].  Moreover, these result correlate with our observation of 
higher expression of miR-221 and miR-222 in TAM-R LY2 cells versus TAM-S MCF-7 
cells [223]. 
miR-375 was downregulated in a mesenchymal TAM-resistant MCF-7 cell line 
[328].  Re-expression of miR-375 sensitized TAM-resistant cells to TAM and reduced 
invasiveness by decreasing expression of mesenchymal markers fibronectin, ZEB1, and 
SNAI2 while increasing epithelial markers E-cadherin and Tight Junction Protein 1 
(TJP1, ZO-1).  This resulted in partial reversal of EMT which is called MET 
(mesenchymal-to-epithelial transformation).  Metadherin (MTDH), a cell surface protein 
upregulated in breast tumors that mediates metastasis [173], was identified as a direct, 
bona fide miR-375 target mediating this response [328].  TAM- treated patients whose 
primary tumor had high MTDH showed shorter-disease-free survival and a higher risk of 
relapse.  Thus, reduced miR-375 may be a biomarker of poor prognosis and TAM-
resistance.  Indeed, a recent report identified upregulation of circulating miR-375 in BC 
patients with recurrence [309]. It is uncertain why up or down regulation of miR-375 is 
associated with TAM resistance in BC however, it should be noted that miR-375 
dysregulation in many cancers is due to several factors including aberrant promoter 
methylation and dysregulation of transcription factors [329].  miR-375 serves a tumor 
suppressor role in other cancers [329].   
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Huo et al. identified four miRNAs to be upregulated in the serum of BC patients 
with recurrent disease: miR-21-5p, miR-375, miR-205-5p, and miR-194-5p and three 
miRNAs to be downregulated: miR-382-5p, miR-376c-3p, and miR-411-5p) [309]. 
Upregulation of miR-205 was previously reported to mediate AI resistance in aromatase-
overexpressing MCF-7 cells and was associated with poor prognosis in breast tumors 
[119]. These studies suggest increased miR-205 may serve as a marker of poor prognostic 
in BC patient serum and may be indicative of AI resistance. Additional studies are 
required to validate the other miRNAs identified in [309] as biomarkers of endocrine 
resistance.  
High breast tumor expression of miR-30a-3p, miR-30c, and miR-182 were 
identified as predictors of clinical benefit from TAM for patients with ERα positive 
primary breast tumors [132].  Global testing pathway analysis associated miR-30c with 
low HER and RAC1 signaling pathways, but other targets are likely involved. High 
expression of miR-30e* was associated with favorable prognosis in luminal tumors from 
BC patients receiving adjuvant trastuzumab treatment [330]. These reports suggest miR-
30 family may be a biomarker for benefit to both endocrine and chemotherapy. However, 
miR-30 is upregulated in tumor-initiating cells (T-ICs); a sub-population of cancer cells 
mediating tumor initiation, tumor progression, metastasis and post-treatment relapse 
[331] suggesting that depending on BC stage, miR-30 may switch form an oncogenic 
miRNA to a tumor suppressor miRNA. There are no reports of miR-30 as a BC 
biomarker in human serum.  
High levels of miR-26a in breast tumors were associated with low levels of 
Enhancer of Zeste Homolog (EZH) and a favorable outcome in BC patients on TAM 
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[332, 333].  EZH is a conserved chromatin modifier required for epigenetic memory and 
maintenance of cellular characteristics [334].  Low levels of cell cycle regulators CCNE1 
and CDC2 were also associated with high levels of miR-26a, although they were not 
shown by authors to be direct targets of miR-26a [333]. There are no reports of miR-26a 
as a BC biomarker in human serum.   
High tumor expression of miR-210 was associated with increased risk of BC 
recurrence [102].  Increased expression of miR-210 was associated with poor clinical 
outcome to TAM treatment.  Serum miR-210 was not found to be a predictive serum 
marker in HER2+ BC patients receiving trastuzumab or lapatinib [335]  
miRNA screening of recurrent versus recurrent-free primary ERα+ breast tumors 
from postmenopausal BC patients treated with adjuvant TAM identified increased miR-
126 and miR-10a as predictive of longer relapse-free survival [130].  A meta-analysis of 
30 studies supported increased miR-126 as predicting favorable survival in various 
cancers [336]. 
Upregulation of miR-1266 is indicative of lower disease-free survival and 
prognostic for BC recurrence, metastasis and TAM response in ER+ BC patients [311].  
miR-1266 was predicted to target the 3’ UTR region of Homeobox B13 (HOXB13) and 
Interleukin 17 Receptor B (IL17BR). The HOXB13 to IL17BR expression ratio is a 




EXOSOMAL MICRORNAs AS POSSIBLE BIOMARKERS OF ENDOCRINE-
RESISTANT BREAST CANCER  
Exosomes are small extracellular vesicles of endosomal origin that are formed by the 
fusion of multivesicular bodies with plasma membrane (PM) [184, 185].  The content of 
exosomes reflects their tissue/cell type of origin [193, 340].  Exosomes contain mRNA, 
miRNA, and small regulatory RNAs as well as Dicer, TRBP, and AGO2 to process pre-
miRNAs into mature miRNAs [193],  which are protected from ribonucleases in 
circulation [183].  Current studies indicate different miRNAs are associated with specific 
endogenous exosomes [191].  There is much excitement about the exploration of 
exosomes in the liquid biopsy field as biomarkers of cancer diagnosis and monitoring 
therapy [341].  Tumor-derived exosomes (TDEs) are thought to play a role in drug 
resistance by exporting drugs, neutralizing antibody-based drugs including trastuzumab 
used in HER2+ BC, and exosome-mediated transfer of miRNAs (reviewed in [342]).  
Exosomal delivery of miRNAs is thought to be important in breast tumorigenesis and 
metastasis.  One of the areas of challenge in miRNAs in exosomes or in blood samples as 
biomarkers is a lack of a standardized approach and which blood fraction is best for 
identifying cancer-related miRNAs is unclear (reviewed in [343]).  Further, various 
techniques are used for isolating exosomes and quantifying exosome-associated proteins, 
e.g., CD9, CD63, as markers (Reviewed in [343]).  Quantitative realtime PCR is used for 
miRNA detection in exosomes.   
Exosomal transfer of miRNAs to cells is implicated in antiestrogen resistance 
[122] (Fig. 14, Table 4).  Wei et al., reported that addition of labelled exosomes from 
TAM-R MCF-7 cells into the culture medium of TAM-S MCF-7 cells resulted in uptake 
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of the labelled exosomes by the TAM-S cells [122].  Moreover, miR-221/222 were 
released from exosomes into TAM-S MCF-7 cells resulting in concomitant reduction in 
the expression of their target genes p27 and ERα, and enhanced TAM resistance.  
Transfection of miR-221/222 inhibitor into the MCF-7 TAM-S cells that were incubated 
with the TAM-R MCF-7 exosomes reduced TAM-resistance.  These data support the 
importance of miR-221/222 in TAM-resistance in MCF-7 cells and a possible role for 
exosomal transfer of miRNAs in TAM-resistance.  The authors also observed that the 
exosomes secreted by TAM-S MCF-7 cells were larger in size and number compared to 









Figure 14. Exosome Transfer of miRNAs from breast cancer cells to normal cells 
may play a role in tumor progression and metastasis. 
Exosomal miRNAs are from Table 2.  While targets of these exosomal miRNAs have not 
been established, experimentally validated by 3’UTR luciferase reporter assay (bona fide) 
targets of these miRNAs have been shown to be involved in breast or other cancers:  
 T-lymphoma invasion and metastasis inducing factor 1 (TIAM1) is inversely 
correlated with miR-10a expression [344] 
 TIAM1 is a bona fide target of miR-10b which results in inhibition of TIAM1-
mediated RAC activation [345]  
 Tissue factor pathway inhibitor (TFPI) α is a bona fide target of miR-27a [346] 
 MAGI-2 is a bona fide target of miR-101 [118] 
 ERα protein expression was repressed by miR-373 in MCF-7 cells [196]   
 Verified targets of miR-373 include LATS2, CD44, DCH1, RAD52, MBD2, 
NFIB, PPP6C, TXNIP, RElA, TGFBR2, mTOR, SIRT, DKK1, BTG1, RNFAIP1, 
TP52INP1, IRAK2, LAMP1, MMP14, JAK1, IRF9, and PIK3CA [347] 
 Programmed cell death protein 4 (PDCD4) and Phosphatase and tensin homolog 
(PTEN) are bona fide targets of miR-21 [348]  
 Suppressor of cytokine signaling 6 (SOCS6) is bona fide target of miR-155 [349] 
 miR-372 and miR-1246 have no confirmed targets in BC, although miR-1246 was 
shown to promote growth and metastasis of colon cancer by directly targeting 










Table 4. Exosomal miRNAs described in human breast cancer cell lines and tumors 
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A miRNA array identified exosomal miR-27a and miR-155 from cultured MCF-7 
and MDA-MB-231 cells [193].  miR-155 acts as an oncomiR and mediates TAM-
resistance by reducing SOCS6 leading to STAT3 activation and increased expression of 
genes involved in proliferation and differentiation in MCF-7 and SKBR3 cells [349].  
MiR-27a/b were reported to negatively regulate TFPIα expression in MCF-7 cells [346] 
and TFPIα induces apoptosis in breast cancer cells [352].  We have modeled these 
potential pathways for exosomal miR-27a and miR-155 in Figure 14.   
High miR-101, miR-372, and miR-282 were identified in the serum of BC 
patients compared to healthy women or those with benign breast disease [196]. MAGI-2 
(membrane-associated guanylate kinase), a scaffold protein required for PTEN activity, is 
a bona fide target of miR-101 [118]. A decrease in MAGI-2 by miR-101 increased PTEN 
and PDCD4 leading to AKT activation [118]. This activity of miR-101 is modeled in 
Figure 14.  Higher exosomal levels of miR-373 in serum from BC patients was indicative 
of a TNBC phenotype [196]. Further, miR-10 and miR-21 were significantly increased in 
exosomes from BC cells and patients sera [193].  miR-10 and miR-21 initiate tumor 
formation in mice [193]. miR-1246 and miR-21 were significantly higher in the 
exosomes from plasma of 16 BC patients compared to the plasma exosomes of healthy 
control subjects [351].  These studies suggest that exosomal miR-10, miR-1246 and miR-
21 are diagnostic biomarkers to distinguish BC patients from healthy controls. 
Exosomal transfer of miR-21 in breast cancer has recently been supported by 
recent studies [353]. These authors demonstrated that exposure of T47D, BT549 and 
MDA-MB-231 breast cancer cells to exosomes (containing miR-21, miR-378e, and miR-
143-3p) from cancer-associated fibroblasts (CAFs) containing miR-21, miR-378e, and 
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miR-143-3p induced stemness and EMT phenotypes in the cancer cells [353]. Upon 
evaluating 744 Breast Invasive Carcinoma patients from The Cancer Genome Atlas 
(TCGA) database, lower miR-378 expression was associated with longer overall survival 
[353]; suggesting a prognostic role of low miR-378. Increased miR-143 expression was 
associated with higher (III/IV) compared to lower (I/II) breast cancer stages [353]. 
Further, a positive correlation between miR-143 and -378 and between miR-143 and 
miR-21 expression was observed [353]. Thus higher exosomal expression of miR-21, 
miR-378e, and miR-143-3p may suggest progression toward metastasis in breast cancer. 
Overall, the clinical use of exosomal miRNAs as candidate biomarkers for cancer 
diagnosis and prognosis remains to be proven [91].  Moreover, the ability manipulate 
exosomes to deliver antitumor agents including doxorubicin [354] and miRNAs such as 
let 7a [355] suggests a new therapeutic approach for drug delivery.  Clearly, additional 
studies encompassing the packaging, formation, and the delivery of exosome-containing 
miRNAs is warranted [186]. 
 
CLINICAL TRIALS OF MICRORNAs AS BIOMARKERS IN BREAST CANCER 
There are two ongoing clinical trials assessing the potential use of miRNA as biomarkers.  
NCT01612871 focuses on identifying circulating miRNAs in patients with metastatic 
invasive BC or locally advanced BC for which TAM or AIs are indicated.  
NCT01722851 aims to identify miRNAs that could be used to monitor a patient’s 
response to chemotherapy and hormonal therapy.  The limited number of miRNA clinical 
trials on endocrine therapy and/or resistance suggest that although miRNAs are 
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promising markers for clinical practice, further research is warranted to understand 




miRNAs are dysregulated in endocrine-resistant BC. Identifying miRNAs that 
will be useful as predictive serum biomarkers of developing endocrine resistance and in 
identifying individuals who will benefit from endocrine therapy is critical for improving 
management for BC patients with ERα+ primary tumors.  No reports have identified 
miR-29 family members as a prognostic or predictive markers of endocrine resistance. 
Nonetheless, low miR-29 expression correlates with poor overall survival in ERα+ breast 
cancer patients (Supplementary Fig. 18)[356]. It is beyond the scope of this chapter to 
detail the genes and pathways involved in each dysregulated miRNA, and much has been 
reviewed in Chapter II and elsewhere [218, 220].  The possibility of using exosomes as a 
biomarkers for endocrine resistance is a promising idea, but additional studies are 
warranted to standardized exosomal isolation techniques for significant progress to be 
made in this area of research. The ability to design synthetic exosomes carrying tumor 
suppressor miRNAs that can be targeted to metastatic cells to inhibit metastasis warrants 
more research.  Future studies are also needed to elucidate the mechanisms behind 
miRNA dysregulation and to develop ‘targeted’ therapeutics to counter miRNA 






CHAPTER VI: RESEARCH IMPLICATIONS 
 
The sustained exposure to endogenous estrogens is involved in the initiation and 
progression of breast cancer [357].  The cellular effects of estrogens are mediated by ERα 
and ERβ and their splice variants [62].  Approximately 70% of primary breast tumors 
express ERα [56, 358], providing the rationale for the successful use of targeted 
endocrine therapies in breast cancer progression (Reviewed in [29]). 
Endocrine therapies including SERMs e.g., tamoxifen (TAM); SERDs, e.g., 
fulvestrant (ICI 182,780), and aromatase (CYP19A) inhibitors (AI), e.g., anastrozole and 
letrozole, are the frontline adjuvant therapies in treatment of women with ERα positive 
breast tumors [359].  These therapies have resulted in substantial improvements in overall 
survival fand quality of lives of breast cancer survivors [360].  Unfortunately, the 
effectiveness of TAM and AI therapy is limited as seen in relapse of ~ 40% of patients 
[55].  When resistance occurs, it is unclear which subsequent endocrine therapy is most 
appropriate [361].  Overall, the mechanisms of endocrine resistance are many and include 
mutations in the ligand binding domain of ERα [62], increased expression of truncated 
forms of ERα (including ERα36) [63], amplification of multiple growth signaling 
pathways [42, 56, 362-364], and dysregulation of miRNAs [68]. In this dissertation, I 
described the role of miR-29b-1 and miR-29a in breast cancer and endocrine resistance. 
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In chapter III, I reported that miR-29b-1 and miR-29a expression in response to 
TAM is dependent on endocrine sensitivity of the breast cancer cell line studied. miR-
29b-1 and miR-29a are members of the miR-29 family and with the same seed sequence 
[227-229]. They are co-transcribed as a single primary transcript, sharing the same 
promoter, with miR-29b-1 upstream of miR-29a [227-229]. Using qPCR, I confirmed the 
original microarray study [223] that 4-OHT decreased miR-29b-1 and miR-29a 
expression in endocrine-sensitive MCF-7 breast cancer cells and 4-OHT increased 
transcription of both microRNAs in MCF-7 derivative, TAM-R LCC2, LCC9 and LY2 
cells [275]. Similar observations were made at the primary (pri-miR) transcript level. As 
TAM exerts its effects, in part, through ERα, I examined the role of ERα in 4-OHT-
induced regulation of miR-29b-1 and miR-29a. Using knockdown studies, ERα was 
shown to mediate 4-OHT regulation of the primary and mature transcripts of miR-29b-1 
and miR-29a in MCF-7 and LCC9 cells [275]. 
I then sought to determine whether ectopic expression of miR-29b-1/a in TAM-S 
MCF-7 cells will desensitize cells to 4-OHT and whether inhibiting miR-29-b-1/a in 
TAM-R LY2 will enhance 4-OHT inhibition of cell proliferation, cell migration and 
colony formation. Transfection of TAM-S MCF-7 with miR-29b-1 or miR-29a did not 
result in endocrine resistance, but it did repress cell proliferation in both TAM-S MCF-7 
and its TAM-R cell line derivatives [275]. Previously, transient overexpression of miR-
29a also inhibited the growth of MDA-MB-453 TNBC cells [236], implying repression 
of cell growth by miR-29b-1 and miR-29a is not dependent on ERα.  Inhibition of miR-
29b-1 or miR-29a did not enhance the sensitivity of the TAM-R LCC9 and LY2 cells to 
4-OHT.  In TAM-R LY2 cells, overexpression of miR-29b-1 and miR-29a decreased cell 
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migration and colony formation. Interestingly, overexpression of miR-29a alone or in 
combination with miR-29b-1 enhanced 4-OHT inhibition of LY2 colony formation [275].  
These data suggest that the 4-OHT-induced increase in miR-29b-1/a in LY2 may be 
involved in TAM-sensitivity, not resistance 
Also in Chapter III, I reported DICER1 protein levels to be down regulated by 
miR-29b-1 and miR-29a in LY2 cells [275].  DICER1 is a validated target of miR-29 
family members [209].  DICER1 regulates cellular processes including cell 
differentiation, programmed cell death, senescence, DNA repair, and chromatin 
remodeling [258-262]. In TAM-R LY2 breast cancer cells, TAM decreased DICER1 
protein expression by upregulating miR-29b-1/a [275], suggesting a decrease in DICER1 
mediates resistance to TAM.  A decrease in DICER1 would be expected to result in lower 
miRNA expression.  In fact, we observed lower overall miRNA expression of 4-OHT-
treated LY2 cells compared with 4-OHT-treated MCF-7 cells ([223]; Klinge, 
unpublished, GSE28267) 
In Chapter VI, RNA-seq was used to identify miR-29b-1 and miR-29a 
transcriptomes in TAM-S MCF-7 and TAM-R LCC9 breast cancer cells. miR-29b-1 and 
miR-29a have common and unique regulated transcripts. Commonly regulated transcripts 
can be attributed to both miRNAs having the same seed sequences. Uniquely regulated 
transcripts can be due to differences in sequences adjacent to the seed sequence and the 
predominant nuclear localization of miR-29b-1 versus cytoplasmic localization of miR-
29a [255, 256]. However, miR-29b-1/a can also indirectly regulate transcripts by 
regulating transcription factors. Overall, miR-29b-1/a regulated more transcripts in LCC9 
than MCF-7 cells. Enrichment analysis of unique miR-29 target transcripts in LCC9 cells 
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identified top regulated pathways including oxidative phosphorylation (OXPHOS), ATP 
metabolism, apoptosis and survival. 
To examine involvement of miR-29 in regulation of OXPHOS, I studied 
mitochondrial bioenergetics in LCC9 cells. Pre-miR-29a transfection in LCC9 cells 
repressed mitochondrial activity by decreasing basal OCR, ATP-linked OCR, and 
mitochondrial (mt) reserve. This suggests that repression of cell proliferation, migration 
and colony formation upon ectopic miR-29b-1/a expression (observed in Chapter VII) 
may in part be due to repression of mitochondrial activity. Repression of miR-29a 
increased OCR and mt reserve, suggesting that repression of miR-29a may serve as an 
adaptive response to meet increased energy demand of cancer cells and promote survival. 
Repression of miR-29a also increased basal ECAR (glycolysis) in LCC9 cells.  RNA-seq 
data identified and qPCR confirmed electron transport chain (ETC) proteins including 
ATP synthase genes ATP5G1 and ATPIF1 as targets of miR-29. Luciferase assay 
confirmed ATP5G1 and ATPIF1 as bona fide miR-29 targets. It will be interesting to 
further investigate the roles of ATP5G1 and ATPIF1 in breast cancer 
In conclusion, this study has provided important insights into the role of miR-29b-
1 and miR-29a in endocrine resistant breast cancer cells.  The suggestion that a 4-OHT-
induced increase in miR-29b-1/a in LY2 may be involved in TAM-sensitivity, not 
resistance warrants further research. The identification of miR-29 targets mediating 
specific cellular processes in MCF-7 TAM-S and LCC9 TAM R cells offers clues for 
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APPENDIX I: SUPPLEMENTARY MATERIAL 
Supplementary Table 1: miR-29 targets experimentally validated in breast cancer 
miRNA
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Supplementary Figure 1. Basal expression of miR-29b-1-3p, miR-29b-1-5p, miR-
29a-3p and miR-29a-5p in MCF-7, LCC9 and LY2 breast cancer cells. Cells were 
grown in hormonally depleted medium for 48 h and miRNA expression was determined 
by qPCR. Each sample was run in triplicates. miR-29a-5p and miR-29b-1-5p CT values 


























Supplementary Figure 2. Knockdown of ERα inhibits pri-miR-29b-1/a transcription 
in LY2 cells. LY2 cells were grown in hormonally depleted medium and transfected with 
siControl or siERα. 48 h post transfection, cells were treated for 6 h with DMSO or 100 
nM 4-OHT. (A) ERα protein was examined in WCE and the blot was stripped and re-
probed for β-actin for normalization.  Values are the ERα/β-actin with siControl set to 
one. Q-PCR for ESR1 (B); pri-miR-29b-1 and pri-miR-29a (C).  Data for MCF-7 and 
LCC9 in panel C are identical to those in Fig. 5C. *p < 0.05 versus control-transfected 
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Supplementary Figure 3. 4-OHT-ERα regulates miR-29b-1/a promoter activity. 
CHO-K1 cells were transfected with a miR-29b-1/a luciferase reporter and an ERα 
expression vector. Cells were treated with EtOH (vehicle control), 100 nM 4-OHT, 100 
nM fulvestrant, or both 100 nM 4OHT+ 100 nM fulvestrant for 24 prior to dual luciferase 
assay.  Relative luciferase expression for EtOH was set to 1.  Values are the average ± of 




































































Supplementary Figure 4. Successful knockdown and overexpression of miR-29b-1 
/a.  (A &C) Demonstrates the knockdown of miR-29b-1/a for up to 6 days after 
transfection. (B &D) Demonstrates the knockdown of miR-29b-1/a for up to 6 days after 
transfection. Q-PCR was performed and miR-29b-1/a was normalized to RNU48 or 
RNU6B. Values are the mean ± SEM of 1-3 independent experiments. Within each 
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Supplementary Figure 5. miR-29b-1/a downregulates PTEN in LY2 cells. LY2 cells 
were transfected with anti-miR control, anti-mIR-29b-1, anti-miR-29a, or the 
combination for 48 h. The blot was probed for PTEN and then for β-actin. Values are the 
ratio of PTEN/ β-actin from the experiment shown.  This is the same blot used for 













































































Supplementary Figure 6. Relative basal and 4-OHT-regulated PTEN expression. A) 
PTEN expression data (FPKM = fragments per kilobase of exon per million fragments 
mapped) from RNA-seq (GSE81620) in MCF-7 and LCC9 cells.  *P < 0.01 versus MCF-
7 cells.  B) Cells were grown in hormonally depleted medium for 48 h and treated with 
vehicle (DMSO) or 100 nM 4-OHT for 6 h.  PTEN mRNA expression was determined by 
qPCR relative to 18S or GAPH. Values are the mean ± SEM of 3 separate experiments. P 
























































Supplementary Figure 7. LY2 cells were grown in hormonally depleted medium and 
transfected with Anti- miR-Control, Anti-miR-29b-1 + Anti-miR-29a. 48 h post 
transfection, cells were treated for 6 h with DMSO or 100 nM 4-OHT.  Q-PCR was 
performed to determine DICER mRNA expression relative to 18S. Values are the mean ± 
SEM of three separate wells in one experiment. *p < 0.05 versus vehicle control-
















































Supplementary Figure 8. Knockdown of ERα inhibits 4-OHT repression of DICER 
transcript expression in LCC9.  LCC9 cells were grown in hormonally depleted 
medium and transfected with siControl or siERα. 48 h post transfection, cells were 
treated for 6 h with DMSO or 100 nM 4-OHT. Q-PCR was performed to determine 
DICER mRNA expression relative to 18S. Values are the mean ± SEM of three separate 
wells in one experiment. *p < 0.05 versus control-transfected cells. #p < 0.05 versus 4-






































Supplementary Figure 9.  Expression of NKX3-1 and SKP2 are significantly 
different in between MCF-7 TAM-sensitive and LCC9 TAM-resistant cells.  Values 
are FPKM = Fragments Per Kilobase of transcript per Million mapped reads and are from 
GSE81620. *p < 0.05 (Two way ANOVA, Bonferroni post hoc test).  POU5F1 is the 



























Supplementary Figure 10. Successful knockdown and upregulation of miR-29b-1 /a 
in MCF-7 and LCC9 cells. Cells were grown in hormone-depleted media and 
transfected with anti-miR-control, anti-miR-29a (3p), pre-miR control or pre-miR-29b-
1/a (3p) as indicated. RNA was extracted 48 h post transfection and qPCR performed. 
Values were normalized to RNU6B. Values are the mean ± SEM of 3 independent 
experiments. Within each experiment, each sample was run in triplicate. *p<0.05 versus 
control transfected cells. Statistical evaluation was performed using one-way ANOVA 













































































































































Supplementary Figure 11. Enrichment analysis of RNA-seq data in MCF-7 and LCC9 cells.  Data are the same as Fig. 9A and B 
with an inclusion of pathways identified. The Venn diagrams show the number of differentially expressed genes identified in pairwise 
comparisons: Pre-miR-29b-1 vs. Anti-miR-29a and Anti-miR-29a vs. Pre-miR-29a using tophat and cufflink-cuff diff2. GeneGo 
Pathways Software (MetaCore™) was then used to obtain the number of common and uniquely expressed genes significantly 

















downregulated pathways in 
MCF-7
Unique miR-29b-1 
downregulated pathways in 
MCF-7
1. Translation: Role of Retinoic acid 
signaling in the initiation of translation
2. Translation: Regulation of 
translation initiation
3. Development: Slit-Robo signaling
4. Signal transduction_mTORC2 
upstream signaling
5. Signal transduction: Erk
Interactions: Inhibition of Erk
1. Neurophysiological process: Dynein-
dynactin motor complex in axonal transport 
in neurons
2. Cell adhesion: Tight junctions
3. Glycolysis and gluconeogenesis
4. Development: Neurotrophin family signaling
5. Development: TGF-beta receptor signaling
1. Immune response: IFN 
alpha/beta signaling pathway
2. NETosis in SLE
3. Cell cycle: Role of APC in cell 
cycle regulation
4. Cell cycle: Start of DNA 
replication in early S phase











5. L-Alanine, L-cysteine, and 
L-methionine metabolism
Common miR-29b-1/a




signaling by ephrin B
2. Protein folding: Membrane 
trafficking and signal 
transduction of G-alpha (i) 
heterotrimeric G-protein
3. Neurophysiological process: 
GABA-B receptor signaling 
in presynaptic nerve 
terminals
4. Neurophysiological process: 
EphB receptors in dendritic 
spine morphogenesis and 
synaptogenesis







3. Cell cycle: Role of NEK in cell 
cycle regulation
4. Cell cycle: Start of DNA 












Supplementary Figure 12. Enrichment onthologies of genes regulated by miR-29b-
1/a in MCF-7 and LCC9 cells. A, C) Gene Ontology (GO) cellular processes. B, D) The 
top scored GO network processes determined using Analyze Networks algorithm with 
default settings in MetaCore™. Thick cyan lines indicate canonical pathways. Items with 
blue circles indicate downregulated genes.   
Top GO Processes in Common miR-29b-1/a
downregulated genes in MCF-7
TOP GO Processes in Common miR-29b-1/a
downregulated genes in LCC9
Top Network map in Common miR-29b-1/a
downregulated genes in MCF-7
Top Network map in Common miR-29b-1/a











Supplementary Figure 13. Enrichment onthologies of genes uniquely downregulated 
in LCC9 cells. Differentially expressed genes unique to LCC9 cells identified in pairwise 
comparisons using cufflink-cuff diff2. MetaCore™ was then used to determine A) top 
Gene Ontology (GO) cellular processes and B) top Process Networks. C) Network 
analysis of genes mediating mitochondrial ATP synthesis coupled proton transport.  miR-

























Supplementary Figure 14. miR-29a regulates mitochondrial function of MCF-7 and 
LCC9 BC cells. MCF-7 and LCC9 cells were plated in XF-24 plates, ‘hormone-
deprived’ and transfected with anti-miR-29a or pre-miR-29a, versus control, as indicated,  
for 28 h prior to running extracellular flux assay to determine mitochondrial activity. 

































































































































































































































































































Supplementary Figure 15. Glycolytic gene expression in MCF-7 and LCC9 BC cells. 
MCF-7 and LCC9 cells were ‘hormone-deprived’ and transfected with pre-miR-29a, pre-
miR-29b-1, or anti-miR-29a. A) Values are the FPKM (Fragments Per Kilobase of 
transcript per Million mapped reads) from GSE81620 RNA-seq dataset.  Bars for pre-
miR-29b-1/a are the average of 6 separate experiments and bars with Anti-miR-29a are 
the average of 3 experiments. B) qPCR of LDHA and ENO1 mRNA transcript expression 
in MCF-7 and LCC9 cells transfected as indicated. Values are the mean ± SEM of 3 
samples in one experiment. *p<0.05 versus control transfected cells. Statistical evaluation 










Supplementary Figure 16. RNA-seq expression profiles of ATP5G1, ATP5C1, 
ATPIF1, ATP5G3, NDUFS6 and NDUFC2 in MCF-7 and LCC9 breast cancer cells. 
Values are FPKM (Fragments Per Kilobase of transcript per Million mapped reads) from 
















































































Supplementary Figure 17. Basal expression levels of putative miR-29b-1/a targets in 
breast cancer cells. MCF7 and LCC9 cells were grown in hormone-depleted media for 
48 h. RNA was isolated and qPCR performed to determine expression levels. Each bar is 






























Supplementary Figure 18. Lower expression of miR-29b-1 and miR-29a is 
statistically associated with decreased relapse-free survival in all breast cancer and 
in patients whose primary tumors are ERα+.  Kaplan-Meier (KM) plots of A) miR-
29b-1 and B) miR-29a expression in all tumors (n = 1262). KM plots of C) miR-29b-1 













Supplementary Table 2: miR-29 targets in MCF-7 cells 
 











OMIM IDs Gene Name 
log2(fold 
change) 
1.  HIBADH 11112 608475 3-hydroxyisobutyrate dehydrogenase 0.463839 
2.  EIF4EBP2 1979 602224 
eukaryotic translation initiation factor 4E 
binding protein 2 
0.503226 





ADAM metallopeptidase with thrombospondin 
type 1 motif 19 
0.895057 
5.  ADAM9 8754 602713;612775 ADAM metallopeptidase domain 9 0.538095 
6.  ADH5 128 103710 
"alcohol dehydrogenase 5 (class III), chi 
polypeptide" 
0.569996 
7.  AHNAK 79026 103390 AHNAK nucleoprotein 0.71501 
8.  AIF1L 83543 No ID allograft inflammatory factor 1 like 0.441216 
9.  AK4 205 103030 adenylate kinase 4 0.779273 
10.  ALDH7A1 501 107323;266100 aldehyde dehydrogenase 7 family member A1 0.609418 
11.  FAM117B 150864 No ID family with sequence similarity 117 member B 0.495994 
12.  AMIGO2 347902 615690 adhesion molecule with Ig like domain 2 0.361687 
13.  GNA14 57037 No ID ankyrin repeat and MYND domain containing 2 0.838909 
14.  ANO6 196527 262890;608663 anoctamin 6 0.504893 
15.  SLC25A5 292 300150 solute carrier family 25 member 5 0.531863 
16.  APLP2 334 104776 amyloid beta precursor like protein 2 0.634654 
17.  APP 351 
104300;104760;60
5714 
amyloid beta precursor protein 0.591877 
18.  NCAM2 401 602078;602753 paired like homeobox 2a 0.793964 
19.  ARL5B 221079 608909 ADP ribosylation factor like GTPase 5B 0.526453 
20.  ARNT 405 126110 aryl hydrocarbon receptor nuclear translocator 0.516884 
21.  ACTR2 10097 604221 ARP2 actin related protein 2 homolog 0.388238 
22.  ATP11B 23200 605869 
ATPase phospholipid transporting 11B 
(putative) 
0.79681 
23.  ATP1B1 481 145500;182330 ATPase Na+/K+ transporting subunit beta 1 0.460634 
24.  ATP5A1 498 
164360;615228;61
6045 
"ATP synthase, H+ transporting, mitochondrial 
F1 complex, alpha subunit 1, cardiac muscle" 
0.4749 
25.  ATP5B 506 102910 
"ATP synthase, H+ transporting, mitochondrial 
F1 complex, beta polypeptide" 
0.526923 
26.  ATP5EP2 432369 No ID 
"ATP synthase, H+ transporting, mitochondrial 
F1 complex, epsilon subunit pseudogene 2" 
0.690007 
27.  ATP6V1A 523 607027 ATPase H+ transporting V1 subunit A 0.786597 
28.  ADK 132 102750;614300 adenosine kinase 0.421368 
29.  ADIPOR2 79602 607946 adiponectin receptor 2 0.489597 
30.  SGCE 8910 159900;604149 sarcoglycan epsilon 1.66249 
31.  PTPLAD1 51495 615940 3-hydroxyacyl-CoA dehydratase 3 0.559162 




33.  SMARCC1 6599 601732 
"SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin subfamily c 
member 1" 
0.67286 
34.  BCAS1 8537 602968 breast carcinoma amplified sequence 1 0.598178 
35.  DBT 1629 248600;248610 
dihydrolipoamide branched chain transacylase 
E2 
0.560221 
36.  BCKDHB 594 248600;248611 
branched chain keto acid dehydrogenase E1 
subunit beta 
0.648202 




galactosidase beta 1 0.728066 
38.  BRI3BP 140707 615627 BRI3 binding protein 0.55248 
39.  BTF3 689 602542 basic transcription factor 3 0.481856 
40.  CTNNB1 1499 
114500;114550;11
6806;132600;1552





41.  APMAP 57136 615884 adipocyte plasma membrane associated protein 0.401089 
42.  LINC00205 102723489 No ID long intergenic non-protein coding RNA 205 0.5533 




57658 No ID calcium binding and coiled-coil domain 1 0.58291 
45.  SLC7A2 6542 601872 solute carrier family 7 member 2 0.448744 
46.  CBLN4 140689 615029 cerebellin 4 precursor 0.974278 
47.  CD302 9936 612246 CD302 molecule 0.766404 
48.  CD44 960 
107269;172290;60
9027 
CD44 molecule (Indian blood group) 0.780123 
49.  CDC42 998 116952;616737 cell division cycle 42 0.484322 
50.  CHP1 11261 606988 calcineurin like EF-hand protein 1 0.466563 
51.  CHSY1 22856 605282;608183 chondroitin sulfate synthase 1 0.45663 
52.  GNS 2799 252940;607664 glucosamine (N-acetyl)-6-sulfatase 0.758816 
53.  CLEC3A 10143 613588 C-type lectin domain family 3 member A 1.36846 
54.  CMTM4 146223 607887 
CKLF like MARVEL transmembrane domain 
containing 4 
0.845446 
55.  CMTM6 54918 607889 
CKLF like MARVEL transmembrane domain 
containing 6 
0.527145 
56.  CREG1 8804 No ID cellular repressor of E1A stimulated genes 1 0.546034 
57.  EMB 7514 602559 exportin 1 0.636447 




619455 No ID SPANXA2 overlapping transcript 1 1.15675 




cytochrome P450 family 1 subfamily B member 
1 
0.589318 
61.  ATP2A2 488 
101900;108740;12
4200 
ATPase sarcoplasmic/endoplasmic reticulum 
Ca2+ transporting 2 
0.486506 
62.  CLSTN2 64084 611323 calsyntenin 2 0.820318 
63.  CETN2 1069 300006 centrin 2 0.545244 
64.  MPP7 8208 601245 chromatin assembly factor 1 subunit B 0.669472 
65.  CLTC 1213 118955 clathrin heavy chain 0.518539 
66.  COL12A1 1303 
120320;616470;61
6471 
collagen type XII alpha 1 chain 0.997639 
67.  COL14A1 7373 120324 collagen type XIV alpha 1 chain 1.07939 
68.  CUL4B 8450 300304;300354 cullin 4B 0.423513 
69.  CCNG2 901 603203 cyclin G2 0.608184 
70.  CCNI 10983 No ID cyclin I 0.704477 
71.  CD55 1604 125240;613793 CD55 molecule (Cromer blood group) 0.445821 
72.  DAZAP2 9802 607431 DAZ associated protein 2 0.471512 
73.  OSTC 58505 No ID 
oligosaccharyltransferase complex non-catalytic 
subunit 
0.72726 
74.  DCLK1 9201 604742 doublecortin like kinase 1 0.709475 
75.  PTPRJ 5795 600925 "protein tyrosine phosphatase, receptor type J" 0.58445 
76.  GLUD1 2746 138130;606762 glutamate dehydrogenase 1 0.534844 




140735 608942 dynein light chain LC8-type 2 0.449333 
79.  DNAJC25 548645 No ID 
DnaJ heat shock protein family (Hsp40) member 
C25 
0.668936 
80.  METTL9 51108 609388 methyltransferase like 9 0.574265 




dentin sialophosphoprotein 0.456755 
82.  DSTN 11034 609114 "destrin, actin depolymerizing factor" 0.521062 
83.  EEF1A1P5 158078 No ID 
eukaryotic translation elongation factor 1 alpha 
1 pseudogene 5 
0.643883 
84.  EEF1A1P9 441032 No ID 
eukaryotic translation elongation factor 1 alpha 
1 pseudogene 9 
0.712999 
85.  EIF3L 51386 No ID 
eukaryotic translation initiation factor 3 subunit 
L 
0.67883 
86.  ELOVL5 60481 611805;615957 ELOVL fatty acid elongase 5 0.424171 
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88.  ETNK2 55224 609859 ethanolamine kinase 2 0.768113 
89.  RUNX1T1 862 133435 RUNX1 translocation partner 1 1.0154 
90.  HSP90B1 7184 191175 heat shock protein 90 beta family member 1 0.483563 
91.  EPCAM 4072 
185535;613217;61
3244 
epithelial cell adhesion molecule 0.437596 
92.  EFNB3 1949 602297 ephrin B3 0.479075 
93.  EPS15 2060 600051 
epidermal growth factor receptor pathway 
substrate 15 
0.470549 
94.  ERGIC3 51614 616971 ERGIC and golgi 3 0.570885 
95.  EXT2 2132 
133701;601224;60
8210;616682 
exostosin glycosyltransferase 2 0.687945 




441027 No ID transmembrane protein 150C 0.490383 
98.  FRAT2 23401 605006 
frequently rearranged in advanced T-cell 
lymphomas 2 
0.467266 
99.  FUCA1 2517 230000;612280 "fucosidase, alpha-L- 1, tissue" 0.487582 
100.  FUT8 2530 602589 fucosyltransferase 8 0.594184 
101.  FZD6 8323 603409;614157 frizzled class receptor 6 0.421184 
102.  PLS1 5357 602734 plastin 1 0.599518 
103.  FRAS1 80144 219000;607830 Fraser extracellular matrix complex subunit 1 0.69899 
104.  FUT9 10690 606865 fucosyltransferase 9 0.59 
105.  GNG12 55970 615405 G protein subunit gamma 12 0.612162 
106.  GDE1 51573 605943 glycerophosphodiester phosphodiesterase 1 0.537638 
107.  GFRA3 2676 605710 GDNF family receptor alpha 3 1.04305 
108.  GPD1L 23171 
272120;611777;61
1778 
glycerol-3-phosphate dehydrogenase 1-like 0.41666 
109.  GPNMB 10457 604368 glycoprotein nmb 0.744162 
110.  TMEM181 57583 613209 transmembrane protein 181 0.553905 
111.  GSTA4 2941 605450 glutathione S-transferase alpha 4 0.934667 
112.  GLO1 2739 138750 glyoxalase I 0.402551 
113.  AGR2 10551 606358 
"anterior gradient 2, protein disulphide 
isomerase family member" 
0.467375 
114.  HINT3 135114 609998 histidine triad nucleotide binding protein 3 0.476442 
115.  HIPK1 204851 608003 homeodomain interacting protein kinase 1 0.559793 
116.  BRK1 55845 611183 
"BRICK1, SCAR/WAVE actin nucleating 
complex subunit" 
0.475471 
117.  HEATR5B 54497 No ID HEAT repeat containing 5B 0.587967 
118.  H3F3A 3020 601058;601128 H3 histone family member 3A 0.414925 
119.  IGBP1 3476 300139;300472 immunoglobulin (CD79A) binding protein 1 0.415533 
120.  IGSF1 3547 300137;300888 immunoglobulin superfamily member 1 0.733403 
121.  IL1R1 3554 147810 interleukin 1 receptor type 1 0.78683 
122.  IL13RA1 3597 300119 interleukin 13 receptor subunit alpha 1 0.618167 
123.  IL1RAPL2 26280 300277 interleukin 1 receptor accessory protein like 2 1.43643 
124.  IL23R 149233 
605606;607562;61
2261 
interleukin 23 receptor 0.643553 
125.  INSIG1 3638 602055 insulin induced gene 1 0.423326 
126.  ITGA6 3655 147556;226730 integrin subunit alpha 6 0.884631 
127.  ARL6IP5 10550 605709 
ADP ribosylation factor like GTPase 6 
interacting protein 5 
0.590619 
128.  PRDX1 56659 607367 
potassium two pore domain channel subfamily 
K member 13 
0.489384 
129.  KCTD20 222658 615932 
potassium channel tetramerization domain 
containing 20 
0.604093 
130.  KCTD3 51133 613272 
potassium channel tetramerization domain 
containing 3 
0.691036 
131.  FAM168A 23201 616316 family with sequence similarity 168 member A 0.502726 
132.  KIAA1244 57221 No ID ARFGEF family member 3 0.440378 
133.  KIAA1324 57535 611298 KIAA1324 0.548838 
134.  TXNDC16 57544 616179 thioredoxin domain containing 16 0.69446 
135.  EPG5 57724 242840;615068 ectopic P-granules autophagy protein 5 homolog 0.619241 
136.  KIAA2018 205717 No ID upstream transcription factor family member 3 0.447222 
137.  KIF1B 23095 
118210;171300;25
6700;605995 
kinesin family member 1B 0.540446 
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138.  KIF3B 9371 603754 kinesin family member 3B 0.526819 
139.  FERMT2 10979 607746 fermitin family member 2 0.588173 
140.  LAMP2 3920 300257;309060 lysosomal associated membrane protein 2 0.463606 
141.  RPSA 3921 150370;271400 ribosomal protein SA 0.444295 
142.  LANCL1 10314 604155 LanC like 1 0.573726 




23365 604763 Rho guanine nucleotide exchange factor 12 0.500601 
145.  LDHA 3939 150000;612933 lactate dehydrogenase A 0.484053 
146.  LDOC1 23641 300402 leucine zipper down-regulated in cancer 1 0.464045 
147.  LRRFIP1 9208 603256 LRR binding FLII interacting protein 1 0.420842 
148.  LSM11 134353 No ID "LSM11, U7 small nuclear RNA associated" 0.491352 
149.  LRRC58 116064 No ID leucine rich repeat containing 58 0.483267 
150.  MAN1A1 4121 604344 mannosidase alpha class 1A member 1 0.666365 
151.  MAML2 84441 607537 mastermind like transcriptional coactivator 2 0.631339 
152.  MAOB 4129 309860 monoamine oxidase B 0.878248 
153.  MAP2 4133 157130 microtubule associated protein 2 0.770299 
154.  MBOAT2 129642 611949 
membrane bound O-acyltransferase domain 
containing 2 
0.764623 
155.  MCCC2 64087 210210;609014 methylcrotonoyl-CoA carboxylase 2 0.586974 
156.  SLC16A7 9194 603654 solute carrier family 16 member 7 0.753861 
157.  ME1 4199 154250 malic enzyme 1 0.482464 
158.  MAP3K1 4214 600982;613762 mitogen-activated protein kinase kinase kinase 1 0.465687 
159.  MEST 4232 601029 mesoderm specific transcript 0.752552 
160.  MGST3 4259 604564 microsomal glutathione S-transferase 3 0.545689 
161.  DUSP4 1846 602747 dual specificity phosphatase 4 0.405569 
162.  MMP16 4325 602262 matrix metallopeptidase 16 1.14912 
163.  MORF4L2 9643 300409 mortality factor 4 like 2 0.413342 
164.  MTMR2 8898 601382;603557 myotubularin related protein 2 0.65462 
165.  MUCL1 118430 610857 mucin like 1 0.762445 
166.  MUT 4594 251000;609058 methylmalonyl-CoA mutase 0.487788 
167.  PAM 23077 610392 
"MYC binding protein 2, E3 ubiquitin protein 
ligase" 
0.934899 
168.  MYO1B 4430 606537 myosin IB 0.632889 
169.  MYOF 26509 604603 myoferlin 0.462151 
170.  MYO6 4646 
600970;606346;60
7821 
myosin VI 0.654896 
171.  N4BP2 55728 No ID NEDD4 binding protein 2 0.685434 
172.  NCKAP5 344148 608789 NCK associated protein 5 1.05894 
173.  SLC8A1 6546 182305 solute carrier family 8 member A1 0.551218 
174.  NDRG3 57446 605273 NDRG family member 3 0.666619 
175.  NEBL 10529 605491 nebulette 0.609686 
176.  NEK6 10783 604884 NIMA related kinase 6 0.502781 
177.  BNIP3L 665 605368 BCL2 interacting protein 3 like 0.588141 
178.  NPC2 10577 601015;607625 NPC intracellular cholesterol transporter 2 0.423578 
179.  NQO1 1728 125860 NAD(P)H quinone dehydrogenase 1 0.46134 
180.  MAGED1 9500 300224 MAGE family member D1 0.787782 
181.  NRCAM 4897 601581 neuronal cell adhesion molecule 0.717003 
182.  NRK 203447 300791 Nik related kinase 1.47776 
183.  REST 5978 600571;616806 RE1 silencing transcription factor 0.481066 
184.  IVNS1ABP 10625 609209 influenza virus NS1A binding protein 0.366829 
185.  PRDX6 9588 602316 peroxiredoxin 6 0.390866 
186.  NRG3 10718 605533 neuregulin 3 1.70994 
187.  NBEA 26960 604889 neurobeachin 0.768566 
188.  NUS1 116150 610463;617082 
NUS1 dehydrodolichyl diphosphate synthase 
subunit 
0.412875 
189.  P4HA1 5033 176710 prolyl 4-hydroxylase subunit alpha 1 0.456554 
190.  PABPC1 26986 604679 poly(A) binding protein cytoplasmic 1 0.624322 
191.  PABPC4L 132430 No ID poly(A) binding protein cytoplasmic 4 like 0.881233 
192.  PAPSS1 9061 603262 






57717 604967;606345 protocadherin beta 16 0.666527 




56128 604967;606334 protocadherin beta 8 0.82234 
196.  PCYOX1 51449 610995 prenylcysteine oxidase 1 0.669556 
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197.  PDE4B 5142 600127 phosphodiesterase 4B 1.3981 
198.  PGK1 5230 300653;311800 phosphoglycerate kinase 1 0.542224 
199.  PGM1 55276 172000 phosphoglucomutase 2 0.744899 
200.  PHLDA1 22822 605335 
pleckstrin homology like domain family A 
member 1 
0.438257 
201.  PHTF2 57157 616785 putative homeodomain transcription factor 2 0.763051 
202.  PIR 11025 604820 leukocyte immunoglobulin like receptor B3 0.681574 
203.  PJA2 9867 No ID praja ring finger ubiquitin ligase 2 0.408532 
204.  PRKACA 5566 601639;615830 
protein kinase cAMP-activated catalytic subunit 
alpha 
0.544697 
205.  PLCXD3 345557 617016 
phosphatidylinositol specific phospholipase C X 
domain containing 3 
0.475518 




207.  PLXDC2 84898 606827 plexin domain containing 2 0.481995 
208.  PPP2R2B 5521 604325;604326 protein phosphatase 2 regulatory subunit Bbeta 1.6416 
209.  PPM1H 57460 616016 
"protein phosphatase, Mg2+/Mn2+ dependent 
1H" 
0.51243 
210.  PRICKLE2 166336 
607459;608501;61
3832 
prickle planar cell polarity protein 2 0.384805 
211.  PRR11 55771 615920 proline rich 11 0.602035 
212.  PSD3 23362 614440 pleckstrin and Sec7 domain containing 3 0.758157 
213.  PTPLA 9200 255310;610467 3-hydroxyacyl-CoA dehydratase 1 0.703489 
214.  PTDSS1 9791 151050;612792 phosphatidylserine synthase 1 0.457234 
215.  RABL5 64792 No ID intraflagellar transport 22 0.534114 
216.  GNB2L1 10399 176981 receptor for activated C kinase 1 0.346332 
217.  SMS 10743 182290;607642 retinoic acid induced 1 0.406627 
218.  REG4 83998 609846 regenerating family member 4 0.92634 
219.  RNF130 55819 No ID ring finger protein 130 0.61701 
220.  ROBO1 6091 602430 roundabout guidance receptor 1 1.05768 
221.  ROCK1 6093 601702 
Rho associated coiled-coil containing protein 
kinase 1 
0.448331 
222.  RPL11 6135 604175;612562 ribosomal protein L11 0.456786 
223.  RPL17 6139 603661 ribosomal protein L17 0.388701 
224.  RPL23A 6147 602326 ribosomal protein L23a 0.372125 
225.  RPL24 6152 604180 ribosomal protein L24 0.342158 
226.  RPL34 6164 616862 ribosomal protein L34 0.423911 
227.  RPL35A 6165 180468;612528 ribosomal protein L35a 0.364678 
228.  RPL39 6170 300899 ribosomal protein L39 0.429273 
229.  RPL4 6124 180479 ribosomal protein L4 0.428614 
230.  RPL41 6171 613315 ribosomal protein L41 0.532606 
231.  RPL5 6125 603634;612561 ribosomal protein L5 0.538675 




6129 604166 ribosomal protein L7 0.47839 
234.  RPL7A 6130 185640 ribosomal protein L7a 0.453726 
235.  RPL9 6133 603686 ribosomal protein L9 0.479611 
236.  RPS15A 6210 603674 ribosomal protein S15a 0.516768 
237.  RPS17 6218 180472;612527 ribosomal protein S17 0.865613 
238.  RPS4X 6191 312760 "ribosomal protein S4, X-linked" 0.495312 
239.  RPS6 6194 180460 ribosomal protein S6 0.460106 
240.  RPS7 6201 603658;612563 ribosomal protein S7 0.360347 
241.  RAB13 5872 602672 "RAB13, member RAS oncogene family" 0.389677 
242.  SASH1 23328 607955 SAM and SH3 domain containing 1 0.535221 
243.  SETD7 80854 606594 
SET domain containing lysine methyltransferase 
7 
0.39308 





SH3 domain binding glutamate rich protein like 
2 
0.741634 
246.  SIDT2 51092 No ID SID1 transmembrane family member 2 0.837797 
247.  SLC19A2 10560 249270;603941 solute carrier family 19 member 2 0.463341 
248.  SLC25A15 10166 238970;603861 solute carrier family 25 member 15 0.477293 
249.  SLC25A24 29957 608744 solute carrier family 25 member 24 0.375516 
250.  SLC25A3 5250 600370;610773 solute carrier family 25 member 3 0.544249 
251.  SLC25A43 203427 300641 solute carrier family 25 member 43 0.609365 
252.  SLC38A1 81539 608490 solute carrier family 38 member 1 0.655669 
253.  SLC39A6 25800 608731 solute carrier family 39 member 6 0.512706 
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254.  SLC44A1 23446 606105 solute carrier family 44 member 1 0.57194 
255.  SLC4A10 57282 605556 solute carrier family 4 member 10 0.74709 
256.  SLC4A7 9497 603353 solute carrier family 4 member 7 0.695701 
257.  SLIT2 9353 603746 slit guidance ligand 2 1.11886 
258.  SNX4 8723 605931 sorting nexin 4 0.522873 
259.  SOX2-OT 347689 616338 SOX2 overlapping transcript 1.37425 
260.  SEC11A 23478 No ID 
"SEC11 homolog A, signal peptidase complex 
subunit" 
0.460174 
261.  SRD5A1 6715 184753 steroid 5 alpha-reductase 1 0.655391 
262.  SSR2 6746 600867 signal sequence receptor subunit 2 0.479507 
263.  NSD1 64324 
117550;130650;60
6681 
nuclear receptor binding SET domain protein 1 0.571588 
264.  SUCLG2 8801 603922 succinate-CoA ligase GDP-forming beta subunit 0.520378 
265.  SULF1 23213 610012 sulfatase 1 0.824325 
266.  SUMF1 285362 272200;607939 sulfatase modifying factor 1 0.552387 
267.  SEC24D 9871 607186;616294 
"SEC24 homolog D, COPII coat complex 
component" 
0.544885 
268.  KIAA1598 57698 611171 shootin 1 0.644697 
269.  SPAST 6683 182601;604277 spastin 0.461301 
270.  STC1 6781 601185 stanniocalcin 1 0.480749 
271.  TANC1 85461 611397 
"tetratricopeptide repeat, ankyrin repeat and 
coiled-coil containing 1" 
0.46755 
272.  TC2N 123036 No ID "tandem C2 domains, nuclear" 0.538673 
273.  TET2 54790 
263300;612839;61
4286 
tet methylcytosine dioxygenase 2 0.526523 
274.  TFPI 7035 152310 tissue factor pathway inhibitor 0.696434 
275.  TGFB2 7042 190220;614816 transforming growth factor beta 2 0.983306 
276.  TIMP2 7077 188825 TIMP metallopeptidase inhibitor 2 0.451907 
277.  TLE4 7091 605132 transducin like enhancer of split 4 0.807059 
278.  TM9SF2 9375 604678 transmembrane 9 superfamily member 2 0.499806 
279.  TMEM2 23670 605835 transmembrane protein 2 1.03637 
280.  TMEM59 9528 617084 transmembrane protein 59 0.557126 
281.  TMEM65 157378 616609 transmembrane protein 65 0.57703 
282.  TMEM66 51669 614768 
store-operated calcium entry associated 
regulatory factor 
0.480183 
283.  LINC00052 145978 No ID long intergenic non-protein coding RNA 52 0.38313 
284.  TPT1 7178 600763 "tumor protein, translationally-controlled 1" 0.449878 
285.  TRIB2 28951 609462 tribbles pseudokinase 2 0.548341 
286.  TRPS1 7227 
150230;190350;19
0351;604386 
transcriptional repressor GATA binding 1 0.702954 
287.  TSPAN6 7105 300191 tetraspanin 6 0.473511 
288.  TTC3 7267 602259 tetratricopeptide repeat domain 3 0.809686 
289.  TUG1 55000 614971 taurine up-regulated 1 (non-protein coding) 0.603472 
290.  TUSC3 7991 601385;611093 tumor suppressor candidate 3 0.545792 
291.  TSPAN3 10099 613134 tetraspanin 3 0.410548 
292.  TMTC1 83857 615855 






153562 610153;610572 MARVEL domain containing 2 0.511093 
294.  TSPAN32 10077 603853 tetraspanin 32 1.96707 
295.  TUBA1A 7846 602529;611603 tubulin alpha 1a 0.784308 
296.  TUBD1 51174 607344 tubulin delta 1 0.463035 
297.  UBL3 5412 604711 ubiquitin like 3 0.437758 
298.  UCP2 7351 601693;607447 uncoupling protein 2 0.494843 
299.  UGDH 7358 603370 UDP-glucose 6-dehydrogenase 0.5911 




UDP glucuronosyltransferase family 1 member 
A4 
0.684012 
301.  CSDE1 7812 191510 cold shock domain containing E1 0.572963 
302.  SLC27A6 28965 604196 solute carrier family 27 member 6 0.686412 
303.  DCAF12 25853 No ID DDB1 and CUL4 associated factor 12 0.64399 
304.  WSB2 55884 No ID WD repeat and SOCS box containing 2 0.591227 
305.  XYLT1 64131 
264800;608124;61
5777 
xylosyltransferase 1 0.664025 
306.  YES1 7525 164880 
"YES proto-oncogene 1, Src family tyrosine 
kinase" 
0.484034 
307.  YPEL2 388403 609723 yippee like 2 0.691608 
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308.  MLTK 51776 609479;616890 
sterile alpha motif and leucine zipper containing 
kinase AZK 
0.481224 
309.  ZFP91 80829 No ID ZFP91 zinc finger protein 0.48339 
310.  ZNF652 22834 613907 zinc finger protein 652 0.397467 
311.  ITGB1 3688 135630 integrin subunit beta 1 0.816957 
312.  EEF1G 1937 130593 
eukaryotic translation elongation factor 1 
gamma 
0.53172 
313.  EIF3F 8665 603914 
eukaryotic translation initiation factor 3 subunit 
F 
0.563518 
314.  EIF3E 3646 602210 
eukaryotic translation initiation factor 3 subunit 
E 
0.566074 

























1.  VAT1L 57687 No ID vesicle amine transport 1 like 1.16268 1.0319 
2.  AIM1 202 601797 absent in melanoma 1 0.778095 0.658569 
3.  AKR1C3 8644 603966 
aldo-keto reductase family 1 
member C3 
0.885048 0.645128 
4.  ANKRD50 57182 No ID ankyrin repeat domain 50 0.73071 0.554446 
5.  ARL4C 10123 604787 
ADP ribosylation factor like 
GTPase 4C 
0.554121 0.695993 
6.  ARPC5 10092 604227 
actin related protein 2/3 
complex subunit 5 
0.586134 0.607786 
7.  ATP1A1 476 182310 
ATPase Na+/K+ transporting 
subunit alpha 1 
0.64489 0.431066 
8.  ATP5C1 509 108729 
"ATP synthase, H+ 
transporting, mitochondrial F1 
complex, gamma polypeptide 
1" 
0.6197 0.540511 
9.  ATP7A 538 
300011;300489;3
04150;309400 
ATPase copper transporting 
alpha 
0.798753 0.616152 
10.  TMSB4X 7114 300159 "thymosin beta 4, X-linked" 0.559619 0.483911 
11.  PGM5 5239 600981 phosphoglucomutase 5 2.04583 1.71094 
12.  ANXA1 301 151690 annexin A1 0.86142 0.786981 
13.  ANXA5 308 131230;614391 annexin A5 0.553169 0.52333 
14.  ATRN 8455 603130 attractin 0.717643 0.492748 
15.  BAK1P1 600 No ID 
BCL2 antagonist/killer 1 
pseudogene 1 
0.72886 0.853615 
16.  BMP5 653 112265 bone morphogenetic protein 5 0.836287 0.658327 
17.  XXYLT1 152002 614552 xyloside xylosyltransferase 1 0.716947 0.799999 
18.  CCDC167 154467 No ID 
coiled-coil domain containing 
167 
0.573969 0.620072 




20.  CD276 80381 605715 CD276 molecule 0.6514 0.687137 




CD36 molecule 0.991681 1.19904 
22.  SCUBE2 57758 611747 
"signal peptide, CUB domain 















25.  CRISP3 10321 No ID 
cysteine rich secretory protein 
3 
1.1613 0.739149 
26.  TET1 80312 607790 
tet methylcytosine dioxygenase 
1 
1.14532 1.06875 
27.  CYP19A1 1588 
107910;139300;6
13546 
cytochrome P450 family 19 
subfamily A member 1 
2.32583 2.35814 
28.  RCN2 10231 604876 regulator of calcineurin 2 0.531026 0.452163 
29.  CAV1 857 
601047;606721;6
12526;615343 
caveolin 1 1.16046 1.01584 
30.  PPIC 5480 123842 peptidylprolyl isomerase C 1.21937 1.17803 
31.  MIB1 57534 608677;615092 
mindbomb E3 ubiquitin protein 
ligase 1 
0.73351 0.521844 
32.  DNAJC28 54943 No ID 
DnaJ heat shock protein family 
(Hsp40) member C28 
1.06775 0.92687 
33.  FILIP1L 11259 612993 
filamin A interacting protein 1 
like 
0.667145 0.583131 
34.  DSC2 1824 125645;610476 desmocollin 2 1.29529 1.10679 
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35.  DYNLT1 6993 601554 dynein light chain Tctex-type 1 0.498623 0.60201 
36.  CLEC7A 64581 
606264;613108;6
14079 
C-type lectin domain family 7 
member A 
1.28516 1.75287 
37.  DSG2 1829 
125671;610193;6
12877 
desmoglein 2 0.743464 0.481257 
38.  VOPP1 81552 611915 
"vesicular, overexpressed in 
cancer, prosurvival protein 1" 
0.476688 0.451507 
39.  EPB41L4B 54566 610340 
erythrocyte membrane protein 
band 4.1 like 4B 
0.59199 0.530691 
40.  ELF5 2001 605169 
E74 like ETS transcription 
factor 5 
1.20403 1.00089 
41.  ENO1 2023 172430 enolase 1 0.499112 0.49841 




43.  EPHA6 285220 600066 EPH receptor A6 1.03363 0.877418 
44.  EPHA7 2045 602190 EPH receptor A7 0.879505 0.701687 
45.  FBP1 2203 229700;611570 fructose-bisphosphatase 1 0.45042 0.490642 
46.  FAM102B 284611 No ID 
family with sequence similarity 
102 member B 
0.61018 0.463769 
47.  FAM127C 441518 No ID 
family with sequence similarity 
127 member C 
0.511481 0.559729 
48.  FECH 2235 177000;612386 ferrochelatase 1.03486 0.802485 
49.  FKBP1A 2280 186945 FK506 binding protein 1A 0.72236 0.541505 
50.  C4orf32 132720 No ID 
chromosome 4 open reading 
frame 32 
0.716821 0.62176 
51.  EFEMP1 2202 126600;601548 
EGF containing fibulin like 
extracellular matrix protein 1 
0.943595 0.981479 
52.  FREM2 341640 219000;608945 
FRAS1 related extracellular 
matrix protein 2 
1.2842 1.13966 





54.  GCSH 2653 238330;605899 
glycine cleavage system 
protein H 
0.812153 0.678064 
55.  GSTM3 2946 138380 glutathione S-transferase mu 2 0.603347 0.474469 
56.  HEPHL1 341208 No ID hephaestin like 1 1.38329 1.14249 
57.  MAP4K4 9448 604666 
mitogen-activated protein 
kinase kinase kinase kinase 4 
0.6531 0.563603 
58.  HMGCLL1 54511 No ID 
3-hydroxymethyl-3-
methylglutaryl-CoA lyase like 
1 
1.15732 1.03274 
59.  S100A16 388697 616293 hornerin 0.669323 0.682906 
60.  HOXC13 3229 142976;614931 homeobox C13 0.546096 0.67975 
61.  IGFBP5 3488 146734 
insulin like growth factor 
binding protein 5 
0.52921 0.390971 




63.  ACO1 48 100880 aconitase 1 0.950629 0.626089 




65.  ITGB1 3688 135630 integrin subunit beta 1 0.816957 0.659117 
66.  F11R 50848 605721 F11 receptor 0.829893 0.805344 
67.  JARID2 3720 601594 
jumonji and AT-rich 
interaction domain containing 
2 
0.474666 0.444702 




channel subfamily J member 8 
0.940332 0.848572 
69.  KDELC1 79070 611613 KDEL motif containing 1 1.0655 1.27176 
70.  KIAA1161 57462 No ID KIAA1161 0.708471 0.59354 
71.  KIAA1549 57670 613344 KIAA1549 0.770061 0.663556 
72.  KLHDC3 116138 611248 kelch domain containing 3 0.612973 0.698181 
73.  KLHL4 56062 300348 kelch like family member 4 1.07248 0.81465 
74.  KLHL5 51088 608064 kelch like family member 5 0.756199 0.602252 
75.  KRT23 25984 606194 keratin 23 0.859914 0.780114 
76.  KRT80 144501 611161 keratin 80 0.387774 0.516173 
77.  LTBP1 4052 150390 
latent transforming growth 




78.  MALL 7851 602022 
"mal, T-cell differentiation 
protein like" 
1.60014 1.58334 
79.  MBTD1 54799 No ID mbt domain containing 1 0.616126 0.501719 
80.  SLC16A2 6567 300095;300523 
solute carrier family 16 
member 2 
1.25596 0.854277 
81.  MAP2K6 5608 601254 
mitogen-activated protein 
kinase kinase 6 
1.35071 1.27931 
82.  METTL7A 25840 No ID methyltransferase like 7A 0.81592 0.96939 
83.  MIR17HG 407975 609415;614326 miR-17-92a-1 cluster host gene 2.37174 2.2729 
84.  MPZL3 196264 611707 myelin protein zero like 3 0.796882 0.842667 
85.  MRFAP1 93621 616905 
Morf4 family associated 
protein 1 
0.465383 0.536648 
86.  MORF4L1 10933 607303 mortality factor 4 like 1 0.614757 0.563526 














acidic dipeptidase like 2 
0.69365 0.67568 
89.  SLC24A3 57419 609839 
solute carrier family 24 
member 3 
0.589257 0.4987 
90.  STK38 11329 606964 serine/threonine kinase 38 0.455075 0.426797 
91.  NPNT 255743 610306 nephronectin 0.774074 0.579707 






pyruvate dehydrogenase kinase 
3 
0.771457 0.564068 
94.  PCP4 5121 601629 Purkinje cell protein 4 0.864802 0.712848 
95.  PERP 64065 609301 
"PERP, TP53 apoptosis 
effector" 
0.587256 0.421452 
96.  PIK3R3 8503 606076 
phosphoinositide-3-kinase 
regulatory subunit 3 
0.801967 0.829185 
97.  C7orf73 647087 No ID 
chromosome 7 open reading 
frame 73 
0.803039 0.703753 
98.  KDM5B 10765 605393 lysine demethylase 5B 0.98413 0.779044 
99.  BPGM 669 222800;613896 bisphosphoglycerate mutase 0.744332 0.734537 












103.  PANX1 24145 608420 pannexin 1 0.666987 0.487432 
104.  PKP1 5317 601975;604536 plakophilin 1 1.25349 1.28295 
105.  RPS24 6229 602412;610629 ribosomal protein S24 0.555705 0.488549 
106.  RPS3A 6189 180478 ribosomal protein S3A 0.687786 0.491714 
107.  RTN3 10313 604249 reticulon 3 0.612048 0.503042 
108.  S100A10 6281 114085 
S100 calcium binding protein 
A10 
0.574568 0.414773 
109.  SERINC5 256987 614551 serine incorporator 5 0.805837 0.548127 
110.  SESTD1 91404 No ID 
SEC14 and spectrin domain 
containing 1 
1.10416 1.06537 
111.  SLITRK6 84189 221200;609681 
SLIT and NTRK like family 
member 6 
0.786628 0.553729 





113.  SCIN 85477 613416 scinderin 1.3387 1.19559 
114.  SEMA3C 10512 602645 semaphorin 3C 0.865222 0.66281 
115.  SEMA3D 223117 609907 semaphorin 3D 1.48777 1.16477 
116.  SORT1 6272 602458;613589 sortilin 1 0.749978 0.522416 
117.  STON1 11037 605357 stonin 1 1.5401 1.4028 
118.  TBC1D7 51256 248000;612655 
TBC1 domain family member 
7 
0.921924 0.83745 
119.  RCC2 55920 609587 
regulator of chromosome 
condensation 2 
0.401982 0.591432 
120.  TDG 6996 601423 thymine DNA glycosylase 0.815785 0.81763 
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121.  TET3 200424 613555 
tet methylcytosine dioxygenase 
3 
0.923868 1.01061 
122.  TMEM117 84216 No ID transmembrane protein 117 1.76039 1.52825 
123.  TMEM164 84187 No ID transmembrane protein 164 0.8879 0.803582 
124.  TMEM45B 120224 No ID transmembrane protein 45B 0.797278 0.752252 
125.  TOP2B 7155 126431 topoisomerase (DNA) II beta 0.707055 0.519007 
126.  NTRK2 4915 600456;613886 
neurotrophic receptor tyrosine 
kinase 2 
0.987398 1.21638 
127.  UBTD2 92181 610174 ubiquitin domain containing 2 0.753085 0.627815 
128.  UNC5C 8633 603610 unc-5 netrin receptor C 1.2494 1.47876 
129.  VAMP7 6845 300053 
vesicle associated membrane 
protein 7 
0.950366 0.81555 
130.  WNT2B 7482 601968 Wnt family member 2B 1.1319 1.0473 
131.  TRAK2 66008 607334 trafficking kinesin protein 2 0.706495 0.568506 


















 Gene Symbol 
Entrez Gene 
IDs 
OMIM IDs Gene Name log2(fold change) 
1.  CDR1 1038 302650 
cerebellar degeneration related 
protein 1 
1.25927 
2.  CASP14 23581 605848 caspase 14 3.26142 
3.  DNMT3B 1789 242860;602900 DNA methyltransferase 3 beta 0.592581 
4.  SGK196 84197 615247;615249;616094 protein-O-mannose kinase 0.792492 
5.  SERPINH1 871 600943;610504;613848 serpin family H member 1 0.691306 
6.  NRBP1 29959 606010 nuclear receptor binding protein 1 0.446701 






Supplementary Table 3: miR-29 targets in LCC9 cells 
 
Supplementary Table 3A: miR-29b-1 unique targets in LCC9 cells 
 




 Input IDs Gene Symbol Gene Name 
log2(fold 
change) 
1.  ENSG00000106049 HIBADH 3-hydroxyisobutyrate dehydrogenase 0.491816 
2.  ENSG00000150756 FAM173B family with sequence similarity 173 member B 0.610799 
3.  ENSG00000204574 ABCF1 ATP binding cassette subfamily F member 1 0.404991 
4.  ENSG00000197150 ABCB8 ATP binding cassette subfamily B member 8 0.490734 
5.  ENSG00000060971 ACAA1 acetyl-CoA acyltransferase 1 0.400058 
6.  ENSG00000141385 AFG3L2 AFG3 like matrix AAA peptidase subunit 2 0.728778 
7.  ENSG00000188266 HYKK hydroxylysine kinase 0.511482 
8.  ENSG00000155085 AK9 adenylate kinase 9 0.652831 
9.  ENSG00000187134 AKR1C1 aldo-keto reductase family 1 member C1 0.648362 
10.  ENSG00000196139 AKR1C3 aldo-keto reductase family 1 member C3 0.556808 
11.  ENSG00000172339 ALG14 ALG14, UDP-N-acetylglucosaminyltransferase subunit 0.826509 
12.  ENSG00000137760 ALKBH8 alkB homolog 8, tRNA methyltransferas" 0.63568 
13.  ENSG00000088448 ANKRD10 ankyrin repeat domain 10 0.692931 
14.  ENSG00000132623 ANKEF1 ankyrin repeat and EF-hand domain containing 1 0.491522 
15.  ENSG00000116819 TFAP2E transcription factor AP-2 epsilon 1.24266 
16.  ENSG00000149089 APIP APAF1 interacting protein 0.585429 
17.  ENSG00000169621 APLF aprataxin and PNKP like factor 0.666282 
18.  ENSG00000113966 ARL6 ADP ribosylation factor like GTPase 6 0.590646 
19.  ENSG00000143437 ARNT aryl hydrocarbon receptor nuclear translocator 0.576123 
20.  ENSG00000130707 ASS1 argininosuccinate synthase 1 0.569205 
21.  ENSG00000176208 ATAD5 ATPase family, AAA domain containing 5 0.409172 
22.  ENSG00000115966 ATF2 activating transcription factor 2 0.636007 
23.  ENSG00000122507 BBS9 Bardet-Biedl syndrome 9 0.732789 
24.  ENSG00000236824 BCYRN1 brain cytoplasmic RNA 1 0.733708 
25.  ENSG00000136573 BLK BLK proto-oncogene, Src family tyrosine kinase 1.73238 
26.  ENSG00000184992 BRI3BP BRI3 binding protein 0.388747 
27.  ENSG00000074317 SNCB synuclein beta 1.28303 
28.  ENSG00000122378 FAM213A family with sequence similarity 213 member A 0.500409 
29.  ENSG00000022277 RTFDC1 replication termination factor 2 domain containing 1 0.382306 
30.  ENSG00000184809 B3GALT5-AS1 B3GALT5 antisense RNA 1 1.15966 
31.  ENSG00000172478 C2orf54 chromosome 2 open reading frame 54 1.28875 
32.  ENSG00000196821 C6orf106 chromosome 6 open reading frame 106 0.542815 
33.  ENSG00000203778 FAM229B family with sequence similarity 229 member B 0.720804 
34.  ENSG00000147894 C9orf72 chromosome 9 open reading frame 72 0.647372 
35.  ENSG00000003989 SLC7A2 solute carrier family 7 member 2 0.476024 
36.  ENSG00000172785 CBWD1 COBW domain containing 1 0.417456 
37.  ENSG00000163001 CFAP36 cilia and flagella associated protein 36 0.533663 
38.  ENSG00000109881 CCDC34 coiled-coil domain containing 34 0.651414 
39.  ENSG00000141519 CCDC40 coiled-coil domain containing 40 1.16175 
40.  ENSG00000173588 CEP83 centrosomal protein 83 0.710338 
41.  ENSG00000081377 CDC14B cell division cycle 14B 0.657699 
42.  ENSG00000100526 CDKN3 cyclin dependent kinase inhibitor 3 0.378184 
43.  ENSG00000166446 CDYL2 chromodomain Y-like 2 0.756545 
44.  ENSG00000114107 CEP70 centrosomal protein 70 0.527855 
45.  ENSG00000188153 COL4A5 collagen type IV alpha 5 chain 1.26463 
46.  ENSG00000138663 COPS4 COP9 signalosome subunit 4 0.575052 
47.  ENSG00000111652 COPS7A COP9 signalosome subunit 7A 0.470495 
48.  ENSG00000096006 CRISP3 cysteine rich secretory protein 3 0.74899 
49.  ENSG00000049656 CLPTM1L CLPTM1 like 0.516426 
50.  ENSG00000145681 HAPLN1 hyaluronan and proteoglycan link protein 1 4.09352 
51.  ENSG00000124207 CSE1L chromosome segregation 1 like 0.396727 
52.  ENSG00000150527 CTAGE5 "CTAGE family member 5, ER export factor" 0.479836 
53.  ENSG00000137770 CTDSPL2 CTD small phosphatase like 2 0.660265 
54.  ENSG00000111249 CUX2 cut like homeobox 2 0.772002 
55.  ENSG00000161921 CXCL16 C-X-C motif chemokine ligand 16 0.654154 
 
 188 
56.  ENSG00000174437 ATP2A2 
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ 
transporting 2 
0.464372 
57.  ENSG00000152495 CAMK4 calcium/calmodulin dependent protein kinase IV 1.09332 
58.  ENSG00000132906 CASP9 caspase 9 0.586727 
59.  ENSG00000150764 DIXDC1 DIX domain containing 1 0.874583 
60.  ENSG00000167670 CHAF1A chromatin assembly factor 1 subunit A 0.759801 
61.  ENSG00000111907 TPD52L1 tumor protein D52-like 1 0.484994 
62.  ENSG00000134107 BHLHE40 basic helix-loop-helix family member e40 0.5102 
63.  ENSG00000155792 DEPTOR DEP domain containing MTOR-interacting protein 1.01048 
64.  ENSG00000136044 APPL2 
"adaptor protein, phosphotyrosine interacting with PH 
domain and leucine zipper 2" 
0.847216 
65.  ENSG00000126698 DNAJC8 DnaJ heat shock protein family (Hsp40) member C8 0.444634 
66.  ENSG00000189212 DPY19L2P1 DPY19L2 pseudogene 1 0.557364 
67.  ENSG00000165891 E2F7 E2F transcription factor 7 0.580426 
68.  ENSG00000164330 EBF1 early B-cell factor 1 2.01344 
69.  ENSG00000109381 ELF2 E74 like ETS transcription factor 2 0.584111 
70.  ENSG00000138185 ENTPD1 ectonucleoside triphosphate diphosphohydrolase 1 0.51802 
71.  ENSG00000187672 ERC2 ELKS/RAB6-interacting/CAST family member 2 0.765149 
72.  ENSG00000170515 PA2G4 proliferation-associated 2G4 0.534069 
73.  ENSG00000185900 POMK protein-O-mannose kinase 0.865861 
74.  ENSG00000133216 EPHB2 EPH receptor B2 0.546443 
75.  ENSG00000031003 FAM13B family with sequence similarity 13 member B 0.523452 
76.  ENSG00000154511 FAM69A family with sequence similarity 69 member A 0.569141 
77.  ENSG00000158169 FANCC Fanconi anemia complementation group C 0.900585 
78.  ENSG00000160752 FDPS farnesyl diphosphate synthase 0.65476 
79.  ENSG00000169018 FEM1B fem-1 homolog B 0.807097 
80.  ENSG00000197296 FITM2 fat storage inducing transmembrane protein 2 0.374061 
81.  ENSG00000198468 FLVCR1-AS1 FLVCR1 antisense RNA 1 (head to head) 0.934593 
82.  ENSG00000138759 FRAS1 Fraser extracellular matrix complex subunit 1 0.825708 
83.  ENSG00000150667 FSIP1 fibrous sheath interacting protein 1 4.68256 
84.  ENSG00000114450 GNB4 G protein subunit beta 4 0.651437 
85.  ENSG00000242616 GNG10 G protein subunit gamma 10 0.677874 
86.  ENSG00000172380 GNG12 G protein subunit gamma 12 0.792578 
87.  ENSG00000164949 GEM GTP binding protein overexpressed in skeletal muscle 0.570737 
88.  ENSG00000198814 GK glycerol kinase 1.29919 
89.  ENSG00000130309 COLGALT1 collagen beta(1-O)galactosyltransferase 1 0.676398 
90.  ENSG00000073605 GSDMB gasdermin B 0.835803 
91.  ENSG00000226259 GTF2H2B general transcription factor IIH subunit 2B (pseudogene) 1.24475 
92.  ENSG00000234741 GAS5 growth arrest specific 5 (non-protein coding) 0.584347 
93.  ENSG00000179409 GEMIN4 gem nuclear organelle associated protein 4 0.498702 
94.  ENSG00000175697 GPR156 G protein-coupled receptor 156 0.564154 
95.  ENSG00000249115 HAUS5 HAUS augmin like complex subunit 5 0.562282 
96.  ENSG00000048052 HDAC9 histone deacetylase 9 1.17183 
97.  ENSG00000206053 HN1L hematological and neurological expressed 1 like 0.716046 
98.  ENSG00000149428 HYOU1 hypoxia up-regulated 1 0.37912 
99.  ENSG00000146674 IGFBP3 insulin like growth factor binding protein 3 1.78987 
100.  ENSG00000032742 IFT88 intraflagellar transport 88 0.561653 
101.  ENSG00000243646 IL10RB interleukin 10 receptor subunit beta 1.09275 
102.  ENSG00000016402 IL20RA interleukin 20 receptor subunit alpha 0.687926 
103.  ENSG00000148950 IMMP1L inner mitochondrial membrane peptidase subunit 1 1.24312 
104.  ENSG00000240682 ISY1 ISY1 splicing factor homolog 0.766524 
105.  ENSG00000082781 ITGB5 integrin subunit beta 5 0.537403 
106.  ENSG00000140057 AK7 adenylate kinase 7 0.986999 
107.  ENSG00000140854 KATNB1 katanin regulatory subunit B1 0.560459 
108.  ENSG00000122778 KIAA1549 KIAA1549 0.738185 
109.  ENSG00000102271 KLHL4 kelch like family member 4 0.978512 
110.  ENSG00000118162 KPTN "kaptin, actin binding protein" 0.648915 
111.  ENSG00000102781 KATNAL1 katanin catalytic subunit A1 like 1 0.545075 
112.  ENSG00000170523 KRT83 keratin 83 0.821228 
113.  ENSG00000170745 KCNS3 
potassium voltage-gated channel modifier subfamily S 
member 3 
0.504918 
114.  ENSG00000131023 LATS1 large tumor suppressor kinase 1 0.454589 
115.  ENSG00000134333 LDHA lactate dehydrogenase A 0.556593 
116.  ENSG00000179241 LDLRAD3 
low density lipoprotein receptor class A domain containing 
3 
0.659617 
117.  ENSG00000117114 ADGRL2 adhesion G protein-coupled receptor L2 1.38087 
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118.  ENSG00000235823 OLMALINC 
oligodendrocyte maturation-associated long intergenic non-
coding RNA 
0.489124 
119.  ENSG00000145832 SLC25A48 solute carrier family 25 member 48 2.62358 
120.  ENSG00000213468 FIRRE firre intergenic repeating RNA element 0.60146 
121.  ENSG00000237732 LOC440934 uncharacterized LOC440934 1.06641 
122.  ENSG00000236850 BMS1P20 "BMS1, ribosome biogenesis factor pseudogene 20" 0.42462 
123.  ENSG00000198121 LPAR1 lysophosphatidic acid receptor 1 1.78063 
124.  ENSG00000117600 PLPPR4 phospholipid phosphatase related 4 2.03628 
125.  ENSG00000168904 LRRC28 leucine rich repeat containing 28 0.44925 
126.  ENSG00000066557 LRRC40 leucine rich repeat containing 40 0.368294 
127.  ENSG00000106853 PTGR1 prostaglandin reductase 1 0.548995 
128.  ENSG00000049323 LTBP1 latent transforming growth factor beta binding protein 1 0.591944 
129.  ENSG00000178802 MPI mannose phosphate isomerase 0.488671 
130.  ENSG00000116586 LAMTOR2 
"late endosomal/lysosomal adaptor, MAPK and MTOR 
activator 2" 
0.365329 
131.  ENSG00000166974 MAPRE2 microtubule associated protein RP/EB family member 2 1.40219 
132.  ENSG00000076003 MCM6 minichromosome maintenance complex component 6 0.531703 
133.  ENSG00000065833 ME1 malic enzyme 1 0.423041 
134.  ENSG00000175581 MRPL48 mitochondrial ribosomal protein L48 0.562058 
135.  ENSG00000048544 MRPS10 mitochondrial ribosomal protein S10 0.366277 
136.  ENSG00000164953 TMEM67 transmembrane protein 67 0.890988 
137.  ENSG00000147166 ITGB1BP2 integrin subunit beta 1 binding protein 2 1.7052 
138.  ENSG00000126858 RHOT1 ras homolog family member T1 0.621903 
139.  ENSG00000078177 N4BP2 NEDD4 binding protein 2 0.775605 
140.  ENSG00000228224 NACAP1 
nascent polypeptide associated complex alpha subunit 
pseudogene 1 
0.852377 
141.  ENSG00000125814 NAPB NSF attachment protein beta 0.41552 
142.  ENSG00000110583 NAA40 "N(alpha)-acetyltransferase 40, NatD catalytic subunit" 0.93559 
143.  ENSG00000196290 NIF3L1 NGG1 interacting factor 3 like 1 0.477036 
144.  ENSG00000176171 BNIP3 BCL2 interacting protein 3 0.400854 
145.  ENSG00000113389 NPR3 natriuretic peptide receptor 3 0.731253 
146.  ENSG00000184117 NIPSNAP1 nipsnap homolog 1 (C. elegans) 0.419627 
147.  ENSG00000084628 NKAIN1 Na+/K+ transporting ATPase interacting 1 0.930873 
148.  ENSG00000218336 TENM3 teneurin transmembrane protein 3 0.946142 
149.  ENSG00000122884 P4HA1 prolyl 4-hydroxylase subunit alpha 1 0.670883 
150.  ENSG00000180228 PRKRA protein activator of interferon induced protein kinase  0.415149 
151.  ENSG00000141127 PRPSAP2 
phosphoribosyl pyrophosphate synthetase associated 
protein 2 
0.413774 
152.  ENSG00000177839 PCDHB9 protocadherin beta 9 0.795703 
153.  ENSG00000205268 PDE7A phosphodiesterase 7A 0.626122 
154.  ENSG00000170962 PDGFD platelet derived growth factor D 1.08647 
155.  ENSG00000100227 POLDIP3 DNA polymerase delta interacting protein 3 0.621359 
156.  ENSG00000198721 ECI2 enoyl-CoA delta isomerase 2 0.724378 
157.  ENSG00000173868 PHOSPHO1 phosphoethanolamine/phosphocholine phosphatase 1.0788 
158.  ENSG00000169756 LIMS1 LIM zinc finger domain containing 1 0.507993 
159.  ENSG00000005249 PRKAR2B protein kinase cAMP-dependent typeII regulatory subunit β 0.96804 
160.  ENSG00000169621 PROKR1 prokineticin receptor 1 0.666282 
161.  ENSG00000106086 PLEKHA8 pleckstrin homology domain containing A8 0.54894 
162.  ENSG00000014138 POLA2 "DNA polymerase alpha 2, accessory subunit" 0.465248 
163.  ENSG00000144231 POLR2D RNA polymerase II subunit D 0.50258 
164.  ENSG00000185238 PRMT3 protein arginine methyltransferase 3 0.399367 
165.  ENSG00000166033 HTRA1 HtrA serine peptidase 1 0.448859 
166.  ENSG00000121766 ZCCHC17 zinc finger CCHC-type containing 17 0.745644 
167.  ENSG00000138430 OLA1 Obg like ATPase 1 0.454699 
168.  ENSG00000139304 PTPRQ "protein tyrosine phosphatase, receptor type Q" 1.30696 
169.  ENSG00000091127 PUS7 pseudouridylate synthase 7 (putative) 1.05676 
170.  ENSG00000059573 ALDH18A1 aldehyde dehydrogenase 18 family member A1 0.531767 
171.  ENSG00000004399 PLXND1 plexin D1 0.785074 
172.  ENSG00000143801 PSEN2 presenilin 2 0.577816 
173.  ENSG00000089050 RBBP9 "RB binding protein 9, serine hydrolase" 0.62783 
174.  ENSG00000213516 RBMXL1 "RNA binding motif protein, X-linked like 1" 0.83167 
175.  ENSG00000162444 RBP7 retinol binding protein 7 0.731566 
176.  ENSG00000122707 RECK reversion inducing cysteine rich protein with kazal motifs 0.634226 
177.  ENSG00000203668 CHML "CHM like, Rab escort protein 2" 0.51309 
178.  ENSG00000111404 RERGL RERG like 2.21964 
179.  ENSG00000165731 RET ret proto-oncogene 0.50531 
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180.  ENSG00000121481 RNF2 ring finger protein 2 0.509205 
181.  ENSG00000180530 NRIP1 nuclear receptor interacting protein 1 0.37917 
182.  ENSG00000110315 RNF141 ring finger protein 141 0.670646 
183.  ENSG00000198242 RPL23A ribosomal protein L23a 0.381132 
184.  ENSG00000089009 RPL6 ribosomal protein L6 0.636679 
185.  ENSG00000146223 RPL7L1 ribosomal protein L7 like 1 0.477004 
186.  ENSG00000139998 RAB15 "RAB15, member RAS oncogene family" 1.00517 
187.  ENSG00000133318 RTN3 reticulon 3 0.404803 
188.  ENSG00000140943 MBTPS1 "membrane bound transcription factor peptidase, site 1" 0.791293 
189.  ENSG00000092108 SCFD1 sec1 family domain containing 1 0.462588 
190.  ENSG00000102098 SCML2 sex comb on midleg-like 2 (Drosophila) 0.614317 
191.  ENSG00000143653 SCCPDH saccharopine dehydrogenase (putative) 0.383584 
192.  ENSG00000086475 SEPHS1 selenophosphate synthetase 1 0.581941 
193.  ENSG00000196136 SERPINA3 serpin family A member 3 0.834504 
194.  ENSG00000176974 SHMT1 serine hydroxymethyltransferase 1 0.464031 
195.  ENSG00000146414 SHPRH SNF2 histone linker PHD RING helicase 0.631553 
196.  ENSG00000072858 SIDT1 SID1 transmembrane family member 1 0.514638 
197.  ENSG00000179542 SLITRK4 SLIT and NTRK like family member 4 0.584921 
198.  ENSG00000139324 TMTC3 transmembrane and tetratricopeptide repeat containing 3 0.659666 
199.  ENSG00000188176 SMTNL2 smoothelin like 2 1.49332 
200.  ENSG00000132639 SNAP25 synaptosome associated protein 25 2.16937 
201.  ENSG00000129673 AANAT aralkylamine N-acetyltransferase 2.09567 
202.  ENSG00000112335 SNX3 sorting nexin 3 0.378761 
203.  ENSG00000145375 SPATA5 spermatogenesis associated 5 0.491729 
204.  ENSG00000149136 SSRP1 structure specific recognition protein 1 0.392846 
205.  ENSG00000110066 KMT5B lysine methyltransferase 5B 0.482419 
206.  ENSG00000159164 SV2A synaptic vesicle glycoprotein 2A 0.398681 
207.  ENSG00000006747 SCIN scinderin 0.478395 
208.  ENSG00000150961 SEC24D "SEC24 homolog D, COPII coat complex component" 0.852999 
209.  ENSG00000167680 SEMA6B semaphorin 6B 0.508275 
210.  ENSG00000198879 SFMBT2 Scm-like with four mbt domains 2 0.390137 
211.  ENSG00000187164 SHTN1 shootin 1 0.496706 
212.  ENSG00000150753 CCT5 chaperonin containing TCP1 subunit 5 0.621055 
213.  ENSG00000204852 TCTN1 tectonic family member 1 0.814604 
214.  ENSG00000083544 TDRD3 tudor domain containing 3 0.599608 
215.  ENSG00000187735 TCEA1 transcription elongation factor A1 0.363363 
216.  ENSG00000118707 TGIF2 TGFB induced factor homeobox 2 0.91099 
217.  ENSG00000111602 TIMELESS timeless circadian clock 0.468897 
218.  ENSG00000100234 TIMP3 TIMP metallopeptidase inhibitor 3 0.884252 
219.  ENSG00000185650 ZFP36L1 ZFP36 ring finger protein like 1 0.363495 
220.  ENSG00000164841 TMEM74 transmembrane protein 74 0.659316 
221.  ENSG00000168234 TTC39C tetratricopeptide repeat domain 39C 0.645904 
222.  ENSG00000114999 TTL tubulin tyrosine ligase 0.436904 
223.  ENSG00000253352 TUG1 taurine up-regulated 1 (non-protein coding) 0.663468 
224.  ENSG00000102241 HTATSF1 HIV-1 Tat specific factor 1 0.438483 
225.  ENSG00000140534 TICRR TOPBP1 interacting checkpoint and replication regulator 0.49207 
226.  ENSG00000152086 TUBA3E tubulin alpha 3e 2.34108 
227.  ENSG00000123416 TUBA1B tubulin alpha 1b 0.396279 
228.  ENSG00000074935 TUBE1 tubulin epsilon 1 0.587981 
229.  ENSG00000117143 UAP1 UDP-N-acetylglucosamine pyrophosphorylase 1 0.455078 
230.  ENSG00000078967 UBE2D4 ubiquitin conjugating enzyme E2 D4 (putative) 0.778811 
231.  ENSG00000165816 VWA2 von Willebrand factor A domain containing 2 0.928517 
232.  ENSG00000132970 WASF3 WAS protein family member 3 0.629683 
233.  ENSG00000065183 WDR3 WD repeat domain 3 0.500013 
234.  ENSG00000176105 YES1 "YES proto-oncogene 1, Src family tyrosine kinase" 0.431171 
235.  ENSG00000257267 ZNF271P "zinc finger protein 271, pseudogene" 0.497983 
236.  ENSG00000130844 ZNF331 zinc finger protein 331 0.516318 
237.  ENSG00000160094 ZNF362 zinc finger protein 362 0.911363 
238.  ENSG00000142556 ZNF614 zinc finger protein 614 0.740139 
239.  ENSG00000186777 ZNF732 zinc finger protein 732 0.491996 
240.  ENSG00000091428 RAPGEF4 Rap guanine nucleotide exchange factor 4 1.03583 
241.  ENSG00000138660 AP1AR 
adaptor related protein complex 1 associated regulatory 
protein 
1.03233 
242.  ENSG00000256806 C17orf100 chromosome 17 open reading frame 100 1.62273 























1.  ENSG00000108953 YWHAE 
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein epsilon 
0.487217 0.457738 
2.  ENSG00000223414 LINC00473 long intergenic non-protein coding RNA 473 4.3032 5.28493 
3.  ENSG00000172243 CLEC7A C-type lectin domain family 7 member A 2.31239 4.17419 
4.  ENSG00000152661 GJA1 gap junction protein alpha 1 4.11427 3.86025 
5.  ENSG00000168306 ACOX2 acyl-CoA oxidase 2 4.65734 3.66441 
6.  ENSG00000187678 SPRY4 sprouty RTK signaling antagonist 4 2.72265 3.40137 
7.  ENSG00000198937 CCDC167 coiled-coil domain containing 167 3.39142 3.38646 
8.  ENSG00000113140 SPARC secreted protein acidic and cysteine rich 2.76873 3.35492 
9.  ENSG00000150779 TIMM8B 
translocase of inner mitochondrial membrane 8 
homolog B 
2.80661 3.09556 
10.  ENSG00000143546 S100A8 S100 calcium binding protein A8 1.92461 3.08523 
11.  ENSG00000175832 ETV4 ETS variant 4 2.98963 2.98716 
12.  ENSG00000128271 ADORA2A adenosine A2a receptor 2.30518 2.9572 
13.  ENSG00000145979 TBC1D7 TBC1 domain family member 7 2.64112 2.93259 
14.  ENSG00000144891 AGTR1 angiotensin II receptor type 1 2.79834 2.8424 
15.  ENSG00000064205 WISP2 WNT1 inducible signaling pathway protein 2 2.80975 2.83438 
16.  ENSG00000169181 GSG1L GSG1 like 3.08116 2.83152 
17.  ENSG00000163485 ADORA1 adenosine A1 receptor 2.51826 2.81189 
18.  ENSG00000160050 CCDC28B coiled-coil domain containing 28B 2.65578 2.80182 
19.  ENSG00000134901 KDELC1 KDEL motif containing 1 3.01117 2.79997 
20.  ENSG00000071575 TRIB2 tribbles pseudokinase 2 2.8007 2.78841 
21.  ENSG00000174453 VWC2L 
von Willebrand factor C domain containing protein 2-
like 
3.02552 2.7854 
22.  ENSG00000123560 PLP1 proteolipid protein 1 1.78971 2.78286 
23.  ENSG00000198890 PRMT6 protein arginine methyltransferase 6 2.51833 2.72602 
24.  ENSG00000126010 GRPR gastrin releasing peptide receptor 2.54854 2.69536 
25.  ENSG00000116774 OLFML3 olfactomedin like 3 2.60869 2.68797 
26.  ENSG00000244405 ETV5 ETS variant 5 1.71214 2.63838 
27.  ENSG00000162892 IL24 interleukin 24 2.76179 2.61736 
28.  ENSG00000064995 TAF11 TATA-box binding protein associated factor 11 2.53393 2.61299 
29.  ENSG00000164120 HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) 2.94784 2.59741 
30.  ENSG00000105671 DDX49 DEAD-box helicase 49 2.34706 2.59104 
31.  ENSG00000163220 S100A9 S100 calcium binding protein A9 1.53666 2.52338 
32.  ENSG00000164761 TNFRSF11B TNF receptor superfamily member 11b 2.27648 2.51838 
33.  ENSG00000179051 RCC2 regulator of chromosome condensation 2 2.40005 2.4671 
34.  ENSG00000132821 VSTM2L V-set and transmembrane domain containing 2 like 2.51467 2.41676 
35.  ENSG00000105967 TFEC transcription factor EC 2.11704 2.40168 
36.  ENSG00000142224 IL19 interleukin 19 3.06232 2.39884 
37.  ENSG00000104147 OIP5 Opa interacting protein 5 2.11953 2.39693 
38.  ENSG00000092208 GEMIN2 gem nuclear organelle associated protein 2 2.09195 2.368 
39.  ENSG00000136783 NIPSNAP3A nipsnap homolog 3A 1.98433 2.36503 
40.  ENSG00000138326 RPS24 ribosomal protein S24 2.25259 2.36119 
41.  ENSG00000198856 OSTC 
oligosaccharyltransferase complex non-catalytic 
subunit 
2.19415 2.35898 
42.  ENSG00000139372 TDG thymine DNA glycosylase 2.25669 2.35879 
43.  ENSG00000163347 CLDN1 claudin 1 1.59109 2.35224 
44.  ENSG00000166106 ADAMTS15 
ADAM metallopeptidase with thrombospondin type 1 
motif 15 
2.63156 2.34575 
45.  ENSG00000256870 SLC5A8 solute carrier family 5 member 8 2.78152 2.31415 
46.  ENSG00000183036 PCP4 Purkinje cell protein 4 2.79053 2.29124 
47.  ENSG00000260231 
JHDM1D-
AS1 
JHDM1D antisense RNA 1 (head to head) 1.91105 2.28899 
48.  ENSG00000173950 XXYLT1 xyloside xylosyltransferase 1 2.16137 2.27884 
49.  ENSG00000179388 EGR3 early growth response 3 2.35585 2.26571 
50.  ENSG00000132004 FBXW9 F-box and WD repeat domain containing 9 1.83408 2.26133 
51.  ENSG00000123364 HOXC13 homeobox C13 2.13121 2.22351 
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52.  ENSG00000158164 TMSB15A thymosin beta 15a 2.53916 2.21981 
53.  ENSG00000169248 CXCL11 C-X-C motif chemokine ligand 11 2.02203 2.21208 
54.  ENSG00000242265 PEG10 paternally expressed 10 2.10984 2.21207 
55.  ENSG00000137441 FGFBP2 fibroblast growth factor binding protein 2 2.90166 2.19779 
56.  ENSG00000135046 ANXA1 annexin A1 2.13207 2.17304 
57.  ENSG00000170855 TRIAP1 TP53 regulated inhibitor of apoptosis 1 2.00172 2.1629 
58.  ENSG00000168938 PPIC peptidylprolyl isomerase C 2.04242 2.15937 
59.  ENSG00000135346 CGA "glycoprotein hormones, alpha polypeptide" 1.43795 2.15628 
60.  ENSG00000108984 MAP2K6 mitogen-activated protein kinase kinase 6 2.61089 2.15353 
61.  ENSG00000006625 GGCT gamma-glutamylcyclotransferase 2.08826 2.14783 
62.  ENSG00000146425 DYNLT1 dynein light chain Tctex-type 1 1.94914 2.14702 
63.  ENSG00000101057 MYBL2 MYB proto-oncogene like 2 2.03609 2.14457 
64.  ENSG00000179010 MRFAP1 Morf4 family associated protein 1 2.03319 2.14254 
65.  ENSG00000108578 BLMH bleomycin hydrolase 2.51864 2.13864 
66.  ENSG00000139055 ERP27 endoplasmic reticulum protein 27 1.63098 2.08328 
67.  ENSG00000075290 WNT8B Wnt family member 8B 1.5311 2.08131 
68.  ENSG00000226950 DANCR differentiation antagonizing non-protein coding RNA 1.67735 2.07894 
69.  ENSG00000124702 KLHDC3 kelch domain containing 3 1.94245 2.07298 
70.  ENSG00000149257 SERPINH1 serpin family H member 1 1.97041 2.06858 
71.  ENSG00000121005 CRISPLD1 
cysteine rich secretory protein LCCL domain 
containing 1 
2.05979 2.05316 
72.  ENSG00000108511 HOXB6 homeobox B6 1.8322 2.04239 
73.  ENSG00000106484 MEST mesoderm specific transcript 2.28148 2.02826 
74.  ENSG00000198729 PPP1R14C protein phosphatase 1 regulatory inhibitor subunit 14C 2.03073 2.02062 
75.  ENSG00000170899 GSTA4 glutathione S-transferase alpha 4 1.77556 2.01732 
76.  ENSG00000153012 LGI2 leucine rich repeat LGI family member 2 2.18862 2.00029 
77.  ENSG00000140905 GCSH glycine cleavage system protein H 2.03522 1.98461 
78.  ENSG00000168256 NKIRAS2 NFKB inhibitor interacting Ras like 2 1.79244 1.98048 
79.  ENSG00000233101 HOXB-AS3 HOXB cluster antisense RNA 3 2.07946 1.9725 
80.  ENSG00000157404 KIT KIT proto-oncogene receptor tyrosine kinase 2.10612 1.97156 
81.  ENSG00000144451 SPAG16 sperm associated antigen 16 2.78745 1.96532 
82.  ENSG00000164362 TERT telomerase reverse transcriptase 1.89687 1.94267 
83.  ENSG00000144857 BOC "BOC cell adhesion associated, oncogene regulated" 2.16198 1.93153 
84.  ENSG00000120875 DUSP4 dual specificity phosphatase 4 2.05306 1.92245 
85.  ENSG00000170465 KRT6C keratin 6C 1.27008 1.92117 
86.  ENSG00000119929 CUTC cutC copper transporter 1.76035 1.9119 
87.  ENSG00000178585 CTNNBIP1 catenin beta interacting protein 1 1.85451 1.90993 
88.  ENSG00000181788 SIAH2 siah E3 ubiquitin protein ligase 2 1.85018 1.90909 
89.  ENSG00000078725 BRINP1 BMP/retinoic acid inducible neural specific 1 1.72664 1.90507 
90.  ENSG00000243317 C7orf73 chromosome 7 open reading frame 73 1.89354 1.90098 
91.  ENSG00000146409 SLC18B1 solute carrier family 18 member B1 1.68871 1.89729 
92.  ENSG00000035141 FAM136A family with sequence similarity 136 member A 1.77743 1.89115 
93.  ENSG00000145632 PLK2 polo like kinase 2 2.01513 1.87612 
94.  ENSG00000174721 FGFBP3 fibroblast growth factor binding protein 3 1.23721 1.87457 
95.  ENSG00000066583 ISOC1 isochorismatase domain containing 1 1.88871 1.87293 
96.  ENSG00000165806 CASP7 caspase 7 1.81119 1.87049 
97.  ENSG00000169282 KCNAB1 
potassium voltage-gated channel subfamily A member 
regulatory beta subunit 1 
2.691 1.84939 
98.  ENSG00000167536 DHRS13 dehydrogenase/reductase 13 1.78083 1.83441 
99.  ENSG00000135930 EIF4E2 
eukaryotic translation initiation factor 4E family 
member 2 
1.81313 1.83072 
100.  ENSG00000114646 CSPG5 chondroitin sulfate proteoglycan 5 1.77322 1.8202 
101.  ENSG00000131153 GINS2 GINS complex subunit 2 1.68133 1.7959 
102.  ENSG00000137965 IFI44 interferon induced protein 44 1.07807 1.79376 
103.  ENSG00000155330 C16orf87 chromosome 16 open reading frame 87 1.76765 1.78206 
104.  ENSG00000118418 HMGN3 high mobility group nucleosomal binding domain 3 1.75435 1.77512 
105.  ENSG00000114744 COMMD2 COMM domain containing 2 1.81109 1.76506 
106.  ENSG00000102683 SGCG sarcoglycan gamma 1.58645 1.76154 
107.  ENSG00000247556 OIP5-AS1 OIP5 antisense RNA 1 1.90865 1.75325 
108.  ENSG00000134258 VTCN1 V-set domain containing T cell activation inhibitor 1 1.77544 1.75288 
109.  ENSG00000174827 PDZK1 PDZ domain containing 1 2.32078 1.75265 
110.  ENSG00000103495 MAZ MYC associated zinc finger protein 1.56603 1.75118 
111.  ENSG00000204103 MAFB MAF bZIP transcription factor B 1.68057 1.74892 
112.  ENSG00000112149 CD83 CD83 molecule 1.92141 1.74713 
113.  ENSG00000140600 SH3GL3 "SH3 domain containing GRB2 like 3, endophilin A3" 1.68462 1.73615 
114.  ENSG00000165061 ZMAT4 zinc finger matrin-type 4 1.53596 1.73342 
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115.  ENSG00000123219 CENPK centromere protein K 1.76657 1.73323 
116.  ENSG00000186480 INSIG1 insulin induced gene 1 1.83312 1.73253 
117.  ENSG00000133466 C1QTNF6 C1q and tumor necrosis factor related protein 6 1.65012 1.72005 
118.  ENSG00000071909 MYO3B myosin IIIB 1.78755 1.71407 
119.  ENSG00000112394 SLC16A10 solute carrier family 16 member 10 1.92999 1.71366 
120.  ENSG00000172331 BPGM bisphosphoglycerate mutase 1.74992 1.71232 
121.  ENSG00000216490 IFI30 "IFI30, lysosomal thiol reductase" 1.18563 1.69327 
122.  ENSG00000163444 TMEM183A transmembrane protein 183A 1.61754 1.69108 
123.  ENSG00000143633 C1orf131 chromosome 1 open reading frame 131 1.49237 1.68842 
124.  ENSG00000148053 NTRK2 neurotrophic receptor tyrosine kinase 2 2.31639 1.68192 
125.  ENSG00000088305 DNMT3B DNA methyltransferase 3 beta 1.75426 1.6786 
126.  ENSG00000115380 EFEMP1 
EGF containing fibulin like extracellular matrix protein 
1 
1.53166 1.67697 
127.  ENSG00000126709 IFI6 interferon alpha inducible protein 6 0.854428 1.67039 
128.  ENSG00000188643 S100A16 S100 calcium binding protein A16 1.68258 1.66285 
129.  ENSG00000141627 DYM dymeclin 1.72405 1.65591 
130.  ENSG00000235123 DSCAM-AS1 DSCAM antisense RNA 1 1.79876 1.65099 
131.  ENSG00000066926 FECH ferrochelatase 1.68044 1.65016 
132.  ENSG00000188613 NANOS1 nanos C2HC-type zinc finger 1 1.56703 1.64991 
133.  ENSG00000164619 BMPER BMP binding endothelial regulator 1.90746 1.64764 
134.  ENSG00000184515 BEX5 brain expressed X-linked 5 1.2185 1.64046 
135.  ENSG00000162704 ARPC5 actin related protein 2/3 complex subunit 5 1.505 1.64043 
136.  ENSG00000197696 NMB neuromedin B 1.57817 1.63764 
137.  ENSG00000113583 C5orf15 chromosome 5 open reading frame 15 1.65814 1.63619 
138.  ENSG00000177971 IMP3 "IMP3, U3 small nucleolar ribonucleoprotein" 1.2763 1.63331 
139.  ENSG00000107833 NPM3 nucleophosmin/nucleoplasmin 3 1.59262 1.6237 
140.  ENSG00000168913 ENHO energy homeostasis associated 1.61978 1.62355 
141.  ENSG00000108423 TUBD1 tubulin delta 1 1.66967 1.62302 
142.  ENSG00000124333 VAMP7 vesicle associated membrane protein 7 1.74104 1.60978 
143.  ENSG00000162599 NFIA nuclear factor I A 1.93518 1.60973 
144.  ENSG00000186470 BTN3A2 butyrophilin subfamily 3 member A2 1.66846 1.60858 
145.  ENSG00000123570 RAB9B "RAB9B, member RAS oncogene family" 1.39674 1.60651 
146.  ENSG00000198797 BRINP2 BMP/retinoic acid inducible neural specific 2 2.03546 1.60345 
147.  ENSG00000141696 P3H4 
prolyl 3-hydroxylase family member 4 (non-
enzymatic) 
1.43784 1.60295 
148.  ENSG00000117148 ACTL8 actin like 8 1.37881 1.60098 
149.  ENSG00000149547 EI24 "EI24, autophagy associated transmembrane protein" 1.58026 1.59393 
150.  ENSG00000149596 JPH2 junctophilin 2 1.83951 1.59197 
151.  ENSG00000223658 
C1GALT1C1
L 
C1GALT1-specific chaperone 1 like 1.17377 1.59184 
152.  ENSG00000165996 HACD1 3-hydroxyacyl-CoA dehydratase 1 1.31717 1.5829 
153.  ENSG00000152766 ANKRD22 ankyrin repeat domain 22 1.83286 1.5803 
154.  ENSG00000180329 CCDC43 coiled-coil domain containing 43 1.47159 1.5781 
155.  ENSG00000246223 LINC01550 long intergenic non-protein coding RNA 1550 1.32543 1.57637 
156.  ENSG00000100362 PVALB parvalbumin 1.21037 1.57428 
157.  ENSG00000144401 METTL21A methyltransferase like 21A 1.81833 1.57057 
158.  ENSG00000157593 SLC35B2 solute carrier family 35 member B2 1.49914 1.5692 
159.  ENSG00000113838 TBCCD1 TBCC domain containing 1 1.68387 1.5637 
160.  ENSG00000152284 TCF7L1 transcription factor 7 like 1 1.48257 1.55383 
161.  ENSG00000122035 RASL11A RAS like family 11 member A 1.18544 1.55333 
162.  ENSG00000236603 RANP1 "RAN, member RAS oncogene family pseudogene 1" 0.818454 1.5527 
163.  ENSG00000136982 DSCC1 DNA replication and sister chromatid cohesion 1 1.65166 1.54324 
164.  ENSG00000134748 PRPF38A pre-mRNA processing factor 38A 1.47559 1.5399 
165.  ENSG00000117122 MFAP2 microfibrillar associated protein 2 1.55689 1.53872 
166.  ENSG00000162642 C1orf52 chromosome 1 open reading frame 52 1.30657 1.53613 
167.  ENSG00000115252 PDE1A phosphodiesterase 1A 1.68231 1.53396 
168.  ENSG00000107562 CXCL12 C-X-C motif chemokine ligand 12 1.71022 1.52676 
169.  ENSG00000087111 PIGS phosphatidylinositol glycan anchor biosynthesis class S 1.71025 1.52542 
170.  ENSG00000164932 CTHRC1 collagen triple helix repeat containing 1 1.78111 1.52537 
171.  ENSG00000103942 HOMER2 homer scaffolding protein 2 1.61365 1.51969 
172.  ENSG00000157502 MUM1L1 MUM1 like 1 1.46894 1.51818 
173.  ENSG00000154274 C4orf19 chromosome 4 open reading frame 19 1.57704 1.5167 
174.  ENSG00000171503 ETFDH electron transfer flavoprotein dehydrogenase 1.6454 1.51574 
175.  ENSG00000104679 R3HCC1 R3H domain and coiled-coil containing 1 1.47594 1.51118 
176.  ENSG00000181274 FRAT2 frequently rearranged in advanced T-cell lymphomas 2 1.26584 1.50653 
177.  ENSG00000148229 POLE3 "DNA polymerase epsilon 3, accessory subunit" 1.31072 1.50374 
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178.  ENSG00000030110 BAK1 BCL2 antagonist/killer 1 1.22959 1.49069 
179.  ENSG00000127124 HIVEP3 
human immunodeficiency virus type I enhancer 
binding protein 3 
1.71264 1.48377 
180.  ENSG00000141540 TTYH2 tweety family member 2 1.39606 1.47698 
181.  ENSG00000196839 ADA adenosine deaminase 1.37348 1.47158 
182.  ENSG00000149600 COMMD7 COMM domain containing 7 1.39645 1.46911 
183.  ENSG00000185745 IFIT1 
interferon induced protein with tetratricopeptide 
repeats 1 
0.683847 1.46504 
184.  ENSG00000171119 NRTN neurturin 1.42941 1.46177 
185.  ENSG00000170775 GPR37 G protein-coupled receptor 37 1.6004 1.4605 
186.  ENSG00000168874 ATOH8 atonal bHLH transcription factor 8 1.53391 1.45938 
187.  ENSG00000180834 MAP6D1 MAP6 domain containing 1 1.64809 1.45758 
188.  ENSG00000168350 DEGS2 "delta 4-desaturase, sphingolipid 2" 1.16509 1.45397 
189.  ENSG00000156299 TIAM1 T-cell lymphoma invasion and metastasis 1 1.78994 1.45061 
190.  ENSG00000157600 TMEM164 transmembrane protein 164 1.45174 1.44885 
191.  ENSG00000135218 CD36 CD36 molecule 1.5895 1.44303 
192.  ENSG00000204950 LRRC10B leucine rich repeat containing 10B 1.33852 1.43715 
193.  ENSG00000004864 SLC25A13 solute carrier family 25 member 13 1.29903 1.43565 
194.  ENSG00000240849 TMEM189 transmembrane protein 189 1.4711 1.43429 
195.  ENSG00000135114 OASL 2'-5'-oligoadenylate synthetase like 0.68925 1.43106 
196.  ENSG00000186184 POLR1D RNA polymerase I subunit D 1.21672 1.4292 
197.  ENSG00000130024 PHF10 PHD finger protein 10 1.47714 1.42481 
198.  ENSG00000186832 KRT16 keratin 16 1.41614 1.42172 
199.  ENSG00000135374 ELF5 E74 like ETS transcription factor 5 1.54622 1.41993 
200.  ENSG00000214063 TSPAN4 tetraspanin 4 1.20445 1.41946 
201.  ENSG00000157303 SUSD3 sushi domain containing 3 1.38012 1.41753 
202.  ENSG00000060138 YBX3 Y-box binding protein 3 1.38701 1.41547 
203.  ENSG00000110330 BIRC2 baculoviral IAP repeat containing 2 1.50289 1.41292 
204.  ENSG00000175928 LRRN1 leucine rich repeat neuronal 1 1.58509 1.41155 
205.  ENSG00000076604 TRAF4 TNF receptor associated factor 4 1.40716 1.41039 
206.  ENSG00000168569 TMEM223 transmembrane protein 223 1.13466 1.40979 
207.  ENSG00000159763 PIP prolactin induced protein 1.58833 1.40631 
208.  ENSG00000166803 KIAA0101 KIAA0101 1.25341 1.39906 
209.  ENSG00000212747 FAM127C family with sequence similarity 127 member C 1.25769 1.39421 
210.  ENSG00000162639 HENMT1 HEN1 methyltransferase homolog 1 1.27558 1.38603 
211.  ENSG00000009844 VTA1 vesicle trafficking 1 1.32726 1.38368 
212.  ENSG00000168246 UBTD2 ubiquitin domain containing 2 1.45232 1.38079 
213.  ENSG00000139173 TMEM117 transmembrane protein 117 1.22016 1.36977 
214.  ENSG00000149043 SYT8 synaptotagmin 8 1.65318 1.36842 
215.  ENSG00000132383 RPA1 replication protein A1 1.3934 1.36769 
216.  ENSG00000042753 AP2S1 adaptor related protein complex 2 sigma 1 subunit 1.22989 1.36345 
217.  ENSG00000117411 B4GALT2 "beta-1,4-galactosyltransferase 2" 1.18107 1.36107 
218.  ENSG00000187601 MAGEH1 MAGE family member H1 1.16952 1.36045 
219.  ENSG00000141985 SH3GL1 "SH3 domain containing GRB2 like 1, endophilin A2" 1.20402 1.35972 
220.  ENSG00000175730 BAK1P1 BCL2 antagonist/killer 1 pseudogene 1 1.33959 1.35957 
221.  ENSG00000128309 MPST mercaptopyruvate sulfurtransferase 0.954081 1.3583 
222.  ENSG00000156113 KCNMA1 
potassium calcium-activated channel subfamily M 
alpha 1 
1.55427 1.35738 
223.  ENSG00000170819 BFSP2 beaded filament structural protein 2 1.60905 1.3469 
224.  ENSG00000172663 TMEM134 transmembrane protein 134 0.907853 1.34654 
225.  ENSG00000165629 ATP5C1 
"ATP synthase, H+ transporting, mitochondrial F1 
complex, gamma polypeptide 1" 
1.43753 1.34628 
226.  ENSG00000145425 RPS3A ribosomal protein S3A 1.35179 1.34338 
227.  ENSG00000213753 CENPBD1P1 
CENPB DNA-binding domains containing 1 
pseudogene 1 
1.15072 1.34084 
228.  ENSG00000134986 NREP neuronal regeneration related protein 1.5593 1.33906 
229.  ENSG00000137959 IFI44L interferon induced protein 44 like 0.595391 1.33428 
230.  ENSG00000138336 TET1 tet methylcytosine dioxygenase 1 1.61365 1.33383 
231.  ENSG00000176396 EID2 EP300 interacting inhibitor of differentiation 2 1.02888 1.32895 
232.  ENSG00000162441 LZIC leucine zipper and CTNNBIP1 domain containing 1.51983 1.32526 
233.  ENSG00000123562 MORF4L2 mortality factor 4 like 2 1.31419 1.32475 
234.  ENSG00000171612 SLC25A33 solute carrier family 25 member 33 1.28595 1.32461 
235.  ENSG00000196620 UGT2B15 UDP glucuronosyltransferase family 2 member B15 1.18061 1.32403 
236.  ENSG00000109321 AREG amphiregulin 1.42032 1.32116 
237.  ENSG00000174599 TRAM1L1 translocation associated membrane protein 1-like 1 1.03518 1.32007 
238.  ENSG00000144677 CTDSPL CTD small phosphatase like 1.29415 1.31864 
239.  ENSG00000239900 ADSL adenylosuccinate lyase 1.28924 1.31677 
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240.  ENSG00000175130 MARCKSL1 MARCKS like 1 1.18066 1.31506 
241.  ENSG00000180992 MRPL14 mitochondrial ribosomal protein L14 1.09525 1.31287 
242.  ENSG00000113648 H2AFY H2A histone family member Y 1.35164 1.31266 
243.  ENSG00000255302 EID1 EP300 interacting inhibitor of differentiation 1 1.13643 1.31191 
244.  ENSG00000188681 TEKT4P2 tektin 4 pseudogene 2 1.25626 1.31105 
245.  ENSG00000180573 HIST1H2AC histone cluster 1 H2A family member c 1.2603 1.30951 
246.  ENSG00000083807 SLC27A5 solute carrier family 27 member 5 1.0881 1.3092 
247.  ENSG00000183688 RFLNB refilin B 1.58933 1.30077 
248.  ENSG00000253719 ATXN7L3B ataxin 7 like 3B 1.23747 1.29717 
249.  ENSG00000205643 CDPF1 cysteine rich DPF motif domain containing 1 0.989699 1.29684 
250.  ENSG00000145808 ADAMTS19 
ADAM metallopeptidase with thrombospondin type 1 
motif 19 
1.47001 1.29029 
251.  ENSG00000131238 PPT1 palmitoyl-protein thioesterase 1 1.33288 1.28796 
252.  ENSG00000037280 FLT4 fms related tyrosine kinase 4 0.967415 1.2875 
253.  ENSG00000105549 THEG theg spermatid protein 1.36115 1.28725 
254.  ENSG00000184678 HIST2H2BE histone cluster 2 H2B family member e 1.19281 1.28682 
255.  ENSG00000163156 
TNFAIP8L2-
SCNM1 
TNFAIP8L2-SCNM1 readthrough 1.15396 1.28294 
256.  ENSG00000172201 ID4 "inhibitor of DNA binding 4, HLH protein" 1.1042 1.28042 
257.  ENSG00000136261 BZW2 basic leucine zipper and W2 domains 2 1.33163 1.28027 
258.  ENSG00000171476 HOPX HOP homeobox 1.87771 1.27803 
259.  ENSG00000163006 CCDC138 coiled-coil domain containing 138 1.54328 1.27542 
260.  ENSG00000256073 URB1-AS1 URB1 antisense RNA 1 (head to head) 0.768621 1.27432 
261.  ENSG00000185885 IFITM1 interferon induced transmembrane protein 1 0.866949 1.27411 
262.  ENSG00000149646 CNBD2 cyclic nucleotide binding domain containing 2 0.837055 1.27329 
263.  ENSG00000197763 TXNRD3NB thioredoxin reductase 3 neighbor 1.05308 1.27236 
264.  ENSG00000160183 TMPRSS3 "transmembrane protease, serine 3" 1.50993 1.27099 
265.  ENSG00000113761 ZNF346 zinc finger protein 346 1.50192 1.26861 
266.  ENSG00000100211 CBY1 "chibby family member 1, beta catenin antagonist" 1.33359 1.26603 
267.  ENSG00000237984 PTENP1 phosphatase and tensin homolog pseudogene 1 1.06433 1.26423 
268.  ENSG00000198054 DSCR8 Down syndrome critical region 8 1.86764 1.26283 
269.  ENSG00000168303 MPLKIP M-phase specific PLK1 interacting protein 0.939126 1.25982 
270.  ENSG00000136295 TTYH3 tweety family member 3 1.29448 1.25873 
271.  ENSG00000172428 COPS9 COP9 signalosome subunit 9 1.02218 1.25621 
272.  ENSG00000137364 TPMT thiopurine S-methyltransferase 1.40831 1.2533 
273.  ENSG00000196739 COL27A1 collagen type XXVII alpha 1 chain 1.67382 1.25171 
274.  ENSG00000165724 ZMYND19 zinc finger MYND-type containing 19 1.05418 1.24949 
275.  ENSG00000167930 FAM234A family with sequence similarity 234 member A 1.20283 1.24764 
276.  ENSG00000111181 SLC6A12 solute carrier family 6 member 12 1.42094 1.24514 
277.  ENSG00000176401 EID2B EP300 interacting inhibitor of differentiation 2B 0.663137 1.24476 
278.  ENSG00000168405 CMAHP 
"cytidine monophospho-N-acetylneuraminic acid 
hydroxylase, pseudogene" 
0.825125 1.24412 
279.  ENSG00000139970 RTN1 reticulon 1 1.33667 1.24382 
280.  ENSG00000186162 CIDECP cell death-inducing DFFA-like effector c pseudogene 1.01528 1.24263 
281.  ENSG00000176022 B3GALT6 "beta-1,3-galactosyltransferase 6" 0.891879 1.24243 
282.  ENSG00000121022 COPS5 COP9 signalosome subunit 5 1.20623 1.24081 
283.  ENSG00000164172 MOCS2 molybdenum cofactor synthesis 2 1.286 1.24044 
284.  ENSG00000166450 PRTG protogenin 1.31376 1.23996 
285.  ENSG00000160180 TFF3 trefoil factor 3 1.06078 1.23842 
286.  ENSG00000115657 ABCB6 
ATP binding cassette subfamily B member 6 
(Langereis blood group) 
1.20686 1.2379 
287.  ENSG00000134809 TIMM10 
translocase of inner mitochondrial membrane 10 
homolog (yeast) 
1.08019 1.23627 
288.  ENSG00000155380 SLC16A1 solute carrier family 16 member 1 1.27052 1.23591 
289.  ENSG00000205363 C15orf59 chromosome 15 open reading frame 59 1.07989 1.23498 
290.  ENSG00000213741 RPS29 ribosomal protein S29 1.07896 1.23262 
291.  ENSG00000134758 RNF138 ring finger protein 138 0.993903 1.2314 
292.  ENSG00000064835 POU1F1 POU class 1 homeobox 1 1.10366 1.22851 
293.  ENSG00000184232 OAF out at first homolog 0.614108 1.2268 
294.  ENSG00000164111 ANXA5 annexin A5 1.17391 1.22543 
295.  ENSG00000160588 MPZL3 myelin protein zero like 3 1.30983 1.22454 
296.  ENSG00000166794 PPIB peptidylprolyl isomerase B 1.11594 1.2242 
297.  ENSG00000262904 TMPOP2 thymopoietin pseudogene 2 0.815511 1.2229 
298.  ENSG00000165512 ZNF22 zinc finger protein 22 1.10956 1.22216 
299.  ENSG00000101098 RIMS4 regulating synaptic membrane exocytosis 4 1.25577 1.2212 
300.  ENSG00000150893 FREM2 FRAS1 related extracellular matrix protein 2 1.6484 1.22025 
301.  ENSG00000137558 PI15 peptidase inhibitor 15 1.38949 1.21943 
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302.  ENSG00000111653 ING4 inhibitor of growth family member 4 1.19538 1.21837 
303.  ENSG00000185787 MORF4L1 mortality factor 4 like 1 1.23656 1.21828 
304.  ENSG00000224287 MSL3P1 
male-specific lethal 3 homolog (Drosophila) 
pseudogene 1 
1.08888 1.21766 
305.  ENSG00000250722 SEPP1 "selenoprotein P, plasma, 1" 1.09129 1.21632 
306.  ENSG00000148300 REXO4 "REX4 homolog, 3'-5' exonuclease" 0.991587 1.21563 
307.  ENSG00000172867 KRT2 keratin 2 1.2364 1.21345 
308.  ENSG00000204228 HSD17B8 hydroxysteroid 17-beta dehydrogenase 8 1.0486 1.21188 
309.  ENSG00000100814 CCNB1IP1 cyclin B1 interacting protein 1 1.22499 1.20591 
310.  ENSG00000171631 P2RY6 pyrimidinergic receptor P2Y6 1.07541 1.20488 
311.  ENSG00000196636 SDHAF3 succinate dehydrogenase complex assembly factor 3 1.03412 1.20257 
312.  ENSG00000102172 SMS spermine synthase 1.1773 1.20089 
313.  ENSG00000154553 PDLIM3 PDZ and LIM domain 3 1.21686 1.19913 
314.  ENSG00000102743 SLC25A15 solute carrier family 25 member 15 1.27744 1.19857 
315.  ENSG00000122068 FYTTD1 forty-two-three domain containing 1 1.3472 1.19733 
316.  ENSG00000167767 KRT80 keratin 80 1.24017 1.19701 
317.  ENSG00000091592 NLRP1 NLR family pyrin domain containing 1 1.09248 1.19686 
318.  ENSG00000102543 CDADC1 cytidine and dCMP deaminase domain containing 1 0.972441 1.19253 
319.  ENSG00000185475 TMEM179B transmembrane protein 179B 1.13071 1.1919 
320.  ENSG00000166073 GPR176 G protein-coupled receptor 176 0.911931 1.19186 
321.  ENSG00000186603 HPDL 4-hydroxyphenylpyruvate dioxygenase like 0.801218 1.19059 
322.  ENSG00000104980 TIMM44 translocase of inner mitochondrial membrane 44 0.990688 1.19053 
323.  ENSG00000178896 EXOSC4 exosome component 4 0.624955 1.19043 
324.  ENSG00000104341 LAPTM4B lysosomal protein transmembrane 4 beta 1.26545 1.18734 
325.  ENSG00000155329 ZCCHC10 zinc finger CCHC-type containing 10 0.96443 1.18733 
326.  ENSG00000164291 ARSK arylsulfatase family member K 1.09553 1.18466 
327.  ENSG00000040275 SPDL1 spindle apparatus coiled-coil protein 1 1.36245 1.18421 
328.  ENSG00000041357 PSMA4 proteasome subunit alpha 4 1.20228 1.18312 
329.  ENSG00000184486 POU3F2 POU class 3 homeobox 2 1.23518 1.18252 
330.  ENSG00000010319 SEMA3G semaphorin 3G 1.08938 1.18135 
331.  ENSG00000131373 HACL1 2-hydroxyacyl-CoA lyase 1 1.08995 1.17999 
332.  ENSG00000185504 FAAP100 Fanconi anemia core complex associated protein 100 0.924334 1.1769 
333.  ENSG00000244187 TMEM141 transmembrane protein 141 1.08181 1.17586 
334.  ENSG00000171984 C20orf196 chromosome 20 open reading frame 196 0.846608 1.17566 
335.  ENSG00000120697 ALG5 "ALG5, dolichyl-phosphate beta-glucosyltransferase" 0.974665 1.17464 
336.  ENSG00000110871 COQ5 "coenzyme Q5, methyltransferase" 1.12072 1.17251 
337.  ENSG00000180611 MB21D2 Mab-21 domain containing 2 1.01576 1.17096 
338.  ENSG00000101255 TRIB3 tribbles pseudokinase 3 1.04783 1.16733 
339.  ENSG00000131475 VPS25 vacuolar protein sorting 25 homolog 1.09281 1.16585 
340.  ENSG00000169908 TM4SF1 transmembrane 4 L six family member 1 0.892293 1.16473 
341.  ENSG00000134864 GGACT gamma-glutamylamine cyclotransferase 0.730741 1.16279 
342.  ENSG00000101546 RBFA ribosome binding factor A (putative) 1.08745 1.15657 
343.  ENSG00000128294 TPST2 tyrosylprotein sulfotransferase 2 1.27295 1.15574 
344.  ENSG00000186767 SPIN4 spindlin family member 4 1.20897 1.15524 
345.  ENSG00000169218 RSPO1 R-spondin 1 1.00213 1.14493 
346.  ENSG00000160446 ZDHHC12 zinc finger DHHC-type containing 12 0.720658 1.1442 
347.  ENSG00000188763 FZD9 frizzled class receptor 9 0.881945 1.14293 
348.  ENSG00000066697 MSANTD3 Myb/SANT DNA binding domain containing 3 1.03394 1.14267 
349.  ENSG00000168785 TSPAN5 tetraspanin 5 1.45388 1.14094 
350.  ENSG00000182575 NXPH3 neurexophilin 3 1.14279 1.13923 
351.  ENSG00000144867 SRPRB SRP receptor beta subunit 1.135 1.13818 
352.  ENSG00000162891 IL20 interleukin 20 1.37049 1.13747 
353.  ENSG00000164128 NPY1R neuropeptide Y receptor Y1 1.33529 1.13624 
354.  ENSG00000169976 SF3B5 splicing factor 3b subunit 5 0.996388 1.13546 
355.  ENSG00000150687 PRSS23 "protease, serine 23" 1.31424 1.13168 
356.  ENSG00000173141 MRPL57 mitochondrial ribosomal protein L57 0.811779 1.13103 
357.  ENSG00000110442 COMMD9 COMM domain containing 9 1.13099 1.13093 
358.  ENSG00000101850 GPR143 G protein-coupled receptor 143 0.864325 1.13005 
359.  ENSG00000182117 NOP10 NOP10 ribonucleoprotein 1.02759 1.12941 
360.  ENSG00000077274 CAPN6 calpain 6 1.02668 1.12836 
361.  ENSG00000188820 FAM26F family with sequence similarity 26 member F 0.969095 1.12822 
362.  ENSG00000124813 RUNX2 runt related transcription factor 2 1.40906 1.12666 
363.  ENSG00000142619 PADI3 peptidyl arginine deiminase 3 1.29671 1.12462 
364.  ENSG00000196741 LINC01560 long intergenic non-protein coding RNA 1560 0.9892 1.12458 
365.  ENSG00000103257 SLC7A5 solute carrier family 7 member 5 1.31711 1.12174 
366.  ENSG00000110435 PDHX pyruvate dehydrogenase complex component X 1.11496 1.1193 
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367.  ENSG00000121753 ADGRB2 adhesion G protein-coupled receptor B2 0.874388 1.11731 
368.  ENSG00000065268 WDR18 WD repeat domain 18 0.938405 1.11267 
369.  ENSG00000168002 POLR2G RNA polymerase II subunit G 1.0195 1.11076 
370.  ENSG00000148824 MTG1 mitochondrial ribosome associated GTPase 1 0.930824 1.10945 
371.  ENSG00000143013 LMO4 LIM domain only 4 1.21488 1.10918 
372.  ENSG00000243646 IL10RB interleukin 10 receptor subunit beta 1.09275 1.10894 
373.  ENSG00000184588 PDE4B phosphodiesterase 4B 1.30251 1.10839 
374.  ENSG00000103415 HMOX2 heme oxygenase 2 0.981092 1.10676 
375.  ENSG00000165389 SPTSSA serine palmitoyltransferase small subunit A 1.13176 1.10577 
376.  ENSG00000139144 PIK3C2G 
phosphatidylinositol-4-phosphate 3-kinase catalytic 
subunit type 2 gamma 
1.32998 1.10551 
377.  ENSG00000145545 SRD5A1 steroid 5 alpha-reductase 1 0.903325 1.10497 
378.  ENSG00000204344 STK19 serine/threonine kinase 19 1.04042 1.10347 
379.  ENSG00000162384 C1orf123 chromosome 1 open reading frame 123 0.966238 1.10235 
380.  ENSG00000103855 CD276 CD276 molecule 1.24127 1.1014 
381.  ENSG00000035687 ADSS adenylosuccinate synthase 0.989145 1.09993 
382.  ENSG00000185090 MANEAL mannosidase endo-alpha like 1.09 1.09727 
383.  ENSG00000087842 PIR pirin 1.18405 1.09699 
384.  ENSG00000169372 CRADD 
CASP2 and RIPK1 domain containing adaptor with 
death domain 
0.94901 1.09059 
385.  ENSG00000133627 ACTR3B ARP3 actin related protein 3 homolog B 1.03853 1.08886 
386.  ENSG00000137992 DBT dihydrolipoamide branched chain transacylase E2 1.19273 1.08744 
387.  ENSG00000109452 INPP4B inositol polyphosphate-4-phosphatase type II B 1.41143 1.08739 
388.  ENSG00000108010 GLRX3 glutaredoxin 3 0.917546 1.0863 
389.  ENSG00000169884 WNT10B Wnt family member 10B 0.553471 1.08361 
390.  ENSG00000122873 CISD1 CDGSH iron sulfur domain 1 1.01027 1.0821 
391.  ENSG00000230844 ZNF674-AS1 ZNF674 antisense RNA 1 (head to head) 0.734379 1.08159 
392.  ENSG00000246705 H2AFJ H2A histone family member J 0.688296 1.08134 
393.  ENSG00000176108 CHMP6 charged multivesicular body protein 6 0.715407 1.0806 
394.  ENSG00000115596 WNT6 Wnt family member 6 0.563029 1.08002 
395.  ENSG00000204576 PRR3 proline rich 3 1.05653 1.07873 
396.  ENSG00000184220 CMSS1 cms1 ribosomal small subunit homolog (yeast) 1.11261 1.07853 
397.  ENSG00000040731 CDH10 cadherin 10 1.37135 1.077 
398.  ENSG00000196776 CD47 CD47 molecule 1.08686 1.07416 
399.  ENSG00000188042 ARL4C ADP ribosylation factor like GTPase 4C 1.11503 1.06863 
400.  ENSG00000166123 GPT2 glutamic--pyruvic transaminase 2 1.20088 1.06805 
401.  ENSG00000119326 CTNNAL1 catenin alpha like 1 1.10965 1.06564 
402.  ENSG00000138670 RASGEF1B RasGEF domain family member 1B 0.863543 1.06333 
403.  ENSG00000168495 POLR3D RNA polymerase III subunit D 0.922376 1.05985 
404.  ENSG00000175137 SH3BP5L SH3 binding domain protein 5 like 1.04061 1.05831 
405.  ENSG00000094804 CDC6 cell division cycle 6 0.995412 1.05737 
406.  ENSG00000171428 NAT1 N-acetyltransferase 1 0.828996 1.0541 
407.  ENSG00000167552 TUBA1A tubulin alpha 1a 1.22901 1.05345 
408.  ENSG00000143845 ETNK2 ethanolamine kinase 2 1.11182 1.05306 
409.  ENSG00000174109 C16orf91 chromosome 16 open reading frame 91 0.529916 1.05276 
410.  ENSG00000135828 RNASEL ribonuclease L 1.11074 1.05212 
411.  ENSG00000110987 BCL7A BCL tumor suppressor 7A 0.971165 1.052 
412.  ENSG00000185615 PDIA2 protein disulfide isomerase family A member 2 0.84232 1.0513 
413.  ENSG00000171135 JAGN1 jagunal homolog 1 0.901859 1.05076 
414.  ENSG00000107968 MAP3K8 mitogen-activated protein kinase kinase kinase 8 0.80049 1.05051 
415.  ENSG00000173894 CBX2 chromobox 2 1.05339 1.05031 
416.  ENSG00000160182 TFF1 trefoil factor 1 1.12383 1.05027 
417.  ENSG00000158715 SLC45A3 solute carrier family 45 member 3 0.928566 1.04996 
418.  ENSG00000143162 CREG1 cellular repressor of E1A stimulated genes 1 1.06377 1.04923 
419.  ENSG00000117461 PIK3R3 phosphoinositide-3-kinase regulatory subunit 3 1.14694 1.04752 
420.  ENSG00000185015 CA13 carbonic anhydrase 13 1.36253 1.04568 
421.  ENSG00000158769 F11R F11 receptor 1.09778 1.04492 
422.  ENSG00000167695 FAM57A family with sequence similarity 57 member A 1.08004 1.04424 
423.  ENSG00000145882 PCYOX1L prenylcysteine oxidase 1 like 1.0197 1.04292 
424.  ENSG00000133142 TCEAL4 transcription elongation factor A like 4 0.865075 1.04156 
425.  ENSG00000163053 SLC16A14 solute carrier family 16 member 14 0.890857 1.04069 
426.  ENSG00000124006 OBSL1 obscurin like 1 0.990759 1.04061 
427.  ENSG00000151917 BEND6 BEN domain containing 6 1.01679 1.03956 
428.  ENSG00000169682 SPNS1 sphingolipid transporter 1 (putative) 0.993692 1.03893 
429.  ENSG00000131043 AAR2 AAR2 splicing factor homolog 0.927601 1.03828 
430.  ENSG00000177614 PGBD5 piggyBac transposable element derived 5 0.874885 1.03782 
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431.  ENSG00000165732 DDX21 DEAD-box helicase 21 1.0968 1.03752 
432.  ENSG00000172171 TEFM "transcription elongation factor, mitochondrial" 0.886352 1.03729 
433.  ENSG00000117479 SLC19A2 solute carrier family 19 member 2 0.994844 1.03721 
434.  ENSG00000270170 NCBP2-AS2 NCBP2 antisense RNA 2 (head to head) 0.585973 1.03664 
435.  ENSG00000197894 ADH5 "alcohol dehydrogenase 5 (class III), chi polypeptide" 1.00464 1.03491 
436.  ENSG00000187231 SESTD1 SEC14 and spectrin domain containing 1 1.24413 1.03235 
437.  ENSG00000135148 TRAFD1 TRAF-type zinc finger domain containing 1 1.11782 1.02991 
438.  ENSG00000153485 TMEM251 transmembrane protein 251 0.873496 1.02926 
439.  ENSG00000113356 POLR3G RNA polymerase III subunit G 0.810646 1.02777 
440.  ENSG00000136527 TRA2B transformer 2 beta homolog (Drosophila) 0.93612 1.02773 
441.  ENSG00000177383 MAGEF1 MAGE family member F1 0.775277 1.0272 
442.  ENSG00000158042 MRPL17 mitochondrial ribosomal protein L17 0.790089 1.02674 
443.  ENSG00000113209 PCDHB5 protocadherin beta 5 1.21352 1.02547 
444.  ENSG00000168101 NUDT16L1 nudix hydrolase 16 like 1 0.742033 1.02527 
445.  ENSG00000158050 DUSP2 dual specificity phosphatase 2 0.861033 1.02365 
446.  ENSG00000167272 POP5 "POP5 homolog, ribonuclease P/MRP subunit" 0.785138 1.02197 
447.  ENSG00000043039 BARX2 BARX homeobox 2 1.10383 1.02157 
448.  ENSG00000131015 ULBP2 UL16 binding protein 2 1.14969 1.02138 
449.  ENSG00000167747 C19orf48 chromosome 19 open reading frame 48 0.550821 1.02046 
450.  ENSG00000140280 LYSMD2 LysM domain containing 2 0.879903 1.02031 
451.  ENSG00000143179 UCK2 uridine-cytidine kinase 2 0.9374 1.01923 
452.  ENSG00000175768 TOMM5 translocase of outer mitochondrial membrane 5 0.924343 1.01822 
453.  ENSG00000151611 MMAA 
methylmalonic aciduria (cobalamin deficiency) cblA 
type 
0.736563 1.01764 
454.  ENSG00000116761 CTH cystathionine gamma-lyase 1.37027 1.01686 
455.  ENSG00000181634 TNFSF15 tumor necrosis factor superfamily member 15 0.836726 1.01551 
456.  ENSG00000221926 TRIM16 tripartite motif containing 16 0.993213 1.01247 
457.  ENSG00000154429 CCSAP "centriole, cilia and spindle associated protein" 1.0959 1.01218 
458.  ENSG00000163041 H3F3A H3 histone family member 3A 0.858372 1.01209 
459.  ENSG00000267368 UPK3BL uroplakin 3B-like 0.806669 1.01034 
460.  ENSG00000163931 TKT transketolase 0.929334 1.00705 
461.  ENSG00000132429 POPDC3 popeye domain containing 3 0.787233 1.0069 
462.  ENSG00000178096 BOLA1 bolA family member 1 0.570531 1.00556 
463.  ENSG00000151575 TEX9 testis expressed 9 0.870901 1.00428 
464.  ENSG00000174013 FBXO45 F-box protein 45 1.04396 1.00334 
465.  ENSG00000139211 AMIGO2 adhesion molecule with Ig like domain 2 1.01909 1.00302 
466.  ENSG00000159640 ACE angiotensin I converting enzyme 1.21031 1.00259 
467.  ENSG00000154518 ATP5G3 
"ATP synthase, H+ transporting, mitochondrial Fo 
complex subunit C3 (subunit 9)" 
0.885476 1.00146 
468.  ENSG00000008083 JARID2 jumonji and AT-rich interaction domain containing 2 1.09834 0.998283 
469.  ENSG00000156374 PCGF6 polycomb group ring finger 6 0.935854 0.998118 
470.  ENSG00000167780 SOAT2 sterol O-acyltransferase 2 0.946383 0.996519 
471.  ENSG00000092841 MYL6 myosin light chain 6 0.876249 0.994649 
472.  ENSG00000113924 HGD "homogentisate 1,2-dioxygenase" 1.31709 0.994539 
473.  ENSG00000232388 LINC00493 long intergenic non-protein coding RNA 493 0.794676 0.993629 
474.  ENSG00000198055 GRK6 G protein-coupled receptor kinase 6 0.718213 0.990066 
475.  ENSG00000136143 SUCLA2 succinate-CoA ligase ADP-forming beta subunit 1.17971 0.989095 
476.  ENSG00000134240 HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2 1.89403 0.988791 
477.  ENSG00000023902 PLEKHO1 pleckstrin homology domain containing O1 0.955779 0.986967 
478.  ENSG00000143061 IGSF3 immunoglobulin superfamily member 3 1.06424 0.986889 
479.  ENSG00000239672 NME1 NME/NM23 nucleoside diphosphate kinase 1 0.856472 0.982628 
480.  ENSG00000130332 LSM7 
"LSM7 homolog, U6 small nuclear RNA and mRNA 
degradation associated" 
0.610844 0.982496 
481.  ENSG00000171863 RPS7 ribosomal protein S7 0.976177 0.982406 
482.  ENSG00000112320 SOBP sine oculis binding protein homolog 1.12312 0.97963 
483.  ENSG00000133874 RNF122 ring finger protein 122 1.14128 0.979431 
484.  ENSG00000030066 NUP160 nucleoporin 160 1.02944 0.977176 
485.  ENSG00000174749 C4orf32 chromosome 4 open reading frame 32 0.895463 0.976444 
486.  ENSG00000163710 PCOLCE2 procollagen C-endopeptidase enhancer 2 0.623997 0.976315 
487.  ENSG00000138166 DUSP5 dual specificity phosphatase 5 1.16304 0.974547 
488.  ENSG00000007392 LUC7L LUC7 like 0.729032 0.973398 
489.  ENSG00000147533 GOLGA7 golgin A7 1.14222 0.971833 
490.  ENSG00000108826 MRPL27 mitochondrial ribosomal protein L27 0.756929 0.97082 
491.  ENSG00000125977 EIF2S2 eukaryotic translation initiation factor 2 subunit beta 0.929427 0.970642 
492.  ENSG00000188636 LDOC1L leucine zipper down-regulated in cancer 1 like 1.00147 0.970258 
493.  ENSG00000189007 ADAT2 "adenosine deaminase, tRNA specific 2" 0.875681 0.969717 
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494.  ENSG00000143947 RPS27A ribosomal protein S27a 0.982195 0.969381 
495.  ENSG00000023697 DERA deoxyribose-phosphate aldolase 0.991452 0.967232 
496.  ENSG00000168291 PDHB pyruvate dehydrogenase (lipoamide) beta 1.02254 0.966478 
497.  ENSG00000267100 ILF3-AS1 ILF3 antisense RNA 1 (head to head) 0.605486 0.965656 
498.  ENSG00000127337 YEATS4 YEATS domain containing 4 0.743376 0.965598 
499.  ENSG00000162244 RPL29 ribosomal protein L29 0.678791 0.965449 
500.  ENSG00000163584 RPL22L1 ribosomal protein L22 like 1 0.864808 0.965201 
501.  ENSG00000100395 L3MBTL2 L3MBTL2 polycomb repressive complex 1 subunit 0.91279 0.965081 
502.  ENSG00000169826 
CSGALNAC
T2 
chondroitin sulfate N-acetylgalactosaminyltransferase 
2 
1.09471 0.964817 
503.  ENSG00000163933 RFT1 RFT1 homolog 1.00573 0.963011 
504.  ENSG00000006459 KDM7A lysine demethylase 7A 1.0876 0.962187 
505.  ENSG00000073536 NLE1 notchless homolog 1 0.739256 0.961983 
506.  ENSG00000145604 SKP2 
"S-phase kinase-associated protein 2, E3 ubiquitin 
protein ligase" 
0.987079 0.961049 
507.  ENSG00000156103 MMP16 matrix metallopeptidase 16 1.33017 0.960805 
508.  ENSG00000131849 ZNF132 zinc finger protein 132 0.974712 0.960395 
509.  ENSG00000079257 LXN latexin 0.957785 0.959065 
510.  ENSG00000183648 NDUFB1 NADH:ubiquinone oxidoreductase subunit B1 0.794603 0.958529 
511.  ENSG00000107020 PLGRKT plasminogen receptor with a C-terminal lysine 1.03486 0.956894 
512.  ENSG00000111361 EIF2B1 eukaryotic translation initiation factor 2B subunit alpha 0.842259 0.955928 
513.  ENSG00000135250 SRPK2 SRSF protein kinase 2 0.962142 0.955164 
514.  ENSG00000134419 RPS15A ribosomal protein S15a 0.97588 0.954983 
515.  ENSG00000205542 TMSB4X "thymosin beta 4, X-linked" 0.828414 0.954921 
516.  ENSG00000166557 TMED3 transmembrane p24 trafficking protein 3 0.862257 0.952594 
517.  ENSG00000170027 YWHAG 
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein gamma 
0.868706 0.950922 
518.  ENSG00000156398 SFXN2 sideroflexin 2 0.977583 0.949226 
519.  ENSG00000259803 SLC22A31 solute carrier family 22 member 31 0.856728 0.948328 
520.  ENSG00000166226 CCT2 chaperonin containing TCP1 subunit 2 0.955846 0.94792 
521.  ENSG00000132768 DPH2 DPH2 homolog 0.873147 0.947896 
522.  ENSG00000107938 EDRF1 erythroid differentiation regulatory factor 1 0.87891 0.947828 
523.  ENSG00000168672 FAM84B family with sequence similarity 84 member B 0.978182 0.9469 
524.  ENSG00000133111 RFXAP regulatory factor X associated protein 1.06703 0.94652 
525.  ENSG00000142864 SERBP1 SERPINE1 mRNA binding protein 1 0.99881 0.945595 
526.  ENSG00000183665 TRMT12 tRNA methyltransferase 12 homolog 0.867535 0.94512 
527.  ENSG00000142632 ARHGEF19 Rho guanine nucleotide exchange factor 19 0.840479 0.944296 
528.  ENSG00000023734 STRAP serine/threonine kinase receptor associated protein 0.923435 0.944209 
529.  ENSG00000111341 MGP matrix Gla protein 0.989572 0.94395 
530.  ENSG00000063241 ISOC2 isochorismatase domain containing 2 0.578063 0.943153 
531.  ENSG00000214194 LINC00998 long intergenic non-protein coding RNA 998 0.915797 0.942618 
532.  ENSG00000154639 CXADR coxsackie virus and adenovirus receptor 1.04079 0.942615 
533.  ENSG00000155254 MARVELD1 MARVEL domain containing 1 0.787191 0.941691 
534.  ENSG00000143977 SNRPG small nuclear ribonucleoprotein polypeptide G 0.722707 0.941404 
535.  ENSG00000093009 CDC45 cell division cycle 45 0.95113 0.941068 
536.  ENSG00000123131 PRDX4 peroxiredoxin 4 0.874995 0.937589 
537.  ENSG00000163479 SSR2 signal sequence receptor subunit 2 0.883125 0.937574 
538.  ENSG00000170779 CDCA4 cell division cycle associated 4 0.679391 0.937433 
539.  ENSG00000184675 AMER1 APC membrane recruitment protein 1 0.999996 0.936081 
540.  ENSG00000221990 EXOC3-AS1 EXOC3 antisense RNA 1 0.65992 0.935699 
541.  ENSG00000066468 FGFR2 fibroblast growth factor receptor 2 0.947844 0.935403 
542.  ENSG00000131873 CHSY1 chondroitin sulfate synthase 1 1.12941 0.935212 
543.  ENSG00000171574 ZNF584 zinc finger protein 584 0.928914 0.934971 
544.  ENSG00000136319 TTC5 tetratricopeptide repeat domain 5 0.895979 0.934807 
545.  ENSG00000006576 PHTF2 putative homeodomain transcription factor 2 0.995553 0.932872 
546.  ENSG00000120341 SEC16B 
"SEC16 homolog B, endoplasmic reticulum export 
factor" 
1.14986 0.932813 
547.  ENSG00000005022 SLC25A5 solute carrier family 25 member 5 0.874204 0.931417 
548.  ENSG00000187605 TET3 tet methylcytosine dioxygenase 3 0.964832 0.931351 
549.  ENSG00000140450 ARRDC4 arrestin domain containing 4 0.676729 0.931238 
550.  ENSG00000090520 DNAJB11 DnaJ heat shock protein family (Hsp40) member B11 0.904611 0.930958 
551.  ENSG00000162377 COA7 cytochrome c oxidase assembly factor 7 (putative) 0.72858 0.930403 
552.  ENSG00000242372 EIF6 eukaryotic translation initiation factor 6 0.77994 0.930112 
553.  ENSG00000188010 MORN2 MORN repeat containing 2 1.01867 0.929174 
554.  ENSG00000107014 RLN2 relaxin 2 0.992626 0.927344 
555.  ENSG00000124588 NQO2 NAD(P)H quinone dehydrogenase 2 0.893087 0.924738 
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556.  ENSG00000100604 CHGA chromogranin A 0.921886 0.924259 
557.  ENSG00000131844 MCCC2 methylcrotonoyl-CoA carboxylase 2 0.928812 0.924177 
558.  ENSG00000196449 YRDC 
yrdC N6-threonylcarbamoyltransferase domain 
containing 
0.756552 0.92334 
559.  ENSG00000166896 ATP23 
ATP23 metallopeptidase and ATP synthase assembly 
factor homolog 
0.957749 0.922681 
560.  ENSG00000108448 TRIM16L tripartite motif containing 16-like 0.910647 0.922332 
561.  ENSG00000100028 SNRPD3 small nuclear ribonucleoprotein D3 polypeptide 0.859864 0.921748 
562.  ENSG00000152229 PSTPIP2 
proline-serine-threonine phosphatase interacting 
protein 2 
0.853152 0.921707 
563.  ENSG00000204315 FKBPL FK506 binding protein like 0.676845 0.921371 
564.  ENSG00000176055 MBLAC2 metallo-beta-lactamase domain containing 2 0.798222 0.920713 
565.  ENSG00000116221 MRPL37 mitochondrial ribosomal protein L37 0.844301 0.91952 
566.  ENSG00000105058 FAM32A family with sequence similarity 32 member A 0.887943 0.919503 
567.  ENSG00000232654 FAM136BP 
"family with sequence similarity 136 member B, 
pseudogene" 
1.19572 0.919494 
568.  ENSG00000071054 MAP4K4 mitogen-activated protein kinase kinase kinase kinase 4 1.24666 0.919106 
569.  ENSG00000165688 PMPCA "peptidase, mitochondrial processing alpha subunit" 0.741118 0.917951 
570.  ENSG00000180817 PPA1 pyrophosphatase (inorganic) 1 0.889133 0.91749 
571.  ENSG00000225470 JPX "JPX transcript, XIST activator (non-protein coding)" 0.797853 0.917472 
572.  ENSG00000109775 UFSP2 UFM1 specific peptidase 2 0.918514 0.915898 
573.  ENSG00000172551 MUCL1 mucin like 1 1.29882 0.915705 
574.  ENSG00000167118 URM1 ubiquitin related modifier 1 0.777266 0.915202 
575.  ENSG00000131469 RPL27 ribosomal protein L27 0.818785 0.914966 
576.  ENSG00000124370 MCEE methylmalonyl-CoA epimerase 0.841898 0.914268 
577.  ENSG00000172819 RARG retinoic acid receptor gamma 0.99176 0.914053 
578.  ENSG00000115204 MPV17 "MPV17, mitochondrial inner membrane protein" 0.799041 0.913382 
579.  ENSG00000227345 PARG poly(ADP-ribose) glycohydrolase 0.88996 0.913123 
580.  ENSG00000087301 TXNDC16 thioredoxin domain containing 16 1.2185 0.912998 
581.  ENSG00000070785 EIF2B3 
eukaryotic translation initiation factor 2B subunit 
gamma 
0.854297 0.912875 
582.  ENSG00000205670 SMIM11A small integral membrane protein 11A 0.844039 0.910736 
583.  ENSG00000163466 ARPC2 actin related protein 2/3 complex subunit 2 0.827089 0.909638 
584.  ENSG00000198133 TMEM229B transmembrane protein 229B 0.964364 0.908993 
585.  ENSG00000167645 YIF1B 
"Yip1 interacting factor homolog B, membrane 
trafficking protein" 
0.721536 0.907742 
586.  ENSG00000033867 SLC4A7 solute carrier family 4 member 7 0.972962 0.90704 
587.  ENSG00000108352 RAPGEFL1 Rap guanine nucleotide exchange factor like 1 1.07791 0.906922 
588.  ENSG00000004059 ARF5 ADP ribosylation factor 5 0.739554 0.905469 
589.  ENSG00000166171 DPCD deleted in primary ciliary dyskinesia homolog (mouse) 0.96135 0.905369 
590.  ENSG00000178053 MLF1 myeloid leukemia factor 1 1.03219 0.903088 
591.  ENSG00000082482 KCNK2 
potassium two pore domain channel subfamily K 
member 2 
1.34367 0.902705 
592.  ENSG00000162636 FAM102B family with sequence similarity 102 member B 1.13096 0.902373 
593.  ENSG00000164627 KIF6 kinesin family member 6 0.904727 0.902278 
594.  ENSG00000180185 FAHD1 fumarylacetoacetate hydrolase domain containing 1 0.636851 0.901924 
595.  ENSG00000183765 CHEK2 checkpoint kinase 2 0.827479 0.90164 
596.  ENSG00000182518 FAM104B family with sequence similarity 104 member B 0.817937 0.900684 
597.  ENSG00000070501 POLB DNA polymerase beta 0.679722 0.900578 
598.  ENSG00000178773 CPNE7 copine 7 0.884544 0.900155 
599.  ENSG00000136997 MYC 
v-myc avian myelocytomatosis viral oncogene 
homolog 
0.888765 0.900107 
600.  ENSG00000166402 TUB tubby bipartite transcription factor 1.14111 0.899701 
601.  ENSG00000113916 BCL6 B-cell CLL/lymphoma 6 1.04653 0.899591 
602.  ENSG00000094880 CDC23 cell division cycle 23 0.89469 0.898371 
603.  ENSG00000197261 C6orf141 chromosome 6 open reading frame 141 0.756503 0.897626 
604.  ENSG00000009950 MLXIPL MLX interacting protein like 0.650685 0.897178 
605.  ENSG00000110042 DTX4 deltex E3 ubiquitin ligase 4 1.46128 0.89692 
606.  ENSG00000112039 FANCE Fanconi anemia complementation group E 0.788509 0.896597 
607.  ENSG00000115486 GGCX gamma-glutamyl carboxylase 0.84325 0.896333 
608.  ENSG00000183741 CBX6 chromobox 6 0.744626 0.895712 
609.  ENSG00000137692 DCUN1D5 defective in cullin neddylation 1 domain containing 5 0.895144 0.894684 
610.  ENSG00000103550 KNOP1 lysine rich nucleolar protein 1 0.996013 0.893312 
611.  ENSG00000100116 GCAT glycine C-acetyltransferase 0.816279 0.888683 
612.  ENSG00000149573 MPZL2 myelin protein zero like 2 0.733585 0.887167 
613.  ENSG00000134202 GSTM3 glutathione S-transferase mu 3 0.95424 0.886405 
614.  ENSG00000165795 NDRG2 NDRG family member 2 1.06254 0.885938 
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615.  ENSG00000125743 SNRPD2 small nuclear ribonucleoprotein D2 polypeptide 0.748278 0.885684 
616.  ENSG00000187889 C1orf168 chromosome 1 open reading frame 168 1.05566 0.884423 
617.  ENSG00000163923 RPL39L ribosomal protein L39 like 0.71943 0.884334 
618.  ENSG00000178449 COX14 "COX14, cytochrome c oxidase assembly factor" 0.697269 0.884169 
619.  ENSG00000158882 TOMM40L translocase of outer mitochondrial membrane 40 like 0.675673 0.883447 
620.  ENSG00000168505 GBX2 gastrulation brain homeobox 2 0.911229 0.883168 
621.  ENSG00000170191 NANP N-acetylneuraminic acid phosphatase 0.857126 0.883009 
622.  ENSG00000126767 ELK1 "ELK1, ETS transcription factor" 0.774281 0.883002 
623.  ENSG00000182195 LDOC1 leucine zipper down-regulated in cancer 1 0.909283 0.882885 
624.  ENSG00000117385 P3H1 prolyl 3-hydroxylase 1 1.17836 0.882606 
625.  ENSG00000160221 C21orf33 chromosome 21 open reading frame 33 0.576514 0.882266 
626.  ENSG00000103187 COTL1 coactosin like F-actin binding protein 1 0.904161 0.881233 
627.  ENSG00000139726 DENR density regulated re-initiation and release factor 0.927438 0.880601 
628.  ENSG00000105227 PRX periaxin 1.08466 0.880227 
629.  ENSG00000075618 FSCN1 fascin actin-bundling protein 1 0.883641 0.88007 
630.  ENSG00000171858 RPS21 ribosomal protein S21 0.612498 0.878411 
631.  ENSG00000235655 H3F3AP4 "H3 histone, family 3A, pseudogene 4" 0.994267 0.877585 
632.  ENSG00000157111 TMEM171 transmembrane protein 171 0.878415 0.876701 
633.  ENSG00000128228 SDF2L1 stromal cell derived factor 2 like 1 0.554218 0.876166 
634.  ENSG00000117407 ARTN artemin 0.779861 0.876064 
635.  ENSG00000128708 HAT1 histone acetyltransferase 1 0.915354 0.875117 
636.  ENSG00000100483 VCPKMT valosin containing protein lysine methyltransferase 0.605394 0.87448 
637.  ENSG00000143155 TIPRL TOR signaling pathway regulator 0.811212 0.873609 
638.  ENSG00000243479 MNX1-AS1 MNX1 antisense RNA 1 (head to head) 0.688844 0.870034 
639.  ENSG00000148925 BTBD10 BTB domain containing 10 0.947219 0.868464 
640.  ENSG00000107949 BCCIP BRCA2 and CDKN1A interacting protein 0.802714 0.867996 
641.  ENSG00000112164 GLP1R glucagon like peptide 1 receptor 0.964153 0.86756 
642.  ENSG00000164039 BDH2 "3-hydroxybutyrate dehydrogenase, type 2" 0.843871 0.866672 
643.  ENSG00000119705 SLIRP SRA stem-loop interacting RNA binding protein 0.769817 0.866559 
644.  ENSG00000215386 MIR99AHG mir-99a-let-7c cluster host gene 0.706262 0.866057 
645.  ENSG00000132780 NASP nuclear autoantigenic sperm protein 0.889616 0.865998 
646.  ENSG00000140395 WDR61 WD repeat domain 61 0.783432 0.865257 
647.  ENSG00000130066 SAT1 spermidine/spermine N1-acetyltransferase 1 0.701296 0.864274 
648.  ENSG00000104756 KCTD9 potassium channel tetramerization domain containing 9 0.999242 0.863835 
649.  ENSG00000108219 TSPAN14 tetraspanin 14 0.869488 0.86275 
650.  ENSG00000131876 SNRPA1 small nuclear ribonucleoprotein polypeptide A' 0.885467 0.861662 
651.  ENSG00000141622 RNF165 ring finger protein 165 1.06013 0.861514 
652.  ENSG00000175061 
LRRC75A-
AS1 
LRRC75A antisense RNA 1 0.730571 0.859008 
653.  ENSG00000109475 RPL34 ribosomal protein L34 0.791899 0.858151 
654.  ENSG00000164983 TMEM65 transmembrane protein 65 1.01325 0.856892 
655.  ENSG00000102996 MMP15 matrix metallopeptidase 15 0.898084 0.856742 
656.  ENSG00000253626 EIF5AL1 eukaryotic translation initiation factor 5A-like 1 0.937528 0.856409 
657.  ENSG00000125901 MRPS26 mitochondrial ribosomal protein S26 0.590285 0.855188 
658.  ENSG00000171953 ATPAF2 
ATP synthase mitochondrial F1 complex assembly 
factor 2 
0.668871 0.853675 
659.  ENSG00000108561 C1QBP complement C1q binding protein 0.842575 0.853417 
660.  ENSG00000092036 HAUS4 HAUS augmin like complex subunit 4 0.81204 0.852708 
661.  ENSG00000143486 EIF2D eukaryotic translation initiation factor 2D 0.89687 0.852116 
662.  ENSG00000120322 PCDHB8 protocadherin beta 8 1.12031 0.851423 
663.  ENSG00000106628 POLD2 "DNA polymerase delta 2, accessory subunit" 0.947729 0.850791 
664.  ENSG00000100600 LGMN legumain 0.997135 0.849279 
665.  ENSG00000139547 RDH16 retinol dehydrogenase 16 (all-trans) 0.549674 0.848992 
666.  ENSG00000173638 SLC19A1 solute carrier family 19 member 1 0.711999 0.848981 
667.  ENSG00000166961 MS4A15 membrane spanning 4-domains A15 1.42859 0.848195 
668.  ENSG00000127152 BCL11B B-cell CLL/lymphoma 11B 0.889491 0.847944 
669.  ENSG00000214113 LYRM4 LYR motif containing 4 0.816561 0.847357 
670.  ENSG00000169740 ZNF32 zinc finger protein 32 0.790834 0.846533 
671.  ENSG00000153574 RPIA ribose 5-phosphate isomerase A 0.794538 0.845553 
672.  ENSG00000222041 LINC00152 long intergenic non-protein coding RNA 152 0.642621 0.845507 
673.  ENSG00000088832 FKBP1A FK506 binding protein 1A 0.791857 0.845083 
674.  ENSG00000075336 TIMM21 translocase of inner mitochondrial membrane 21 0.679132 0.844579 
675.  ENSG00000174672 BRSK2 BR serine/threonine kinase 2 1.05141 0.844313 
676.  ENSG00000111911 HINT3 histidine triad nucleotide binding protein 3 0.862346 0.844222 
677.  ENSG00000150433 TMEM218 transmembrane protein 218 0.819994 0.843916 
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678.  ENSG00000197563 PIGN 
phosphatidylinositol glycan anchor biosynthesis class 
N 
1.27463 0.843688 
679.  ENSG00000148803 FUOM fucose mutarotase 0.512164 0.843375 
680.  ENSG00000126953 TIMM8A 
translocase of inner mitochondrial membrane 8 
homolog A (yeast) 
0.716225 0.843205 
681.  ENSG00000088035 ALG6 "ALG6, alpha-1,3-glucosyltransferase" 0.725901 0.842662 
682.  ENSG00000229117 RPL41 ribosomal protein L41 0.863473 0.842525 
683.  ENSG00000145912 NHP2 NHP2 ribonucleoprotein 0.656477 0.842416 
684.  ENSG00000087510 TFAP2C transcription factor AP-2 gamma 0.827 0.84 
685.  ENSG00000152939 MARVELD2 MARVEL domain containing 2 0.848956 0.83838 
686.  ENSG00000106603 COA1 cytochrome c oxidase assembly factor 1 homolog 0.866394 0.834569 
687.  ENSG00000122406 RPL5 ribosomal protein L5 0.876493 0.834361 
688.  ENSG00000241127 YAE1D1 Yae1 domain containing 1 0.528961 0.833542 
689.  ENSG00000165916 PSMC3 "proteasome 26S subunit, ATPase 3" 0.867627 0.83266 
690.  ENSG00000131174 COX7B cytochrome c oxidase subunit 7B 0.743747 0.832255 
691.  ENSG00000134882 UBAC2 UBA domain containing 2 0.761043 0.832168 
692.  ENSG00000114054 PCCB propionyl-CoA carboxylase beta subunit 0.879864 0.830985 
693.  ENSG00000137834 SMAD6 SMAD family member 6 0.666859 0.829978 
694.  ENSG00000157827 FMNL2 formin like 2 0.941409 0.829786 
695.  ENSG00000136636 KCTD3 potassium channel tetramerization domain containing 3 0.882766 0.829573 
696.  ENSG00000204308 RNF5 ring finger protein 5 0.74448 0.82896 
697.  ENSG00000170836 PPM1D "protein phosphatase, Mg2+/Mn2+ dependent 1D" 0.805558 0.828481 
698.  ENSG00000189046 ALKBH2 
"alkB homolog 2, alpha-ketoglutarate dependent 
dioxygenase" 
0.534917 0.826004 
699.  ENSG00000116833 NR5A2 nuclear receptor subfamily 5 group A member 2 1.21764 0.825542 
700.  ENSG00000183010 PYCR1 pyrroline-5-carboxylate reductase 1 0.667415 0.824556 
701.  ENSG00000261437 
LOC1002887
48 
uncharacterized LOC100288748 0.514374 0.824425 
702.  ENSG00000250588 IQCJ-SCHIP1 IQCJ-SCHIP1 readthrough 1.07634 0.824338 
703.  ENSG00000164967 RPP25L ribonuclease P/MRP subunit p25 like 0.589825 0.823949 
704.  ENSG00000073464 CLCN4 chloride voltage-gated channel 4 1.05748 0.823801 
705.  ENSG00000169902 TPST1 tyrosylprotein sulfotransferase 1 0.973886 0.823435 
706.  ENSG00000181350 LRRC75A leucine rich repeat containing 75A 0.828751 0.822573 
707.  ENSG00000135549 PKIB 
"protein kinase (cAMP-dependent, catalytic) inhibitor 
beta" 
0.923158 0.820975 
708.  ENSG00000169021 UQCRFS1 
"ubiquinol-cytochrome c reductase, Rieske iron-sulfur 
polypeptide 1" 
0.673997 0.820654 
709.  ENSG00000138035 PNPT1 polyribonucleotide nucleotidyltransferase 1 0.771053 0.820103 
710.  ENSG00000099284 H2AFY2 H2A histone family member Y2 0.758477 0.819214 
711.  ENSG00000105552 BCAT2 branched chain amino acid transaminase 2 0.627225 0.819078 
712.  ENSG00000003436 TFPI tissue factor pathway inhibitor 0.685574 0.818259 
713.  ENSG00000111850 SMIM8 small integral membrane protein 8 0.664991 0.817361 
714.  ENSG00000139428 MMAB 
methylmalonic aciduria (cobalamin deficiency) cblB 
type 
0.698355 0.816792 
715.  ENSG00000165028 NIPSNAP3B nipsnap homolog 3B 0.977539 0.816229 
716.  ENSG00000176124 DLEU1 deleted in lymphocytic leukemia 1 1.11632 0.816194 
717.  ENSG00000072954 TMEM38A transmembrane protein 38A 0.820518 0.816127 
718.  ENSG00000203875 SNHG5 small nucleolar RNA host gene 5 0.587049 0.815636 
719.  ENSG00000173467 AGR3 
"anterior gradient 3, protein disulphide isomerase 
family member" 
0.59845 0.815454 
720.  ENSG00000164163 ABCE1 ATP binding cassette subfamily E member 1 0.876384 0.815314 
721.  ENSG00000137038 TMEM261 transmembrane protein 261 0.671823 0.814308 
722.  ENSG00000155508 CNOT8 CCR4-NOT transcription complex subunit 8 0.78093 0.812067 
723.  ENSG00000164096 C4orf3 chromosome 4 open reading frame 3 0.665988 0.811939 
724.  ENSG00000026950 BTN3A1 butyrophilin subfamily 3 member A1 0.701139 0.811308 
725.  ENSG00000155876 RRAGA Ras related GTP binding A 0.713067 0.811297 
726.  ENSG00000171421 MRPL36 mitochondrial ribosomal protein L36 0.541391 0.810266 
727.  ENSG00000164751 PEX2 peroxisomal biogenesis factor 2 0.769444 0.809132 
728.  ENSG00000071462 WBSCR22 Williams-Beuren syndrome chromosome region 22 0.693725 0.809007 
729.  ENSG00000112667 DNPH1 2'-deoxynucleoside 5'-phosphate N-hydrolase 1 0.415004 0.808615 
730.  ENSG00000120093 HOXB3 homeobox B3 0.917468 0.808306 
731.  ENSG00000134759 ELP2 elongator acetyltransferase complex subunit 2 0.751258 0.807974 
732.  ENSG00000150093 ITGB1 integrin subunit beta 1 0.987881 0.80671 
733.  ENSG00000168389 MFSD2A major facilitator superfamily domain containing 2A 1.167 0.806571 
734.  ENSG00000145220 LYAR Ly1 antibody reactive 0.775255 0.806391 
735.  ENSG00000104064 GABPB1 GA binding protein transcription factor beta subunit 1 0.78914 0.806187 
 
 203 
736.  ENSG00000134375 TIMM17A 
translocase of inner mitochondrial membrane 17 
homolog A (yeast) 
0.741463 0.806169 
737.  ENSG00000169020 ATP5I 
"ATP synthase, H+ transporting, mitochondrial Fo 
complex subunit E" 
0.572728 0.805795 
738.  ENSG00000128694 OSGEPL1 O-sialoglycoprotein endopeptidase like 1 0.946834 0.805438 
739.  ENSG00000113621 TXNDC15 thioredoxin domain containing 15 0.674132 0.804971 
740.  ENSG00000172345 STARD5 StAR related lipid transfer domain containing 5 0.757691 0.804855 
741.  ENSG00000151729 SLC25A4 solute carrier family 25 member 4 0.688413 0.804581 
742.  ENSG00000114391 RPL24 ribosomal protein L24 0.775667 0.80338 
743.  ENSG00000185627 PSMD13 "proteasome 26S subunit, non-ATPase 13" 0.720864 0.803083 
744.  ENSG00000168769 TET2 tet methylcytosine dioxygenase 2 0.974007 0.8011 
745.  ENSG00000165264 NDUFB6 NADH:ubiquinone oxidoreductase subunit B6 0.611903 0.800763 
746.  ENSG00000124641 MED20 mediator complex subunit 20 0.783132 0.800067 
747.  ENSG00000167693 NXN nucleoredoxin 0.717945 0.799884 
748.  ENSG00000140740 UQCRC2 ubiquinol-cytochrome c reductase core protein II 0.756596 0.79963 
749.  ENSG00000146950 SHROOM2 shroom family member 2 0.930158 0.799281 
750.  ENSG00000170260 ZNF212 zinc finger protein 212 0.573246 0.799225 
751.  ENSG00000184182 UBE2F ubiquitin conjugating enzyme E2 F (putative) 0.847813 0.799021 
752.  ENSG00000254999 BRK1 
"BRICK1, SCAR/WAVE actin nucleating complex 
subunit" 
0.750387 0.79901 
753.  ENSG00000189120 SP6 Sp6 transcription factor 0.627875 0.798127 
754.  ENSG00000163682 RPL9 ribosomal protein L9 0.790399 0.797841 
755.  ENSG00000181392 SYNE4 
spectrin repeat containing nuclear envelope family 
member 4 
0.83352 0.797764 
756.  ENSG00000237190 
CDKN2AIPN
L 
CDKN2A interacting protein N-terminal like 0.749947 0.797643 
757.  ENSG00000129195 FAM64A family with sequence similarity 64 member A 0.685687 0.797623 
758.  ENSG00000238227 C9orf69 chromosome 9 open reading frame 69 0.476335 0.79721 
759.  ENSG00000108830 RND2 Rho family GTPase 2 0.528641 0.797044 
760.  ENSG00000198042 MAK16 MAK16 homolog 0.777235 0.79678 
761.  ENSG00000132661 NXT1 nuclear transport factor 2 like export factor 1 0.594323 0.796174 
762.  ENSG00000262814 MRPL12 mitochondrial ribosomal protein L12 0.508657 0.795649 
763.  ENSG00000088356 PDRG1 p53 and DNA damage regulated 1 0.59653 0.79471 
764.  ENSG00000243147 MRPL33 mitochondrial ribosomal protein L33 0.747995 0.79456 
765.  ENSG00000198918 RPL39 ribosomal protein L39 0.790025 0.793589 
766.  ENSG00000156384 SFR1 
SWI5 dependent homologous recombination repair 
protein 1 
0.733793 0.792653 
767.  ENSG00000184402 SS18L1 
"SS18L1, nBAF chromatin remodeling complex 
subunit" 
0.699734 0.792439 
768.  ENSG00000112290 WASF1 WAS protein family member 1 1.0033 0.791938 
769.  ENSG00000013561 RNF14 ring finger protein 14 0.744299 0.790873 
770.  ENSG00000138138 ATAD1 "ATPase family, AAA domain containing 1" 0.789302 0.790079 
771.  ENSG00000069956 MAPK6 mitogen-activated protein kinase 6 0.93147 0.789119 
772.  ENSG00000106153 CHCHD2 coiled-coil-helix-coiled-coil-helix domain containing 2 0.673485 0.788832 
773.  ENSG00000104131 EIF3J eukaryotic translation initiation factor 3 subunit J 0.920679 0.788568 
774.  ENSG00000173660 UQCRH ubiquinol-cytochrome c reductase hinge protein 0.730635 0.787734 
775.  ENSG00000023892 DEF6 "DEF6, guanine nucleotide exchange factor" 0.674619 0.787547 
776.  ENSG00000136897 MRPL50 mitochondrial ribosomal protein L50 0.727963 0.787498 
777.  ENSG00000166347 CYB5A cytochrome b5 type A 0.776375 0.787099 
778.  ENSG00000179431 FJX1 four jointed box 1 0.673003 0.786922 
779.  ENSG00000173436 MINOS1 mitochondrial inner membrane organizing system 1 0.553804 0.786255 
780.  ENSG00000135469 COQ10A coenzyme Q10A 0.61573 0.786051 
781.  ENSG00000223802 GDF1 growth differentiation factor 1 0.939212 0.785672 
782.  ENSG00000113387 SUB1 "SUB1 homolog, transcriptional regulator" 0.789299 0.78565 
783.  ENSG00000160703 NLRX1 NLR family member X1 0.861659 0.784992 
784.  ENSG00000118690 ARMC2 armadillo repeat containing 2 0.696103 0.782873 
785.  ENSG00000027001 MIPEP mitochondrial intermediate peptidase 0.710182 0.782334 
786.  ENSG00000214114 MYCBP MYC binding protein 0.834701 0.780983 
787.  ENSG00000175279 APITD1 "apoptosis-inducing, TAF9-like domain 1" 0.815897 0.780221 
788.  ENSG00000180777 ANKRD30B ankyrin repeat domain 30B 0.863248 0.779758 
789.  ENSG00000163138 PACRGL PARK2 coregulated like 0.71929 0.778749 
790.  ENSG00000076248 UNG uracil DNA glycosylase 0.816379 0.778265 
791.  ENSG00000170846 LOC93622 Morf4 family associated protein 1 like 1 pseudogene 0.617748 0.775301 
792.  ENSG00000267296 CEBPA-AS1 CEBPA antisense RNA 1 (head to head) 0.653322 0.775162 
793.  ENSG00000125991 ERGIC3 ERGIC and golgi 3 0.703577 0.774335 
794.  ENSG00000124614 RPS10 ribosomal protein S10 0.69203 0.772701 
795.  ENSG00000185432 METTL7A methyltransferase like 7A 0.867371 0.772139 
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796.  ENSG00000143622 RIT1 Ras like without CAAX 1 0.743862 0.771635 
797.  ENSG00000114686 MRPL3 mitochondrial ribosomal protein L3 0.752811 0.771381 
798.  ENSG00000137168 PPIL1 peptidylprolyl isomerase like 1 0.72316 0.771098 
799.  ENSG00000114650 SCAP SREBF chaperone 0.857089 0.770539 
800.  ENSG00000120158 RCL1 RNA terminal phosphate cyclase like 1 0.58902 0.770248 
801.  ENSG00000133818 RRAS2 related RAS viral (r-ras) oncogene homolog 2 0.839157 0.770152 
802.  ENSG00000156253 RWDD2B RWD domain containing 2B 0.760684 0.77008 
803.  ENSG00000168116 KIAA1586 KIAA1586 0.802731 0.769537 
804.  ENSG00000101003 GINS1 GINS complex subunit 1 0.825391 0.768927 
805.  ENSG00000177508 IRX3 iroquois homeobox 3 0.704955 0.768635 
806.  ENSG00000143621 ILF2 interleukin enhancer binding factor 2 0.778354 0.768432 
807.  ENSG00000125843 AP5S1 adaptor related protein complex 5 sigma 1 subunit 0.456215 0.768152 
808.  ENSG00000079739 PGM1 phosphoglucomutase 1 0.901442 0.766433 
809.  ENSG00000106367 AP1S1 adaptor related protein complex 1 sigma 1 subunit 0.712681 0.766289 
810.  ENSG00000142937 RPS8 ribosomal protein S8 0.798614 0.76595 
811.  ENSG00000166902 MRPL16 mitochondrial ribosomal protein L16 0.6387 0.765245 
812.  ENSG00000112972 HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 0.995823 0.765179 
813.  ENSG00000183527 PSMG1 proteasome assembly chaperone 1 0.681266 0.765086 
814.  ENSG00000164687 FABP5 fatty acid binding protein 5 0.582434 0.764601 
815.  ENSG00000002549 LAP3 leucine aminopeptidase 3 0.654389 0.76435 
816.  ENSG00000155660 PDIA4 protein disulfide isomerase family A member 4 0.832177 0.763579 
817.  ENSG00000114812 VIPR1 vasoactive intestinal peptide receptor 1 0.945101 0.763107 
818.  ENSG00000132507 EIF5A eukaryotic translation initiation factor 5A 0.682438 0.762379 
819.  ENSG00000154930 ACSS1 acyl-CoA synthetase short-chain family member 1 0.732909 0.762267 
820.  ENSG00000073282 TP63 tumor protein p63 1.17284 0.761436 
821.  ENSG00000169139 UBE2V2 ubiquitin conjugating enzyme E2 V2 0.847768 0.761367 
822.  ENSG00000189403 HMGB1 high mobility group box 1 0.862235 0.760277 
823.  ENSG00000165506 DNAAF2 dynein axonemal assembly factor 2 0.627346 0.76001 
824.  ENSG00000071994 PDCD2 programmed cell death 2 0.709717 0.75917 
825.  ENSG00000143319 ISG20L2 interferon stimulated exonuclease gene 20 like 2 0.800567 0.759151 
826.  ENSG00000138587 MNS1 meiosis specific nuclear structural 1 0.840035 0.758889 
827.  ENSG00000175093 SPSB4 
splA/ryanodine receptor domain and SOCS box 
containing 4 
1.17641 0.758689 
828.  ENSG00000265688 MAFG-AS1 MAFG antisense RNA 1 (head to head) 0.488091 0.758365 
829.  ENSG00000139620 KANSL2 KAT8 regulatory NSL complex subunit 2 0.647085 0.758256 
830.  ENSG00000137210 TMEM14B transmembrane protein 14B 0.746991 0.758224 
831.  ENSG00000181924 COA4 cytochrome c oxidase assembly factor 4 homolog 0.567114 0.757669 
832.  ENSG00000146963 LUC7L2 "LUC7 like 2, pre-mRNA splicing factor" 0.803454 0.757396 
833.  ENSG00000170425 ADORA2B adenosine A2b receptor 0.715716 0.757347 
834.  ENSG00000116353 MECR mitochondrial trans-2-enoyl-CoA reductase 0.629844 0.756609 
835.  ENSG00000159792 PSKH1 protein serine kinase H1 0.564947 0.756137 
836.  ENSG00000090971 NAT14 N-acetyltransferase 14 (putative) 0.436621 0.755597 
837.  ENSG00000182899 RPL35A ribosomal protein L35a 0.687875 0.754828 
838.  ENSG00000196782 MAML3 mastermind like transcriptional coactivator 3 1.17245 0.753546 
839.  ENSG00000102390 PBDC1 polysaccharide biosynthesis domain containing 1 0.702885 0.752183 
840.  ENSG00000198876 DCAF12 DDB1 and CUL4 associated factor 12 0.792873 0.751584 
841.  ENSG00000035499 DEPDC1B DEP domain containing 1B 0.948026 0.751444 
842.  ENSG00000137154 RPS6 ribosomal protein S6 0.80126 0.751089 
843.  ENSG00000109534 GAR1 GAR1 ribonucleoprotein 0.712978 0.750716 
844.  ENSG00000105948 TTC26 tetratricopeptide repeat domain 26 0.645484 0.750698 
845.  ENSG00000198755 RPL10A ribosomal protein L10a 0.714578 0.750405 
846.  ENSG00000091140 DLD dihydrolipoamide dehydrogenase 0.797122 0.750107 
847.  ENSG00000140416 TPM1 tropomyosin 1 (alpha) 0.801783 0.748702 
848.  ENSG00000071553 ATP6AP1 ATPase H+ transporting accessory protein 1 0.725615 0.747385 
849.  ENSG00000106588 PSMA2 proteasome subunit alpha 2 0.711013 0.747366 
850.  ENSG00000104915 STX10 syntaxin 10 0.682659 0.746872 
851.  ENSG00000105173 CCNE1 cyclin E1 0.708192 0.746412 
852.  ENSG00000214706 IFRD2 interferon related developmental regulator 2 0.559552 0.745983 
853.  ENSG00000164182 NDUFAF2 
NADH:ubiquinone oxidoreductase complex assembly 
factor 2 
0.783876 0.745836 
854.  ENSG00000164305 CASP3 caspase 3 0.729553 0.745127 
855.  ENSG00000149273 RPS3 ribosomal protein S3 0.756681 0.745014 
856.  ENSG00000172500 FIBP FGF1 intracellular binding protein 0.762325 0.744858 
857.  ENSG00000144120 TMEM177 transmembrane protein 177 0.455281 0.744802 
858.  ENSG00000161267 BDH1 "3-hydroxybutyrate dehydrogenase, type 1" 0.715878 0.744706 
859.  ENSG00000213782 DDX47 DEAD-box helicase 47 0.765994 0.743859 
 
 205 
860.  ENSG00000164978 NUDT2 nudix hydrolase 2 0.587172 0.742747 
861.  ENSG00000215021 PHB2 prohibitin 2 0.658567 0.742473 
862.  ENSG00000130414 NDUFA10 NADH:ubiquinone oxidoreductase subunit A10 0.587629 0.742002 
863.  ENSG00000163738 MTHFD2L 
methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 2-like 
0.589263 0.741144 
864.  ENSG00000047634 SCML1 sex comb on midleg-like 1 (Drosophila) 0.763639 0.740902 
865.  ENSG00000129071 MBD4 "methyl-CpG binding domain 4, DNA glycosylase" 0.679262 0.740153 
866.  ENSG00000174173 TRMT10C 
"tRNA methyltransferase 10C, mitochondrial RNase P 
subunit" 
0.656297 0.739582 
867.  ENSG00000083845 RPS5 ribosomal protein S5 0.563525 0.738254 
868.  ENSG00000165997 ARL5B ADP ribosylation factor like GTPase 5B 0.799245 0.737761 
869.  ENSG00000122026 RPL21 ribosomal protein L21 0.755891 0.73765 
870.  ENSG00000070831 CDC42 cell division cycle 42 0.724433 0.737603 
871.  ENSG00000152795 HNRNPDL heterogeneous nuclear ribonucleoprotein D like 0.624528 0.737366 
872.  ENSG00000182512 GLRX5 glutaredoxin 5 0.741695 0.736694 
873.  ENSG00000056736 IL17RB interleukin 17 receptor B 0.884077 0.736462 
874.  ENSG00000105607 GCDH glutaryl-CoA dehydrogenase 0.848594 0.735966 
875.  ENSG00000059378 PARP12 poly(ADP-ribose) polymerase family member 12 0.41123 0.735736 
876.  ENSG00000232112 TMA7 translation machinery associated 7 homolog 0.568972 0.735707 
877.  ENSG00000164405 UQCRQ 
ubiquinol-cytochrome c reductase complex III subunit 
VII 
0.655835 0.735397 
878.  ENSG00000110955 ATP5B 
"ATP synthase, H+ transporting, mitochondrial F1 
complex, beta polypeptide" 
0.738957 0.734603 
879.  ENSG00000105677 TMEM147 transmembrane protein 147 0.659977 0.73448 
880.  ENSG00000136930 PSMB7 proteasome subunit beta 7 0.703839 0.733512 
881.  ENSG00000183605 SFXN4 sideroflexin 4 0.706769 0.733447 
882.  ENSG00000135587 SMPD2 sphingomyelin phosphodiesterase 2 0.898892 0.733124 
883.  ENSG00000133678 TMEM254 transmembrane protein 254 0.725767 0.733062 
884.  ENSG00000123600 METTL8 methyltransferase like 8 0.803202 0.731764 
885.  ENSG00000231500 RPS18 ribosomal protein S18 0.638633 0.730978 
886.  ENSG00000152782 PANK1 pantothenate kinase 1 0.797274 0.730937 
887.  ENSG00000146535 GNA12 G protein subunit alpha 12 0.878071 0.730274 
888.  ENSG00000181817 LSM10 "LSM10, U7 small nuclear RNA associated" 0.568817 0.730227 
889.  ENSG00000109911 ELP4 elongator acetyltransferase complex subunit 4 0.670908 0.728065 
890.  ENSG00000169738 DCXR dicarbonyl and L-xylulose reductase 0.639569 0.72724 
891.  ENSG00000100865 CINP cyclin dependent kinase 2 interacting protein 0.658014 0.726846 
892.  ENSG00000147155 EBP emopamil binding protein (sterol isomerase) 0.72739 0.726358 
893.  ENSG00000087053 MTMR2 myotubularin related protein 2 0.910336 0.726056 
894.  ENSG00000161980 POLR3K RNA polymerase III subunit K 0.601195 0.724844 
895.  ENSG00000206503 HLA-A "major histocompatibility complex, class I, A" 0.642678 0.723941 
896.  ENSG00000198142 SOWAHC sosondowah ankyrin repeat domain family member C 0.757397 0.721909 
897.  ENSG00000141384 TAF4B TATA-box binding protein associated factor 4b 0.927441 0.721482 
898.  ENSG00000196976 LAGE3 L antigen family member 3 0.51342 0.72033 
899.  ENSG00000137563 GGH gamma-glutamyl hydrolase 0.863208 0.719927 
900.  ENSG00000140718 FTO fat mass and obesity associated 0.807692 0.719746 
901.  ENSG00000224877 NDUFAF8 
NADH:ubiquinone oxidoreductase complex assembly 
factor 8 
0.438455 0.719152 
902.  ENSG00000132341 RAN "RAN, member RAS oncogene family" 0.649795 0.716611 
903.  ENSG00000070761 CFAP20 cilia and flagella associated protein 20 0.673339 0.71513 
904.  ENSG00000185989 RASA3 RAS p21 protein activator 3 0.752342 0.715053 
905.  ENSG00000154642 C21orf91 chromosome 21 open reading frame 91 0.691422 0.713411 
906.  ENSG00000167283 ATP5L 
"ATP synthase, H+ transporting, mitochondrial Fo 
complex subunit G" 
0.641905 0.713396 
907.  ENSG00000197345 MRPL21 mitochondrial ribosomal protein L21 0.620408 0.711494 
908.  ENSG00000108651 UTP6 "UTP6, small subunit processome component" 0.626186 0.711473 
909.  ENSG00000171954 CYP4F22 cytochrome P450 family 4 subfamily F member 22 0.607833 0.711376 
910.  ENSG00000197728 RPS26 ribosomal protein S26 0.600671 0.710175 
911.  ENSG00000122783 C7orf49 chromosome 7 open reading frame 49 0.651726 0.709833 
912.  ENSG00000116285 ERRFI1 ERBB receptor feedback inhibitor 1 0.525362 0.709608 
913.  ENSG00000075413 MARK3 microtubule affinity regulating kinase 3 0.541086 0.708198 
914.  ENSG00000159228 CBR1 carbonyl reductase 1 0.60378 0.707936 
915.  ENSG00000123179 EBPL emopamil binding protein like 0.759841 0.707649 
916.  ENSG00000136770 DNAJC1 DnaJ heat shock protein family (Hsp40) member C1 0.628416 0.707132 
917.  ENSG00000051596 THOC3 THO complex 3 0.747607 0.706681 
918.  ENSG00000092094 OSGEP O-sialoglycoprotein endopeptidase 0.590015 0.706425 
919.  ENSG00000127334 DYRK2 





920.  ENSG00000217555 CKLF chemokine like factor 0.618983 0.705915 
921.  ENSG00000178537 SLC25A20 solute carrier family 25 member 20 0.55318 0.705508 
922.  ENSG00000132591 ERAL1 Era like 12S mitochondrial rRNA chaperone 1 0.638027 0.704868 
923.  ENSG00000167862 MRPL58 mitochondrial ribosomal protein L58 0.589747 0.704769 
924.  ENSG00000125484 GTF3C4 general transcription factor IIIC subunit 4 0.760099 0.704617 
925.  ENSG00000116922 C1orf109 chromosome 1 open reading frame 109 0.578077 0.703725 
926.  ENSG00000111832 RWDD1 RWD domain containing 1 0.790947 0.703144 
927.  ENSG00000187713 TMEM203 transmembrane protein 203 0.536841 0.70267 
928.  ENSG00000144354 CDCA7 cell division cycle associated 7 0.780818 0.700558 
929.  ENSG00000107223 EDF1 endothelial differentiation related factor 1 0.499046 0.698612 
930.  ENSG00000154217 PITPNC1 "phosphatidylinositol transfer protein, cytoplasmic 1" 0.752945 0.698521 
931.  ENSG00000137267 TUBB2A tubulin beta 2A class IIa 0.556047 0.69846 
932.  ENSG00000175322 ZNF519 zinc finger protein 519 0.57224 0.698319 
933.  ENSG00000047621 C12orf4 chromosome 12 open reading frame 4 0.589379 0.697994 
934.  ENSG00000055211 GINM1 glycoprotein integral membrane 1 0.775513 0.697549 
935.  ENSG00000066379 ZNRD1 zinc ribbon domain containing 1 0.479523 0.696981 
936.  ENSG00000080189 SLC35C2 solute carrier family 35 member C2 0.614949 0.696564 
937.  ENSG00000179862 CITED4 
Cbp/p300 interacting transactivator with Glu/Asp rich 
carboxy-terminal domain 4 
0.482466 0.696028 
938.  ENSG00000076067 RBMS2 
RNA binding motif single stranded interacting protein 
2 
0.988779 0.695869 
939.  ENSG00000088451 TGDS "TDP-glucose 4,6-dehydratase" 0.708024 0.695662 
940.  ENSG00000182307 C8orf33 chromosome 8 open reading frame 33 0.660074 0.695409 
941.  ENSG00000166441 RPL27A ribosomal protein L27a 0.602351 0.694477 
942.  ENSG00000186132 C2orf76 chromosome 2 open reading frame 76 0.748832 0.69391 
943.  ENSG00000004779 NDUFAB1 NADH:ubiquinone oxidoreductase subunit AB1 0.596311 0.692596 
944.  ENSG00000112977 DAP death associated protein 0.676437 0.692041 
945.  ENSG00000168028 RPSA ribosomal protein SA 0.728888 0.69114 
946.  ENSG00000078070 MCCC1 methylcrotonoyl-CoA carboxylase 1 0.606684 0.691066 
947.  ENSG00000169684 CHRNA5 cholinergic receptor nicotinic alpha 5 subunit 0.704088 0.690746 
948.  ENSG00000142541 RPL13A ribosomal protein L13a 0.565281 0.690617 
949.  ENSG00000117691 NENF neudesin neurotrophic factor 0.63689 0.689993 
950.  ENSG00000231584 FAHD2CP 
"fumarylacetoacetate hydrolase domain containing 2C, 
pseudogene" 
0.698245 0.689497 
951.  ENSG00000109919 MTCH2 mitochondrial carrier 2 0.643666 0.688932 
952.  ENSG00000012660 ELOVL5 ELOVL fatty acid elongase 5 0.835545 0.688405 
953.  ENSG00000164976 KIAA1161 KIAA1161 0.655048 0.688324 
954.  ENSG00000164442 CITED2 
Cbp/p300 interacting transactivator with Glu/Asp rich 
carboxy-terminal domain 2 
0.558277 0.687849 
955.  ENSG00000137513 NARS2 
"asparaginyl-tRNA synthetase 2, mitochondrial 
(putative)" 
0.792649 0.687521 
956.  ENSG00000163818 LZTFL1 leucine zipper transcription factor like 1 0.597137 0.686555 
957.  ENSG00000187193 MT1X metallothionein 1X 0.426134 0.685788 
958.  ENSG00000076513 ANKRD13A ankyrin repeat domain 13A 0.696859 0.685671 
959.  ENSG00000176903 PNMA1 paraneoplastic Ma antigen 1 0.569994 0.68552 
960.  ENSG00000100804 PSMB5 proteasome subunit beta 5 0.647283 0.685028 
961.  ENSG00000132467 UTP3 
"UTP3, small subunit processome component homolog 
(S. cerevisiae)" 
0.539582 0.683986 
962.  ENSG00000166710 B2M beta-2-microglobulin 0.660654 0.683885 
963.  ENSG00000172115 CYCS "cytochrome c, somatic" 0.634708 0.683778 
964.  ENSG00000163249 CCNYL1 cyclin Y like 1 0.891729 0.683649 
965.  ENSG00000164109 MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) 0.684397 0.683566 
966.  ENSG00000074201 CLNS1A chloride nucleotide-sensitive channel 1A 0.581412 0.683439 
967.  ENSG00000077549 CAPZB capping actin protein of muscle Z-line beta subunit 0.666538 0.682933 
968.  ENSG00000163382 NAXE NAD(P)HX epimerase 0.699496 0.682152 
969.  ENSG00000148335 NTMT1 N-terminal Xaa-Pro-Lys N-methyltransferase 1 0.366753 0.68196 
970.  ENSG00000136942 RPL35 ribosomal protein L35 0.587071 0.681671 
971.  ENSG00000162961 DPY30 
"dpy-30, histone methyltransferase complex regulatory 
subunit" 
0.745031 0.681298 
972.  ENSG00000152455 SUV39H2 suppressor of variegation 3-9 homolog 2 0.68922 0.680572 
973.  ENSG00000116273 PHF13 PHD finger protein 13 0.548822 0.679934 
974.  ENSG00000117697 NSL1 "NSL1, MIS12 kinetochore complex component" 0.575272 0.679574 
975.  ENSG00000204392 LSM2 
"LSM2 homolog, U6 small nuclear RNA and mRNA 
degradation associated" 
0.576788 0.679191 
976.  ENSG00000138764 CCNG2 cyclin G2 0.662931 0.679027 
977.  ENSG00000186468 RPS23 ribosomal protein S23 0.644234 0.677774 
978.  ENSG00000114850 SSR3 signal sequence receptor subunit 3 0.712814 0.67759 
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979.  ENSG00000145990 GFOD1 glucose-fructose oxidoreductase domain containing 1 0.655897 0.677425 
980.  ENSG00000111669 TPI1 triosephosphate isomerase 1 0.662608 0.676696 
981.  ENSG00000162894 FCMR Fc fragment of IgM receptor 0.62598 0.67407 
982.  ENSG00000174547 MRPL11 mitochondrial ribosomal protein L11 0.561701 0.673595 
983.  ENSG00000177519 RPRM 
"reprimo, TP53 dependent G2 arrest mediator 
candidate" 
0.725484 0.672673 
984.  ENSG00000145386 CCNA2 cyclin A2 0.683344 0.672626 
985.  ENSG00000198680 TUSC1 tumor suppressor candidate 1 0.434468 0.671859 
986.  ENSG00000139832 RAB20 "RAB20, member RAS oncogene family" 0.54106 0.671545 
987.  ENSG00000138442 WDR12 WD repeat domain 12 0.631358 0.671058 
988.  ENSG00000187049 TMEM216 transmembrane protein 216 0.578493 0.670693 
989.  ENSG00000137393 RNF144B ring finger protein 144B 0.536437 0.670161 
990.  ENSG00000150456 EEF1AKMT1 
eukaryotic translation elongation factor 1 alpha lysine 
methyltransferase 1 
0.694379 0.670003 
991.  ENSG00000075223 SEMA3C semaphorin 3C 0.907207 0.669273 
992.  ENSG00000160783 PMF1 polyamine modulated factor 1 0.49455 0.668554 
993.  ENSG00000103121 CMC2 C-X9-C motif containing 2 0.595229 0.668355 
994.  ENSG00000077152 UBE2T ubiquitin conjugating enzyme E2 T 0.641735 0.668278 
995.  ENSG00000109255 NMU neuromedin U 1.0744 0.667768 
996.  ENSG00000088766 CRLS1 cardiolipin synthase 1 0.531102 0.667133 
997.  ENSG00000256269 HMBS hydroxymethylbilane synthase 0.562652 0.666744 
998.  ENSG00000111845 PAK1IP1 PAK1 interacting protein 1 0.562759 0.666736 
999.  ENSG00000158427 TMSB15B thymosin beta 15B 0.668357 0.666676 
1000.  ENSG00000100462 PRMT5 protein arginine methyltransferase 5 0.737209 0.665835 
1001.  ENSG00000062582 MRPS24 mitochondrial ribosomal protein S24 0.555455 0.665775 
1002.  ENSG00000114942 EEF1B2 eukaryotic translation elongation factor 1 beta 2 0.68232 0.665074 
1003.  ENSG00000095203 EPB41L4B erythrocyte membrane protein band 4.1 like 4B 0.73561 0.664133 
1004.  ENSG00000171735 CAMTA1 calmodulin binding transcription activator 1 0.642045 0.662908 
1005.  ENSG00000164587 RPS14 ribosomal protein S14 0.610268 0.66288 
1006.  ENSG00000198807 PAX9 paired box 9 0.58445 0.662648 
1007.  ENSG00000173207 CKS1B CDC28 protein kinase regulatory subunit 1B 0.59821 0.662221 
1008.  ENSG00000132275 RRP8 
"ribosomal RNA processing 8, methyltransferase, 
homolog (yeast)" 
0.501806 0.66187 
1009.  ENSG00000213339 QTRT1 queuine tRNA-ribosyltransferase catalytic subunit 1 0.471824 0.661715 
1010.  ENSG00000272047 GTF2H5 general transcription factor IIH subunit 5 0.482877 0.661587 
1011.  ENSG00000108443 RPS6KB1 ribosomal protein S6 kinase B1 0.690924 0.661297 
1012.  ENSG00000167526 RPL13 ribosomal protein L13 0.48154 0.660912 
1013.  ENSG00000116685 KIAA2013 KIAA2013 0.458529 0.66025 
1014.  ENSG00000164008 C1orf50 chromosome 1 open reading frame 50 0.506735 0.660153 
1015.  ENSG00000176422 SPRYD4 SPRY domain containing 4 0.498969 0.658557 
1016.  ENSG00000125691 RPL23 ribosomal protein L23 0.713014 0.658251 
1017.  ENSG00000178913 TAF7 TATA-box binding protein associated factor 7 0.495937 0.658128 
1018.  ENSG00000135617 PRADC1 protease associated domain containing 1 0.539953 0.658061 
1019.  ENSG00000188372 ZP3 zona pellucida glycoprotein 3 0.598498 0.657539 
1020.  ENSG00000165502 RPL36AL ribosomal protein L36a like 0.544335 0.657496 
1021.  ENSG00000117139 KDM5B lysine demethylase 5B 0.845657 0.65676 
1022.  ENSG00000137274 BPHL biphenyl hydrolase like 0.722898 0.655604 
1023.  ENSG00000065328 MCM10 
minichromosome maintenance 10 replication initiation 
factor 
0.658391 0.655249 
1024.  ENSG00000182004 SNRPE small nuclear ribonucleoprotein polypeptide E 0.579614 0.655083 
1025.  ENSG00000114491 UMPS uridine monophosphate synthetase 0.618575 0.654156 
1026.  ENSG00000118181 RPS25 ribosomal protein S25 0.679746 0.654124 
1027.  ENSG00000100811 YY1 YY1 transcription factor 0.656623 0.652961 
1028.  ENSG00000139289 PHLDA1 pleckstrin homology like domain family A member 1 0.52809 0.652852 
1029.  ENSG00000104549 SQLE squalene epoxidase 0.859419 0.65273 
1030.  ENSG00000114125 RNF7 ring finger protein 7 0.475151 0.652396 
1031.  ENSG00000174444 RPL4 ribosomal protein L4 0.727798 0.651767 
1032.  ENSG00000114023 FAM162A family with sequence similarity 162 member A 0.512759 0.651472 
1033.  ENSG00000205581 HMGN1 high mobility group nucleosome binding domain 1 0.671758 0.650796 
1034.  ENSG00000134533 RERG RAS like estrogen regulated growth inhibitor 0.739758 0.650693 
1035.  ENSG00000107882 SUFU SUFU negative regulator of hedgehog signaling 0.632929 0.650479 
1036.  ENSG00000164258 NDUFS4 NADH:ubiquinone oxidoreductase subunit S4 0.599484 0.649652 
1037.  ENSG00000133247 KMT5C lysine methyltransferase 5C 0.564812 0.649637 
1038.  ENSG00000170089 LOC728554 THO complex 3 pseudogene 0.691449 0.649272 
1039.  ENSG00000155438 NIFK 
nucleolar protein interacting with the FHA domain of 
MKI67 
0.614676 0.649105 
1040.  ENSG00000186998 EMID1 EMI domain containing 1 0.485272 0.647797 
 
 208 
1041.  ENSG00000089157 RPLP0 ribosomal protein lateral stalk subunit P0 0.690141 0.646959 
1042.  ENSG00000105193 RPS16 ribosomal protein S16 0.595941 0.646833 
1043.  ENSG00000092068 SLC7A8 solute carrier family 7 member 8 0.772529 0.646335 
1044.  ENSG00000198034 RPS4X "ribosomal protein S4, X-linked" 0.617263 0.645454 
1045.  ENSG00000109016 DHRS7B dehydrogenase/reductase 7B 0.519399 0.643293 
1046.  ENSG00000184076 UQCR10 
"ubiquinol-cytochrome c reductase, complex III 
subunit X" 
0.440544 0.643124 
1047.  ENSG00000169093 ASMTL acetylserotonin O-methyltransferase-like 0.627943 0.643094 
1048.  ENSG00000162594 IL23R interleukin 23 receptor 0.901047 0.643077 
1049.  ENSG00000214253 FIS1 "fission, mitochondrial 1" 0.477 0.64285 
1050.  ENSG00000121691 CAT catalase 0.739667 0.642768 
1051.  ENSG00000172965 
MIR4435-
2HG 
MIR4435-2 host gene 0.680475 0.642404 
1052.  ENSG00000152102 FAM168B family with sequence similarity 168 member B 0.732542 0.642111 
1053.  ENSG00000171204 TMEM126B transmembrane protein 126B 0.727283 0.641183 
1054.  ENSG00000088986 DYNLL1 dynein light chain LC8-type 1 0.629238 0.640647 
1055.  ENSG00000266967 AARSD1 alanyl-tRNA synthetase domain containing 1 0.659615 0.639813 
1056.  ENSG00000223797 ENTPD3-AS1 ENTPD3 antisense RNA 1 0.509316 0.639276 
1057.  ENSG00000147654 EBAG9 "estrogen receptor binding site associated, antigen, 9" 0.596474 0.638776 
1058.  ENSG00000109270 LAMTOR3 
"late endosomal/lysosomal adaptor, MAPK and MTOR 
activator 3" 
0.519875 0.638155 
1059.  ENSG00000143207 RFWD2 ring finger and WD repeat domain 2 0.768969 0.637484 
1060.  ENSG00000180739 S1PR5 sphingosine-1-phosphate receptor 5 0.544561 0.637201 
1061.  ENSG00000173409 ARV1 "ARV1 homolog, fatty acid homeostasis modulator" 0.443626 0.636535 
1062.  ENSG00000168393 DTYMK deoxythymidylate kinase 0.550339 0.636515 
1063.  ENSG00000179941 BBS10 Bardet-Biedl syndrome 10 0.549438 0.635606 
1064.  ENSG00000198805 PNP purine nucleoside phosphorylase 0.562185 0.634676 
1065.  ENSG00000186205 MARC1 mitochondrial amidoxime reducing component 1 0.739496 0.634046 
1066.  ENSG00000100316 RPL3 ribosomal protein L3 0.643843 0.633513 
1067.  ENSG00000148677 ANKRD1 ankyrin repeat domain 1 0.498224 0.633051 
1068.  ENSG00000165283 STOML2 stomatin like 2 0.620558 0.633006 
1069.  ENSG00000213281 NRAS neuroblastoma RAS viral oncogene homolog 0.650742 0.632976 
1070.  ENSG00000117395 EBNA1BP2 EBNA1 binding protein 2 0.637167 0.63253 
1071.  ENSG00000175970 UNC119B unc-119 lipid binding chaperone B 0.57547 0.632513 
1072.  ENSG00000146242 TPBG trophoblast glycoprotein 0.510288 0.632264 
1073.  ENSG00000198130 HIBCH 3-hydroxyisobutyryl-CoA hydrolase 0.842222 0.631806 
1074.  ENSG00000138385 SSB Sjogren syndrome antigen B 0.68798 0.631619 
1075.  ENSG00000175334 BANF1 barrier to autointegration factor 1 0.576179 0.631429 
1076.  ENSG00000116898 MRPS15 mitochondrial ribosomal protein S15 0.589601 0.631072 
1077.  ENSG00000183291 SEP15 15 kDa selenoprotein 0.612944 0.630963 
1078.  ENSG00000145982 FARS2 "phenylalanyl-tRNA synthetase 2, mitochondrial" 0.604479 0.630769 
1079.  ENSG00000113368 LMNB1 lamin B1 0.627999 0.630477 
1080.  ENSG00000169288 MRPL1 mitochondrial ribosomal protein L1 0.613311 0.6288 
1081.  ENSG00000198324 FAM109A family with sequence similarity 109 member A 0.510703 0.628693 
1082.  ENSG00000128581 IFT22 intraflagellar transport 22 0.595712 0.628508 
1083.  ENSG00000111906 HDDC2 HD domain containing 2 0.704719 0.628219 
1084.  ENSG00000136830 FAM129B family with sequence similarity 129 member B 0.567133 0.628176 
1085.  ENSG00000000003 TSPAN6 tetraspanin 6 0.6999 0.627904 
1086.  ENSG00000104408 EIF3E eukaryotic translation initiation factor 3 subunit E 0.693977 0.627349 
1087.  ENSG00000125356 NDUFA1 NADH:ubiquinone oxidoreductase subunit A1 0.481754 0.626363 
1088.  ENSG00000241343 RPL36A ribosomal protein L36a 0.665105 0.625905 
1089.  ENSG00000101361 NOP56 NOP56 ribonucleoprotein 0.588583 0.625073 
1090.  ENSG00000100528 CNIH1 cornichon family AMPA receptor auxiliary protein 1 0.527042 0.625035 
1091.  ENSG00000106610 STAG3L4 stromal antigen 3-like 4 (pseudogene) 0.59115 0.623864 
1092.  ENSG00000165948 IFI27L1 interferon alpha inducible protein 27 like 1 0.498304 0.623056 
1093.  ENSG00000053371 AKR7A2 aldo-keto reductase family 7 member A2 0.590043 0.622283 
1094.  ENSG00000188313 PLSCR1 phospholipid scramblase 1 0.400567 0.622252 
1095.  ENSG00000187189 TSPYL4 TSPY like 4 0.461534 0.620688 
1096.  ENSG00000120662 MTRF1 mitochondrial translational release factor 1 0.447792 0.619521 
1097.  ENSG00000119335 SET SET nuclear proto-oncogene 0.742598 0.618882 
1098.  ENSG00000169567 HINT1 histidine triad nucleotide binding protein 1 0.531404 0.618637 
1099.  ENSG00000147684 NDUFB9 NADH:ubiquinone oxidoreductase subunit B9 0.555857 0.618531 
1100.  ENSG00000143333 RGS16 regulator of G-protein signaling 16 0.542244 0.617958 
1101.  ENSG00000143420 ENSA endosulfine alpha 0.669224 0.617762 
1102.  ENSG00000101193 GID8 GID complex subunit 8 homolog 0.555707 0.617716 
1103.  ENSG00000172315 TP53RK TP53 regulating kinase 0.565331 0.617696 
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1104.  ENSG00000174371 EXO1 exonuclease 1 0.586883 0.616257 
1105.  ENSG00000079459 FDFT1 farnesyl-diphosphate farnesyltransferase 1 0.83121 0.616238 
1106.  ENSG00000170889 RPS9 ribosomal protein S9 0.494933 0.615055 
1107.  ENSG00000254093 PINX1 "PIN2/TERF1 interacting, telomerase inhibitor 1" 0.563699 0.614464 
1108.  ENSG00000069998 CECR5 "cat eye syndrome chromosome region, candidate 5" 0.4713 0.614461 
1109.  ENSG00000161057 PSMC2 "proteasome 26S subunit, ATPase 2" 0.556815 0.614312 
1110.  ENSG00000130713 EXOSC2 exosome component 2 0.584958 0.614102 
1111.  ENSG00000152402 GUCY1A2 guanylate cyclase 1 soluble subunit alpha 2 0.645431 0.613243 
1112.  ENSG00000109084 TMEM97 transmembrane protein 97 0.833185 0.612911 
1113.  ENSG00000155755 TMEM237 transmembrane protein 237 0.646639 0.612708 
1114.  ENSG00000126088 UROD uroporphyrinogen decarboxylase 0.562775 0.612601 
1115.  ENSG00000166598 HSP90B1 heat shock protein 90 beta family member 1 0.780005 0.61235 
1116.  ENSG00000196683 TOMM7 translocase of outer mitochondrial membrane 7 0.557692 0.611233 
1117.  ENSG00000166415 WDR72 WD repeat domain 72 0.705664 0.610389 
1118.  ENSG00000176890 TYMS thymidylate synthetase 0.594336 0.609152 
1119.  ENSG00000116815 CD58 CD58 molecule 0.574278 0.608606 
1120.  ENSG00000118939 UCHL3 ubiquitin C-terminal hydrolase L3 0.62191 0.608182 
1121.  ENSG00000011260 UTP18 "UTP18, small subunit processome component" 0.537868 0.60794 
1122.  ENSG00000214954 LRRC69 leucine rich repeat containing 69 0.555951 0.606239 
1123.  ENSG00000170142 UBE2E1 ubiquitin conjugating enzyme E2 E1 0.619358 0.605514 
1124.  ENSG00000116459 ATP5F1 
"ATP synthase, H+ transporting, mitochondrial Fo 
complex subunit B1" 
0.570357 0.604812 
1125.  ENSG00000142676 RPL11 ribosomal protein L11 0.642594 0.604273 
1126.  ENSG00000124172 ATP5E 
"ATP synthase, H+ transporting, mitochondrial F1 
complex, epsilon subunit" 
0.553854 0.60387 
1127.  ENSG00000122034 GTF3A general transcription factor IIIA 0.639956 0.603777 
1128.  ENSG00000161981 SNRNP25 small nuclear ribonucleoprotein U11/U12 subunit 25 0.656031 0.603566 
1129.  ENSG00000160049 DFFA DNA fragmentation factor subunit alpha 0.675709 0.602846 
1130.  ENSG00000159873 CCDC117 coiled-coil domain containing 117 0.801064 0.602464 
1131.  ENSG00000143315 PIGM 
phosphatidylinositol glycan anchor biosynthesis class 
M 
0.537811 0.601687 
1132.  ENSG00000169439 SDC2 syndecan 2 0.629612 0.601104 
1133.  ENSG00000004455 AK2 adenylate kinase 2 0.58514 0.599814 
1134.  ENSG00000163002 NUP35 nucleoporin 35 0.649279 0.599748 
1135.  ENSG00000008283 CYB561 cytochrome b561 0.490292 0.599664 
1136.  ENSG00000136933 RABEPK Rab9 effector protein with kelch motifs 0.550754 0.599569 
1137.  ENSG00000116030 SUMO1 small ubiquitin-like modifier 1 0.650273 0.599114 
1138.  ENSG00000100982 PCIF1 PDX1 C-terminal inhibiting factor 1 0.398303 0.598229 
1139.  ENSG00000230989 HSBP1 heat shock factor binding protein 1 0.545827 0.597753 
1140.  ENSG00000185842 DNAH14 dynein axonemal heavy chain 14 0.576577 0.597049 
1141.  ENSG00000115216 NRBP1 nuclear receptor binding protein 1 0.590665 0.596604 
1142.  ENSG00000139197 PEX5 peroxisomal biogenesis factor 5 0.622786 0.595623 
1143.  ENSG00000135070 ISCA1 iron-sulfur cluster assembly 1 0.603147 0.595407 
1144.  ENSG00000172380 GNG12 G protein subunit gamma 12 0.792578 0.595368 
1145.  ENSG00000114446 IFT57 intraflagellar transport 57 0.619088 0.594426 
1146.  ENSG00000203760 CENPW centromere protein W 0.460512 0.594347 
1147.  ENSG00000178307 TMEM11 transmembrane protein 11 0.395127 0.594322 
1148.  ENSG00000104979 C19orf53 chromosome 19 open reading frame 53 0.508361 0.593913 
1149.  ENSG00000117448 AKR1A1 aldo-keto reductase family 1 member A1 0.690468 0.593904 
1150.  ENSG00000187607 ZNF286A zinc finger protein 286A 0.765241 0.59238 
1151.  ENSG00000189043 NDUFA4 "NDUFA4, mitochondrial complex associated" 0.620783 0.591739 
1152.  ENSG00000197958 RPL12 ribosomal protein L12 0.609403 0.591557 
1153.  ENSG00000198015 MRPL42 mitochondrial ribosomal protein L42 0.558932 0.591286 
1154.  ENSG00000173085 COQ2 "coenzyme Q2, polyprenyltransferase" 0.51358 0.591104 
1155.  ENSG00000186416 NKRF NFKB repressing factor 0.562578 0.591047 
1156.  ENSG00000111843 TMEM14C transmembrane protein 14C 0.620905 0.590898 
1157.  ENSG00000156411 C14orf2 chromosome 14 open reading frame 2 0.523541 0.590597 
1158.  ENSG00000115875 SRSF7 serine and arginine rich splicing factor 7 0.558072 0.589317 
1159.  ENSG00000172586 CHCHD1 coiled-coil-helix-coiled-coil-helix domain containing 1 0.506416 0.588876 
1160.  ENSG00000118579 MED28 mediator complex subunit 28 0.537528 0.58869 
1161.  ENSG00000151743 AMN1 antagonist of mitotic exit network 1 homolog 0.683819 0.588496 
1162.  ENSG00000117906 RCN2 reticulocalbin 2 0.698454 0.588073 
1163.  ENSG00000132646 PCNA proliferating cell nuclear antigen 0.420561 0.587194 
1164.  ENSG00000100632 ERH enhancer of rudimentary homolog (Drosophila) 0.573351 0.58719 
1165.  ENSG00000175193 PARL presenilin associated rhomboid like 0.535057 0.586764 
1166.  ENSG00000145293 ENOPH1 enolase-phosphatase 1 0.606649 0.586319 
 
 210 
1167.  ENSG00000156110 ADK adenosine kinase 0.60946 0.586069 
1168.  ENSG00000197756 RPL37A ribosomal protein L37a 0.534367 0.585879 
1169.  ENSG00000156471 PTDSS1 phosphatidylserine synthase 1 0.677304 0.585521 
1170.  ENSG00000186625 KATNA1 katanin catalytic subunit A1 0.442418 0.585361 
1171.  ENSG00000143033 MTF2 metal response element binding transcription factor 2 0.620632 0.58535 
1172.  ENSG00000163634 THOC7 THO complex 7 0.662423 0.585282 
1173.  ENSG00000113269 RNF130 ring finger protein 130 0.700167 0.585128 
1174.  ENSG00000168288 MMADHC 
"methylmalonic aciduria and homocystinuria, cblD 
type" 
0.552518 0.585056 
1175.  ENSG00000183978 COA3 cytochrome c oxidase assembly factor 3 0.454443 0.58493 
1176.  ENSG00000106355 LSM5 
"LSM5 homolog, U6 small nuclear RNA and mRNA 
degradation associated" 
0.556302 0.584585 
1177.  ENSG00000256525 POLG2 "DNA polymerase gamma 2, accessory subunit" 0.496162 0.584555 
1178.  ENSG00000050405 LIMA1 LIM domain and actin binding 1 0.590325 0.584341 
1179.  ENSG00000166562 SEC11C "SEC11 homolog C, signal peptidase complex subunit" 0.493302 0.583424 
1180.  ENSG00000179918 SEPHS2 selenophosphate synthetase 2 0.470174 0.583339 
1181.  ENSG00000168653 NDUFS5 NADH:ubiquinone oxidoreductase subunit S5 0.447218 0.58327 
1182.  ENSG00000078668 VDAC3 voltage dependent anion channel 3 0.599311 0.583252 
1183.  ENSG00000141401 IMPA2 inositol monophosphatase 2 0.564067 0.582915 
1184.  ENSG00000156469 MTERF3 mitochondrial transcription termination factor 3 0.452698 0.582238 
1185.  ENSG00000106993 CDC37L1 cell division cycle 37 like 1 0.652822 0.581541 
1186.  ENSG00000133872 SARAF 
store-operated calcium entry associated regulatory 
factor 
0.651737 0.581324 
1187.  ENSG00000254858 MPV17L2 MPV17 mitochondrial inner membrane protein like 2 0.55069 0.580507 
1188.  ENSG00000131269 ABCB7 ATP binding cassette subfamily B member 7 0.688644 0.580453 
1189.  ENSG00000110063 DCPS "decapping enzyme, scavenger" 0.545144 0.580398 
1190.  ENSG00000265681 RPL17 ribosomal protein L17 0.608482 0.579599 
1191.  ENSG00000065911 MTHFD2 
"methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 2, methenyltetrahydrofolate 
cyclohydrolase" 
0.67394 0.578727 
1192.  ENSG00000113211 PCDHB6 protocadherin beta 6 0.547292 0.578213 
1193.  ENSG00000149923 PPP4C protein phosphatase 4 catalytic subunit 0.389742 0.577441 
1194.  ENSG00000115350 POLE4 "DNA polymerase epsilon 4, accessory subunit" 0.373808 0.576856 
1195.  ENSG00000179958 DCTPP1 dCTP pyrophosphatase 1 0.486552 0.575999 
1196.  ENSG00000169570 DTWD2 DTW domain containing 2 0.732857 0.575587 
1197.  ENSG00000172062 SMN1 "survival of motor neuron 1, telomeric" 0.581755 0.575289 
1198.  ENSG00000239779 WBP1 WW domain binding protein 1 0.580605 0.575147 
1199.  ENSG00000006831 ADIPOR2 adiponectin receptor 2 0.690701 0.574571 
1200.  ENSG00000144713 RPL32 ribosomal protein L32 0.541315 0.574202 
1201.  ENSG00000106268 NUDT1 nudix hydrolase 1 0.488716 0.574153 
1202.  ENSG00000068383 INPP5A inositol polyphosphate-5-phosphatase A 0.67894 0.574134 
1203.  ENSG00000178035 IMPDH2 inosine monophosphate dehydrogenase 2 0.480604 0.573689 
1204.  ENSG00000249264 EEF1A1P9 
eukaryotic translation elongation factor 1 alpha 1 
pseudogene 9 
0.580221 0.572346 
1205.  ENSG00000176273 SLC35G1 solute carrier family 35 member G1 0.497059 0.57222 
1206.  ENSG00000067064 IDI1 isopentenyl-diphosphate delta isomerase 1 0.710248 0.57221 
1207.  ENSG00000167085 PHB prohibitin 0.558869 0.571996 
1208.  ENSG00000198860 TSEN15 tRNA splicing endonuclease subunit 15 0.543937 0.571189 
1209.  ENSG00000148334 PTGES2 prostaglandin E synthase 2 0.415851 0.570339 
1210.  ENSG00000187626 ZKSCAN4 zinc finger with KRAB and SCAN domains 4 0.541057 0.569274 
1211.  ENSG00000101182 PSMA7 proteasome subunit alpha 7 0.611977 0.569242 
1212.  ENSG00000183283 DAZAP2 DAZ associated protein 2 0.572756 0.569066 
1213.  ENSG00000091483 FH fumarate hydratase 0.517003 0.568854 
1214.  ENSG00000011052 NME1-NME2 NME1-NME2 readthrough 0.537902 0.568051 
1215.  ENSG00000113460 BRIX1 "BRX1, biogenesis of ribosomes" 0.518963 0.56702 
1216.  ENSG00000160298 C21orf58 chromosome 21 open reading frame 58 0.574076 0.566849 
1217.  ENSG00000112306 RPS12 ribosomal protein S12 0.585658 0.565778 
1218.  ENSG00000100764 PSMC1 "proteasome 26S subunit, ATPase 1" 0.568718 0.565683 
1219.  ENSG00000136943 CTSV cathepsin V 0.653027 0.565642 
1220.  ENSG00000130935 NOL11 nucleolar protein 11 0.584325 0.564753 
1221.  ENSG00000132423 COQ3 "coenzyme Q3, methyltransferase" 0.454187 0.564536 
1222.  ENSG00000242616 GNG10 G protein subunit gamma 10 0.677874 0.564374 
1223.  ENSG00000101444 AHCY adenosylhomocysteinase 0.494678 0.563421 
1224.  ENSG00000164904 ALDH7A1 aldehyde dehydrogenase 7 family member A1 0.711066 0.563229 
1225.  ENSG00000162433 AK4 adenylate kinase 4 0.59315 0.563226 
1226.  ENSG00000139343 SNRPF small nuclear ribonucleoprotein polypeptide F 0.378183 0.562532 
1227.  ENSG00000133119 RFC3 replication factor C subunit 3 0.585816 0.562186 
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1228.  ENSG00000113811 SELK selenoprotein K 0.506295 0.561729 
1229.  ENSG00000116120 FARSB phenylalanyl-tRNA synthetase beta subunit 0.589758 0.56169 
1230.  ENSG00000117592 PRDX6 peroxiredoxin 6 0.644178 0.561437 
1231.  ENSG00000102967 DHODH dihydroorotate dehydrogenase (quinone) 0.584332 0.561185 
1232.  ENSG00000171960 PPIH peptidylprolyl isomerase H 0.40786 0.56116 
1233.  ENSG00000128039 SRD5A3 steroid 5 alpha-reductase 3 0.53407 0.56115 
1234.  ENSG00000132950 ZMYM5 zinc finger MYM-type containing 5 0.458967 0.56089 
1235.  ENSG00000110700 RPS13 ribosomal protein S13 0.506 0.560536 
1236.  ENSG00000141101 NOB1 NIN1/PSMD8 binding protein 1 homolog 0.454083 0.560442 
1237.  ENSG00000161970 RPL26 ribosomal protein L26 0.635677 0.560063 
1238.  ENSG00000198830 HMGN2 high mobility group nucleosomal binding domain 2 0.431841 0.559308 
1239.  ENSG00000169714 CNBP CCHC-type zinc finger nucleic acid binding protein 0.47528 0.558615 
1240.  ENSG00000138641 HERC3 
HECT and RLD domain containing E3 ubiquitin 
protein ligase 3 
0.458215 0.557969 
1241.  ENSG00000198176 TFDP1 transcription factor Dp-1 0.598627 0.557178 
1242.  ENSG00000188529 SRSF10 serine and arginine rich splicing factor 10 0.581423 0.557139 
1243.  ENSG00000169174 PCSK9 proprotein convertase subtilisin/kexin type 9 0.536665 0.556471 
1244.  ENSG00000158470 B4GALT5 "beta-1,4-galactosyltransferase 5" 0.648518 0.556421 
1245.  ENSG00000147400 CETN2 centrin 2 0.67484 0.556184 
1246.  ENSG00000141543 EIF4A3 eukaryotic translation initiation factor 4A3 0.444924 0.555671 
1247.  ENSG00000104884 ERCC2 
"ERCC excision repair 2, TFIIH core complex helicase 
subunit" 
0.760713 0.555621 
1248.  ENSG00000108298 RPL19 ribosomal protein L19 0.501585 0.555254 
1249.  ENSG00000071082 RPL31 ribosomal protein L31 0.500837 0.553839 
1250.  ENSG00000103035 PSMD7 "proteasome 26S subunit, non-ATPase 7" 0.485609 0.55362 
1251.  ENSG00000100216 TOMM22 translocase of outer mitochondrial membrane 22 0.494304 0.551779 
1252.  ENSG00000114520 SNX4 sorting nexin 4 0.537189 0.550717 
1253.  ENSG00000100372 SLC25A17 solute carrier family 25 member 17 0.567036 0.550626 
1254.  ENSG00000152147 GEMIN6 gem nuclear organelle associated protein 6 0.527315 0.549781 
1255.  ENSG00000004142 POLDIP2 DNA polymerase delta interacting protein 2 0.545445 0.547899 
1256.  ENSG00000143384 MCL1 BCL2 family apoptosis regulator 0.514158 0.547684 
1257.  ENSG00000100442 FKBP3 FK506 binding protein 3 0.598451 0.547113 
1258.  ENSG00000183207 RUVBL2 RuvB like AAA ATPase 2 0.370826 0.545808 
1259.  ENSG00000126602 TRAP1 TNF receptor associated protein 1 0.620316 0.54511 
1260.  ENSG00000138439 FAM117B family with sequence similarity 117 member B 0.800434 0.544344 
1261.  ENSG00000011258 MBTD1 mbt domain containing 1 0.65506 0.544341 
1262.  ENSG00000119408 NEK6 NIMA related kinase 6 0.713992 0.544106 
1263.  ENSG00000141429 GALNT1 polypeptide N-acetylgalactosaminyltransferase 1 0.673639 0.543714 
1264.  ENSG00000174748 RPL15 ribosomal protein L15 0.477561 0.543018 
1265.  ENSG00000165672 PRDX3 peroxiredoxin 3 0.627377 0.542784 
1266.  ENSG00000149196 HIKESHI "Hikeshi, heat shock protein nuclear import factor" 0.467457 0.541752 
1267.  ENSG00000018699 TTC27 tetratricopeptide repeat domain 27 0.506052 0.541612 
1268.  ENSG00000223768 LINC00205 long intergenic non-protein coding RNA 205 0.510607 0.541599 
1269.  ENSG00000162694 EXTL2 exostosin like glycosyltransferase 2 0.709238 0.541277 
1270.  ENSG00000072062 PRKACA protein kinase cAMP-activated catalytic subunit alpha 0.628271 0.54078 
1271.  ENSG00000162063 CCNF cyclin F 0.4926 0.539965 
1272.  ENSG00000135373 EHF ETS homologous factor 0.793912 0.539603 
1273.  ENSG00000151287 TEX30 testis expressed 30 0.591534 0.539069 
1274.  ENSG00000120526 NUDCD1 NudC domain containing 1 0.605891 0.538786 
1275.  ENSG00000139684 ESD esterase D 0.528035 0.538701 
1276.  ENSG00000151465 CDC123 cell division cycle 123 0.579892 0.537706 
1277.  ENSG00000157978 LDLRAP1 low density lipoprotein receptor adaptor protein 1 0.541318 0.537152 
1278.  ENSG00000140612 SEC11A "SEC11 homolog A, signal peptidase complex subunit" 0.489579 0.537134 
1279.  ENSG00000108468 CBX1 chromobox 1 0.608134 0.536891 
1280.  ENSG00000164253 WDR41 WD repeat domain 41 0.607608 0.536312 
1281.  ENSG00000143314 MRPL24 mitochondrial ribosomal protein L24 0.506235 0.53577 
1282.  ENSG00000205981 DNAJC19 DnaJ heat shock protein family (Hsp40) member C19 0.487561 0.535434 
1283.  ENSG00000142657 PGD phosphogluconate dehydrogenase 0.551699 0.534879 
1284.  ENSG00000163832 ELP6 elongator acetyltransferase complex subunit 6 0.412246 0.534597 
1285.  ENSG00000166851 PLK1 polo like kinase 1 0.502805 0.534145 
1286.  ENSG00000100294 MCAT malonyl-CoA-acyl carrier protein transacylase 0.383907 0.533893 
1287.  ENSG00000171202 TMEM126A transmembrane protein 126A 0.457839 0.533496 
1288.  ENSG00000008988 RPS20 ribosomal protein S20 0.495754 0.533154 
1289.  ENSG00000155858 LSM11 "LSM11, U7 small nuclear RNA associated" 0.573773 0.53311 
1290.  ENSG00000106803 SEC61B Sec61 translocon beta subunit 0.380985 0.532805 
1291.  ENSG00000092010 PSME1 proteasome activator subunit 1 0.489988 0.532391 
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1292.  ENSG00000023572 GLRX2 glutaredoxin 2 0.493896 0.530772 
1293.  ENSG00000138028 CGREF1 cell growth regulator with EF-hand domain 1 0.532261 0.530638 
1294.  ENSG00000108947 EFNB3 ephrin B3 0.713137 0.530624 
1295.  ENSG00000164919 COX6C cytochrome c oxidase subunit 6C 0.473092 0.529371 
1296.  ENSG00000115944 COX7A2L cytochrome c oxidase subunit 7A2 like 0.583686 0.527884 
1297.  ENSG00000100504 PYGL "phosphorylase, glycogen, liver" 0.598803 0.527726 
1298.  ENSG00000091651 ORC6 origin recognition complex subunit 6 0.500223 0.527708 
1299.  ENSG00000140374 ETFA electron transfer flavoprotein alpha subunit 0.591116 0.527411 
1300.  ENSG00000135624 CCT7 chaperonin containing TCP1 subunit 7 0.61167 0.525603 
1301.  ENSG00000101400 SNTA1 syntrophin alpha 1 0.470681 0.524896 
1302.  ENSG00000186660 ZFP91 ZFP91 zinc finger protein 0.636921 0.52485 
1303.  ENSG00000102178 UBL4A ubiquitin like 4A 0.412535 0.524187 
1304.  ENSG00000164091 WDR82 WD repeat domain 82 0.498426 0.52336 
1305.  ENSG00000138175 ARL3 ADP ribosylation factor like GTPase 3 0.606915 0.522059 
1306.  ENSG00000224531 SMIM13 small integral membrane protein 13 0.483039 0.520542 
1307.  ENSG00000082515 MRPL22 mitochondrial ribosomal protein L22 0.41355 0.520083 
1308.  ENSG00000197977 ELOVL2 ELOVL fatty acid elongase 2 0.649693 0.519209 
1309.  ENSG00000168795 ZBTB5 zinc finger and BTB domain containing 5 0.434602 0.518307 
1310.  ENSG00000163528 CHCHD4 coiled-coil-helix-coiled-coil-helix domain containing 4 0.454512 0.51827 
1311.  ENSG00000139180 NDUFA9 NADH:ubiquinone oxidoreductase subunit A9 0.482408 0.51758 
1312.  ENSG00000116288 PARK7 Parkinsonism associated deglycase 0.541766 0.515431 
1313.  ENSG00000183077 AFMID arylformamidase 0.518471 0.514579 
1314.  ENSG00000130560 UBAC1 UBA domain containing 1 0.517836 0.514537 
1315.  ENSG00000107262 BAG1 BCL2 associated athanogene 1 0.383929 0.514251 
1316.  ENSG00000156482 RPL30 ribosomal protein L30 0.483029 0.514125 
1317.  ENSG00000060762 MPC1 mitochondrial pyruvate carrier 1 0.595465 0.512531 
1318.  ENSG00000135446 CDK4 cyclin dependent kinase 4 0.466874 0.512105 
1319.  ENSG00000171314 PGAM1 phosphoglycerate mutase 1 0.452985 0.512096 
1320.  ENSG00000143742 SRP9 signal recognition particle 9 0.611286 0.511968 
1321.  ENSG00000113845 TIMMDC1 
translocase of inner mitochondrial membrane domain 
containing 1 
0.470364 0.511371 
1322.  ENSG00000168701 TMEM208 transmembrane protein 208 0.434963 0.511256 
1323.  ENSG00000141759 TXNL4A thioredoxin like 4A 0.436729 0.51071 
1324.  ENSG00000124767 GLO1 glyoxalase I 0.596599 0.510487 
1325.  ENSG00000065978 YBX1 Y-box binding protein 1 0.608175 0.510208 
1326.  ENSG00000101190 TCFL5 transcription factor like 5 0.531116 0.509004 
1327.  ENSG00000171490 RSL1D1 ribosomal L1 domain containing 1 0.599977 0.50853 
1328.  ENSG00000176788 BASP1 brain abundant membrane attached signal protein 1 0.483084 0.508448 
1329.  ENSG00000132541 RIDA reactive intermediate imine deaminase A homolog 0.692374 0.508209 
1330.  ENSG00000112699 GMDS "GDP-mannose 4,6-dehydratase" 0.567183 0.508126 
1331.  ENSG00000014641 MDH1 malate dehydrogenase 1 0.483648 0.507619 
1332.  ENSG00000159377 PSMB4 proteasome subunit beta 4 0.447662 0.505157 
1333.  ENSG00000197006 METTL9 methyltransferase like 9 0.619183 0.505024 
1334.  ENSG00000127184 COX7C cytochrome c oxidase subunit 7C 0.420544 0.504002 
1335.  ENSG00000178741 COX5A cytochrome c oxidase subunit 5A 0.440628 0.503475 
1336.  ENSG00000115368 WDR75 WD repeat domain 75 0.497876 0.500219 
1337.  ENSG00000089220 PEBP1 phosphatidylethanolamine binding protein 1 0.5634 0.499523 
1338.  ENSG00000101935 AMMECR1 
"Alport syndrome, mental retardation, midface 
hypoplasia and elliptocytosis chromosomal region gene 
1" 
0.486683 0.499441 
1339.  ENSG00000118600 TMEM5 transmembrane protein 5 0.426584 0.498614 
1340.  ENSG00000196363 WDR5 WD repeat domain 5 0.458789 0.498514 
1341.  ENSG00000171155 C1GALT1C1 C1GALT1 specific chaperone 1 0.504905 0.496875 
1342.  ENSG00000142534 RPS11 ribosomal protein S11 0.516476 0.496856 
1343.  ENSG00000188342 GTF2F2 general transcription factor IIF subunit 2 0.413409 0.496262 
1344.  ENSG00000176244 ACBD7 acyl-CoA binding domain containing 7 0.700393 0.496153 
1345.  ENSG00000103502 CDIPT CDP-diacylglycerol--inositol 3-phosphatidyltransferase 0.50783 0.492623 
1346.  ENSG00000167977 KCTD5 potassium channel tetramerization domain containing 5 0.425124 0.492212 
1347.  ENSG00000123349 PFDN5 prefoldin subunit 5 0.546246 0.491788 
1348.  ENSG00000137106 GRHPR glyoxylate and hydroxypyruvate reductase 0.445495 0.490305 
1349.  ENSG00000158089 GALNT14 polypeptide N-acetylgalactosaminyltransferase 14 0.608762 0.488799 
1350.  ENSG00000134291 TMEM106C transmembrane protein 106C 0.585347 0.488068 
1351.  ENSG00000136574 GATA4 GATA binding protein 4 0.816668 0.487858 
1352.  ENSG00000145741 BTF3 basic transcription factor 3 0.506364 0.487342 
1353.  ENSG00000103429 BFAR bifunctional apoptosis regulator 0.519609 0.486401 
1354.  ENSG00000160014 CALM3 calmodulin 3 0.570431 0.485807 
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1355.  ENSG00000127955 GNAI1 G protein subunit alpha i1 0.590945 0.485692 
1356.  ENSG00000100784 RPS6KA5 ribosomal protein S6 kinase A5 0.591567 0.484197 
1357.  ENSG00000148303 RPL7A ribosomal protein L7a 0.525127 0.483312 
1358.  ENSG00000100558 PLEK2 pleckstrin 2 0.612746 0.482887 
1359.  ENSG00000161016 RPL8 ribosomal protein L8 0.447702 0.482796 
1360.  ENSG00000115365 LANCL1 LanC like 1 0.596777 0.482519 
1361.  ENSG00000133773 CCDC59 coiled-coil domain containing 59 0.410004 0.482381 
1362.  ENSG00000125863 MKKS McKusick-Kaufman syndrome 0.509373 0.481629 
1363.  ENSG00000164815 ORC5 origin recognition complex subunit 5 0.451018 0.481556 
1364.  ENSG00000145050 MANF mesencephalic astrocyte derived neurotrophic factor 0.454652 0.481426 
1365.  ENSG00000136158 SPRY2 sprouty RTK signaling antagonist 2 0.550961 0.481338 
1366.  ENSG00000140391 TSPAN3 tetraspanin 3 0.452084 0.480864 





1368.  ENSG00000170632 ARMC10 armadillo repeat containing 10 0.678404 0.480358 
1369.  ENSG00000181610 MRPS23 mitochondrial ribosomal protein S23 0.403958 0.480255 
1370.  ENSG00000178988 MRFAP1L1 Morf4 family associated protein 1 like 1 0.361048 0.479952 
1371.  ENSG00000228409 CCT6P1 chaperonin containing TCP1 subunit 6 pseudogene 1 0.440193 0.479515 
1372.  ENSG00000079785 DDX1 DEAD/H-box helicase 1 0.493408 0.479488 
1373.  ENSG00000112081 SRSF3 serine and arginine rich splicing factor 3 0.459896 0.479402 
1374.  ENSG00000065621 GSTO2 glutathione S-transferase omega 2 0.4087 0.479226 
1375.  ENSG00000136682 CBWD2 COBW domain containing 2 0.552169 0.479109 
1376.  ENSG00000026297 RNASET2 ribonuclease T2 0.439969 0.479086 
1377.  ENSG00000103876 FAH fumarylacetoacetate hydrolase 0.553601 0.478695 
1378.  ENSG00000166295 ANAPC16 anaphase promoting complex subunit 16 0.486764 0.477979 
1379.  ENSG00000124787 RPP40 ribonuclease P/MRP subunit p40 0.442086 0.477138 
1380.  ENSG00000245694 CRNDE 
colorectal neoplasia differentially expressed (non-
protein coding) 
0.437687 0.476426 
1381.  ENSG00000180389 ATP5EP2 
"ATP synthase, H+ transporting, mitochondrial F1 
complex, epsilon subunit pseudogene 2" 
1.06228 0.475944 
1382.  ENSG00000129518 EAPP E2F associated phosphoprotein 0.426617 0.475068 
1383.  ENSG00000138777 PPA2 pyrophosphatase (inorganic) 2 0.417186 0.475001 
1384.  ENSG00000055044 NOP58 NOP58 ribonucleoprotein 0.57573 0.474755 
1385.  ENSG00000147604 RPL7 ribosomal protein L7 0.540895 0.474478 
1386.  ENSG00000074800 ENO1 enolase 1 0.546022 0.474453 
1387.  ENSG00000169230 PRELID1 PRELI domain containing 1 0.526265 0.474331 
1388.  ENSG00000204628 RACK1 receptor for activated C kinase 1 0.479845 0.474264 
1389.  ENSG00000159593 NAE1 NEDD8 activating enzyme E1 subunit 1 0.493453 0.473918 
1390.  ENSG00000086061 DNAJA1 DnaJ heat shock protein family (Hsp40) member A1 0.475614 0.472945 
1391.  ENSG00000161904 LEMD2 LEM domain containing 2 0.483313 0.472819 
1392.  ENSG00000159055 MIS18A MIS18 kinetochore protein A 0.390648 0.472706 
1393.  ENSG00000119718 EIF2B2 eukaryotic translation initiation factor 2B subunit beta 0.438912 0.472013 
1394.  ENSG00000198356 ASNA1 
"arsA arsenite transporter, ATP-binding, homolog 1 
(bacterial)" 
0.380803 0.471845 
1395.  ENSG00000119778 ATAD2B "ATPase family, AAA domain containing 2B" 0.623753 0.47118 
1396.  ENSG00000049541 RFC2 replication factor C subunit 2 0.554049 0.470145 
1397.  ENSG00000115484 CCT4 chaperonin containing TCP1 subunit 4 0.507679 0.468577 
1398.  ENSG00000169241 SLC50A1 solute carrier family 50 member 1 0.490646 0.467501 
1399.  ENSG00000161960 EIF4A1 eukaryotic translation initiation factor 4A1 0.506091 0.467426 
1400.  ENSG00000196154 S100A4 S100 calcium binding protein A4 0.677395 0.465981 
1401.  ENSG00000172172 MRPL13 mitochondrial ribosomal protein L13 0.515309 0.464846 
1402.  ENSG00000182054 IDH2 
"isocitrate dehydrogenase (NADP(+)) 2, 
mitochondrial" 
0.358842 0.464326 
1403.  ENSG00000163017 ACTG2 "actin, gamma 2, smooth muscle, enteric" 0.411173 0.462855 
1404.  ENSG00000147180 ZNF711 zinc finger protein 711 0.597437 0.462778 
1405.  ENSG00000124535 WRNIP1 Werner helicase interacting protein 1 0.463639 0.461986 
1406.  ENSG00000153989 NUS1 NUS1 dehydrodolichyl diphosphate synthase subunit 0.588642 0.461185 
1407.  ENSG00000189334 S100A14 S100 calcium binding protein A14 0.526757 0.460932 
1408.  ENSG00000228474 OST4 
"oligosaccharyltransferase complex subunit 4, non-
catalytic" 
0.446121 0.460205 
1409.  ENSG00000163541 SUCLG1 succinate-CoA ligase alpha subunit 0.393309 0.459611 
1410.  ENSG00000090263 MRPS33 mitochondrial ribosomal protein S33 0.401031 0.459406 
1411.  ENSG00000139826 ABHD13 abhydrolase domain containing 13 0.488825 0.459061 
1412.  ENSG00000089053 ANAPC5 anaphase promoting complex subunit 5 0.562191 0.456977 
1413.  ENSG00000073712 FERMT2 fermitin family member 2 0.511322 0.456936 
1414.  ENSG00000156261 CCT8 chaperonin containing TCP1 subunit 8 0.516095 0.456799 
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1415.  ENSG00000112062 MAPK14 mitogen-activated protein kinase 14 0.578104 0.456541 
1416.  ENSG00000124098 FAM210B family with sequence similarity 210 member B 0.494677 0.455537 
1417.  ENSG00000165775 FUNDC2 FUN14 domain containing 2 0.465033 0.455508 
1418.  ENSG00000139800 ZIC5 Zic family member 5 0.519752 0.454947 
1419.  ENSG00000177954 RPS27 ribosomal protein S27 0.508871 0.454789 
1420.  ENSG00000008018 PSMB1 proteasome subunit beta 1 0.365698 0.454699 
1421.  ENSG00000105248 CCDC94 coiled-coil domain containing 94 0.459384 0.454246 
1422.  ENSG00000101391 CDK5RAP1 CDK5 regulatory subunit associated protein 1 0.421749 0.452614 
1423.  ENSG00000168118 RAB4A "RAB4A, member RAS oncogene family" 0.553993 0.451898 
1424.  ENSG00000001497 LAS1L "LAS1 like, ribosome biogenesis factor" 0.473209 0.451075 
1425.  ENSG00000178952 TUFM "Tu translation elongation factor, mitochondrial" 0.445132 0.450125 
1426.  ENSG00000144746 ARL6IP5 
ADP ribosylation factor like GTPase 6 interacting 
protein 5 
0.510344 0.450079 
1427.  ENSG00000168710 AHCYL1 adenosylhomocysteinase like 1 0.599927 0.449753 
1428.  ENSG00000198258 UBL5 ubiquitin like 5 0.372425 0.448646 
1429.  ENSG00000112592 TBP TATA-box binding protein 0.439215 0.44549 
1430.  ENSG00000174669 SLC29A2 solute carrier family 29 member 2 0.357566 0.444176 
1431.  ENSG00000104723 TUSC3 tumor suppressor candidate 3 0.476439 0.443338 
1432.  ENSG00000146733 PSPH phosphoserine phosphatase 0.415752 0.442755 
1433.  ENSG00000101347 SAMHD1 
SAM and HD domain containing deoxynucleoside 
triphosphate triphosphohydrolase 1 
0.422929 0.441313 
1434.  ENSG00000182890 GLUD2 glutamate dehydrogenase 2 0.54971 0.439276 
1435.  ENSG00000044574 HSPA5 heat shock protein family A (Hsp70) member 5 0.461655 0.437272 
1436.  ENSG00000072506 HSD17B10 hydroxysteroid 17-beta dehydrogenase 10 0.404017 0.437113 
1437.  ENSG00000065154 OAT ornithine aminotransferase 0.61619 0.435381 
1438.  ENSG00000165943 MOAP1 modulator of apoptosis 1 0.358154 0.435341 
1439.  ENSG00000111802 TDP2 tyrosyl-DNA phosphodiesterase 2 0.488266 0.43491 
1440.  ENSG00000112078 KCTD20 
potassium channel tetramerization domain containing 
20 
0.59754 0.434534 
1441.  ENSG00000127884 ECHS1 "enoyl-CoA hydratase, short chain 1" 0.423954 0.434189 
1442.  ENSG00000154582 TCEB1 transcription elongation factor B subunit 1 0.384157 0.433829 
1443.  ENSG00000133112 TPT1 "tumor protein, translationally-controlled 1" 0.512395 0.431892 
1444.  ENSG00000196262 PPIA peptidylprolyl isomerase A 0.404212 0.429638 
1445.  ENSG00000179399 GPC5 glypican 5 0.529826 0.4271 
1446.  ENSG00000188211 NCR3LG1 natural killer cell cytotoxicity receptor 3 ligand 1 0.504336 0.427074 
1447.  ENSG00000139990 DCAF5 DDB1 and CUL4 associated factor 5 0.49886 0.426772 
1448.  ENSG00000131778 CHD1L chromodomain helicase DNA binding protein 1 like 0.459906 0.425305 
1449.  ENSG00000104047 DTWD1 DTW domain containing 1 0.501435 0.424841 
1450.  ENSG00000132963 POMP proteasome maturation protein 0.398388 0.424103 
1451.  ENSG00000129562 DAD1 defender against cell death 1 0.483024 0.423811 
1452.  ENSG00000092199 HNRNPC heterogeneous nuclear ribonucleoprotein C (C1/C2) 0.47602 0.42311 
1453.  ENSG00000117118 SDHB succinate dehydrogenase complex iron sulfur subunit B 0.436855 0.422219 
1454.  ENSG00000143870 PDIA6 protein disulfide isomerase family A member 6 0.540674 0.422012 
1455.  ENSG00000146433 TMEM181 transmembrane protein 181 0.528742 0.421469 
1456.  ENSG00000197771 MCMBP 
minichromosome maintenance complex binding 
protein 
0.539588 0.420955 
1457.  ENSG00000108384 RAD51C RAD51 paralog C 0.445142 0.420747 
1458.  ENSG00000120696 KBTBD7 kelch repeat and BTB domain containing 7 0.400185 0.420395 
1459.  ENSG00000148834 GSTO1 glutathione S-transferase omega 1 0.382099 0.419248 
1460.  ENSG00000173145 NOC3L NOC3 like DNA replication regulator 0.463655 0.418221 
1461.  ENSG00000154978 VOPP1 
"vesicular, overexpressed in cancer, prosurvival protein 
1" 
0.46844 0.41793 
1462.  ENSG00000175691 ZNF77 zinc finger protein 77 0.396748 0.416536 
1463.  ENSG00000128463 EMC4 ER membrane protein complex subunit 4 0.519872 0.416206 
1464.  ENSG00000164930 FZD6 frizzled class receptor 6 0.513988 0.416162 
1465.  ENSG00000129103 SUMF2 sulfatase modifying factor 2 0.425012 0.415504 
1466.  ENSG00000058804 NDC1 NDC1 transmembrane nucleoporin 0.581386 0.415238 
1467.  ENSG00000152234 ATP5A1 
"ATP synthase, H+ transporting, mitochondrial F1 
complex, alpha subunit 1, cardiac muscle" 
0.424851 0.412725 
1468.  ENSG00000182768 NGRN "neugrin, neurite outgrowth associated" 0.449335 0.411608 
1469.  ENSG00000115234 SNX17 sorting nexin 17 0.352968 0.410153 
1470.  ENSG00000074219 TEAD2 TEA domain transcription factor 2 0.477682 0.408097 
1471.  ENSG00000148019 CEP78 centrosomal protein 78 0.579872 0.407027 
1472.  ENSG00000124570 SERPINB6 serpin family B member 6 0.400069 0.406089 
1473.  ENSG00000107874 CUEDC2 CUE domain containing 2 0.421961 0.40473 
1474.  ENSG00000156709 AIFM1 "apoptosis inducing factor, mitochondria associated 1" 0.517603 0.400808 
1475.  ENSG00000173281 PPP1R3B protein phosphatase 1 regulatory subunit 3B 0.433307 0.398739 
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1476.  ENSG00000122042 UBL3 ubiquitin like 3 0.578444 0.397981 
1477.  ENSG00000135845 PIGC 
phosphatidylinositol glycan anchor biosynthesis class 
C 
0.41005 0.397585 
1478.  ENSG00000131370 SH3BP5 SH3 domain binding protein 5 0.463129 0.394409 
1479.  ENSG00000181751 C5orf30 chromosome 5 open reading frame 30 0.465594 0.3944 
1480.  ENSG00000254772 EEF1G eukaryotic translation elongation factor 1 gamma 0.50351 0.394335 
1481.  ENSG00000141698 NT5C3B "5'-nucleotidase, cytosolic IIIB" 0.390653 0.394116 
1482.  ENSG00000140259 MFAP1 microfibrillar associated protein 1 0.40971 0.392112 
1483.  ENSG00000187514 PTMA "prothymosin, alpha" 0.472511 0.39151 
1484.  ENSG00000163902 RPN1 ribophorin I 0.436504 0.390911 
1485.  ENSG00000164332 UBLCP1 ubiquitin like domain containing CTD phosphatase 1 0.457536 0.390483 
1486.  ENSG00000115241 PPM1G "protein phosphatase, Mg2+/Mn2+ dependent 1G" 0.421925 0.389986 
1487.  ENSG00000170185 USP38 ubiquitin specific peptidase 38 0.48234 0.389678 
1488.  ENSG00000100271 TTLL1 tubulin tyrosine ligase like 1 0.686081 0.387382 
1489.  ENSG00000134716 CYP2J2 cytochrome P450 family 2 subfamily J member 2 0.405508 0.386161 
1490.  ENSG00000136156 ITM2B integral membrane protein 2B 0.455403 0.385767 
1491.  ENSG00000164626 KCNK5 
potassium two pore domain channel subfamily K 
member 5 
0.424791 0.385622 
1492.  ENSG00000116679 IVNS1ABP influenza virus NS1A binding protein 0.500592 0.379788 
1493.  ENSG00000175785 PRIMA1 proline rich membrane anchor 1 0.382483 0.378951 
1494.  ENSG00000101544 ADNP2 ADNP homeobox 2 0.389951 0.375037 
1495.  ENSG00000160124 CCDC58 coiled-coil domain containing 58 0.382227 0.374341 
1496.  ENSG00000196584 XRCC2 X-ray repair cross complementing 2 0.497408 0.37365 
1497.  ENSG00000196659 TTC30B tetratricopeptide repeat domain 30B 0.431373 0.372918 
1498.  ENSG00000081870 HSPB11 heat shock protein family B (small) member 11 0.468481 0.371903 
1499.  ENSG00000084623 EIF3I eukaryotic translation initiation factor 3 subunit I 0.502812 0.370749 
1500.  ENSG00000188021 UBQLN2 ubiquilin 2 0.454439 0.36814 
1501.  ENSG00000125821 DTD1 D-tyrosyl-tRNA deacylase 1 0.439774 0.362775 
1502.  ENSG00000016391 CHDH choline dehydrogenase 0.460734 0.362754 
1503.  ENSG00000137054 POLR1E RNA polymerase I subunit E 0.416051 0.360962 
1504.  ENSG00000147669 POLR2K RNA polymerase II subunit K 0.36188 0.359019 
1505.  ENSG00000163428 LRRC58 leucine rich repeat containing 58 0.529406 0.357706 
1506.  ENSG00000095002 MSH2 mutS homolog 2 0.453754 0.355227 
1507.  ENSG00000087302 C14orf166 chromosome 14 open reading frame 166 0.363788 0.346326 








Supplementary Table 3C:  miR-29a unique targets in LCC9 cells 
 
 
LCC9 Pre-miR-29a vs 
Anti-miR-29a 
 Input IDs Gene Symbol Gene Name log2(fold change) 
1.  ENSG00000089127 OAS1 2'-5'-oligoadenylate synthetase 1 1.00467 
2.  ENSG00000174137 FAM53A family with sequence similarity 53 member A 0.857463 
3.  ENSG00000183513 COA5 cytochrome c oxidase assembly factor 5 0.542847 
4.  ENSG00000119688 ABCD4 ATP binding cassette subfamily D member 4 0.487976 
5.  ENSG00000118777 ABCG2 
ATP binding cassette subfamily G member 2 
(Junior blood group) 
1.55682 
6.  ENSG00000162482 AKR7A3 aldo-keto reductase family 7 member A3 0.843423 
7.  ENSG00000137124 ALDH1B1 aldehyde dehydrogenase 1 family member B1 0.441378 
8.  ENSG00000119523 ALG2 "ALG2, alpha-1,3/1,6-mannosyltransferase" 0.343699 
9.  ENSG00000176248 ANAPC2 anaphase promoting complex subunit 2 0.69434 
10.  ENSG00000213337 ANKRD39 ankyrin repeat domain 39 0.790548 
11.  ENSG00000186106 ANKRD46 ankyrin repeat domain 46 0.550979 
12.  ENSG00000214293 APTR 
Alu-mediated CDKN1A/p21 transcriptional 
regulator (non-protein coding) 
0.407018 
13.  ENSG00000102030 NAA10 
"N(alpha)-acetyltransferase 10, NatA catalytic 
subunit" 
0.547257 
14.  ENSG00000182196 ARL6IP4 
ADP ribosylation factor like GTPase 6 interacting 
protein 4 
0.631648 
15.  ENSG00000136950 ARPC5L actin related protein 2/3 complex subunit 5 like 0.352874 
16.  ENSG00000126756 UXT ubiquitously expressed prefoldin like chaperone 0.423882 
17.  ENSG00000130768 SMPDL3B sphingomyelin phosphodiesterase acid like 3B 0.508441 
18.  ENSG00000128272 ATF4 activating transcription factor 4 0.456274 
19.  ENSG00000152234 ATP5A1 
"ATP synthase, H+ transporting, mitochondrial F1 
complex, alpha subunit 1, cardiac muscle" 
0.412725 
20.  ENSG00000110955 ATP5B 
"ATP synthase, H+ transporting, mitochondrial F1 
complex, beta polypeptide" 
0.734603 
21.  ENSG00000099624 ATP5D 
"ATP synthase, H+ transporting, mitochondrial F1 
complex, delta subunit" 
0.575794 
22.  ENSG00000124172 ATP5E 
"ATP synthase, H+ transporting, mitochondrial F1 
complex, epsilon subunit" 
0.60387 
23.  ENSG00000165629 ATP5C1 
"ATP synthase, H+ transporting, mitochondrial F1 
complex, gamma polypeptide 1" 
1.34628 
24.  ENSG00000128524 ATP6V1F ATPase H+ transporting V1 subunit F 0.541429 
25.  ENSG00000130770 ATPIF1 ATPase inhibitory factor 1 0.792053 
26.  ENSG00000148090 AUH AU RNA binding methylglutaconyl-CoA hydratase 0.583462 
27.  ENSG00000198563 DDX39B DEAD-box helicase 39B 0.506986 
28.  ENSG00000054116 TRAPPC3 trafficking protein particle complex 3 0.455165 
29.  ENSG00000163170 BOLA3 bolA family member 3 0.453897 
30.  ENSG00000130303 BST2 bone marrow stromal cell antigen 2 0.503736 
31.  ENSG00000078401 EDN1 endothelin 1 0.605404 
32.  ENSG00000100290 BIK BCL2 interacting killer 0.434716 
33.  ENSG00000165233 CARD19 caspase recruitment domain family member 19 0.680634 
34.  ENSG00000112578 BYSL bystin like 0.470095 
35.  ENSG00000111678 C12orf57 chromosome 12 open reading frame 57 0.421145 
36.  ENSG00000171224 C10orf35 chromosome 10 open reading frame 35 0.354218 
37.  ENSG00000171067 C11orf24 chromosome 11 open reading frame 24 0.643369 
38.  ENSG00000139438 FAM222A family with sequence similarity 222 member A 0.560663 
39.  ENSG00000151131 C12orf45 chromosome 12 open reading frame 45 0.721034 
40.  ENSG00000129480 DTD2 D-tyrosyl-tRNA deacylase 2 (putative) 0.712165 
41.  ENSG00000134153 EMC7 ER membrane protein complex subunit 7 0.399016 
42.  ENSG00000130731 METTL26 methyltransferase like 26 0.411608 
43.  ENSG00000124074 ENKD1 enkurin domain containing 1 1.20299 
44.  ENSG00000182831 C16orf72 chromosome 16 open reading frame 72 0.518243 
45.  ENSG00000175643 RMI2 RecQ mediated genome instability 2 0.359454 
46.  ENSG00000074842 MYDGF myeloid derived growth factor 0.462685 
47.  ENSG00000197223 C1D C1D nuclear receptor corepressor 0.440034 
48.  ENSG00000057757 PITHD1 PITH domain containing 1 0.387639 
49.  ENSG00000198912 C1orf174 chromosome 1 open reading frame 174 0.358429 
50.  ENSG00000163866 SMIM12 small integral membrane protein 12 0.503397 
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51.  ENSG00000168275 COA6 cytochrome c oxidase assembly factor 6 0.436718 
52.  ENSG00000203724 C1orf53 chromosome 1 open reading frame 53 0.567423 
53.  ENSG00000162757 C1orf74 chromosome 1 open reading frame 74 0.715414 
54.  ENSG00000116205 TCEANC2 
transcription elongation factor A N-terminal and 
central domain containing 2 
0.580425 
55.  ENSG00000101220 C20orf27 chromosome 20 open reading frame 27 0.377463 
56.  ENSG00000228314 CYP4F29P 
"cytochrome P450 family 4 subfamily F member 
29, pseudogene" 
0.676683 
57.  ENSG00000159079 C21orf59 chromosome 21 open reading frame 59 0.777816 
58.  ENSG00000160256 FAM207A family with sequence similarity 207 member A 0.405904 
59.  ENSG00000250486 FAM218A family with sequence similarity 218 member A 0.541897 
60.  ENSG00000243449 C4orf48 chromosome 4 open reading frame 48 0.518415 
61.  ENSG00000134830 C5AR2 complement component 5a receptor 2 0.41513 
62.  ENSG00000151881 TMEM267 transmembrane protein 267 0.504625 
63.  ENSG00000124541 RRP36 ribosomal RNA processing 36 0.454369 
64.  ENSG00000204387 C6orf48 chromosome 6 open reading frame 48 0.389673 
65.  ENSG00000232956 SNHG15 small nucleolar RNA host gene 15 0.773507 
66.  ENSG00000146540 C7orf50 chromosome 7 open reading frame 50 0.642142 
67.  ENSG00000188186 LAMTOR4 
"late endosomal/lysosomal adaptor, MAPK and 
MTOR activator 4" 
0.414919 
68.  ENSG00000130193 THEM6 thioesterase superfamily member 6 0.420549 
69.  ENSG00000148362 C9orf142 chromosome 9 open reading frame 142 0.387802 
70.  ENSG00000163050 COQ8A coenzyme Q8A 0.690812 
71.  ENSG00000007080 CCDC124 coiled-coil domain containing 124 0.361384 
72.  ENSG00000221978 CCNL2 cyclin L2 0.472603 
73.  ENSG00000156345 CDK20 cyclin dependent kinase 20 0.448019 
74.  ENSG00000184990 SIVA1 SIVA1 apoptosis inducing factor 0.601179 
75.  ENSG00000123374 CDK2 cyclin dependent kinase 2 0.562828 
76.  ENSG00000125817 CENPB centromere protein B 0.337413 
77.  ENSG00000100162 CENPM centromere protein M 0.370338 
78.  ENSG00000179604 CDC42EP4 CDC42 effector protein 4 0.416077 
79.  ENSG00000166595 FAM96B family with sequence similarity 96 member B 0.373062 




81.  ENSG00000179271 GADD45GIP1 GADD45G interacting protein 1 0.427637 
82.  ENSG00000122705 CLTA clathrin light chain A 0.385781 
83.  ENSG00000143771 CNIH4 
cornichon family AMPA receptor auxiliary protein 
4 
0.421596 
84.  ENSG00000188986 NELFB negative elongation factor complex member B 0.363338 
85.  ENSG00000135775 COG2 component of oligomeric golgi complex 2 0.403504 
86.  ENSG00000170619 COMMD5 COMM domain containing 5 0.655131 
87.  ENSG00000168090 COPS6 COP9 signalosome subunit 6 0.443229 
88.  ENSG00000088682 COQ9 coenzyme Q9 0.821226 
89.  ENSG00000131143 COX4I1 cytochrome c oxidase subunit 4I1 0.448878 
90.  ENSG00000176340 COX8A cytochrome c oxidase subunit 8A 0.517129 
91.  ENSG00000112695 COX7A2 cytochrome c oxidase subunit 7A2 0.459814 
92.  ENSG00000111775 COX6A1 cytochrome c oxidase subunit 6A1 0.508716 
93.  ENSG00000135940 COX5B cytochrome c oxidase subunit 5B 0.46617 
94.  ENSG00000184164 CRELD2 cysteine rich with EGF like domains 2 0.52218 
95.  ENSG00000233382 NKAPP1 NFKB activating protein pseudogene 1 1.42496 
96.  ENSG00000179091 CYC1 cytochrome c1 0.397388 
97.  ENSG00000140465 CYP1A1 cytochrome P450 family 1 subfamily A member 1 0.685945 
98.  ENSG00000058404 CAMK2B 
calcium/calmodulin dependent protein kinase II 
beta 
0.714147 
99.  ENSG00000004948 CALCR calcitonin receptor 0.620437 
100.  ENSG00000186222 BLOC1S4 
biogenesis of lysosomal organelles complex 1 
subunit 4 
0.568415 
101.  ENSG00000144021 CIAO1 cytosolic iron-sulfur assembly component 1 0.377027 
102.  ENSG00000165215 CLDN3 claudin 3 0.476786 
103.  ENSG00000181885 CLDN7 claudin 7 0.720218 
104.  ENSG00000125656 CLPP 
caseinolytic mitochondrial matrix peptidase 
proteolytic subunit 
0.398841 
105.  ENSG00000178531 CTXN1 cortexin 1 1.41001 
106.  ENSG00000157456 CCNB2 cyclin B2 0.37596 
107.  ENSG00000134480 CCNH cyclin H 0.775269 
108.  ENSG00000110104 CCDC86 coiled-coil domain containing 86 0.387673 
109.  ENSG00000084072 PPIE peptidylprolyl isomerase E 0.422785 
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110.  ENSG00000142871 CYR61 cysteine rich angiogenic inducer 61 0.4951 
111.  ENSG00000184752 NDUFA12 NADH:ubiquinone oxidoreductase subunit A12 0.464626 
112.  ENSG00000167969 ECI1 enoyl-CoA delta isomerase 1 0.525164 
113.  ENSG00000137100 DCTN3 dynactin subunit 3 0.470114 
114.  ENSG00000099977 DDT D-dopachrome tautomerase 0.569309 
115.  ENSG00000123136 DDX39A DEAD-box helicase 39A 0.373273 
116.  ENSG00000136271 DDX56 DEAD-box helicase 56 0.619725 
117.  ENSG00000143753 DEGS1 "delta 4-desaturase, sphingolipid 1" 0.50347 
118.  ENSG00000128185 DGCR6L DiGeorge syndrome critical region gene 6-like 0.559326 
119.  ENSG00000114956 DGUOK deoxyguanosine kinase 0.398229 
120.  ENSG00000104808 DHDH dihydrodiol dehydrogenase 1.69723 
121.  ENSG00000100867 DHRS2 dehydrogenase/reductase 2 0.555358 
122.  ENSG00000175602 CCDC85B coiled-coil domain containing 85B 0.992711 
123.  ENSG00000203950 FAM127B family with sequence similarity 127 member B 0.447223 
124.  ENSG00000167130 DOLPP1 dolichyldiphosphatase 1 0.896244 
125.  ENSG00000179085 DPM3 dolichyl-phosphate mannosyltransferase subunit 3 0.986599 
126.  ENSG00000081721 DUSP12 dual specificity phosphatase 12 0.492875 
127.  ENSG00000158716 DUSP23 dual specificity phosphatase 23 0.378719 
128.  ENSG00000196205 EEF1A1P5 
eukaryotic translation elongation factor 1 alpha 1 
pseudogene 5 
0.461171 
129.  ENSG00000120533 ENY2 
"ENY2, transcription and export complex 2 
subunit" 
0.63482 
130.  ENSG00000224032 
EPB41L4A-
AS1 
EPB41L4A antisense RNA 1 0.901618 
131.  ENSG00000112029 FBXO5 F-box protein 5 0.374508 
132.  ENSG00000144199 FAHD2B 
fumarylacetoacetate hydrolase domain containing 
2B 
0.681793 
133.  ENSG00000158234 FAIM Fas apoptotic inhibitory molecule 0.410446 
134.  ENSG00000225663 MCRIP1 MAPK regulated corepressor interacting protein 1 0.491688 
135.  ENSG00000164451 FAM26D family with sequence similarity 26 member D 1.88422 
136.  ENSG00000154864 PIEZO2 
piezo type mechanosensitive ion channel 
component 2 
3.29995 
137.  ENSG00000251669 FAM86EP 
"family with sequence similarity 86 member E, 
pseudogene" 
0.737164 
138.  ENSG00000183161 FANCF Fanconi anemia complementation group F 0.471178 
139.  ENSG00000104870 FCGRT Fc fragment of IgG receptor and transporter 0.776339 
140.  ENSG00000156427 FGF18 fibroblast growth factor 18 0.719496 
141.  ENSG00000115641 FHL2 four and a half LIM domains 2 0.445715 
142.  ENSG00000160688 FLAD1 flavin adenine dinucleotide synthetase 1 0.556943 
143.  ENSG00000155393 HEATR3 HEAT repeat containing 3 0.716759 
144.  ENSG00000165792 METTL17 methyltransferase like 17 0.682262 
145.  ENSG00000106125 FAM188B family with sequence similarity 188 member B 0.602637 
146.  ENSG00000223764 LOC100130417 uncharacterized LOC100130417 0.430213 
147.  ENSG00000126391 FRMD8 FERM domain containing 8 0.585091 
148.  ENSG00000186628 FSD2 fibronectin type III and SPRY domain containing 2 0.926203 




150.  ENSG00000068438 FTSJ1 FtsJ RNA methyltransferase homolog 1 (E. coli) 0.55001 
151.  ENSG00000137726 FXYD6 FXYD domain containing ion transport regulator 6 0.580413 
152.  ENSG00000180340 FZD2 frizzled class receptor 2 0.413671 
153.  ENSG00000165060 FXN frataxin 0.529412 
154.  ENSG00000149100 EIF3M eukaryotic translation initiation factor 3 subunit M 0.43418 
155.  ENSG00000110328 GALNT18 polypeptide N-acetylgalactosaminyltransferase 18 0.394038 




157.  ENSG00000197308 GATA3-AS1 GATA3 antisense RNA 1 0.671649 
158.  ENSG00000034713 GABARAPL2 GABA type A receptor associated protein like 2 0.564498 
159.  ENSG00000117228 GBP1 guanylate binding protein 1 0.784455 
160.  ENSG00000120820 GLT8D2 glycosyltransferase 8 domain containing 2 1.69809 
161.  ENSG00000197858 GPAA1 glycosylphosphatidylinositol anchor attachment 1 0.486139 
162.  ENSG00000167468 GPX4 glutathione peroxidase 4 0.410368 
163.  ENSG00000172432 GTPBP2 GTP binding protein 2 0.490921 
164.  ENSG00000178605 GTPBP6 GTP binding protein 6 (putative) 0.489066 
165.  ENSG00000069482 GAL galanin and GMAP prepropeptide 0.695747 
166.  ENSG00000112312 GMNN "geminin, DNA replication inhibitor" 0.406285 
167.  ENSG00000184897 H1FX H1 histone family member X 0.388129 
168.  ENSG00000213397 HAUS7 HAUS augmin like complex subunit 7 0.566935 
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169.  ENSG00000113070 HBEGF heparin binding EGF like growth factor 0.895028 
170.  ENSG00000164683 HEY1 
hes related family bHLH transcription factor with 
YRPW motif 1 
1.22995 
171.  ENSG00000135547 HEY2 
hes related family bHLH transcription factor with 
YRPW motif 2 
0.424438 
172.  ENSG00000168269 FOXI1 forkhead box I1 3.43907 
173.  ENSG00000196787 HIST1H2AG histone cluster 1 H2A family member g 0.390069 
174.  ENSG00000196747 HIST1H2AI histone cluster 1 H2A family member i 0.842689 
175.  ENSG00000184260 HIST2H2AC histone cluster 2 H2A family member c 0.939071 
176.  ENSG00000181218 HIST3H2A histone cluster 3 H2A 1.69035 
177.  ENSG00000214821 HMGB1P4 high mobility group box 1 pseudogene 4 3.41823 
178.  ENSG00000173917 HOXB2 homeobox B2 2.31017 
179.  ENSG00000060688 SNRNP40 small nuclear ribonucleoprotein U5 subunit 40 0.487184 
180.  ENSG00000133265 HSPBP1 HSPA (Hsp70) binding protein 1 0.56981 
181.  ENSG00000048162 NOP16 NOP16 nucleolar protein 0.959119 
182.  ENSG00000150316 CWC15 CWC15 spliceosome associated protein homolog 0.391368 
183.  ENSG00000189060 H1F0 H1 histone family member 0 0.371105 
184.  ENSG00000187837 HIST1H1C histone cluster 1 H1 family member c 0.353865 
185.  ENSG00000188486 H2AFX H2A histone family member X 0.744619 
186.  ENSG00000115457 IGFBP2 insulin like growth factor binding protein 2 0.597234 
187.  ENSG00000125968 ID1 "inhibitor of DNA binding 1, HLH protein" 0.589337 
188.  ENSG00000117318 ID3 "inhibitor of DNA binding 3, HLH protein" 0.718576 
189.  ENSG00000165949 IFI27 interferon alpha inducible protein 27 1.18678 
190.  ENSG00000185201 IFITM2 interferon induced transmembrane protein 2 0.714871 
191.  ENSG00000142089 IFITM3 interferon induced transmembrane protein 3 0.597062 
192.  ENSG00000171855 IFNB1 interferon beta 1 0.816242 
193.  ENSG00000109083 IFT20 intraflagellar transport 20 1.00115 
194.  ENSG00000189108 IL1RAPL2 interleukin 1 receptor accessory protein like 2 2.30333 
195.  ENSG00000182393 IFNL1 interferon lambda 1 1.56572 
196.  ENSG00000153391 INO80C INO80 complex subunit C 0.530949 
197.  ENSG00000169245 CXCL10 C-X-C motif chemokine ligand 10 2.51181 
198.  ENSG00000160051 IQCC IQ motif containing C 0.499756 
199.  ENSG00000185507 IRF7 interferon regulatory factor 7 0.713054 
200.  ENSG00000176842 IRX5 iroquois homeobox 5 0.563473 
201.  ENSG00000187608 ISG15 ISG15 ubiquitin-like modifier 0.945481 
202.  ENSG00000083457 ITGAE integrin subunit alpha E 0.607598 
203.  ENSG00000124249 KCNK15 
potassium two pore domain channel subfamily K 
member 15 
1.01492 
204.  ENSG00000185760 KCNQ5 
potassium voltage-gated channel subfamily Q 
member 5 
1.45194 
205.  ENSG00000080608 PUM3 pumilio RNA binding family member 3 0.629458 
206.  ENSG00000167566 NCKAP5L NCK associated protein 5 like 0.887664 
207.  ENSG00000183655 KLHL25 kelch like family member 25 0.558841 
208.  ENSG00000124743 KLHL31 kelch like family member 31 1.17539 
209.  ENSG00000139187 KLRG1 killer cell lectin like receptor G1 2.02421 
210.  ENSG00000157992 KRTCAP3 keratinocyte associated protein 3 0.574384 
211.  ENSG00000167768 KRT1 keratin 1 1.27951 
212.  ENSG00000186395 KRT10 keratin 10 0.51963 
213.  ENSG00000132434 LANCL2 LanC like 2 0.746629 
214.  ENSG00000106852 LHX6 LIM homeobox 6 0.774015 
215.  ENSG00000224843 LINC00240 long intergenic non-protein coding RNA 240 1.60272 
216.  ENSG00000203930 LINC00632 long intergenic non-protein coding RNA 632 1.50538 
217.  ENSG00000175701 LINC00116 long intergenic non-protein coding RNA 116 0.452601 
218.  ENSG00000221821 C6orf226 chromosome 6 open reading frame 226 0.630026 
219.  ENSG00000262587 LOC554206 leucine carboxyl methyltransferase 1 pseudogene 1.35132 
220.  ENSG00000223756 TSSC2 
tumor suppressing subtransferable candidate 2 
pseudogene 
0.767636 
221.  ENSG00000128011 LRFN1 
leucine rich repeat and fibronectin type III domain 
containing 1 
0.611146 
222.  ENSG00000116212 LRRC42 leucine rich repeat containing 42 0.358644 
223.  ENSG00000257103 LSM14A LSM14A, mRNA processing body assembly factor 0.645035 
224.  ENSG00000164167 LSM6 
LSM6 homolog, U6 small nuclear RNA and 
mRNA degradation associated 
0.417445 
225.  ENSG00000073803 MAP3K13 mitogen-activated protein kinase kinase kinase 13 0.874193 
226.  ENSG00000178982 EIF3K eukaryotic translation initiation factor 3 subunit K 0.384723 
227.  ENSG00000247626 MARS2 "methionyl-tRNA synthetase 2, mitochondrial" 0.42871 
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228.  ENSG00000168906 MAT2A methionine adenosyltransferase 2A 0.483105 
229.  ENSG00000071655 MBD3 methyl-CpG binding domain protein 3 0.865492 
230.  ENSG00000106305 AIMP2 
aminoacyl tRNA synthetase complex interacting 
multifunctional protein 2 
1.51209 
231.  ENSG00000076706 MCAM melanoma cell adhesion molecule 1.18409 
232.  ENSG00000037897 METTL1 methyltransferase like 1 0.906915 
233.  ENSG00000087995 METTL2A methyltransferase like 2A 0.395521 
234.  ENSG00000167700 MFSD3 major facilitator superfamily domain containing 3 0.585684 
235.  ENSG00000133808 MICALCL MICAL C-terminal like 1.32669 
236.  ENSG00000240972 MIF macrophage migration inhibitory factor  0.833516 
237.  ENSG00000230937 MIR205HG MIR205 host gene 1.11661 
238.  ENSG00000227195 MIR663AHG MIR663A host gene 1.20766 
239.  ENSG00000108961 RANGRF RAN guanine nucleotide release factor 0.5459 
240.  ENSG00000137547 MRPL15 mitochondrial ribosomal protein L15 0.474103 
241.  ENSG00000242485 MRPL20 mitochondrial ribosomal protein L20 0.531287 
242.  ENSG00000106591 MRPL32 mitochondrial ribosomal protein L32 0.858848 
243.  ENSG00000130312 MRPL34 mitochondrial ribosomal protein L34 0.870551 
244.  ENSG00000105364 MRPL4 mitochondrial ribosomal protein L4 0.409564 
245.  ENSG00000055950 MRPL43 mitochondrial ribosomal protein L43 0.599647 
246.  ENSG00000259494 MRPL46 mitochondrial ribosomal protein L46 0.762839 
247.  ENSG00000183617 MRPL54 mitochondrial ribosomal protein L54 0.556519 
248.  ENSG00000128626 MRPS12 mitochondrial ribosomal protein S12 0.583302 
249.  ENSG00000239789 MRPS17 mitochondrial ribosomal protein S17 0.736926 
250.  ENSG00000096080 MRPS18A mitochondrial ribosomal protein S18A 0.393735 
251.  ENSG00000074071 MRPS34 mitochondrial ribosomal protein S34 0.627567 
252.  ENSG00000243927 MRPS6 mitochondrial ribosomal protein S6 0.739482 
253.  ENSG00000183155 RABIF RAB interacting factor 0.357549 
254.  ENSG00000182551 ADI1 acireductone dioxygenase 1 0.481005 
255.  ENSG00000242114 MTFP1 mitochondrial fission process 1 1.47424 
256.  ENSG00000162385 MAGOH 
mago homolog, exon junction complex core 
component 
0.457134 
257.  ENSG00000173171 MTX1 metaxin 1 0.663453 
258.  ENSG00000182208 MOB2 MOB kinase activator 2 0.524078 
259.  ENSG00000176101 SSNA1 SS nuclear autoantigen 1 0.430655 
260.  ENSG00000166681 BEX3 brain expressed X-linked 3 0.43456 
261.  ENSG00000147813 NAPRT nicotinate phosphoribosyltransferase 0.653233 
262.  ENSG00000174886 NDUFA11 NADH:ubiquinone oxidoreductase subunit A11 0.599199 
263.  ENSG00000131495 NDUFA2 NADH:ubiquinone oxidoreductase subunit A2 0.823501 
264.  ENSG00000128609 NDUFA5 NADH:ubiquinone oxidoreductase subunit A5 0.41167 
265.  ENSG00000119421 NDUFA8 NADH:ubiquinone oxidoreductase subunit A8 0.45136 
266.  ENSG00000147123 NDUFB11 NADH:ubiquinone oxidoreductase subunit B11 0.603894 
267.  ENSG00000090266 NDUFB2 NADH:ubiquinone oxidoreductase subunit B2 0.578461 
268.  ENSG00000099795 NDUFB7 NADH:ubiquinone oxidoreductase subunit B7 0.592951 
269.  ENSG00000151366 NDUFC2 NADH:ubiquinone oxidoreductase subunit C2 0.539958 
270.  ENSG00000145494 NDUFS6 NADH:ubiquinone oxidoreductase subunit S6 0.406572 
271.  ENSG00000167792 NDUFV1 NADH:ubiquinone oxidoreductase core subunit V1 0.384126 
272.  ENSG00000160949 TONSL "tonsoku-like, DNA repair protein" 0.477561 
273.  ENSG00000100138 SNU13 SNU13 homolog, small nuclear ribonucleoprotein 0.587735 
274.  ENSG00000123609 NMI N-myc and STAT interactor 0.517159 
275.  ENSG00000110107 PRPF19 pre-mRNA processing factor 19 0.526223 
276.  ENSG00000107672 NSMCE4A NSE4 homolog A, SMC5-6 complex component 0.423395 
277.  ENSG00000205309 NT5M 5',3'-nucleotidase, mitochondrial 0.501565 
278.  ENSG00000151413 NUBPL nucleotide binding protein like 0.558354 
279.  ENSG00000083635 NUFIP1 "NUFIP1, FMR1 interacting protein 1" 0.513718 
280.  ENSG00000185818 NAT8L N-acetyltransferase 8 like 0.361264 
281.  ENSG00000163938 GNL3 G protein nucleolar 3 0.741709 
282.  ENSG00000154814 OXNAD1 oxidoreductase NAD binding domain containing 1 0.488446 
283.  ENSG00000092010 PSME1 proteasome activator subunit 1 0.532391 
284.  ENSG00000100911 PSME2 proteasome activator subunit 2 0.608229 
285.  ENSG00000107951 MTPAP mitochondrial poly(A) polymerase 0.434545 
286.  ENSG00000100300 TSPO translocator protein 0.522258 
287.  ENSG00000125450 NUP85 nucleoporin 85 0.687256 
288.  ENSG00000197461 PDGFA platelet derived growth factor subunit A 0.413027 
289.  ENSG00000255185 PDXDC2P 
"pyridoxal dependent decarboxylase domain 
containing 2, pseudogene" 
1.52514 
290.  ENSG00000143256 PFDN2 prefoldin subunit 2 0.726832 
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291.  ENSG00000184207 PGP phosphoglycolate phosphatase 0.457967 
292.  ENSG00000173457 PPP1R14B 
protein phosphatase 1 regulatory inhibitor subunit 
14B 
0.378728 
293.  ENSG00000054148 PHPT1 phosphohistidine phosphatase 1 0.418984 
294.  ENSG00000105559 PLEKHA4 pleckstrin homology domain containing A4 0.787814 
295.  ENSG00000102934 PLLP plasmolipin 0.437388 
296.  ENSG00000114631 PODXL2 podocalyxin like 2 0.404692 
297.  ENSG00000062822 POLD1 "DNA polymerase delta 1, catalytic subunit" 0.75975 
298.  ENSG00000100479 POLE2 "DNA polymerase epsilon 2, accessory subunit" 0.603001 
299.  ENSG00000205808 PLPP6 phospholipid phosphatase 6 0.490681 
300.  ENSG00000219797 PPIAP9 peptidylprolyl isomerase A pseudogene 9 0.404168 
301.  ENSG00000049769 PPP1R3F protein phosphatase 1 regulatory subunit 3F 0.839678 
302.  ENSG00000122490 PQLC1 PQ loop repeat containing 1 0.720016 
303.  ENSG00000204673 AKT1S1 AKT1 substrate 1 0.445086 
304.  ENSG00000123143 PKN1 protein kinase N1 0.51293 
305.  ENSG00000126457 PRMT1 protein arginine methyltransferase 1 0.414225 
306.  ENSG00000224940 PRRT4 proline rich transmembrane protein 4 0.60223 
307.  ENSG00000205220 PSMB10 proteasome subunit beta 10 0.904058 
308.  ENSG00000142507 PSMB6 proteasome subunit beta 6 0.354566 
309.  ENSG00000163636 PSMD6 "proteasome 26S subunit, non-ATPase 6" 0.389134 
310.  ENSG00000110801 PSMD9 "proteasome 26S subunit, non-ATPase 9" 0.380317 
311.  ENSG00000157778 PSMG3 proteasome assembly chaperone 3 0.788305 
312.  ENSG00000176894 PXMP2 peroxisomal membrane protein 2 1.22584 
313.  ENSG00000101417 PXMP4 peroxisomal membrane protein 4 0.512692 
314.  ENSG00000173599 PC pyruvate carboxylase 1.34458 
315.  ENSG00000104524 PYCRL pyrroline-5-carboxylate reductase-like 0.68122 
316.  ENSG00000099864 PALM paralemmin 0.534304 
317.  ENSG00000127445 PIN1 
peptidylprolyl cis/trans isomerase, NIMA-
interacting 1 
0.517536 
318.  ENSG00000102312 PORCN porcupine homolog (Drosophila) 0.7285 
319.  ENSG00000102109 PCSK1N 
proprotein convertase subtilisin/kexin type 1 
inhibitor 
0.468133 
320.  ENSG00000167964 RAB26 RAB26, member RAS oncogene family 0.801729 
321.  ENSG00000141542 RAB40B RAB40B, member RAS oncogene family 0.766176 
322.  ENSG00000128045 RASL11B RAS like family 11 member B 0.63957 
323.  ENSG00000102317 RBM3 "RNA binding motif (RNP1, RRM) protein 3" 0.410045 
324.  ENSG00000204977 TRIM13 tripartite motif containing 13 0.462184 
325.  ENSG00000116741 RGS2 regulator of G-protein signaling 2 0.603821 
326.  ENSG00000107201 DDX58 DEXD/H-box helicase 58 0.530166 
327.  ENSG00000183421 RIPK4 receptor interacting serine/threonine kinase 4 0.396886 
328.  ENSG00000269900 RMRP 
RNA component of mitochondrial RNA processing 
endoribonuclease 
1.02715 
329.  ENSG00000202198 RN7SK "RNA, 7SK small nuclear" 0.491338 
330.  ENSG00000158717 RNF166 ring finger protein 166 0.601905 
331.  ENSG00000117748 RPA2 replication protein A2 0.446348 
332.  ENSG00000100142 POLR2F RNA polymerase II subunit F 0.468156 
333.  ENSG00000063177 RPL18 ribosomal protein L18 0.44233 
334.  ENSG00000105640 RPL18A ribosomal protein L18a 0.691689 
335.  ENSG00000130255 RPL36 ribosomal protein L36 0.724443 
336.  ENSG00000213553 RPLP0P6 
ribosomal protein lateral stalk subunit P0 
pseudogene 6 
0.619279 
337.  ENSG00000137818 RPLP1 ribosomal protein lateral stalk subunit P1 0.500618 
338.  ENSG00000177600 RPLP2 ribosomal protein lateral stalk subunit P2 0.440122 
339.  ENSG00000172336 POP7 "POP7 homolog, ribonuclease P/MRP subunit" 0.719657 
340.  ENSG00000115268 RPS15 ribosomal protein S15 0.440372 
341.  ENSG00000105372 RPS19 ribosomal protein S19 0.404088 
342.  ENSG00000140988 RPS2 ribosomal protein S2 0.443262 
343.  ENSG00000179041 RRS1 ribosome biogenesis regulator homolog 0.481912 
344.  ENSG00000136444 RSAD1 radical S-adenosyl methionine domain containing 1 0.475825 
345.  ENSG00000222014 RAB6C "RAB6C, member RAS oncogene family" 0.768564 
346.  ENSG00000123595 RAB9A "RAB9A, member RAS oncogene family" 0.435617 
347.  ENSG00000169750 RAC3 
"ras-related C3 botulinum toxin substrate 3 (rho 
family, small GTP binding protein Rac3)" 
0.460522 
348.  ENSG00000099901 RANBP1 RAN binding protein 1 0.631193 
349.  ENSG00000142552 RCN3 reticulocalbin 3 1.34694 
350.  ENSG00000173156 RHOD ras homolog family member D 0.615585 
351.  ENSG00000166788 SAAL1 serum amyloid A like 1 0.448924 
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352.  ENSG00000168061 SAC3D1 SAC3 domain containing 1 0.824352 
353.  ENSG00000205413 SAMD9 sterile alpha motif domain containing 9 0.587933 
354.  ENSG00000150459 SAP18 Sin3A associated protein 18 0.407532 
355.  ENSG00000105472 CLEC11A C-type lectin domain family 11 member A 1.68108 
356.  ENSG00000133028 SCO1 "SCO1, cytochrome c oxidase assembly protein" 0.387032 
357.  ENSG00000121064 SCPEP1 serine carboxypeptidase 1 0.44248 
358.  ENSG00000205138 SDHAF1 
succinate dehydrogenase complex assembly factor 
1 
0.578079 
359.  ENSG00000171222 SCAND1 SCAN domain containing 1 0.981319 
360.  ENSG00000085415 SEH1L SEH1 like nucleoporin 0.48006 
361.  ENSG00000141295 SCRN2 secernin 2 0.474364 
362.  ENSG00000161547 SRSF2 serine and arginine rich splicing factor 2 0.540135 
363.  ENSG00000129946 SHC2 SHC adaptor protein 2 0.701544 
364.  ENSG00000108528 SLC25A11 solute carrier family 25 member 11 0.529239 
365.  ENSG00000125454 SLC25A19 solute carrier family 25 member 19 0.903744 
366.  ENSG00000177542 SLC25A22 solute carrier family 25 member 22 0.81186 
367.  ENSG00000155287 SLC25A28 solute carrier family 25 member 28 0.469913 
368.  ENSG00000075415 SLC25A3 solute carrier family 25 member 3 0.430978 
369.  ENSG00000122692 SMU1 DNA replication regulator and spliceosomal factor 0.391938 
370.  ENSG00000188338 SLC38A3 solute carrier family 38 member 3 1.45116 
371.  ENSG00000174365 SNHG11 small nucleolar RNA host gene 11 0.508052 
372.  ENSG00000269893 SNHG8 small nucleolar RNA host gene 8 0.748491 
373.  ENSG00000255198 SNHG9 small nucleolar RNA host gene 9 0.799658 
374.  ENSG00000263934 SNORD3A "small nucleolar RNA, C/D box 3A" 1.36868 
375.  ENSG00000125835 SNRPB 
small nuclear ribonucleoprotein polypeptides B and 
B1 
0.614339 
376.  ENSG00000028528 SNX1 sorting nexin 1 0.726085 
377.  ENSG00000158792 SPATA2L spermatogenesis associated 2 like 1.18964 
378.  ENSG00000124193 SRSF6 serine and arginine rich splicing factor 6 0.382337 
379.  ENSG00000106028 SSBP1 single stranded DNA binding protein 1 0.443889 
380.  ENSG00000180879 SSR4 signal sequence receptor subunit 4 0.559991 
381.  ENSG00000180953 ST20 suppressor of tumorigenicity 20 0.847186 
382.  ENSG00000169689 STRA13 stimulated by retinoic acid 13 0.585916 
383.  ENSG00000148290 SURF1 SURF1 cytochrome c oxidase assembly factor" 0.530676 
384.  ENSG00000148296 SURF6 surfeit 6 0.394365 
385.  ENSG00000157703 SVOPL SVOP like 1.37631 
386.  ENSG00000100321 SYNGR1 synaptogyrin 1 0.498366 
387.  ENSG00000180104 EXOC3 exocyst complex component 3 0.550317 
388.  ENSG00000073169 SELO selenoprotein O 0.435145 
389.  ENSG00000170892 TSEN34 tRNA splicing endonuclease subunit 34 0.365 
390.  ENSG00000162878 PKDCC "protein kinase domain containing, cytoplasmic" 0.511279 
391.  ENSG00000144040 SFXN5 sideroflexin 5 1.0396 
392.  ENSG00000089163 SIRT4 sirtuin 4 1.43437 
393.  ENSG00000184047 DIABLO diablo IAP-binding mitochondrial protein 0.674556 
394.  ENSG00000197457 STMN3 stathmin 3 0.666294 
395.  ENSG00000135111 TBX3 T-box 3 0.958524 
396.  ENSG00000261787 TCF24 transcription factor 24 0.967519 
397.  ENSG00000148308 GTF3C5 general transcription factor IIIC subunit 5 0.479835 
398.  ENSG00000168286 THAP11 THAP domain containing 11 0.720457 
399.  ENSG00000184436 THAP7 THAP domain containing 7 0.749494 
400.  ENSG00000161277 THAP8 THAP domain containing 8 0.669541 
401.  ENSG00000133321 RARRES3 retinoic acid receptor responder 3 0.850546 
402.  ENSG00000180346 TIGD2 tigger transposable element derived 2 0.38924 
403.  ENSG00000105197 TIMM50 translocase of inner mitochondrial membrane 50 0.566558 
404.  ENSG00000075131 TIPIN TIMELESS interacting protein 0.433057 
405.  ENSG00000134851 TMEM165 transmembrane protein 165 0.539908 
406.  ENSG00000226287 TMEM191A transmembrane protein 191A (pseudogene) 1.01268 
407.  ENSG00000188807 TMEM201 transmembrane protein 201 0.624589 
408.  ENSG00000180730 SHISA2 shisa family member 2 0.457364 
409.  ENSG00000178821 TMEM52 transmembrane protein 52 0.772302 
410.  ENSG00000135211 TMEM60 transmembrane protein 60 0.510866 
411.  ENSG00000175606 TMEM70 transmembrane protein 70 0.484836 
412.  ENSG00000127774 EMC6 ER membrane protein complex subunit 6 0.852474 
413.  ENSG00000187653 TMSB4XP8 "thymosin beta 4, X-linked pseudogene 8" 1.1459 
414.  ENSG00000164758 MED30 mediator complex subunit 30 0.408796 
415.  ENSG00000181029 TRAPPC5 trafficking protein particle complex 5 0.784778 
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416.  ENSG00000123297 TSFM "Ts translation elongation factor, mitochondrial" 0.512266 
417.  ENSG00000180543 TSPYL5 TSPY like 5 0.435672 
418.  ENSG00000128311 TST thiosulfate sulfurtransferase 0.563092 
419.  ENSG00000104522 TSTA3 tissue specific transplantation antigen P35B 0.469903 
420.  ENSG00000011295 TTC19 tetratricopeptide repeat domain 19 0.883377 
421.  ENSG00000183891 TTC32 tetratricopeptide repeat domain 32 0.483994 
422.  ENSG00000129235 TXNDC17 thioredoxin domain containing 17 0.462714 
423.  ENSG00000156521 TYSND1 trypsin domain containing 1 0.487563 
424.  ENSG00000177370 TIMM22 
translocase of inner mitochondrial membrane 22 
homolog 
0.343774 
425.  ENSG00000170315 UBB ubiquitin B 0.431675 
426.  ENSG00000160087 UBE2J2 ubiquitin conjugating enzyme E2 J2 0.371906 
427.  ENSG00000156587 UBE2L6 ubiquitin conjugating enzyme E2 L6 0.405366 
428.  ENSG00000115446 UNC50 
unc-50 inner nuclear membrane RNA binding 
protein 
0.381783 
429.  ENSG00000127540 UQCR11 
"ubiquinol-cytochrome c reductase, complex III 
subunit XI" 
0.70226 
430.  ENSG00000184979 USP18 ubiquitin specific peptidase 18 0.673708 
431.  ENSG00000176125 UFSP1 UFM1 specific peptidase 1 (inactive) 0.82111 
432.  ENSG00000136146 MED4 mediator complex subunit 4 0.486201 
433.  ENSG00000167397 VKORC1 vitamin K epoxide reductase complex subunit 1 0.60749 
434.  ENSG00000100749 VRK1 vaccinia related kinase 1 0.561483 
435.  ENSG00000085449 WDFY1 WD repeat and FYVE domain containing 1 0.477846 
436.  ENSG00000119333 WDR34 WD repeat domain 34 0.967734 
437.  ENSG00000133316 WDR74 WD repeat domain 74 0.430277 
438.  ENSG00000152763 WDR78 WD repeat domain 78 1.73907 
439.  ENSG00000136936 XPA "XPA, DNA damage recognition and repair factor" 0.635993 
440.  ENSG00000103489 XYLT1 xylosyltransferase 1 0.468212 
441.  ENSG00000247315 ZCCHC3 zinc finger CCHC-type containing 3 0.530817 
442.  ENSG00000112473 SLC39A7 solute carrier family 39 member 7 0.427647 
443.  ENSG00000197961 ZNF121 zinc finger protein 121 0.478525 
444.  ENSG00000249471 ZNF324B zinc finger protein 324B 0.824604 
445.  ENSG00000131116 ZNF428 zinc finger protein 428 0.664193 
446.  ENSG00000198298 ZNF485 zinc finger protein 485 0.48972 
447.  ENSG00000204946 ZNF783 zinc finger family member 783 0.774064 
448.  ENSG00000152475 ZNF837 zinc finger protein 837 0.399333 
449.  ENSG00000166707 ZCCHC18 zinc finger CCHC-type containing 18 1.40314 
450.  ENSG00000115194 SLC30A3 solute carrier family 30 member 3 1.0649 





Supplementary Table 4: miR-29 targets common in MCF-7 and LCC9s 
 
Supplementary Table 4B: Common miR-29b-1 and miR-29a targets common to both 
MCF-7 and LCC9 cells 
 
































1.  ANXA1 annexin A1 0.86142 0.786981 2.13207 2.17304 
2.  ANXA5 annexin A5 0.553169 0.52333 1.17391 1.22543 
3.  ARL4C ADP ribosylation factor like GTPase 4C 0.554121 0.695993 1.11503 1.06863 
4.  ARPC5 actin related protein 2/3 complex subunit 5 0.586134 0.607786 1.505 1.64043 
5.  ATP5C1 
"ATP synthase, H+ transporting, mitochondrial F1 
complex, gamma polypeptide 1" 
0.6197 0.540511 1.43753 1.34628 
6.  BAK1P1 BCL2 antagonist/killer 1 pseudogene 1 0.72886 0.853615 1.33959 1.35957 
7.  BPGM bisphosphoglycerate mutase 0.744332 0.734537 1.74992 1.71232 
8.  C4orf32 chromosome 4 open reading frame 32 0.716821 0.62176 0.895463 0.976444 
9.  C7orf73 chromosome 7 open reading frame 73 0.803039 0.703753 1.89354 1.90098 
10.  CCDC167 coiled-coil domain containing 167 0.573969 0.620072 3.39142 3.38646 
11.  CD276 CD276 molecule 0.6514 0.687137 1.24127 1.1014 
12.  CD36 CD36 molecule 0.991681 1.19904 1.5895 1.44303 
13.  CLEC7A C-type lectin domain family 7 member A 1.28516 1.75287 2.31239 4.17419 
14.  DYNLT1 dynein light chain Tctex-type 1 0.498623 0.60201 1.94914 2.14702 
15.  EFEMP1 
EGF containing fibulin like extracellular matrix 
protein 1 
0.943595 0.981479 1.53166 1.67697 
16.  ELF5 E74 like ETS transcription factor 5 1.20403 1.00089 1.54622 1.41993 
17.  ENO1 enolase 1 0.499112 0.49841 0.546022 0.474453 
18.  EPB41L4B erythrocyte membrane protein band 4.1 like 4B 0.59199 0.530691 0.73561 0.664133 
19.  F11R F11 receptor 0.829893 0.805344 1.09778 1.04492 
20.  FAM102B family with sequence similarity 102 member B 0.61018 0.463769 1.13096 0.902373 
21.  FAM127C family with sequence similarity 127 member C 0.511481 0.559729 1.25769 1.39421 
22.  FECH ferrochelatase 1.03486 0.802485 1.68044 1.65016 
23.  FKBP1A FK506 binding protein 1A 0.72236 0.541505 0.791857 0.845083 
24.  FREM2 FRAS1 related extracellular matrix protein 2 1.2842 1.13966 1.6484 1.22025 
25.  GALNT1 polypeptide N-acetylgalactosaminyltransferase 1 0.95207 0.767107 0.673639 0.543714 
26.  GCSH glycine cleavage system protein H 0.812153 0.678064 2.03522 1.98461 
27.  GINM1 glycoprotein integral membrane 1 0.688129 0.599535 0.775513 0.697549 
28.  GSTM3 glutathione S-transferase mu 3 0.603347 0.474469 0.95424 0.886405 
29.  HOXC13 homeobox C13 0.546096 0.67975 2.13121 2.22351 
30.  IGSF3 immunoglobulin superfamily member 3 0.98228 1.12764 1.06424 0.986889 
31.  ISOC1 isochorismatase domain containing 1 0.720805 0.671419 1.88871 1.87293 
32.  ITGB1 integrin subunit beta 1 0.816957 0.659117 0.987881 0.80671 
33.  JARID2 jumonji and AT-rich interaction domain containing 2 0.474666 0.444702 1.09834 0.998283 
34.  KDELC1 KDEL motif containing 1 1.0655 1.27176 3.01117 2.79997 
35.  KDM5B lysine demethylase 5B 0.98413 0.779044 0.845657 0.65676 
36.  KIAA1161 KIAA1161 0.708471 0.59354 0.655048 0.688324 
37.  KIT KIT proto-oncogene receptor tyrosine kinase 1.99239 1.71144 2.10612 1.97156 
38.  KLHDC3 kelch domain containing 3 0.612973 0.698181 1.94245 2.07298 
39.  KRT80 keratin 80 0.387774 0.516173 1.24017 1.19701 
40.  MAP2K6 mitogen-activated protein kinase kinase 6 1.35071 1.27931 2.61089 2.15353 
41.  MAP4K4 
mitogen-activated protein kinase kinase kinase kinase 
4 
0.6531 0.563603 1.24666 0.919106 
42.  MBTD1 mbt domain containing 1 0.616126 0.501719 0.65506 0.544341 
43.  METTL7A methyltransferase like 7A 0.81592 0.96939 0.867371 0.772139 
44.  MORF4L1 mortality factor 4 like 1 0.614757 0.563526 1.23656 1.21828 
45.  MPZL3 myelin protein zero like 3 0.796882 0.842667 1.30983 1.22454 
46.  MRFAP1 Morf4 family associated protein 1 0.465383 0.536648 2.03319 2.14254 
47.  NANOS1 nanos C2HC-type zinc finger 1 0.858277 0.9082 1.56703 1.64991 
48.  NRAS neuroblastoma RAS viral oncogene homolog 0.552152 0.43652 0.650742 0.632976 
49.  NTRK2 neurotrophic receptor tyrosine kinase 2 0.987398 1.21638 2.31639 1.68192 
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50.  PCP4 Purkinje cell protein 4 0.864802 0.712848 2.79053 2.29124 
51.  PIK3R3 phosphoinositide-3-kinase regulatory subunit 3 0.801967 0.829185 1.14694 1.04752 
52.  PPIC peptidylprolyl isomerase C 1.21937 1.17803 2.04242 2.15937 
53.  PPT1 palmitoyl-protein thioesterase 1 0.742549 0.688119 1.33288 1.28796 
54.  PRMT6 protein arginine methyltransferase 6 0.576114 0.729643 2.51833 2.72602 
55.  RCC2 regulator of chromosome condensation 2 0.401982 0.591432 2.40005 2.4671 
56.  RCN2 reticulocalbin 2 0.531026 0.452163 0.698454 0.588073 
57.  RPS24 ribosomal protein S24 0.555705 0.488549 2.25259 2.36119 
58.  RPS3A ribosomal protein S3A 0.687786 0.491714 1.35179 1.34338 
59.  S100A16 S100 calcium binding protein A16 0.669323 0.682906 1.68258 1.66285 
60.  SEMA3C semaphorin 3C 0.865222 0.66281 0.907207 0.669273 
61.  SESTD1 SEC14 and spectrin domain containing 1 1.10416 1.06537 1.24413 1.03235 
62.  TBC1D7 TBC1 domain family member 7 0.921924 0.83745 2.64112 2.93259 
63.  TDG thymine DNA glycosylase 0.815785 0.81763 2.25669 2.35879 
64.  TET1 tet methylcytosine dioxygenase 1 1.14532 1.06875 1.61365 1.33383 
65.  TET3 tet methylcytosine dioxygenase 3 0.923868 1.01061 0.964832 0.931351 
66.  TMEM117 transmembrane protein 117 1.76039 1.52825 1.22016 1.36977 
67.  TMEM164 transmembrane protein 164 0.8879 0.803582 1.45174 1.44885 
68.  TMSB4X "thymosin beta 4, X-linked" 0.559619 0.483911 0.828414 0.954921 
69.  UBTD2 ubiquitin domain containing 2 0.753085 0.627815 1.45232 1.38079 
70.  VAMP7 vesicle associated membrane protein 7 0.950366 0.81555 1.74104 1.60978 
71.  VOPP1 
"vesicular, overexpressed in cancer, prosurvival 
protein 1" 
0.476688 0.451507 0.46844 0.41793 







Supplementary Table 4A: Common miR-29b-1 and miR-29a targets unique MCF-7 cells 
 





 Gene Symbol Gene Name log2(fold change) log2(fold change) 
1.  ACO1 aconitase 1 0.950629 0.626089 
2.  AIM1 absent in melanoma 1 0.778095 0.658569 
3.  AKR1C3 aldo-keto reductase family 1 member C3 0.885048 0.645128 
4.  ANKRD50 ankyrin repeat domain 50 0.73071 0.554446 
5.  ATP1A1 ATPase Na+/K+ transporting subunit alpha 1 0.64489 0.431066 
6.  ATP7A ATPase copper transporting alpha 0.798753 0.616152 
7.  ATRN attractin 0.717643 0.492748 
8.  BMP5 bone morphogenetic protein 5 0.836287 0.658327 
9.  CAV1 caveolin 1 1.16046 1.01584 
10.  CMBL carboxymethylenebutenolidase homolog 0.765169 0.549379 







13.  CYP19A1 
cytochrome P450 family 19 subfamily A member 
1 
2.32583 2.35814 
14.  DNAJC28 
DnaJ heat shock protein family (Hsp40) member 
C28 
1.06775 0.92687 
15.  DSC2 desmocollin 2 1.29529 1.10679 
16.  DSG2 desmoglein 2 0.743464 0.481257 
17.  EPHA6 EPH receptor A6 1.03363 0.877418 
18.  EPHA7 EPH receptor A7 0.879505 0.701687 
19.  ERMP1 endoplasmic reticulum metallopeptidase 1 0.939574 0.679547 
20.  FBP1 fructose-bisphosphatase 1 0.45042 0.490642 
21.  FILIP1L filamin A interacting protein 1 like 0.667145 0.583131 
22.  HEPHL1 hephaestin like 1 1.38329 1.14249 




24.  IGFBP5 insulin like growth factor binding protein 5 0.52921 0.390971 
25.  KCNJ8 
potassium voltage-gated channel subfamily J 
member 8 
0.940332 0.848572 
26.  KIAA1549 KIAA1549 0.770061 0.663556 
27.  KLHL4 kelch like family member 4 1.07248 0.81465 
28.  KLHL5 kelch like family member 5 0.756199 0.602252 
29.  KRT23 keratin 23 0.859914 0.780114 
30.  LTBP1 
latent transforming growth factor beta binding 
protein 1 
1.32021 0.921458 
31.  MALL "mal, T-cell differentiation protein like" 1.60014 1.58334 
32.  MIB1 mindbomb E3 ubiquitin protein ligase 1 0.73351 0.521844 
33.  MIR17HG miR-17-92a-1 cluster host gene 2.37174 2.2729 
34.  NAALADL2 
N-acetylated alpha-linked acidic dipeptidase like 
2 
0.69365 0.67568 
35.  NPNT nephronectin 0.774074 0.579707 
36.  PANX1 pannexin 1 0.666987 0.487432 
37.  PDK3 pyruvate dehydrogenase kinase 3 0.771457 0.564068 
38.  PERP "PERP, TP53 apoptosis effector" 0.587256 0.421452 
39.  PGM5 phosphoglucomutase 5 2.04583 1.71094 
40.  PKP1 plakophilin 1 1.25349 1.28295 
41.  PSG9 pregnancy specific beta-1-glycoprotein 9 0.84128 0.757355 
42.  RTN3 reticulon 3 0.612048 0.503042 
43.  S100A10 S100 calcium binding protein A10 0.574568 0.414773 
44.  SCIN scinderin 1.3387 1.19559 
45.  SCUBE2 
"signal peptide, CUB domain and EGF like 
domain containing 2" 
0.935904 0.815793 
46.  SEMA3D semaphorin 3D 1.48777 1.16477 
47.  SERINC5 serine incorporator 5 0.805837 0.548127 
48.  SLC16A2 solute carrier family 16 member 2 1.25596 0.854277 
49.  SLC24A3 solute carrier family 24 member 3 0.589257 0.4987 
50.  SLITRK6 SLIT and NTRK like family member 6 0.786628 0.553729 
51.  SORT1 sortilin 1 0.749978 0.522416 
52.  STK38 serine/threonine kinase 38 0.455075 0.426797 
53.  STON1 stonin 1 1.5401 1.4028 
 
 227 
54.  TMEM45B transmembrane protein 45B 0.797278 0.752252 
55.  TMTC3 
transmembrane and tetratricopeptide repeat 
containing 3 
0.828496 0.643048 
56.  TOP2B topoisomerase (DNA) II beta 0.707055 0.519007 
57.  TRAK2 trafficking kinesin protein 2 0.706495 0.568506 
58.  UNC5C unc-5 netrin receptor C 1.2494 1.47876 
59.  VAT1L vesicle amine transport 1 like 1.16268 1.0319 















 Gene Symbol Gene Name log2(fold change) log2(fold change) 
1.  AAR2 AAR2 splicing factor homolog 0.927601 1.03828 
2.  AARSD1 alanyl-tRNA synthetase domain containing 1 0.659615 0.639813 
3.  ABCB6 ATP binding cassette subfamily B member 6  1.20686 1.2379 
4.  ABCB7 ATP binding cassette subfamily B member 7 0.688644 0.580453 
5.  ABCE1 ATP binding cassette subfamily E member 1 0.876384 0.815314 
6.  ABHD13 abhydrolase domain containing 13 0.488825 0.459061 
7.  ACBD7 acyl-CoA binding domain containing 7 0.700393 0.496153 
8.  ACE angiotensin I converting enzyme 1.21031 1.00259 
9.  ACOX2 acyl-CoA oxidase 2 4.65734 3.66441 
10.  ACSS1 acyl-CoA synthetase short-chain family member 1 0.732909 0.762267 
11.  ACTG2 "actin, gamma 2, smooth muscle, enteric" 0.411173 0.462855 
12.  ACTL8 actin like 8 1.37881 1.60098 
13.  ACTR3B ARP3 actin related protein 3 homolog B 1.03853 1.08886 
14.  ADA adenosine deaminase 1.37348 1.47158 
15.  ADAMTS15 
ADAM metallopeptidase with thrombospondin type 1 motif 
15 
2.63156 2.34575 
16.  ADAMTS19 
ADAM metallopeptidase with thrombospondin type 1 motif 
19 
1.47001 1.29029 
17.  ADAT2 "adenosine deaminase, tRNA specific 2" 0.875681 0.969717 
18.  ADGRB2 adhesion G protein-coupled receptor B2 0.874388 1.11731 
19.  ADH5 "alcohol dehydrogenase 5 (class III), chi polypeptide" 1.00464 1.03491 
20.  ADIPOR2 adiponectin receptor 2 0.690701 0.574571 
21.  ADK adenosine kinase 0.60946 0.586069 
22.  ADNP2 ADNP homeobox 2 0.389951 0.375037 
23.  ADORA1 adenosine A1 receptor 2.51826 2.81189 
24.  ADORA2A adenosine A2a receptor 2.30518 2.9572 
25.  ADORA2B adenosine A2b receptor 0.715716 0.757347 
26.  ADSL adenylosuccinate lyase 1.28924 1.31677 
27.  ADSS adenylosuccinate synthase 0.989145 1.09993 
28.  AFMID arylformamidase 0.518471 0.514579 
29.  AGR3 
"anterior gradient 3, protein disulphide isomerase family 
member" 
0.59845 0.815454 
30.  AGTR1 angiotensin II receptor type 1 2.79834 2.8424 
31.  AHCY adenosylhomocysteinase 0.494678 0.563421 
32.  AHCYL1 adenosylhomocysteinase like 1 0.599927 0.449753 
33.  AIFM1 "apoptosis inducing factor, mitochondria associated 1" 0.517603 0.400808 
34.  AK2 adenylate kinase 2 0.58514 0.599814 
35.  AK4 adenylate kinase 4 0.59315 0.563226 
36.  AKR1A1 aldo-keto reductase family 1 member A1 0.690468 0.593904 
37.  AKR7A2 aldo-keto reductase family 7 member A2 0.590043 0.622283 
38.  ALDH7A1 aldehyde dehydrogenase 7 family member A1 0.711066 0.563229 
39.  ALG5 "ALG5, dolichyl-phosphate beta-glucosyltransferase" 0.974665 1.17464 
40.  ALG6 "ALG6, alpha-1,3-glucosyltransferase" 0.725901 0.842662 
41.  ALKBH2 
"alkB homolog 2, alpha-ketoglutarate dependent 
dioxygenase" 
0.534917 0.826004 
42.  AMER1 APC membrane recruitment protein 1 0.999996 0.936081 
43.  AMIGO2 adhesion molecule with Ig like domain 2 1.01909 1.00302 
44.  AMMECR1 
"Alport syndrome, mental retardation, midface hypoplasia 
and elliptocytosis chromosomal region gene 1" 
0.486683 0.499441 
45.  AMN1 antagonist of mitotic exit network 1 homolog 0.683819 0.588496 
46.  ANAPC16 anaphase promoting complex subunit 16 0.486764 0.477979 
47.  ANAPC5 anaphase promoting complex subunit 5 0.562191 0.456977 
48.  ANKRD1 ankyrin repeat domain 1 0.498224 0.633051 
49.  ANKRD13A ankyrin repeat domain 13A 0.696859 0.685671 
50.  ANKRD22 ankyrin repeat domain 22 1.83286 1.5803 
51.  ANKRD30B ankyrin repeat domain 30B 0.863248 0.779758 
52.  AP1S1 adaptor related protein complex 1 sigma 1 subunit 0.712681 0.766289 
53.  AP2S1 adaptor related protein complex 2 sigma 1 subunit 1.22989 1.36345 
54.  AP5S1 adaptor related protein complex 5 sigma 1 subunit 0.456215 0.768152 
55.  APITD1 "apoptosis-inducing, TAF9-like domain 1" 0.815897 0.780221 
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56.  AREG amphiregulin 1.42032 1.32116 
57.  ARF5 ADP ribosylation factor 5 0.739554 0.905469 
58.  ARHGEF19 Rho guanine nucleotide exchange factor 19 0.840479 0.944296 
59.  ARL3 ADP ribosylation factor like GTPase 3 0.606915 0.522059 
60.  ARL5B ADP ribosylation factor like GTPase 5B 0.799245 0.737761 
61.  ARL6IP5 ADP ribosylation factor like GTPase 6 interacting protein 5 0.510344 0.450079 
62.  ARMC10 armadillo repeat containing 10 0.678404 0.480358 
63.  ARMC2 armadillo repeat containing 2 0.696103 0.782873 
64.  ARPC2 actin related protein 2/3 complex subunit 2 0.827089 0.909638 
65.  ARRDC4 arrestin domain containing 4 0.676729 0.931238 
66.  ARSK arylsulfatase family member K 1.09553 1.18466 
67.  ARTN artemin 0.779861 0.876064 
68.  ARV1 "ARV1 homolog, fatty acid homeostasis modulator" 0.443626 0.636535 
69.  ASMTL acetylserotonin O-methyltransferase-like 0.627943 0.643094 
70.  ASNA1 
"arsA arsenite transporter, ATP-binding, homolog 1 
(bacterial)" 
0.380803 0.471845 
71.  ATAD1 "ATPase family, AAA domain containing 1" 0.789302 0.790079 
72.  ATAD2B "ATPase family, AAA domain containing 2B" 0.623753 0.47118 
73.  ATOH8 atonal bHLH transcription factor 8 1.53391 1.45938 
74.  ATP23 
ATP23 metallopeptidase and ATP synthase assembly factor 
homolog 
0.957749 0.922681 
75.  ATP5A1 
"ATP synthase, H+ transporting, mitochondrial F1 complex, 
alpha subunit 1, cardiac muscle" 
0.424851 0.412725 
76.  ATP5B 
"ATP synthase, H+ transporting, mitochondrial F1 complex, 
beta polypeptide" 
0.738957 0.734603 
77.  ATP5E 
"ATP synthase, H+ transporting, mitochondrial F1 complex, 
epsilon subunit" 
0.553854 0.60387 
78.  ATP5EP2 
"ATP synthase, H+ transporting, mitochondrial F1 complex, 
epsilon subunit pseudogene 2" 
1.06228 0.475944 
79.  ATP5F1 
"ATP synthase, H+ transporting, mitochondrial Fo complex 
subunit B1" 
0.570357 0.604812 
80.  ATP5G3 
"ATP synthase, H+ transporting, mitochondrial Fo complex 
subunit C3 (subunit 9)" 
0.885476 1.00146 
81.  ATP5I 
"ATP synthase, H+ transporting, mitochondrial Fo complex 
subunit E" 
0.572728 0.805795 
82.  ATP5L 
"ATP synthase, H+ transporting, mitochondrial Fo complex 
subunit G" 
0.641905 0.713396 
83.  ATP6AP1 ATPase H+ transporting accessory protein 1 0.725615 0.747385 
84.  ATPAF2 ATP synthase mitochondrial F1 complex assembly factor 2 0.668871 0.853675 
85.  ATXN7L3B ataxin 7 like 3B 1.23747 1.29717 
86.  B2M beta-2-microglobulin 0.660654 0.683885 
87.  B3GALT6 "beta-1,3-galactosyltransferase 6" 0.891879 1.24243 
88.  B4GALT2 "beta-1,4-galactosyltransferase 2" 1.18107 1.36107 
89.  B4GALT5 "beta-1,4-galactosyltransferase 5" 0.648518 0.556421 
90.  BAG1 BCL2 associated athanogene 1 0.383929 0.514251 
91.  BAK1 BCL2 antagonist/killer 1 1.22959 1.49069 
92.  BANF1 barrier to autointegration factor 1 0.576179 0.631429 
93.  BARX2 BARX homeobox 2 1.10383 1.02157 
94.  BASP1 brain abundant membrane attached signal protein 1 0.483084 0.508448 
95.  BBS10 Bardet-Biedl syndrome 10 0.549438 0.635606 
96.  BCAT2 branched chain amino acid transaminase 2 0.627225 0.819078 
97.  BCCIP BRCA2 and CDKN1A interacting protein 0.802714 0.867996 
98.  BCL11B B-cell CLL/lymphoma 11B 0.889491 0.847944 
99.  BCL6 B-cell CLL/lymphoma 6 1.04653 0.899591 
100.  BCL7A BCL tumor suppressor 7A 0.971165 1.052 
101.  BDH1 "3-hydroxybutyrate dehydrogenase, type 1" 0.715878 0.744706 
102.  BDH2 "3-hydroxybutyrate dehydrogenase, type 2" 0.843871 0.866672 
103.  BEND6 BEN domain containing 6 1.01679 1.03956 
104.  BEX5 brain expressed X-linked 5 1.2185 1.64046 
105.  BFAR bifunctional apoptosis regulator 0.519609 0.486401 
106.  BFSP2 beaded filament structural protein 2 1.60905 1.3469 
107.  BIRC2 baculoviral IAP repeat containing 2 1.50289 1.41292 
108.  BLMH bleomycin hydrolase 2.51864 2.13864 
109.  BMPER BMP binding endothelial regulator 1.90746 1.64764 
110.  BOC "BOC cell adhesion associated, oncogene regulated" 2.16198 1.93153 
111.  BOLA1 bolA family member 1 0.570531 1.00556 
112.  BPHL biphenyl hydrolase like 0.722898 0.655604 
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113.  BRINP1 BMP/retinoic acid inducible neural specific 1 1.72664 1.90507 
114.  BRINP2 BMP/retinoic acid inducible neural specific 2 2.03546 1.60345 
115.  BRIX1 "BRX1, biogenesis of ribosomes" 0.518963 0.56702 
116.  BRK1 "BRICK1, SCAR/WAVE actin nucleating complex subunit" 0.750387 0.79901 
117.  BRSK2 BR serine/threonine kinase 2 1.05141 0.844313 
118.  BTBD10 BTB domain containing 10 0.947219 0.868464 
119.  BTF3 basic transcription factor 3 0.506364 0.487342 
120.  BTN3A1 butyrophilin subfamily 3 member A1 0.701139 0.811308 
121.  BTN3A2 butyrophilin subfamily 3 member A2 1.66846 1.60858 
122.  BZW2 basic leucine zipper and W2 domains 2 1.33163 1.28027 
123.  C12orf4 chromosome 12 open reading frame 4 0.589379 0.697994 
124.  C14orf166 chromosome 14 open reading frame 166 0.363788 0.346326 
125.  C14orf2 chromosome 14 open reading frame 2 0.523541 0.590597 
126.  C15orf59 chromosome 15 open reading frame 59 1.07989 1.23498 
127.  C16orf87 chromosome 16 open reading frame 87 1.76765 1.78206 
128.  C16orf91 chromosome 16 open reading frame 91 0.529916 1.05276 
129.  C19orf48 chromosome 19 open reading frame 48 0.550821 1.02046 
130.  C19orf53 chromosome 19 open reading frame 53 0.508361 0.593913 
131.  C1GALT1C1 C1GALT1 specific chaperone 1 0.504905 0.496875 
132.  C1GALT1C1L C1GALT1-specific chaperone 1 like 1.17377 1.59184 
133.  C1orf109 chromosome 1 open reading frame 109 0.578077 0.703725 
134.  C1orf123 chromosome 1 open reading frame 123 0.966238 1.10235 
135.  C1orf131 chromosome 1 open reading frame 131 1.49237 1.68842 
136.  C1orf168 chromosome 1 open reading frame 168 1.05566 0.884423 
137.  C1orf50 chromosome 1 open reading frame 50 0.506735 0.660153 
138.  C1orf52 chromosome 1 open reading frame 52 1.30657 1.53613 
139.  C1QBP complement C1q binding protein 0.842575 0.853417 
140.  C1QTNF6 C1q and tumor necrosis factor related protein 6 1.65012 1.72005 
141.  C20orf196 chromosome 20 open reading frame 196 0.846608 1.17566 
142.  C21orf33 chromosome 21 open reading frame 33 0.576514 0.882266 
143.  C21orf58 chromosome 21 open reading frame 58 0.574076 0.566849 
144.  C21orf91 chromosome 21 open reading frame 91 0.691422 0.713411 
145.  C2orf76 chromosome 2 open reading frame 76 0.748832 0.69391 
146.  C4orf19 chromosome 4 open reading frame 19 1.57704 1.5167 
147.  C4orf3 chromosome 4 open reading frame 3 0.665988 0.811939 
148.  C5orf15 chromosome 5 open reading frame 15 1.65814 1.63619 
149.  C5orf30 chromosome 5 open reading frame 30 0.465594 0.3944 
150.  C6orf141 chromosome 6 open reading frame 141 0.756503 0.897626 
151.  C7orf49 chromosome 7 open reading frame 49 0.651726 0.709833 
152.  C8orf33 chromosome 8 open reading frame 33 0.660074 0.695409 
153.  C9orf69 chromosome 9 open reading frame 69 0.476335 0.79721 
154.  CA13 carbonic anhydrase 13 1.36253 1.04568 
155.  CALM3 calmodulin 3 0.570431 0.485807 
156.  CAMTA1 calmodulin binding transcription activator 1 0.642045 0.662908 
157.  CAPN6 calpain 6 1.02668 1.12836 
158.  CAPZB capping actin protein of muscle Z-line beta subunit 0.666538 0.682933 
159.  CASP3 caspase 3 0.729553 0.745127 
160.  CASP7 caspase 7 1.81119 1.87049 
161.  CAT catalase 0.739667 0.642768 
162.  CBR1 carbonyl reductase 1 0.60378 0.707936 
163.  CBWD2 COBW domain containing 2 0.552169 0.479109 
164.  CBX1 chromobox 1 0.608134 0.536891 
165.  CBX2 chromobox 2 1.05339 1.05031 
166.  CBX6 chromobox 6 0.744626 0.895712 
167.  CBY1 "chibby family member 1, beta catenin antagonist" 1.33359 1.26603 
168.  CCDC117 coiled-coil domain containing 117 0.801064 0.602464 
169.  CCDC138 coiled-coil domain containing 138 1.54328 1.27542 
170.  CCDC28B coiled-coil domain containing 28B 2.65578 2.80182 
171.  CCDC43 coiled-coil domain containing 43 1.47159 1.5781 
172.  CCDC58 coiled-coil domain containing 58 0.382227 0.374341 
173.  CCDC59 coiled-coil domain containing 59 0.410004 0.482381 
174.  CCDC94 coiled-coil domain containing 94 0.459384 0.454246 
175.  CCNA2 cyclin A2 0.683344 0.672626 
176.  CCNB1IP1 cyclin B1 interacting protein 1 1.22499 1.20591 
177.  CCNE1 cyclin E1 0.708192 0.746412 
178.  CCNF cyclin F 0.4926 0.539965 
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179.  CCNG2 cyclin G2 0.662931 0.679027 
180.  CCNYL1 cyclin Y like 1 0.891729 0.683649 
181.  CCSAP "centriole, cilia and spindle associated protein" 1.0959 1.01218 
182.  CCT2 chaperonin containing TCP1 subunit 2 0.955846 0.94792 
183.  CCT4 chaperonin containing TCP1 subunit 4 0.507679 0.468577 
184.  CCT6P1 chaperonin containing TCP1 subunit 6 pseudogene 1 0.440193 0.479515 
185.  CCT7 chaperonin containing TCP1 subunit 7 0.61167 0.525603 
186.  CCT8 chaperonin containing TCP1 subunit 8 0.516095 0.456799 
187.  CD47 CD47 molecule 1.08686 1.07416 
188.  CD58 CD58 molecule 0.574278 0.608606 
189.  CD83 CD83 molecule 1.92141 1.74713 
190.  CDADC1 cytidine and dCMP deaminase domain containing 1 0.972441 1.19253 
191.  CDC123 cell division cycle 123 0.579892 0.537706 
192.  CDC23 cell division cycle 23 0.89469 0.898371 
193.  CDC37L1 cell division cycle 37 like 1 0.652822 0.581541 
194.  CDC42 cell division cycle 42 0.724433 0.737603 
195.  CDC45 cell division cycle 45 0.95113 0.941068 
196.  CDC6 cell division cycle 6 0.995412 1.05737 
197.  CDCA4 cell division cycle associated 4 0.679391 0.937433 
198.  CDCA7 cell division cycle associated 7 0.780818 0.700558 
199.  CDH10 cadherin 10 1.37135 1.077 
200.  CDIPT CDP-diacylglycerol--inositol 3-phosphatidyltransferase 0.50783 0.492623 
201.  CDK4 cyclin dependent kinase 4 0.466874 0.512105 
202.  CDK5RAP1 CDK5 regulatory subunit associated protein 1 0.421749 0.452614 
203.  CDKN2AIPNL CDKN2A interacting protein N-terminal like 0.749947 0.797643 
204.  CDPF1 cysteine rich DPF motif domain containing 1 0.989699 1.29684 
205.  CEBPA-AS1 CEBPA antisense RNA 1 (head to head) 0.653322 0.775162 
206.  CECR5 "cat eye syndrome chromosome region, candidate 5" 0.4713 0.614461 
207.  CENPBD1P1 CENPB DNA-binding domains containing 1 pseudogene 1 1.15072 1.34084 
208.  CENPK centromere protein K 1.76657 1.73323 
209.  CENPW centromere protein W 0.460512 0.594347 
210.  CEP78 centrosomal protein 78 0.579872 0.407027 
211.  CETN2 centrin 2 0.67484 0.556184 
212.  CFAP20 cilia and flagella associated protein 20 0.673339 0.71513 
213.  CGA "glycoprotein hormones, alpha polypeptide" 1.43795 2.15628 
214.  CGREF1 cell growth regulator with EF-hand domain 1 0.532261 0.530638 
215.  CHCHD1 coiled-coil-helix-coiled-coil-helix domain containing 1 0.506416 0.588876 
216.  CHCHD2 coiled-coil-helix-coiled-coil-helix domain containing 2 0.673485 0.788832 
217.  CHCHD4 coiled-coil-helix-coiled-coil-helix domain containing 4 0.454512 0.51827 
218.  CHD1L chromodomain helicase DNA binding protein 1 like 0.459906 0.425305 
219.  CHDH choline dehydrogenase 0.460734 0.362754 
220.  CHEK2 checkpoint kinase 2 0.827479 0.90164 
221.  CHGA chromogranin A 0.921886 0.924259 
222.  CHMP6 charged multivesicular body protein 6 0.715407 1.0806 
223.  CHRNA5 cholinergic receptor nicotinic alpha 5 subunit 0.704088 0.690746 
224.  CHSY1 chondroitin sulfate synthase 1 1.12941 0.935212 
225.  CIDECP cell death-inducing DFFA-like effector c pseudogene 1.01528 1.24263 
226.  CINP cyclin dependent kinase 2 interacting protein 0.658014 0.726846 
227.  CISD1 CDGSH iron sulfur domain 1 1.01027 1.0821 
228.  CITED2 
Cbp/p300 interacting transactivator with Glu/Asp rich 
carboxy-terminal domain 2 
0.558277 0.687849 
229.  CITED4 
Cbp/p300 interacting transactivator with Glu/Asp rich 
carboxy-terminal domain 4 
0.482466 0.696028 
230.  CKLF chemokine like factor 0.618983 0.705915 
231.  CKS1B CDC28 protein kinase regulatory subunit 1B 0.59821 0.662221 
232.  CLCN4 chloride voltage-gated channel 4 1.05748 0.823801 
233.  CLDN1 claudin 1 1.59109 2.35224 
234.  CLNS1A chloride nucleotide-sensitive channel 1A 0.581412 0.683439 
235.  CMAHP 
"cytidine monophospho-N-acetylneuraminic acid 
hydroxylase, pseudogene" 
0.825125 1.24412 
236.  CMC2 C-X9-C motif containing 2 0.595229 0.668355 
237.  CMSS1 cms1 ribosomal small subunit homolog (yeast) 1.11261 1.07853 
238.  CNBD2 cyclic nucleotide binding domain containing 2 0.837055 1.27329 
239.  CNBP CCHC-type zinc finger nucleic acid binding protein 0.47528 0.558615 
240.  CNIH1 cornichon family AMPA receptor auxiliary protein 1 0.527042 0.625035 
241.  CNOT8 CCR4-NOT transcription complex subunit 8 0.78093 0.812067 
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242.  COA1 cytochrome c oxidase assembly factor 1 homolog 0.866394 0.834569 
243.  COA3 cytochrome c oxidase assembly factor 3 0.454443 0.58493 
244.  COA4 cytochrome c oxidase assembly factor 4 homolog 0.567114 0.757669 
245.  COA7 cytochrome c oxidase assembly factor 7 (putative) 0.72858 0.930403 
246.  COL27A1 collagen type XXVII alpha 1 chain 1.67382 1.25171 
247.  COMMD2 COMM domain containing 2 1.81109 1.76506 
248.  COMMD7 COMM domain containing 7 1.39645 1.46911 
249.  COMMD9 COMM domain containing 9 1.13099 1.13093 
250.  COPS5 COP9 signalosome subunit 5 1.20623 1.24081 
251.  COPS9 COP9 signalosome subunit 9 1.02218 1.25621 
252.  COQ10A coenzyme Q10A 0.61573 0.786051 
253.  COQ2 "coenzyme Q2, polyprenyltransferase" 0.51358 0.591104 
254.  COQ3 "coenzyme Q3, methyltransferase" 0.454187 0.564536 
255.  COQ5 "coenzyme Q5, methyltransferase" 1.12072 1.17251 
256.  COTL1 coactosin like F-actin binding protein 1 0.904161 0.881233 
257.  COX14 "COX14, cytochrome c oxidase assembly factor" 0.697269 0.884169 
258.  COX5A cytochrome c oxidase subunit 5A 0.440628 0.503475 
259.  COX6C cytochrome c oxidase subunit 6C 0.473092 0.529371 
260.  COX7A2L cytochrome c oxidase subunit 7A2 like 0.583686 0.527884 
261.  COX7B cytochrome c oxidase subunit 7B 0.743747 0.832255 
262.  COX7C cytochrome c oxidase subunit 7C 0.420544 0.504002 
263.  CPNE7 copine 7 0.884544 0.900155 
264.  CRADD 
CASP2 and RIPK1 domain containing adaptor with death 
domain 
0.94901 1.09059 
265.  CREG1 cellular repressor of E1A stimulated genes 1 1.06377 1.04923 
266.  CRISPLD1 cysteine rich secretory protein LCCL domain containing 1 2.05979 2.05316 
267.  CRLS1 cardiolipin synthase 1 0.531102 0.667133 
268.  CRNDE 
colorectal neoplasia differentially expressed (non-protein 
coding) 
0.437687 0.476426 
269.  CSGALNACT2 chondroitin sulfate N-acetylgalactosaminyltransferase 2 1.09471 0.964817 
270.  CSPG5 chondroitin sulfate proteoglycan 5 1.77322 1.8202 
271.  CTDSPL CTD small phosphatase like 1.29415 1.31864 
272.  CTH cystathionine gamma-lyase 1.37027 1.01686 
273.  CTHRC1 collagen triple helix repeat containing 1 1.78111 1.52537 
274.  CTNNAL1 catenin alpha like 1 1.10965 1.06564 
275.  CTNNBIP1 catenin beta interacting protein 1 1.85451 1.90993 
276.  CTSV cathepsin V 0.653027 0.565642 
277.  CUEDC2 CUE domain containing 2 0.421961 0.40473 
278.  CUTC cutC copper transporter 1.76035 1.9119 
279.  CXADR coxsackie virus and adenovirus receptor 1.04079 0.942615 
280.  CXCL11 C-X-C motif chemokine ligand 11 2.02203 2.21208 
281.  CXCL12 C-X-C motif chemokine ligand 12 1.71022 1.52676 
282.  CYB561 cytochrome b561 0.490292 0.599664 
283.  CYB5A cytochrome b5 type A 0.776375 0.787099 
284.  CYCS "cytochrome c, somatic" 0.634708 0.683778 
285.  CYP2J2 cytochrome P450 family 2 subfamily J member 2 0.405508 0.386161 
286.  CYP4F22 cytochrome P450 family 4 subfamily F member 22 0.607833 0.711376 
287.  DAD1 defender against cell death 1 0.483024 0.423811 
288.  DANCR differentiation antagonizing non-protein coding RNA 1.67735 2.07894 
289.  DAP death associated protein 0.676437 0.692041 
290.  DAZAP2 DAZ associated protein 2 0.572756 0.569066 
291.  DBT dihydrolipoamide branched chain transacylase E2 1.19273 1.08744 
292.  DCAF12 DDB1 and CUL4 associated factor 12 0.792873 0.751584 
293.  DCAF5 DDB1 and CUL4 associated factor 5 0.49886 0.426772 
294.  DCPS "decapping enzyme, scavenger" 0.545144 0.580398 
295.  DCTPP1 dCTP pyrophosphatase 1 0.486552 0.575999 
296.  DCUN1D5 defective in cullin neddylation 1 domain containing 5 0.895144 0.894684 
297.  DCXR dicarbonyl and L-xylulose reductase 0.639569 0.72724 
298.  DDX1 DEAD/H-box helicase 1 0.493408 0.479488 
299.  DDX21 DEAD-box helicase 21 1.0968 1.03752 
300.  DDX47 DEAD-box helicase 47 0.765994 0.743859 
301.  DDX49 DEAD-box helicase 49 2.34706 2.59104 
302.  DEF6 "DEF6, guanine nucleotide exchange factor" 0.674619 0.787547 
303.  DEGS2 "delta 4-desaturase, sphingolipid 2" 1.16509 1.45397 
304.  DENR density regulated re-initiation and release factor 0.927438 0.880601 
305.  DEPDC1B DEP domain containing 1B 0.948026 0.751444 
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306.  DERA deoxyribose-phosphate aldolase 0.991452 0.967232 
307.  DFFA DNA fragmentation factor subunit alpha 0.675709 0.602846 
308.  DHODH dihydroorotate dehydrogenase (quinone) 0.584332 0.561185 
309.  DHRS13 dehydrogenase/reductase 13 1.78083 1.83441 
310.  DHRS7B dehydrogenase/reductase 7B 0.519399 0.643293 
311.  DLD dihydrolipoamide dehydrogenase 0.797122 0.750107 
312.  DLEU1 deleted in lymphocytic leukemia 1 1.11632 0.816194 
313.  DNAAF2 dynein axonemal assembly factor 2 0.627346 0.76001 
314.  DNAH14 dynein axonemal heavy chain 14 0.576577 0.597049 
315.  DNAJA1 DnaJ heat shock protein family (Hsp40) member A1 0.475614 0.472945 
316.  DNAJB11 DnaJ heat shock protein family (Hsp40) member B11 0.904611 0.930958 
317.  DNAJC1 DnaJ heat shock protein family (Hsp40) member C1 0.628416 0.707132 
318.  DNAJC19 DnaJ heat shock protein family (Hsp40) member C19 0.487561 0.535434 
319.  DNMT3B DNA methyltransferase 3 beta 1.75426 1.6786 
320.  DNPH1 2'-deoxynucleoside 5'-phosphate N-hydrolase 1 0.415004 0.808615 
321.  DPCD deleted in primary ciliary dyskinesia homolog (mouse) 0.96135 0.905369 
322.  DPH2 DPH2 homolog 0.873147 0.947896 
323.  DPY30 
dpy-30, histone methyltransferase complex regulatory 
subunit 
0.745031 0.681298 
324.  DSCAM-AS1 DSCAM antisense RNA 1 1.79876 1.65099 
325.  DSCC1 DNA replication and sister chromatid cohesion 1 1.65166 1.54324 
326.  DSCR8 Down syndrome critical region 8 1.86764 1.26283 
327.  DTD1 D-tyrosyl-tRNA deacylase 1 0.439774 0.362775 
328.  DTWD1 DTW domain containing 1 0.501435 0.424841 
329.  DTWD2 DTW domain containing 2 0.732857 0.575587 
330.  DTX4 deltex E3 ubiquitin ligase 4 1.46128 0.89692 
331.  DTYMK deoxythymidylate kinase 0.550339 0.636515 
332.  DUSP2 dual specificity phosphatase 2 0.861033 1.02365 
333.  DUSP4 dual specificity phosphatase 4 2.05306 1.92245 
334.  DUSP5 dual specificity phosphatase 5 1.16304 0.974547 
335.  DYM dymeclin 1.72405 1.65591 
336.  DYNLL1 dynein light chain LC8-type 1 0.629238 0.640647 
337.  DYRK2 dual specificity tyrosine phosphorylation regulated kinase 2 0.937423 0.706077 
338.  EAPP E2F associated phosphoprotein 0.426617 0.475068 
339.  EBAG9 "estrogen receptor binding site associated, antigen, 9" 0.596474 0.638776 
340.  EBNA1BP2 EBNA1 binding protein 2 0.637167 0.63253 
341.  EBP emopamil binding protein (sterol isomerase) 0.72739 0.726358 
342.  EBPL emopamil binding protein like 0.759841 0.707649 
343.  ECHS1 "enoyl-CoA hydratase, short chain 1" 0.423954 0.434189 
344.  EDF1 endothelial differentiation related factor 1 0.499046 0.698612 
345.  EDRF1 erythroid differentiation regulatory factor 1 0.87891 0.947828 
346.  EEF1A1P9 
eukaryotic translation elongation factor 1 alpha1 pseudogene 
9 
0.580221 0.572346 
347.  EEF1AKMT1 
eukaryotic translation elongation factor 1 alpha lysine 
methyltransferase 1 
0.694379 0.670003 
348.  EEF1B2 eukaryotic translation elongation factor 1 beta 2 0.68232 0.665074 
349.  EEF1G eukaryotic translation elongation factor 1 gamma 0.50351 0.394335 
350.  EFNB3 ephrin B3 0.713137 0.530624 
351.  EGR3 early growth response 3 2.35585 2.26571 
352.  EHF ETS homologous factor 0.793912 0.539603 
353.  EI24 "EI24, autophagy associated transmembrane protein" 1.58026 1.59393 
354.  EID1 EP300 interacting inhibitor of differentiation 1 1.13643 1.31191 
355.  EID2 EP300 interacting inhibitor of differentiation 2 1.02888 1.32895 
356.  EID2B EP300 interacting inhibitor of differentiation 2B 0.663137 1.24476 
357.  EIF2B1 eukaryotic translation initiation factor 2B subunit alpha 0.842259 0.955928 
358.  EIF2B2 eukaryotic translation initiation factor 2B subunit beta 0.438912 0.472013 
359.  EIF2B3 eukaryotic translation initiation factor 2B subunit gamma 0.854297 0.912875 
360.  EIF2D eukaryotic translation initiation factor 2D 0.89687 0.852116 
361.  EIF2S2 eukaryotic translation initiation factor 2 subunit beta 0.929427 0.970642 
362.  EIF3E eukaryotic translation initiation factor 3 subunit E 0.693977 0.627349 
363.  EIF3I eukaryotic translation initiation factor 3 subunit I 0.502812 0.370749 
364.  EIF3J eukaryotic translation initiation factor 3 subunit J 0.920679 0.788568 
365.  EIF4A1 eukaryotic translation initiation factor 4A1 0.506091 0.467426 
366.  EIF4A3 eukaryotic translation initiation factor 4A3 0.444924 0.555671 
367.  EIF4E2 eukaryotic translation initiation factor 4E family member 2 1.81313 1.83072 
368.  EIF5A eukaryotic translation initiation factor 5A 0.682438 0.762379 
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369.  EIF5AL1 eukaryotic translation initiation factor 5A-like 1 0.937528 0.856409 
370.  EIF6 eukaryotic translation initiation factor 6 0.77994 0.930112 
371.  ELK1 "ELK1, ETS transcription factor" 0.774281 0.883002 
372.  ELOVL2 ELOVL fatty acid elongase 2 0.649693 0.519209 
373.  ELOVL5 ELOVL fatty acid elongase 5 0.835545 0.688405 
374.  ELP2 elongator acetyltransferase complex subunit 2 0.751258 0.807974 
375.  ELP4 elongator acetyltransferase complex subunit 4 0.670908 0.728065 
376.  ELP6 elongator acetyltransferase complex subunit 6 0.412246 0.534597 
377.  EMC4 ER membrane protein complex subunit 4 0.519872 0.416206 
378.  EMID1 EMI domain containing 1 0.485272 0.647797 
379.  ENHO energy homeostasis associated 1.61978 1.62355 
380.  ENOPH1 enolase-phosphatase 1 0.606649 0.586319 
381.  ENSA endosulfine alpha 0.669224 0.617762 
382.  ENTPD3-AS1 ENTPD3 antisense RNA 1 0.509316 0.639276 
383.  ERAL1 Era like 12S mitochondrial rRNA chaperone 1 0.638027 0.704868 
384.  ERCC2 
"ERCC excision repair 2, TFIIH core complex helicase 
subunit" 
0.760713 0.555621 
385.  ERGIC3 ERGIC and golgi 3 0.703577 0.774335 
386.  ERH enhancer of rudimentary homolog (Drosophila) 0.573351 0.58719 
387.  ERP27 endoplasmic reticulum protein 27 1.63098 2.08328 
388.  ERRFI1 ERBB receptor feedback inhibitor 1 0.525362 0.709608 
389.  ESD esterase D 0.528035 0.538701 
390.  ETFA electron transfer flavoprotein alpha subunit 0.591116 0.527411 
391.  ETFDH electron transfer flavoprotein dehydrogenase 1.6454 1.51574 
392.  ETNK2 ethanolamine kinase 2 1.11182 1.05306 
393.  ETV4 ETS variant 4 2.98963 2.98716 
394.  ETV5 ETS variant 5 1.71214 2.63838 
395.  EXO1 exonuclease 1 0.586883 0.616257 
396.  EXOC3-AS1 EXOC3 antisense RNA 1 0.65992 0.935699 
397.  EXOSC2 exosome component 2 0.584958 0.614102 
398.  EXOSC4 exosome component 4 0.624955 1.19043 
399.  EXTL2 exostosin like glycosyltransferase 2 0.709238 0.541277 
400.  FAAP100 Fanconi anemia core complex associated protein 100 0.924334 1.1769 
401.  FABP5 fatty acid binding protein 5 0.582434 0.764601 
402.  FAH fumarylacetoacetate hydrolase 0.553601 0.478695 
403.  FAHD1 fumarylacetoacetate hydrolase domain containing 1 0.636851 0.901924 
404.  FAHD2CP 
"fumarylacetoacetate hydrolase domain containing 2C, 
pseudogene" 
0.698245 0.689497 
405.  FAM104B family with sequence similarity 104 member B 0.817937 0.900684 
406.  FAM109A family with sequence similarity 109 member A 0.510703 0.628693 
407.  FAM117B family with sequence similarity 117 member B 0.800434 0.544344 
408.  FAM129B family with sequence similarity 129 member B 0.567133 0.628176 
409.  FAM136A family with sequence similarity 136 member A 1.77743 1.89115 
410.  FAM136BP 
"family with sequence similarity 136 member B, 
pseudogene" 
1.19572 0.919494 
411.  FAM162A family with sequence similarity 162 member A 0.512759 0.651472 
412.  FAM168B family with sequence similarity 168 member B 0.732542 0.642111 
413.  FAM210B family with sequence similarity 210 member B 0.494677 0.455537 
414.  FAM234A family with sequence similarity 234 member A 1.20283 1.24764 
415.  FAM26F family with sequence similarity 26 member F 0.969095 1.12822 
416.  FAM32A family with sequence similarity 32 member A 0.887943 0.919503 
417.  FAM57A family with sequence similarity 57 member A 1.08004 1.04424 
418.  FAM64A family with sequence similarity 64 member A 0.685687 0.797623 
419.  FAM84B family with sequence similarity 84 member B 0.978182 0.9469 
420.  FANCE Fanconi anemia complementation group E 0.788509 0.896597 
421.  FARS2 "phenylalanyl-tRNA synthetase 2, mitochondrial" 0.604479 0.630769 
422.  FARSB phenylalanyl-tRNA synthetase beta subunit 0.589758 0.56169 
423.  FBXO45 F-box protein 45 1.04396 1.00334 
424.  FBXW9 F-box and WD repeat domain containing 9 1.83408 2.26133 
425.  FCMR Fc fragment of IgM receptor 0.62598 0.67407 
426.  FDFT1 farnesyl-diphosphate farnesyltransferase 1 0.83121 0.616238 
427.  FERMT2 fermitin family member 2 0.511322 0.456936 
428.  FGFBP2 fibroblast growth factor binding protein 2 2.90166 2.19779 
429.  FGFBP3 fibroblast growth factor binding protein 3 1.23721 1.87457 
430.  FGFR2 fibroblast growth factor receptor 2 0.947844 0.935403 
431.  FH fumarate hydratase 0.517003 0.568854 
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432.  FIBP FGF1 intracellular binding protein 0.762325 0.744858 
433.  FIS1 "fission, mitochondrial 1" 0.477 0.64285 
434.  FJX1 four jointed box 1 0.673003 0.786922 
435.  FKBP3 FK506 binding protein 3 0.598451 0.547113 
436.  FKBPL FK506 binding protein like 0.676845 0.921371 
437.  FLT4 fms related tyrosine kinase 4 0.967415 1.2875 
438.  FMNL2 formin like 2 0.941409 0.829786 
439.  FRAT2 frequently rearranged in advanced T-cell lymphomas 2 1.26584 1.50653 
440.  FSCN1 fascin actin-bundling protein 1 0.883641 0.88007 
441.  FTO fat mass and obesity associated 0.807692 0.719746 
442.  FUNDC2 FUN14 domain containing 2 0.465033 0.455508 
443.  FUOM fucose mutarotase 0.512164 0.843375 
444.  FYTTD1 forty-two-three domain containing 1 1.3472 1.19733 
445.  FZD6 frizzled class receptor 6 0.513988 0.416162 
446.  FZD9 frizzled class receptor 9 0.881945 1.14293 
447.  GABPB1 GA binding protein transcription factor beta subunit 1 0.78914 0.806187 
448.  GALNT14 polypeptide N-acetylgalactosaminyltransferase 14 0.608762 0.488799 
449.  GAR1 GAR1 ribonucleoprotein 0.712978 0.750716 
450.  GATA4 GATA binding protein 4 0.816668 0.487858 
451.  GBX2 gastrulation brain homeobox 2 0.911229 0.883168 
452.  GCAT glycine C-acetyltransferase 0.816279 0.888683 
453.  GCDH glutaryl-CoA dehydrogenase 0.848594 0.735966 
454.  GDF1 growth differentiation factor 1 0.939212 0.785672 
455.  GEMIN2 gem nuclear organelle associated protein 2 2.09195 2.368 
456.  GEMIN6 gem nuclear organelle associated protein 6 0.527315 0.549781 
457.  GFOD1 glucose-fructose oxidoreductase domain containing 1 0.655897 0.677425 
458.  GGACT gamma-glutamylamine cyclotransferase 0.730741 1.16279 
459.  GGCT gamma-glutamylcyclotransferase 2.08826 2.14783 
460.  GGCX gamma-glutamyl carboxylase 0.84325 0.896333 
461.  GGH gamma-glutamyl hydrolase 0.863208 0.719927 
462.  GID8 GID complex subunit 8 homolog 0.555707 0.617716 
463.  GINS1 GINS complex subunit 1 0.825391 0.768927 
464.  GINS2 GINS complex subunit 2 1.68133 1.7959 
465.  GJA1 gap junction protein alpha 1 4.11427 3.86025 
466.  GLO1 glyoxalase I 0.596599 0.510487 
467.  GLP1R glucagon like peptide 1 receptor 0.964153 0.86756 
468.  GLRX2 glutaredoxin 2 0.493896 0.530772 
469.  GLRX3 glutaredoxin 3 0.917546 1.0863 
470.  GLRX5 glutaredoxin 5 0.741695 0.736694 
471.  GLUD2 glutamate dehydrogenase 2 0.54971 0.439276 
472.  GMDS "GDP-mannose 4,6-dehydratase" 0.567183 0.508126 
473.  GNA12 G protein subunit alpha 12 0.878071 0.730274 
474.  GNAI1 G protein subunit alpha i1 0.590945 0.485692 
475.  GNG10 G protein subunit gamma 10 0.677874 0.564374 
476.  GNG12 G protein subunit gamma 12 0.792578 0.595368 
477.  GOLGA7 golgin A7 1.14222 0.971833 
478.  GPC5 glypican 5 0.529826 0.4271 
479.  GPR143 G protein-coupled receptor 143 0.864325 1.13005 
480.  GPR176 G protein-coupled receptor 176 0.911931 1.19186 
481.  GPR37 G protein-coupled receptor 37 1.6004 1.4605 
482.  GPT2 glutamic--pyruvic transaminase 2 1.20088 1.06805 
483.  GRHPR glyoxylate and hydroxypyruvate reductase 0.445495 0.490305 
484.  GRK6 G protein-coupled receptor kinase 6 0.718213 0.990066 
485.  GRPR gastrin releasing peptide receptor 2.54854 2.69536 
486.  GSG1L GSG1 like 3.08116 2.83152 
487.  GSTA4 glutathione S-transferase alpha 4 1.77556 2.01732 
488.  GSTO1 glutathione S-transferase omega 1 0.382099 0.419248 
489.  GSTO2 glutathione S-transferase omega 2 0.4087 0.479226 
490.  GTF2F2 general transcription factor IIF subunit 2 0.413409 0.496262 
491.  GTF2H5 general transcription factor IIH subunit 5 0.482877 0.661587 
492.  GTF3A general transcription factor IIIA 0.639956 0.603777 
493.  GTF3C4 general transcription factor IIIC subunit 4 0.760099 0.704617 
494.  GUCY1A2 guanylate cyclase 1 soluble subunit alpha 2 0.645431 0.613243 
495.  H2AFJ H2A histone family member J 0.688296 1.08134 
496.  H2AFY H2A histone family member Y 1.35164 1.31266 
497.  H2AFY2 H2A histone family member Y2 0.758477 0.819214 
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498.  H3F3A H3 histone family member 3A 0.858372 1.01209 
499.  H3F3AP4 "H3 histone, family 3A, pseudogene 4" 0.994267 0.877585 
500.  HACD1 3-hydroxyacyl-CoA dehydratase 1 1.31717 1.5829 
501.  HACL1 2-hydroxyacyl-CoA lyase 1 1.08995 1.17999 
502.  HAT1 histone acetyltransferase 1 0.915354 0.875117 
503.  HAUS4 HAUS augmin like complex subunit 4 0.81204 0.852708 
504.  HDDC2 HD domain containing 2 0.704719 0.628219 
505.  HENMT1 HEN1 methyltransferase homolog 1 1.27558 1.38603 
506.  HERC3 
HECT and RLD domain containing E3 ubiquitin protein 
ligase 3 
0.458215 0.557969 
507.  HGD "homogentisate 1,2-dioxygenase" 1.31709 0.994539 
508.  HIBCH 3-hydroxyisobutyryl-CoA hydrolase 0.842222 0.631806 
509.  HIKESHI "Hikeshi, heat shock protein nuclear import factor" 0.467457 0.541752 
510.  HINT1 histidine triad nucleotide binding protein 1 0.531404 0.618637 
511.  HINT3 histidine triad nucleotide binding protein 3 0.862346 0.844222 
512.  HIST1H2AC histone cluster 1 H2A family member c 1.2603 1.30951 
513.  HIST2H2BE histone cluster 2 H2B family member e 1.19281 1.28682 
514.  HIVEP3 
human immunodeficiency virus type I enhancer binding 
protein 3 
1.71264 1.48377 
515.  HLA-A "major histocompatibility complex, class I, A" 0.642678 0.723941 
516.  HMBS hydroxymethylbilane synthase 0.562652 0.666744 
517.  HMGB1 high mobility group box 1 0.862235 0.760277 
518.  HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 0.995823 0.765179 
519.  HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2 1.89403 0.988791 
520.  HMGN1 high mobility group nucleosome binding domain 1 0.671758 0.650796 
521.  HMGN2 high mobility group nucleosomal binding domain 2 0.431841 0.559308 
522.  HMGN3 high mobility group nucleosomal binding domain 3 1.75435 1.77512 
523.  HMOX2 heme oxygenase 2 0.981092 1.10676 
524.  HNRNPC heterogeneous nuclear ribonucleoprotein C (C1/C2) 0.47602 0.42311 
525.  HNRNPDL heterogeneous nuclear ribonucleoprotein D like 0.624528 0.737366 
526.  HOMER2 homer scaffolding protein 2 1.61365 1.51969 
527.  HOPX HOP homeobox 1.87771 1.27803 
528.  HOXB3 homeobox B3 0.917468 0.808306 
529.  HOXB6 homeobox B6 1.8322 2.04239 
530.  HOXB-AS3 HOXB cluster antisense RNA 3 2.07946 1.9725 
531.  HPDL 4-hydroxyphenylpyruvate dioxygenase like 0.801218 1.19059 
532.  HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) 2.94784 2.59741 
533.  HSBP1 heat shock factor binding protein 1 0.545827 0.597753 
534.  HSD17B10 hydroxysteroid 17-beta dehydrogenase 10 0.404017 0.437113 
535.  HSD17B8 hydroxysteroid 17-beta dehydrogenase 8 1.0486 1.21188 
536.  HSP90B1 heat shock protein 90 beta family member 1 0.780005 0.61235 
537.  HSPA5 heat shock protein family A (Hsp70) member 5 0.461655 0.437272 
538.  HSPB11 heat shock protein family B (small) member 11 0.468481 0.371903 
539.  ID4 "inhibitor of DNA binding 4, HLH protein" 1.1042 1.28042 
540.  IDH2 "isocitrate dehydrogenase (NADP(+)) 2, mitochondrial" 0.358842 0.464326 
541.  IDI1 isopentenyl-diphosphate delta isomerase 1 0.710248 0.57221 
542.  IFI27L1 interferon alpha inducible protein 27 like 1 0.498304 0.623056 
543.  IFI30 "IFI30, lysosomal thiol reductase" 1.18563 1.69327 
544.  IFI44 interferon induced protein 44 1.07807 1.79376 
545.  IFI44L interferon induced protein 44 like 0.595391 1.33428 
546.  IFI6 interferon alpha inducible protein 6 0.854428 1.67039 
547.  IFIT1 interferon induced protein with tetratricopeptide repeats 1 0.683847 1.46504 
548.  IFITM1 interferon induced transmembrane protein 1 0.866949 1.27411 
549.  IFRD2 interferon related developmental regulator 2 0.559552 0.745983 
550.  IFT22 intraflagellar transport 22 0.595712 0.628508 
551.  IFT57 intraflagellar transport 57 0.619088 0.594426 
552.  IL10RB interleukin 10 receptor subunit beta 1.09275 1.10894 
553.  IL17RB interleukin 17 receptor B 0.884077 0.736462 
554.  IL19 interleukin 19 3.06232 2.39884 
555.  IL20 interleukin 20 1.37049 1.13747 
556.  IL23R interleukin 23 receptor 0.901047 0.643077 
557.  IL24 interleukin 24 2.76179 2.61736 
558.  ILF2 interleukin enhancer binding factor 2 0.778354 0.768432 
559.  ILF3-AS1 ILF3 antisense RNA 1 (head to head) 0.605486 0.965656 
560.  IMP3 "IMP3, U3 small nucleolar ribonucleoprotein" 1.2763 1.63331 
561.  IMPA2 inositol monophosphatase 2 0.564067 0.582915 
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562.  IMPDH2 inosine monophosphate dehydrogenase 2 0.480604 0.573689 
563.  ING4 inhibitor of growth family member 4 1.19538 1.21837 
564.  INPP4B inositol polyphosphate-4-phosphatase type II B 1.41143 1.08739 
565.  INPP5A inositol polyphosphate-5-phosphatase A 0.67894 0.574134 
566.  INSIG1 insulin induced gene 1 1.83312 1.73253 
567.  IQCJ-SCHIP1 IQCJ-SCHIP1 readthrough 1.07634 0.824338 
568.  IRX3 iroquois homeobox 3 0.704955 0.768635 
569.  ISCA1 iron-sulfur cluster assembly 1 0.603147 0.595407 
570.  ISG20L2 interferon stimulated exonuclease gene 20 like 2 0.800567 0.759151 
571.  ISOC2 isochorismatase domain containing 2 0.578063 0.943153 
572.  ITM2B integral membrane protein 2B 0.455403 0.385767 
573.  IVNS1ABP influenza virus NS1A binding protein 0.500592 0.379788 
574.  JAGN1 jagunal homolog 1 0.901859 1.05076 
575.  JHDM1D-AS1 JHDM1D antisense RNA 1 (head to head) 1.91105 2.28899 
576.  JPH2 junctophilin 2 1.83951 1.59197 
577.  JPX "JPX transcript, XIST activator (non-protein coding)" 0.797853 0.917472 
578.  KANSL2 KAT8 regulatory NSL complex subunit 2 0.647085 0.758256 
579.  KATNA1 katanin catalytic subunit A1 0.442418 0.585361 
580.  KBTBD7 kelch repeat and BTB domain containing 7 0.400185 0.420395 
581.  KCNAB1 
potassium voltage-gated channel subfamily A member 
regulatory beta subunit 1 
2.691 1.84939 
582.  KCNK2 potassium two pore domain channel subfamily K member 2 1.34367 0.902705 
583.  KCNK5 potassium two pore domain channel subfamily K member 5 0.424791 0.385622 
584.  KCNMA1 potassium calcium-activated channel subfamily M alpha 1 1.55427 1.35738 
585.  KCTD20 potassium channel tetramerization domain containing 20 0.59754 0.434534 
586.  KCTD3 potassium channel tetramerization domain containing 3 0.882766 0.829573 
587.  KCTD5 potassium channel tetramerization domain containing 5 0.425124 0.492212 
588.  KCTD9 potassium channel tetramerization domain containing 9 0.999242 0.863835 
589.  KDM7A lysine demethylase 7A 1.0876 0.962187 
590.  KIAA0101 KIAA0101 1.25341 1.39906 
591.  KIAA1586 KIAA1586 0.802731 0.769537 
592.  KIAA2013 KIAA2013 0.458529 0.66025 
593.  KIF6 kinesin family member 6 0.904727 0.902278 
594.  KMT5C lysine methyltransferase 5C 0.564812 0.649637 
595.  KNOP1 lysine rich nucleolar protein 1 0.996013 0.893312 
596.  KRT16 keratin 16 1.41614 1.42172 
597.  KRT2 keratin 2 1.2364 1.21345 
598.  KRT6C keratin 6C 1.27008 1.92117 
599.  L3MBTL2 L3MBTL2 polycomb repressive complex 1 subunit 0.91279 0.965081 
600.  LAGE3 L antigen family member 3 0.51342 0.72033 
601.  LAMTOR3 
"late endosomal/lysosomal adaptor, MAPK and MTOR 
activator 3" 
0.519875 0.638155 
602.  LANCL1 LanC like 1 0.596777 0.482519 
603.  LAP3 leucine aminopeptidase 3 0.654389 0.76435 
604.  LAPTM4B lysosomal protein transmembrane 4 beta 1.26545 1.18734 
605.  LAS1L "LAS1 like, ribosome biogenesis factor" 0.473209 0.451075 
606.  LDLRAP1 low density lipoprotein receptor adaptor protein 1 0.541318 0.537152 
607.  LDOC1 leucine zipper down-regulated in cancer 1 0.909283 0.882885 
608.  LDOC1L leucine zipper down-regulated in cancer 1 like 1.00147 0.970258 
609.  LEMD2 LEM domain containing 2 0.483313 0.472819 
610.  LGI2 leucine rich repeat LGI family member 2 2.18862 2.00029 
611.  LGMN legumain 0.997135 0.849279 
612.  LIMA1 LIM domain and actin binding 1 0.590325 0.584341 
613.  LINC00152 long intergenic non-protein coding RNA 152 0.642621 0.845507 
614.  LINC00205 long intergenic non-protein coding RNA 205 0.510607 0.541599 
615.  LINC00473 long intergenic non-protein coding RNA 473 4.3032 5.28493 
616.  LINC00493 long intergenic non-protein coding RNA 493 0.794676 0.993629 
617.  LINC00998 long intergenic non-protein coding RNA 998 0.915797 0.942618 
618.  LINC01550 long intergenic non-protein coding RNA 1550 1.32543 1.57637 
619.  LINC01560 long intergenic non-protein coding RNA 1560 0.9892 1.12458 
620.  LMNB1 lamin B1 0.627999 0.630477 
621.  LMO4 LIM domain only 4 1.21488 1.10918 
622.  LOC100288748 uncharacterized LOC100288748 0.514374 0.824425 
623.  LOC728554 THO complex 3 pseudogene 0.691449 0.649272 
624.  LOC93622 Morf4 family associated protein 1 like 1 pseudogene 0.617748 0.775301 
625.  LRRC10B leucine rich repeat containing 10B 1.33852 1.43715 
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626.  LRRC58 leucine rich repeat containing 58 0.529406 0.357706 
627.  LRRC69 leucine rich repeat containing 69 0.555951 0.606239 
628.  LRRC75A leucine rich repeat containing 75A 0.828751 0.822573 
629.  LRRC75A-AS1 LRRC75A antisense RNA 1 0.730571 0.859008 
630.  LRRN1 leucine rich repeat neuronal 1 1.58509 1.41155 
631.  LSM10 "LSM10, U7 small nuclear RNA associated" 0.568817 0.730227 
632.  LSM11 "LSM11, U7 small nuclear RNA associated" 0.573773 0.53311 
633.  LSM2 
"LSM2 homolog, U6 small nuclear RNA and mRNA 
degradation associated" 
0.576788 0.679191 
634.  LSM5 
"LSM5 homolog, U6 small nuclear RNA and mRNA 
degradation associated" 
0.556302 0.584585 
635.  LSM7 
"LSM7 homolog, U6 small nuclear RNA and mRNA 
degradation associated" 
0.610844 0.982496 
636.  LUC7L LUC7 like 0.729032 0.973398 
637.  LUC7L2 "LUC7 like 2, pre-mRNA splicing factor" 0.803454 0.757396 
638.  LXN latexin 0.957785 0.959065 
639.  LYAR Ly1 antibody reactive 0.775255 0.806391 
640.  LYRM4 LYR motif containing 4 0.816561 0.847357 
641.  LYSMD2 LysM domain containing 2 0.879903 1.02031 
642.  LZIC leucine zipper and CTNNBIP1 domain containing 1.51983 1.32526 
643.  LZTFL1 leucine zipper transcription factor like 1 0.597137 0.686555 
644.  MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) 0.684397 0.683566 
645.  MAFB MAF bZIP transcription factor B 1.68057 1.74892 
646.  MAFG-AS1 MAFG antisense RNA 1 (head to head) 0.488091 0.758365 
647.  MAGEF1 MAGE family member F1 0.775277 1.0272 
648.  MAGEH1 MAGE family member H1 1.16952 1.36045 
649.  MAK16 MAK16 homolog 0.777235 0.79678 
650.  MAML3 mastermind like transcriptional coactivator 3 1.17245 0.753546 
651.  MANEAL mannosidase endo-alpha like 1.09 1.09727 
652.  MANF mesencephalic astrocyte derived neurotrophic factor 0.454652 0.481426 
653.  MAP3K8 mitogen-activated protein kinase kinase kinase 8 0.80049 1.05051 
654.  MAP6D1 MAP6 domain containing 1 1.64809 1.45758 
655.  MAPK14 mitogen-activated protein kinase 14 0.578104 0.456541 
656.  MAPK6 mitogen-activated protein kinase 6 0.93147 0.789119 
657.  MARC1 mitochondrial amidoxime reducing component 1 0.739496 0.634046 
658.  MARCKSL1 MARCKS like 1 1.18066 1.31506 
659.  MARK3 microtubule affinity regulating kinase 3 0.541086 0.708198 
660.  MARVELD1 MARVEL domain containing 1 0.787191 0.941691 
661.  MARVELD2 MARVEL domain containing 2 0.848956 0.83838 
662.  MAZ MYC associated zinc finger protein 1.56603 1.75118 
663.  MB21D2 Mab-21 domain containing 2 1.01576 1.17096 
664.  MBD4 "methyl-CpG binding domain 4, DNA glycosylase" 0.679262 0.740153 
665.  MBLAC2 metallo-beta-lactamase domain containing 2 0.798222 0.920713 
666.  MCAT malonyl-CoA-acyl carrier protein transacylase 0.383907 0.533893 
667.  MCCC1 methylcrotonoyl-CoA carboxylase 1 0.606684 0.691066 
668.  MCCC2 methylcrotonoyl-CoA carboxylase 2 0.928812 0.924177 
669.  MCEE methylmalonyl-CoA epimerase 0.841898 0.914268 
670.  MCL1 BCL2 family apoptosis regulator 0.514158 0.547684 
671.  MCM10 minichromosome maintenance 10 replication initiation factor 0.658391 0.655249 
672.  MCMBP minichromosome maintenance complex binding protein 0.539588 0.420955 
673.  MDH1 malate dehydrogenase 1 0.483648 0.507619 
674.  MECR mitochondrial trans-2-enoyl-CoA reductase 0.629844 0.756609 
675.  MED20 mediator complex subunit 20 0.783132 0.800067 
676.  MED28 mediator complex subunit 28 0.537528 0.58869 
677.  MEST mesoderm specific transcript 2.28148 2.02826 
678.  METTL21A methyltransferase like 21A 1.81833 1.57057 
679.  METTL8 methyltransferase like 8 0.803202 0.731764 
680.  METTL9 methyltransferase like 9 0.619183 0.505024 
681.  MFAP1 microfibrillar associated protein 1 0.40971 0.392112 
682.  MFAP2 microfibrillar associated protein 2 1.55689 1.53872 
683.  MFSD2A major facilitator superfamily domain containing 2A 1.167 0.806571 
684.  MGP matrix Gla protein 0.989572 0.94395 
685.  MINOS1 mitochondrial inner membrane organizing system 1 0.553804 0.786255 
686.  MIPEP mitochondrial intermediate peptidase 0.710182 0.782334 
687.  MIR4435-2HG MIR4435-2 host gene 0.680475 0.642404 
688.  MIR99AHG mir-99a-let-7c cluster host gene 0.706262 0.866057 
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689.  MIS18A MIS18 kinetochore protein A 0.390648 0.472706 
690.  MKKS McKusick-Kaufman syndrome 0.509373 0.481629 
691.  MLF1 myeloid leukemia factor 1 1.03219 0.903088 
692.  MLXIPL MLX interacting protein like 0.650685 0.897178 
693.  MMAA methylmalonic aciduria (cobalamin deficiency) cblA type 0.736563 1.01764 
694.  MMAB methylmalonic aciduria (cobalamin deficiency) cblB type 0.698355 0.816792 
695.  MMADHC "methylmalonic aciduria and homocystinuria, cblD type" 0.552518 0.585056 
696.  MMP15 matrix metallopeptidase 15 0.898084 0.856742 
697.  MMP16 matrix metallopeptidase 16 1.33017 0.960805 
698.  MNS1 meiosis specific nuclear structural 1 0.840035 0.758889 
699.  MNX1-AS1 MNX1 antisense RNA 1 (head to head) 0.688844 0.870034 
700.  MOAP1 modulator of apoptosis 1 0.358154 0.435341 
701.  MOCS2 molybdenum cofactor synthesis 2 1.286 1.24044 
702.  MORF4L2 mortality factor 4 like 2 1.31419 1.32475 
703.  MORN2 MORN repeat containing 2 1.01867 0.929174 
704.  MPC1 mitochondrial pyruvate carrier 1 0.595465 0.512531 
705.  MPLKIP M-phase specific PLK1 interacting protein 0.939126 1.25982 
706.  MPST mercaptopyruvate sulfurtransferase 0.954081 1.3583 
707.  MPV17 "MPV17, mitochondrial inner membrane protein" 0.799041 0.913382 
708.  MPV17L2 MPV17 mitochondrial inner membrane protein like 2 0.55069 0.580507 
709.  MPZL2 myelin protein zero like 2 0.733585 0.887167 
710.  MRFAP1L1 Morf4 family associated protein 1 like 1 0.361048 0.479952 
711.  MRPL1 mitochondrial ribosomal protein L1 0.613311 0.6288 
712.  MRPL11 mitochondrial ribosomal protein L11 0.561701 0.673595 
713.  MRPL12 mitochondrial ribosomal protein L12 0.508657 0.795649 
714.  MRPL13 mitochondrial ribosomal protein L13 0.515309 0.464846 
715.  MRPL14 mitochondrial ribosomal protein L14 1.09525 1.31287 
716.  MRPL16 mitochondrial ribosomal protein L16 0.6387 0.765245 
717.  MRPL17 mitochondrial ribosomal protein L17 0.790089 1.02674 
718.  MRPL21 mitochondrial ribosomal protein L21 0.620408 0.711494 
719.  MRPL22 mitochondrial ribosomal protein L22 0.41355 0.520083 
720.  MRPL24 mitochondrial ribosomal protein L24 0.506235 0.53577 
721.  MRPL27 mitochondrial ribosomal protein L27 0.756929 0.97082 
722.  MRPL3 mitochondrial ribosomal protein L3 0.752811 0.771381 
723.  MRPL33 mitochondrial ribosomal protein L33 0.747995 0.79456 
724.  MRPL36 mitochondrial ribosomal protein L36 0.541391 0.810266 
725.  MRPL37 mitochondrial ribosomal protein L37 0.844301 0.91952 
726.  MRPL42 mitochondrial ribosomal protein L42 0.558932 0.591286 
727.  MRPL50 mitochondrial ribosomal protein L50 0.727963 0.787498 
728.  MRPL57 mitochondrial ribosomal protein L57 0.811779 1.13103 
729.  MRPL58 mitochondrial ribosomal protein L58 0.589747 0.704769 
730.  MRPS15 mitochondrial ribosomal protein S15 0.589601 0.631072 
731.  MRPS23 mitochondrial ribosomal protein S23 0.403958 0.480255 
732.  MRPS24 mitochondrial ribosomal protein S24 0.555455 0.665775 
733.  MRPS26 mitochondrial ribosomal protein S26 0.590285 0.855188 
734.  MRPS33 mitochondrial ribosomal protein S33 0.401031 0.459406 
735.  MS4A15 membrane spanning 4-domains A15 1.42859 0.848195 
736.  MSANTD3 Myb/SANT DNA binding domain containing 3 1.03394 1.14267 
737.  MSH2 mutS homolog 2 0.453754 0.355227 
738.  MSL3P1 male-specific lethal 3 homolog (Drosophila) pseudogene 1 1.08888 1.21766 
739.  MT1X metallothionein 1X 0.426134 0.685788 
740.  MTCH2 mitochondrial carrier 2 0.643666 0.688932 
741.  MTERF3 mitochondrial transcription termination factor 3 0.452698 0.582238 
742.  MTF2 metal response element binding transcription factor 2 0.620632 0.58535 
743.  MTG1 mitochondrial ribosome associated GTPase 1 0.930824 1.10945 
744.  MTHFD2 
"methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 2, methenyltetrahydrofolate cyclohydrolase" 
0.67394 0.578727 
745.  MTHFD2L 
methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 2-like 
0.589263 0.741144 
746.  MTMR2 myotubularin related protein 2 0.910336 0.726056 
747.  MTRF1 mitochondrial translational release factor 1 0.447792 0.619521 
748.  MUCL1 mucin like 1 1.29882 0.915705 
749.  MUM1L1 MUM1 like 1 1.46894 1.51818 
750.  MYBL2 MYB proto-oncogene like 2 2.03609 2.14457 
751.  MYC v-myc avian myelocytomatosis viral oncogene homolog 0.888765 0.900107 
752.  MYCBP MYC binding protein 0.834701 0.780983 
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753.  MYL6 myosin light chain 6 0.876249 0.994649 
754.  MYO3B myosin IIIB 1.78755 1.71407 
755.  NAE1 NEDD8 activating enzyme E1 subunit 1 0.493453 0.473918 
756.  NANP N-acetylneuraminic acid phosphatase 0.857126 0.883009 
757.  NARS2 "asparaginyl-tRNA synthetase 2, mitochondrial (putative)" 0.792649 0.687521 
758.  NASP nuclear autoantigenic sperm protein 0.889616 0.865998 
759.  NAT1 N-acetyltransferase 1 0.828996 1.0541 
760.  NAT14 N-acetyltransferase 14 (putative) 0.436621 0.755597 
761.  NAXE NAD(P)HX epimerase 0.699496 0.682152 
762.  NCBP2-AS2 NCBP2 antisense RNA 2 (head to head) 0.585973 1.03664 
763.  NCR3LG1 natural killer cell cytotoxicity receptor 3 ligand 1 0.504336 0.427074 
764.  NDC1 NDC1 transmembrane nucleoporin 0.581386 0.415238 
765.  NDRG2 NDRG family member 2 1.06254 0.885938 
766.  NDUFA1 NADH:ubiquinone oxidoreductase subunit A1 0.481754 0.626363 
767.  NDUFA10 NADH:ubiquinone oxidoreductase subunit A10 0.587629 0.742002 
768.  NDUFA4 "NDUFA4, mitochondrial complex associated" 0.620783 0.591739 
769.  NDUFA9 NADH:ubiquinone oxidoreductase subunit A9 0.482408 0.51758 
770.  NDUFAB1 NADH:ubiquinone oxidoreductase subunit AB1 0.596311 0.692596 
771.  NDUFAF2 
NADH:ubiquinone oxidoreductase complex assembly factor 
2 
0.783876 0.745836 
772.  NDUFAF8 
NADH:ubiquinone oxidoreductase complex assembly factor 
8 
0.438455 0.719152 
773.  NDUFB1 NADH:ubiquinone oxidoreductase subunit B1 0.794603 0.958529 
774.  NDUFB6 NADH:ubiquinone oxidoreductase subunit B6 0.611903 0.800763 
775.  NDUFB9 NADH:ubiquinone oxidoreductase subunit B9 0.555857 0.618531 
776.  NDUFS4 NADH:ubiquinone oxidoreductase subunit S4 0.599484 0.649652 
777.  NDUFS5 NADH:ubiquinone oxidoreductase subunit S5 0.447218 0.58327 
778.  NEK6 NIMA related kinase 6 0.713992 0.544106 
779.  NENF neudesin neurotrophic factor 0.63689 0.689993 
780.  NFIA nuclear factor I A 1.93518 1.60973 
781.  NGRN "neugrin, neurite outgrowth associated" 0.449335 0.411608 
782.  NHP2 NHP2 ribonucleoprotein 0.656477 0.842416 
783.  NIFK nucleolar protein interacting with the FHA domain of MKI67 0.614676 0.649105 
784.  NIPSNAP3A nipsnap homolog 3A 1.98433 2.36503 
785.  NIPSNAP3B nipsnap homolog 3B 0.977539 0.816229 
786.  NKIRAS2 NFKB inhibitor interacting Ras like 2 1.79244 1.98048 
787.  NKRF NFKB repressing factor 0.562578 0.591047 
788.  NLE1 notchless homolog 1 0.739256 0.961983 
789.  NLRP1 NLR family pyrin domain containing 1 1.09248 1.19686 
790.  NLRX1 NLR family member X1 0.861659 0.784992 
791.  NMB neuromedin B 1.57817 1.63764 
792.  NME1 NME/NM23 nucleoside diphosphate kinase 1 0.856472 0.982628 
793.  NME1-NME2 NME1-NME2 readthrough 0.537902 0.568051 
794.  NMU neuromedin U 1.0744 0.667768 
795.  NOB1 NIN1/PSMD8 binding protein 1 homolog 0.454083 0.560442 
796.  NOC3L NOC3 like DNA replication regulator 0.463655 0.418221 
797.  NOL11 nucleolar protein 11 0.584325 0.564753 
798.  NOP10 NOP10 ribonucleoprotein 1.02759 1.12941 
799.  NOP56 NOP56 ribonucleoprotein 0.588583 0.625073 
800.  NOP58 NOP58 ribonucleoprotein 0.57573 0.474755 
801.  NPM3 nucleophosmin/nucleoplasmin 3 1.59262 1.6237 
802.  NPY1R neuropeptide Y receptor Y1 1.33529 1.13624 
803.  NQO2 NAD(P)H quinone dehydrogenase 2 0.893087 0.924738 
804.  NR5A2 nuclear receptor subfamily 5 group A member 2 1.21764 0.825542 
805.  NRBP1 nuclear receptor binding protein 1 0.590665 0.596604 
806.  NREP neuronal regeneration related protein 1.5593 1.33906 
807.  NRTN neurturin 1.42941 1.46177 
808.  NSL1 "NSL1, MIS12 kinetochore complex component" 0.575272 0.679574 
809.  NT5C3B "5'-nucleotidase, cytosolic IIIB" 0.390653 0.394116 
810.  NTMT1 N-terminal Xaa-Pro-Lys N-methyltransferase 1 0.366753 0.68196 
811.  NUDCD1 NudC domain containing 1 0.605891 0.538786 
812.  NUDT1 nudix hydrolase 1 0.488716 0.574153 
813.  NUDT16L1 nudix hydrolase 16 like 1 0.742033 1.02527 
814.  NUDT2 nudix hydrolase 2 0.587172 0.742747 
815.  NUP160 nucleoporin 160 1.02944 0.977176 
816.  NUP35 nucleoporin 35 0.649279 0.599748 
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817.  NUS1 NUS1 dehydrodolichyl diphosphate synthase subunit 0.588642 0.461185 
818.  NXN nucleoredoxin 0.717945 0.799884 
819.  NXPH3 neurexophilin 3 1.14279 1.13923 
820.  NXT1 nuclear transport factor 2 like export factor 1 0.594323 0.796174 
821.  OAF out at first homolog 0.614108 1.2268 
822.  OASL 2'-5'-oligoadenylate synthetase like 0.68925 1.43106 
823.  OAT ornithine aminotransferase 0.61619 0.435381 
824.  OBSL1 obscurin like 1 0.990759 1.04061 
825.  OIP5 Opa interacting protein 5 2.11953 2.39693 
826.  OIP5-AS1 OIP5 antisense RNA 1 1.90865 1.75325 
827.  OLFML3 olfactomedin like 3 2.60869 2.68797 
828.  ORC5 origin recognition complex subunit 5 0.451018 0.481556 
829.  ORC6 origin recognition complex subunit 6 0.500223 0.527708 
830.  OSGEP O-sialoglycoprotein endopeptidase 0.590015 0.706425 
831.  OSGEPL1 O-sialoglycoprotein endopeptidase like 1 0.946834 0.805438 
832.  OST4 "oligosaccharyltransferase complex subunit 4, non-catalytic" 0.446121 0.460205 
833.  OSTC oligosaccharyltransferase complex non-catalytic subunit 2.19415 2.35898 
834.  P2RY6 pyrimidinergic receptor P2Y6 1.07541 1.20488 
835.  P3H1 prolyl 3-hydroxylase 1 1.17836 0.882606 
836.  P3H4 prolyl 3-hydroxylase family member 4 (non-enzymatic) 1.43784 1.60295 
837.  PACRGL PARK2 coregulated like 0.71929 0.778749 
838.  PADI3 peptidyl arginine deiminase 3 1.29671 1.12462 
839.  PAICS phosphoribosylaminoimidazole carboxylase;  0.627836 0.480478 
840.  PAK1IP1 PAK1 interacting protein 1 0.562759 0.666736 
841.  PANK1 pantothenate kinase 1 0.797274 0.730937 
842.  PARG poly(ADP-ribose) glycohydrolase 0.88996 0.913123 
843.  PARK7 Parkinsonism associated deglycase 0.541766 0.515431 
844.  PARL presenilin associated rhomboid like 0.535057 0.586764 
845.  PARP12 poly(ADP-ribose) polymerase family member 12 0.41123 0.735736 
846.  PAX9 paired box 9 0.58445 0.662648 
847.  PBDC1 polysaccharide biosynthesis domain containing 1 0.702885 0.752183 
848.  PCCB propionyl-CoA carboxylase beta subunit 0.879864 0.830985 
849.  PCDHB5 protocadherin beta 5 1.21352 1.02547 
850.  PCDHB6 protocadherin beta 6 0.547292 0.578213 
851.  PCDHB8 protocadherin beta 8 1.12031 0.851423 
852.  PCGF6 polycomb group ring finger 6 0.935854 0.998118 
853.  PCIF1 PDX1 C-terminal inhibiting factor 1 0.398303 0.598229 
854.  PCNA proliferating cell nuclear antigen 0.420561 0.587194 
855.  PCOLCE2 procollagen C-endopeptidase enhancer 2 0.623997 0.976315 
856.  PCSK9 proprotein convertase subtilisin/kexin type 9 0.536665 0.556471 
857.  PCYOX1L prenylcysteine oxidase 1 like 1.0197 1.04292 
858.  PDCD2 programmed cell death 2 0.709717 0.75917 
859.  PDE1A phosphodiesterase 1A 1.68231 1.53396 
860.  PDE4B phosphodiesterase 4B 1.30251 1.10839 
861.  PDHB pyruvate dehydrogenase (lipoamide) beta 1.02254 0.966478 
862.  PDHX pyruvate dehydrogenase complex component X 1.11496 1.1193 
863.  PDIA2 protein disulfide isomerase family A member 2 0.84232 1.0513 
864.  PDIA4 protein disulfide isomerase family A member 4 0.832177 0.763579 
865.  PDIA6 protein disulfide isomerase family A member 6 0.540674 0.422012 
866.  PDLIM3 PDZ and LIM domain 3 1.21686 1.19913 
867.  PDRG1 p53 and DNA damage regulated 1 0.59653 0.79471 
868.  PDZK1 PDZ domain containing 1 2.32078 1.75265 
869.  PEBP1 phosphatidylethanolamine binding protein 1 0.5634 0.499523 
870.  PEG10 paternally expressed 10 2.10984 2.21207 
871.  PEX2 peroxisomal biogenesis factor 2 0.769444 0.809132 
872.  PEX5 peroxisomal biogenesis factor 5 0.622786 0.595623 
873.  PFDN5 prefoldin subunit 5 0.546246 0.491788 
874.  PGAM1 phosphoglycerate mutase 1 0.452985 0.512096 
875.  PGBD5 piggyBac transposable element derived 5 0.874885 1.03782 
876.  PGD phosphogluconate dehydrogenase 0.551699 0.534879 
877.  PGM1 phosphoglucomutase 1 0.901442 0.766433 
878.  PHB prohibitin 0.558869 0.571996 
879.  PHB2 prohibitin 2 0.658567 0.742473 
880.  PHF10 PHD finger protein 10 1.47714 1.42481 
881.  PHF13 PHD finger protein 13 0.548822 0.679934 
882.  PHLDA1 pleckstrin homology like domain family A member 1 0.52809 0.652852 
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883.  PHTF2 putative homeodomain transcription factor 2 0.995553 0.932872 
884.  PI15 peptidase inhibitor 15 1.38949 1.21943 
885.  PIGC phosphatidylinositol glycan anchor biosynthesis class C 0.41005 0.397585 
886.  PIGM phosphatidylinositol glycan anchor biosynthesis class M 0.537811 0.601687 
887.  PIGN phosphatidylinositol glycan anchor biosynthesis class N 1.27463 0.843688 
888.  PIGS phosphatidylinositol glycan anchor biosynthesis class S 1.71025 1.52542 
889.  PIK3C2G 
phosphatidylinositol-4-phosphate 3-kinase catalytic subunit 
type 2 gamma 
1.32998 1.10551 
890.  PINX1 "PIN2/TERF1 interacting, telomerase inhibitor 1" 0.563699 0.614464 
891.  PIP prolactin induced protein 1.58833 1.40631 
892.  PIR pirin 1.18405 1.09699 
893.  PITPNC1 "phosphatidylinositol transfer protein, cytoplasmic 1" 0.752945 0.698521 
894.  PKIB "protein kinase (cAMP-dependent, catalytic) inhibitor beta" 0.923158 0.820975 
895.  PLEK2 pleckstrin 2 0.612746 0.482887 
896.  PLEKHO1 pleckstrin homology domain containing O1 0.955779 0.986967 
897.  PLGRKT plasminogen receptor with a C-terminal lysine 1.03486 0.956894 
898.  PLK1 polo like kinase 1 0.502805 0.534145 
899.  PLK2 polo like kinase 2 2.01513 1.87612 
900.  PLP1 proteolipid protein 1 1.78971 2.78286 
901.  PLSCR1 phospholipid scramblase 1 0.400567 0.622252 
902.  PMF1 polyamine modulated factor 1 0.49455 0.668554 
903.  PMPCA "peptidase, mitochondrial processing alpha subunit" 0.741118 0.917951 
904.  PNMA1 paraneoplastic Ma antigen 1 0.569994 0.68552 
905.  PNP purine nucleoside phosphorylase 0.562185 0.634676 
906.  PNPT1 polyribonucleotide nucleotidyltransferase 1 0.771053 0.820103 
907.  POLB DNA polymerase beta 0.679722 0.900578 
908.  POLD2 "DNA polymerase delta 2, accessory subunit" 0.947729 0.850791 
909.  POLDIP2 DNA polymerase delta interacting protein 2 0.545445 0.547899 
910.  POLE3 "DNA polymerase epsilon 3, accessory subunit" 1.31072 1.50374 
911.  POLE4 "DNA polymerase epsilon 4, accessory subunit" 0.373808 0.576856 
912.  POLG2 "DNA polymerase gamma 2, accessory subunit" 0.496162 0.584555 
913.  POLR1D RNA polymerase I subunit D 1.21672 1.4292 
914.  POLR1E RNA polymerase I subunit E 0.416051 0.360962 
915.  POLR2G RNA polymerase II subunit G 1.0195 1.11076 
916.  POLR2K RNA polymerase II subunit K 0.36188 0.359019 
917.  POLR3D RNA polymerase III subunit D 0.922376 1.05985 
918.  POLR3G RNA polymerase III subunit G 0.810646 1.02777 
919.  POLR3K RNA polymerase III subunit K 0.601195 0.724844 
920.  POMP proteasome maturation protein 0.398388 0.424103 
921.  POP5 "POP5 homolog, ribonuclease P/MRP subunit" 0.785138 1.02197 
922.  POPDC3 popeye domain containing 3 0.787233 1.0069 
923.  POU1F1 POU class 1 homeobox 1 1.10366 1.22851 
924.  POU3F2 POU class 3 homeobox 2 1.23518 1.18252 
925.  PPA1 pyrophosphatase (inorganic) 1 0.889133 0.91749 
926.  PPA2 pyrophosphatase (inorganic) 2 0.417186 0.475001 
927.  PPIA peptidylprolyl isomerase A 0.404212 0.429638 
928.  PPIB peptidylprolyl isomerase B 1.11594 1.2242 
929.  PPIH peptidylprolyl isomerase H 0.40786 0.56116 
930.  PPIL1 peptidylprolyl isomerase like 1 0.72316 0.771098 
931.  PPM1D "protein phosphatase, Mg2+/Mn2+ dependent 1D" 0.805558 0.828481 
932.  PPM1G "protein phosphatase, Mg2+/Mn2+ dependent 1G" 0.421925 0.389986 
933.  PPP1R14C protein phosphatase 1 regulatory inhibitor subunit 14C 2.03073 2.02062 
934.  PPP1R3B protein phosphatase 1 regulatory subunit 3B 0.433307 0.398739 
935.  PPP4C protein phosphatase 4 catalytic subunit 0.389742 0.577441 
936.  PRADC1 protease associated domain containing 1 0.539953 0.658061 
937.  PRDX3 peroxiredoxin 3 0.627377 0.542784 
938.  PRDX4 peroxiredoxin 4 0.874995 0.937589 
939.  PRDX6 peroxiredoxin 6 0.644178 0.561437 
940.  PRELID1 PRELI domain containing 1 0.526265 0.474331 
941.  PRIMA1 proline rich membrane anchor 1 0.382483 0.378951 
942.  PRKACA protein kinase cAMP-activated catalytic subunit alpha 0.628271 0.54078 
943.  PRMT5 protein arginine methyltransferase 5 0.737209 0.665835 
944.  PRPF38A pre-mRNA processing factor 38A 1.47559 1.5399 
945.  PRR3 proline rich 3 1.05653 1.07873 
946.  PRSS23 "protease, serine 23" 1.31424 1.13168 
947.  PRTG protogenin 1.31376 1.23996 
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948.  PRX periaxin 1.08466 0.880227 
949.  PSKH1 protein serine kinase H1 0.564947 0.756137 
950.  PSMA2 proteasome subunit alpha 2 0.711013 0.747366 
951.  PSMA4 proteasome subunit alpha 4 1.20228 1.18312 
952.  PSMA7 proteasome subunit alpha 7 0.611977 0.569242 
953.  PSMB1 proteasome subunit beta 1 0.365698 0.454699 
954.  PSMB4 proteasome subunit beta 4 0.447662 0.505157 
955.  PSMB5 proteasome subunit beta 5 0.647283 0.685028 
956.  PSMB7 proteasome subunit beta 7 0.703839 0.733512 
957.  PSMC1 "proteasome 26S subunit, ATPase 1" 0.568718 0.565683 
958.  PSMC2 "proteasome 26S subunit, ATPase 2" 0.556815 0.614312 
959.  PSMC3 "proteasome 26S subunit, ATPase 3" 0.867627 0.83266 
960.  PSMD13 "proteasome 26S subunit, non-ATPase 13" 0.720864 0.803083 
961.  PSMD7 "proteasome 26S subunit, non-ATPase 7" 0.485609 0.55362 
962.  PSME1 proteasome activator subunit 1 0.489988 0.532391 
963.  PSMG1 proteasome assembly chaperone 1 0.681266 0.765086 
964.  PSPH phosphoserine phosphatase 0.415752 0.442755 
965.  PSTPIP2 proline-serine-threonine phosphatase interacting protein 2 0.853152 0.921707 
966.  PTDSS1 phosphatidylserine synthase 1 0.677304 0.585521 
967.  PTENP1 phosphatase and tensin homolog pseudogene 1 1.06433 1.26423 
968.  PTGES2 prostaglandin E synthase 2 0.415851 0.570339 
969.  PTMA "prothymosin, alpha" 0.472511 0.39151 
970.  PVALB parvalbumin 1.21037 1.57428 
971.  PYCR1 pyrroline-5-carboxylate reductase 1 0.667415 0.824556 
972.  PYGL "phosphorylase, glycogen, liver" 0.598803 0.527726 
973.  QTRT1 queuine tRNA-ribosyltransferase catalytic subunit 1 0.471824 0.661715 
974.  R3HCC1 R3H domain and coiled-coil containing 1 1.47594 1.51118 
975.  RAB20 "RAB20, member RAS oncogene family" 0.54106 0.671545 
976.  RAB4A "RAB4A, member RAS oncogene family" 0.553993 0.451898 
977.  RAB9B "RAB9B, member RAS oncogene family" 1.39674 1.60651 
978.  RABEPK Rab9 effector protein with kelch motifs 0.550754 0.599569 
979.  RACK1 receptor for activated C kinase 1 0.479845 0.474264 
980.  RAD51C RAD51 paralog C 0.445142 0.420747 
981.  RAN "RAN, member RAS oncogene family" 0.649795 0.716611 
982.  RANP1 "RAN, member RAS oncogene family pseudogene 1" 0.818454 1.5527 
983.  RAPGEFL1 Rap guanine nucleotide exchange factor like 1 1.07791 0.906922 
984.  RARG retinoic acid receptor gamma 0.99176 0.914053 
985.  RASA3 RAS p21 protein activator 3 0.752342 0.715053 
986.  RASGEF1B RasGEF domain family member 1B 0.863543 1.06333 
987.  RASL11A RAS like family 11 member A 1.18544 1.55333 
988.  RBFA ribosome binding factor A (putative) 1.08745 1.15657 
989.  RBMS2 RNA binding motif single stranded interacting protein 2 0.988779 0.695869 
990.  RCL1 RNA terminal phosphate cyclase like 1 0.58902 0.770248 
991.  RDH16 retinol dehydrogenase 16 (all-trans) 0.549674 0.848992 
992.  RERG RAS like estrogen regulated growth inhibitor 0.739758 0.650693 
993.  REXO4 "REX4 homolog, 3'-5' exonuclease" 0.991587 1.21563 
994.  RFC2 replication factor C subunit 2 0.554049 0.470145 
995.  RFC3 replication factor C subunit 3 0.585816 0.562186 
996.  RFLNB refilin B 1.58933 1.30077 
997.  RFT1 RFT1 homolog 1.00573 0.963011 
998.  RFWD2 ring finger and WD repeat domain 2 0.768969 0.637484 
999.  RFXAP regulatory factor X associated protein 1.06703 0.94652 
1000.  RGS16 regulator of G-protein signaling 16 0.542244 0.617958 
1001.  RIDA reactive intermediate imine deaminase A homolog 0.692374 0.508209 
1002.  RIMS4 regulating synaptic membrane exocytosis 4 1.25577 1.2212 
1003.  RIT1 Ras like without CAAX 1 0.743862 0.771635 
1004.  RLN2 relaxin 2 0.992626 0.927344 
1005.  RNASEL ribonuclease L 1.11074 1.05212 
1006.  RNASET2 ribonuclease T2 0.439969 0.479086 
1007.  RND2 Rho family GTPase 2 0.528641 0.797044 
1008.  RNF122 ring finger protein 122 1.14128 0.979431 
1009.  RNF130 ring finger protein 130 0.700167 0.585128 
1010.  RNF138 ring finger protein 138 0.993903 1.2314 
1011.  RNF14 ring finger protein 14 0.744299 0.790873 
1012.  RNF144B ring finger protein 144B 0.536437 0.670161 
1013.  RNF165 ring finger protein 165 1.06013 0.861514 
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1014.  RNF5 ring finger protein 5 0.74448 0.82896 
1015.  RNF7 ring finger protein 7 0.475151 0.652396 
1016.  RPA1 replication protein A1 1.3934 1.36769 
1017.  RPIA ribose 5-phosphate isomerase A 0.794538 0.845553 
1018.  RPL10A ribosomal protein L10a 0.714578 0.750405 
1019.  RPL11 ribosomal protein L11 0.642594 0.604273 
1020.  RPL12 ribosomal protein L12 0.609403 0.591557 
1021.  RPL13 ribosomal protein L13 0.48154 0.660912 
1022.  RPL13A ribosomal protein L13a 0.565281 0.690617 
1023.  RPL15 ribosomal protein L15 0.477561 0.543018 
1024.  RPL17 ribosomal protein L17 0.608482 0.579599 
1025.  RPL19 ribosomal protein L19 0.501585 0.555254 
1026.  RPL21 ribosomal protein L21 0.755891 0.73765 
1027.  RPL22L1 ribosomal protein L22 like 1 0.864808 0.965201 
1028.  RPL23 ribosomal protein L23 0.713014 0.658251 
1029.  RPL24 ribosomal protein L24 0.775667 0.80338 
1030.  RPL26 ribosomal protein L26 0.635677 0.560063 
1031.  RPL27 ribosomal protein L27 0.818785 0.914966 
1032.  RPL27A ribosomal protein L27a 0.602351 0.694477 
1033.  RPL29 ribosomal protein L29 0.678791 0.965449 
1034.  RPL3 ribosomal protein L3 0.643843 0.633513 
1035.  RPL30 ribosomal protein L30 0.483029 0.514125 
1036.  RPL31 ribosomal protein L31 0.500837 0.553839 
1037.  RPL32 ribosomal protein L32 0.541315 0.574202 
1038.  RPL34 ribosomal protein L34 0.791899 0.858151 
1039.  RPL35 ribosomal protein L35 0.587071 0.681671 
1040.  RPL35A ribosomal protein L35a 0.687875 0.754828 
1041.  RPL36A ribosomal protein L36a 0.665105 0.625905 
1042.  RPL36AL ribosomal protein L36a like 0.544335 0.657496 
1043.  RPL37A ribosomal protein L37a 0.534367 0.585879 
1044.  RPL39 ribosomal protein L39 0.790025 0.793589 
1045.  RPL39L ribosomal protein L39 like 0.71943 0.884334 
1046.  RPL4 ribosomal protein L4 0.727798 0.651767 
1047.  RPL41 ribosomal protein L41 0.863473 0.842525 
1048.  RPL5 ribosomal protein L5 0.876493 0.834361 
1049.  RPL7 ribosomal protein L7 0.540895 0.474478 
1050.  RPL7A ribosomal protein L7a 0.525127 0.483312 
1051.  RPL8 ribosomal protein L8 0.447702 0.482796 
1052.  RPL9 ribosomal protein L9 0.790399 0.797841 
1053.  RPLP0 ribosomal protein lateral stalk subunit P0 0.690141 0.646959 
1054.  RPN1 ribophorin I 0.436504 0.390911 
1055.  RPP25L ribonuclease P/MRP subunit p25 like 0.589825 0.823949 
1056.  RPP40 ribonuclease P/MRP subunit p40 0.442086 0.477138 
1057.  RPRM "reprimo, TP53 dependent G2 arrest mediator candidate" 0.725484 0.672673 
1058.  RPS10 ribosomal protein S10 0.69203 0.772701 
1059.  RPS11 ribosomal protein S11 0.516476 0.496856 
1060.  RPS12 ribosomal protein S12 0.585658 0.565778 
1061.  RPS13 ribosomal protein S13 0.506 0.560536 
1062.  RPS14 ribosomal protein S14 0.610268 0.66288 
1063.  RPS15A ribosomal protein S15a 0.97588 0.954983 
1064.  RPS16 ribosomal protein S16 0.595941 0.646833 
1065.  RPS18 ribosomal protein S18 0.638633 0.730978 
1066.  RPS20 ribosomal protein S20 0.495754 0.533154 
1067.  RPS21 ribosomal protein S21 0.612498 0.878411 
1068.  RPS23 ribosomal protein S23 0.644234 0.677774 
1069.  RPS25 ribosomal protein S25 0.679746 0.654124 
1070.  RPS26 ribosomal protein S26 0.600671 0.710175 
1071.  RPS27 ribosomal protein S27 0.508871 0.454789 
1072.  RPS27A ribosomal protein S27a 0.982195 0.969381 
1073.  RPS29 ribosomal protein S29 1.07896 1.23262 
1074.  RPS3 ribosomal protein S3 0.756681 0.745014 
1075.  RPS4X "ribosomal protein S4, X-linked" 0.617263 0.645454 
1076.  RPS5 ribosomal protein S5 0.563525 0.738254 
1077.  RPS6 ribosomal protein S6 0.80126 0.751089 
1078.  RPS6KA5 ribosomal protein S6 kinase A5 0.591567 0.484197 
1079.  RPS6KB1 ribosomal protein S6 kinase B1 0.690924 0.661297 
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1080.  RPS7 ribosomal protein S7 0.976177 0.982406 
1081.  RPS8 ribosomal protein S8 0.798614 0.76595 
1082.  RPS9 ribosomal protein S9 0.494933 0.615055 
1083.  RPSA ribosomal protein SA 0.728888 0.69114 
1084.  RRAGA Ras related GTP binding A 0.713067 0.811297 
1085.  RRAS2 related RAS viral (r-ras) oncogene homolog 2 0.839157 0.770152 
1086.  RRP8 ribosomal RNA processing 8, methyltransferase, homolog  0.501806 0.66187 
1087.  RSL1D1 ribosomal L1 domain containing 1 0.599977 0.50853 
1088.  RSPO1 R-spondin 1 1.00213 1.14493 
1089.  RTN1 reticulon 1 1.33667 1.24382 
1090.  RUNX2 runt related transcription factor 2 1.40906 1.12666 
1091.  RUVBL2 RuvB like AAA ATPase 2 0.370826 0.545808 
1092.  RWDD1 RWD domain containing 1 0.790947 0.703144 
1093.  RWDD2B RWD domain containing 2B 0.760684 0.77008 
1094.  S100A14 S100 calcium binding protein A14 0.526757 0.460932 
1095.  S100A4 S100 calcium binding protein A4 0.677395 0.465981 
1096.  S100A8 S100 calcium binding protein A8 1.92461 3.08523 
1097.  S100A9 S100 calcium binding protein A9 1.53666 2.52338 
1098.  S1PR5 sphingosine-1-phosphate receptor 5 0.544561 0.637201 
1099.  SAMHD1 
SAM and HD domain containing deoxynucleoside 
triphosphate triphosphohydrolase 1 
0.422929 0.441313 
1100.  SARAF store-operated calcium entry associated regulatory factor 0.651737 0.581324 
1101.  SAT1 spermidine/spermine N1-acetyltransferase 1 0.701296 0.864274 
1102.  SCAP SREBF chaperone 0.857089 0.770539 
1103.  SCML1 sex comb on midleg-like 1 (Drosophila) 0.763639 0.740902 
1104.  SDC2 syndecan 2 0.629612 0.601104 
1105.  SDF2L1 stromal cell derived factor 2 like 1 0.554218 0.876166 
1106.  SDHAF3 succinate dehydrogenase complex assembly factor 3 1.03412 1.20257 
1107.  SDHB succinate dehydrogenase complex iron sulfur subunit B 0.436855 0.422219 
1108.  SEC11A "SEC11 homolog A, signal peptidase complex subunit" 0.489579 0.537134 
1109.  SEC11C "SEC11 homolog C, signal peptidase complex subunit" 0.493302 0.583424 
1110.  SEC16B "SEC16 homolog B, endoplasmic reticulum export factor" 1.14986 0.932813 
1111.  SEC61B Sec61 translocon beta subunit 0.380985 0.532805 
1112.  SELK selenoprotein K 0.506295 0.561729 
1113.  SEMA3G semaphorin 3G 1.08938 1.18135 
1114.  SEP15 15 kDa selenoprotein 0.612944 0.630963 
1115.  SEPHS2 selenophosphate synthetase 2 0.470174 0.583339 
1116.  SEPP1 "selenoprotein P, plasma, 1" 1.09129 1.21632 
1117.  SERBP1 SERPINE1 mRNA binding protein 1 0.99881 0.945595 
1118.  SERPINB6 serpin family B member 6 0.400069 0.406089 
1119.  SERPINH1 serpin family H member 1 1.97041 2.06858 
1120.  SET SET nuclear proto-oncogene 0.742598 0.618882 
1121.  SF3B5 splicing factor 3b subunit 5 0.996388 1.13546 
1122.  SF3B6 splicing factor 3b subunit 6 0.369752 0.345683 
1123.  SFR1 SWI5 dependent homologous recombination repair protein 1 0.733793 0.792653 
1124.  SFXN2 sideroflexin 2 0.977583 0.949226 
1125.  SFXN4 sideroflexin 4 0.706769 0.733447 
1126.  SGCG sarcoglycan gamma 1.58645 1.76154 
1127.  SH3BP5 SH3 domain binding protein 5 0.463129 0.394409 
1128.  SH3BP5L SH3 binding domain protein 5 like 1.04061 1.05831 
1129.  SH3GL1 "SH3 domain containing GRB2 like 1, endophilin A2" 1.20402 1.35972 
1130.  SH3GL3 "SH3 domain containing GRB2 like 3, endophilin A3" 1.68462 1.73615 
1131.  SHROOM2 shroom family member 2 0.930158 0.799281 
1132.  SIAH2 siah E3 ubiquitin protein ligase 2 1.85018 1.90909 
1133.  SKP2 
S-phase kinase-associated protein 2, E3 ubiquitin protein 
ligase 
0.987079 0.961049 
1134.  SLC16A1 solute carrier family 16 member 1 1.27052 1.23591 
1135.  SLC16A10 solute carrier family 16 member 10 1.92999 1.71366 
1136.  SLC16A14 solute carrier family 16 member 14 0.890857 1.04069 
1137.  SLC18B1 solute carrier family 18 member B1 1.68871 1.89729 
1138.  SLC19A1 solute carrier family 19 member 1 0.711999 0.848981 
1139.  SLC19A2 solute carrier family 19 member 2 0.994844 1.03721 
1140.  SLC22A31 solute carrier family 22 member 31 0.856728 0.948328 
1141.  SLC25A13 solute carrier family 25 member 13 1.29903 1.43565 
1142.  SLC25A15 solute carrier family 25 member 15 1.27744 1.19857 
1143.  SLC25A17 solute carrier family 25 member 17 0.567036 0.550626 
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1144.  SLC25A20 solute carrier family 25 member 20 0.55318 0.705508 
1145.  SLC25A33 solute carrier family 25 member 33 1.28595 1.32461 
1146.  SLC25A4 solute carrier family 25 member 4 0.688413 0.804581 
1147.  SLC25A5 solute carrier family 25 member 5 0.874204 0.931417 
1148.  SLC27A5 solute carrier family 27 member 5 1.0881 1.3092 
1149.  SLC29A2 solute carrier family 29 member 2 0.357566 0.444176 
1150.  SLC35B2 solute carrier family 35 member B2 1.49914 1.5692 
1151.  SLC35C2 solute carrier family 35 member C2 0.614949 0.696564 
1152.  SLC35G1 solute carrier family 35 member G1 0.497059 0.57222 
1153.  SLC45A3 solute carrier family 45 member 3 0.928566 1.04996 
1154.  SLC4A7 solute carrier family 4 member 7 0.972962 0.90704 
1155.  SLC50A1 solute carrier family 50 member 1 0.490646 0.467501 
1156.  SLC5A8 solute carrier family 5 member 8 2.78152 2.31415 
1157.  SLC6A12 solute carrier family 6 member 12 1.42094 1.24514 
1158.  SLC7A5 solute carrier family 7 member 5 1.31711 1.12174 
1159.  SLC7A8 solute carrier family 7 member 8 0.772529 0.646335 
1160.  SLIRP SRA stem-loop interacting RNA binding protein 0.769817 0.866559 
1161.  SMAD6 SMAD family member 6 0.666859 0.829978 
1162.  SMIM11A small integral membrane protein 11A 0.844039 0.910736 
1163.  SMIM13 small integral membrane protein 13 0.483039 0.520542 
1164.  SMIM8 small integral membrane protein 8 0.664991 0.817361 
1165.  SMN1 "survival of motor neuron 1, telomeric" 0.581755 0.575289 
1166.  SMPD2 sphingomyelin phosphodiesterase 2 0.898892 0.733124 
1167.  SMS spermine synthase 1.1773 1.20089 
1168.  SNHG5 small nucleolar RNA host gene 5 0.587049 0.815636 
1169.  SNRNP25 small nuclear ribonucleoprotein U11/U12 subunit 25 0.656031 0.603566 
1170.  SNRPA1 small nuclear ribonucleoprotein polypeptide A' 0.885467 0.861662 
1171.  SNRPD2 small nuclear ribonucleoprotein D2 polypeptide 0.748278 0.885684 
1172.  SNRPD3 small nuclear ribonucleoprotein D3 polypeptide 0.859864 0.921748 
1173.  SNRPE small nuclear ribonucleoprotein polypeptide E 0.579614 0.655083 
1174.  SNRPF small nuclear ribonucleoprotein polypeptide F 0.378183 0.562532 
1175.  SNRPG small nuclear ribonucleoprotein polypeptide G 0.722707 0.941404 
1176.  SNTA1 syntrophin alpha 1 0.470681 0.524896 
1177.  SNX17 sorting nexin 17 0.352968 0.410153 
1178.  SNX4 sorting nexin 4 0.537189 0.550717 
1179.  SOAT2 sterol O-acyltransferase 2 0.946383 0.996519 
1180.  SOBP sine oculis binding protein homolog 1.12312 0.97963 
1181.  SOWAHC sosondowah ankyrin repeat domain family member C 0.757397 0.721909 
1182.  SP6 Sp6 transcription factor 0.627875 0.798127 
1183.  SPAG16 sperm associated antigen 16 2.78745 1.96532 
1184.  SPARC secreted protein acidic and cysteine rich 2.76873 3.35492 
1185.  SPDL1 spindle apparatus coiled-coil protein 1 1.36245 1.18421 
1186.  SPIN4 spindlin family member 4 1.20897 1.15524 
1187.  SPNS1 sphingolipid transporter 1 (putative) 0.993692 1.03893 
1188.  SPRY2 sprouty RTK signaling antagonist 2 0.550961 0.481338 
1189.  SPRY4 sprouty RTK signaling antagonist 4 2.72265 3.40137 
1190.  SPRYD4 SPRY domain containing 4 0.498969 0.658557 
1191.  SPSB4 splA/ryanodine receptor domain and SOCS box containing 4 1.17641 0.758689 
1192.  SPTSSA serine palmitoyltransferase small subunit A 1.13176 1.10577 
1193.  SQLE squalene epoxidase 0.859419 0.65273 
1194.  SRD5A1 steroid 5 alpha-reductase 1 0.903325 1.10497 
1195.  SRD5A3 steroid 5 alpha-reductase 3 0.53407 0.56115 
1196.  SRP9 signal recognition particle 9 0.611286 0.511968 
1197.  SRPK2 SRSF protein kinase 2 0.962142 0.955164 
1198.  SRPRB SRP receptor beta subunit 1.135 1.13818 
1199.  SRSF10 serine and arginine rich splicing factor 10 0.581423 0.557139 
1200.  SRSF3 serine and arginine rich splicing factor 3 0.459896 0.479402 
1201.  SRSF7 serine and arginine rich splicing factor 7 0.558072 0.589317 
1202.  SS18L1 "SS18L1, nBAF chromatin remodeling complex subunit" 0.699734 0.792439 
1203.  SSB Sjogren syndrome antigen B 0.68798 0.631619 
1204.  SSR2 signal sequence receptor subunit 2 0.883125 0.937574 
1205.  SSR3 signal sequence receptor subunit 3 0.712814 0.67759 
1206.  STAG3L4 stromal antigen 3-like 4 (pseudogene) 0.59115 0.623864 
1207.  STARD5 StAR related lipid transfer domain containing 5 0.757691 0.804855 
1208.  STK19 serine/threonine kinase 19 1.04042 1.10347 
1209.  STOML2 stomatin like 2 0.620558 0.633006 
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1210.  STRAP serine/threonine kinase receptor associated protein 0.923435 0.944209 
1211.  STX10 syntaxin 10 0.682659 0.746872 
1212.  SUB1 "SUB1 homolog, transcriptional regulator" 0.789299 0.78565 
1213.  SUCLA2 succinate-CoA ligase ADP-forming beta subunit 1.17971 0.989095 
1214.  SUCLG1 succinate-CoA ligase alpha subunit 0.393309 0.459611 
1215.  SUFU SUFU negative regulator of hedgehog signaling 0.632929 0.650479 
1216.  SUMF2 sulfatase modifying factor 2 0.425012 0.415504 
1217.  SUMO1 small ubiquitin-like modifier 1 0.650273 0.599114 
1218.  SUSD3 sushi domain containing 3 1.38012 1.41753 
1219.  SUV39H2 suppressor of variegation 3-9 homolog 2 0.68922 0.680572 
1220.  SYNE4 spectrin repeat containing nuclear envelope family member 4 0.83352 0.797764 
1221.  SYT8 synaptotagmin 8 1.65318 1.36842 
1222.  TAF11 TATA-box binding protein associated factor 11 2.53393 2.61299 
1223.  TAF4B TATA-box binding protein associated factor 4b 0.927441 0.721482 
1224.  TAF7 TATA-box binding protein associated factor 7 0.495937 0.658128 
1225.  TBCCD1 TBCC domain containing 1 1.68387 1.5637 
1226.  TBP TATA-box binding protein 0.439215 0.44549 
1227.  TCEAL4 transcription elongation factor A like 4 0.865075 1.04156 
1228.  TCEB1 transcription elongation factor B subunit 1 0.384157 0.433829 
1229.  TCF7L1 transcription factor 7 like 1 1.48257 1.55383 
1230.  TCFL5 transcription factor like 5 0.531116 0.509004 
1231.  TDP2 tyrosyl-DNA phosphodiesterase 2 0.488266 0.43491 
1232.  TEAD2 TEA domain transcription factor 2 0.477682 0.408097 
1233.  TEFM "transcription elongation factor, mitochondrial" 0.886352 1.03729 
1234.  TEKT4P2 tektin 4 pseudogene 2 1.25626 1.31105 
1235.  TERT telomerase reverse transcriptase 1.89687 1.94267 
1236.  TET2 tet methylcytosine dioxygenase 2 0.974007 0.8011 
1237.  TEX30 testis expressed 30 0.591534 0.539069 
1238.  TEX9 testis expressed 9 0.870901 1.00428 
1239.  TFAP2C transcription factor AP-2 gamma 0.827 0.84 
1240.  TFDP1 transcription factor Dp-1 0.598627 0.557178 
1241.  TFEC transcription factor EC 2.11704 2.40168 
1242.  TFF1 trefoil factor 1 1.12383 1.05027 
1243.  TFF3 trefoil factor 3 1.06078 1.23842 
1244.  TFPI tissue factor pathway inhibitor 0.685574 0.818259 
1245.  TGDS "TDP-glucose 4,6-dehydratase" 0.708024 0.695662 
1246.  THEG theg spermatid protein 1.36115 1.28725 
1247.  THOC3 THO complex 3 0.747607 0.706681 
1248.  THOC7 THO complex 7 0.662423 0.585282 
1249.  TIAM1 T-cell lymphoma invasion and metastasis 1 1.78994 1.45061 
1250.  TIMM10 translocase of inner mitochondrial membrane 10 homolog  1.08019 1.23627 
1251.  TIMM17A translocase of inner mitochondrial membrane 17 homolog A  0.741463 0.806169 
1252.  TIMM21 translocase of inner mitochondrial membrane 21 0.679132 0.844579 
1253.  TIMM44 translocase of inner mitochondrial membrane 44 0.990688 1.19053 
1254.  TIMM8A translocase of inner mitochondrial membrane 8 homolog A  0.716225 0.843205 
1255.  TIMM8B translocase of inner mitochondrial membrane 8 homolog B 2.80661 3.09556 
1256.  TIMMDC1 
translocase of inner mitochondrial membrane domain 
containing 1 
0.470364 0.511371 
1257.  TIPRL TOR signaling pathway regulator 0.811212 0.873609 
1258.  TKT transketolase 0.929334 1.00705 
1259.  TM4SF1 transmembrane 4 L six family member 1 0.892293 1.16473 
1260.  TMA7 translation machinery associated 7 homolog 0.568972 0.735707 
1261.  TMED3 transmembrane p24 trafficking protein 3 0.862257 0.952594 
1262.  TMEM106C transmembrane protein 106C 0.585347 0.488068 
1263.  TMEM11 transmembrane protein 11 0.395127 0.594322 
1264.  TMEM126A transmembrane protein 126A 0.457839 0.533496 
1265.  TMEM126B transmembrane protein 126B 0.727283 0.641183 
1266.  TMEM134 transmembrane protein 134 0.907853 1.34654 
1267.  TMEM141 transmembrane protein 141 1.08181 1.17586 
1268.  TMEM147 transmembrane protein 147 0.659977 0.73448 
1269.  TMEM14B transmembrane protein 14B 0.746991 0.758224 
1270.  TMEM14C transmembrane protein 14C 0.620905 0.590898 
1271.  TMEM171 transmembrane protein 171 0.878415 0.876701 
1272.  TMEM177 transmembrane protein 177 0.455281 0.744802 
1273.  TMEM179B transmembrane protein 179B 1.13071 1.1919 
1274.  TMEM181 transmembrane protein 181 0.528742 0.421469 
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1275.  TMEM183A transmembrane protein 183A 1.61754 1.69108 
1276.  TMEM189 transmembrane protein 189 1.4711 1.43429 
1277.  TMEM203 transmembrane protein 203 0.536841 0.70267 
1278.  TMEM208 transmembrane protein 208 0.434963 0.511256 
1279.  TMEM216 transmembrane protein 216 0.578493 0.670693 
1280.  TMEM218 transmembrane protein 218 0.819994 0.843916 
1281.  TMEM223 transmembrane protein 223 1.13466 1.40979 
1282.  TMEM229B transmembrane protein 229B 0.964364 0.908993 
1283.  TMEM237 transmembrane protein 237 0.646639 0.612708 
1284.  TMEM251 transmembrane protein 251 0.873496 1.02926 
1285.  TMEM254 transmembrane protein 254 0.725767 0.733062 
1286.  TMEM261 transmembrane protein 261 0.671823 0.814308 
1287.  TMEM38A transmembrane protein 38A 0.820518 0.816127 
1288.  TMEM5 transmembrane protein 5 0.426584 0.498614 
1289.  TMEM65 transmembrane protein 65 1.01325 0.856892 
1290.  TMEM97 transmembrane protein 97 0.833185 0.612911 
1291.  TMPOP2 thymopoietin pseudogene 2 0.815511 1.2229 
1292.  TMPRSS3 "transmembrane protease, serine 3" 1.50993 1.27099 
1293.  TMSB15A thymosin beta 15a 2.53916 2.21981 




TNFAIP8L2-SCNM1 readthrough 1.15396 1.28294 
1296.  TNFRSF11B TNF receptor superfamily member 11b 2.27648 2.51838 
1297.  TNFSF15 tumor necrosis factor superfamily member 15 0.836726 1.01551 
1298.  TOMM22 translocase of outer mitochondrial membrane 22 0.494304 0.551779 
1299.  TOMM40L translocase of outer mitochondrial membrane 40 like 0.675673 0.883447 
1300.  TOMM5 translocase of outer mitochondrial membrane 5 0.924343 1.01822 
1301.  TOMM7 translocase of outer mitochondrial membrane 7 0.557692 0.611233 
1302.  TP53RK TP53 regulating kinase 0.565331 0.617696 
1303.  TP63 tumor protein p63 1.17284 0.761436 
1304.  TPBG trophoblast glycoprotein 0.510288 0.632264 
1305.  TPI1 triosephosphate isomerase 1 0.662608 0.676696 
1306.  TPM1 tropomyosin 1 (alpha) 0.801783 0.748702 
1307.  TPMT thiopurine S-methyltransferase 1.40831 1.2533 
1308.  TPST1 tyrosylprotein sulfotransferase 1 0.973886 0.823435 
1309.  TPST2 tyrosylprotein sulfotransferase 2 1.27295 1.15574 
1310.  TPT1 "tumor protein, translationally-controlled 1" 0.512395 0.431892 
1311.  TRA2B transformer 2 beta homolog (Drosophila) 0.93612 1.02773 
1312.  TRAF4 TNF receptor associated factor 4 1.40716 1.41039 
1313.  TRAFD1 TRAF-type zinc finger domain containing 1 1.11782 1.02991 
1314.  TRAM1L1 translocation associated membrane protein 1-like 1 1.03518 1.32007 
1315.  TRAP1 TNF receptor associated protein 1 0.620316 0.54511 
1316.  TRIAP1 TP53 regulated inhibitor of apoptosis 1 2.00172 2.1629 
1317.  TRIB2 tribbles pseudokinase 2 2.8007 2.78841 
1318.  TRIB3 tribbles pseudokinase 3 1.04783 1.16733 
1319.  TRIM16 tripartite motif containing 16 0.993213 1.01247 
1320.  TRIM16L tripartite motif containing 16-like 0.910647 0.922332 
1321.  TRMT10C 
"tRNA methyltransferase 10C, mitochondrial RNase P 
subunit" 
0.656297 0.739582 
1322.  TRMT12 tRNA methyltransferase 12 homolog 0.867535 0.94512 
1323.  TSEN15 tRNA splicing endonuclease subunit 15 0.543937 0.571189 
1324.  TSPAN14 tetraspanin 14 0.869488 0.86275 
1325.  TSPAN3 tetraspanin 3 0.452084 0.480864 
1326.  TSPAN4 tetraspanin 4 1.20445 1.41946 
1327.  TSPAN5 tetraspanin 5 1.45388 1.14094 
1328.  TSPAN6 tetraspanin 6 0.6999 0.627904 
1329.  TSPYL4 TSPY like 4 0.461534 0.620688 
1330.  TTC26 tetratricopeptide repeat domain 26 0.645484 0.750698 
1331.  TTC27 tetratricopeptide repeat domain 27 0.506052 0.541612 
1332.  TTC30B tetratricopeptide repeat domain 30B 0.431373 0.372918 
1333.  TTC5 tetratricopeptide repeat domain 5 0.895979 0.934807 
1334.  TTLL1 tubulin tyrosine ligase like 1 0.686081 0.387382 
1335.  TTYH2 tweety family member 2 1.39606 1.47698 
1336.  TTYH3 tweety family member 3 1.29448 1.25873 
1337.  TUB tubby bipartite transcription factor 1.14111 0.899701 
1338.  TUBA1A tubulin alpha 1a 1.22901 1.05345 
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1339.  TUBB2A tubulin beta 2A class IIa 0.556047 0.69846 
1340.  TUBD1 tubulin delta 1 1.66967 1.62302 
1341.  TUFM "Tu translation elongation factor, mitochondrial" 0.445132 0.450125 
1342.  TUSC1 tumor suppressor candidate 1 0.434468 0.671859 
1343.  TUSC3 tumor suppressor candidate 3 0.476439 0.443338 
1344.  TXNDC15 thioredoxin domain containing 15 0.674132 0.804971 
1345.  TXNDC16 thioredoxin domain containing 16 1.2185 0.912998 
1346.  TXNL4A thioredoxin like 4A 0.436729 0.51071 
1347.  TXNRD3NB thioredoxin reductase 3 neighbor 1.05308 1.27236 
1348.  TYMS thymidylate synthetase 0.594336 0.609152 
1349.  UBAC1 UBA domain containing 1 0.517836 0.514537 
1350.  UBAC2 UBA domain containing 2 0.761043 0.832168 
1351.  UBE2E1 ubiquitin conjugating enzyme E2 E1 0.619358 0.605514 
1352.  UBE2F ubiquitin conjugating enzyme E2 F (putative) 0.847813 0.799021 
1353.  UBE2T ubiquitin conjugating enzyme E2 T 0.641735 0.668278 
1354.  UBE2V2 ubiquitin conjugating enzyme E2 V2 0.847768 0.761367 
1355.  UBL3 ubiquitin like 3 0.578444 0.397981 
1356.  UBL4A ubiquitin like 4A 0.412535 0.524187 
1357.  UBL5 ubiquitin like 5 0.372425 0.448646 
1358.  UBLCP1 ubiquitin like domain containing CTD phosphatase 1 0.457536 0.390483 
1359.  UBQLN2 ubiquilin 2 0.454439 0.36814 
1360.  UCHL3 ubiquitin C-terminal hydrolase L3 0.62191 0.608182 
1361.  UCK2 uridine-cytidine kinase 2 0.9374 1.01923 
1362.  UFSP2 UFM1 specific peptidase 2 0.918514 0.915898 
1363.  UGT2B15 UDP glucuronosyltransferase family 2 member B15 1.18061 1.32403 
1364.  ULBP2 UL16 binding protein 2 1.14969 1.02138 
1365.  UMPS uridine monophosphate synthetase 0.618575 0.654156 
1366.  UNC119B unc-119 lipid binding chaperone B 0.57547 0.632513 
1367.  UNG uracil DNA glycosylase 0.816379 0.778265 
1368.  UPK3BL uroplakin 3B-like 0.806669 1.01034 
1369.  UQCR10 "ubiquinol-cytochrome c reductase, complex III subunit X" 0.440544 0.643124 
1370.  UQCRC2 ubiquinol-cytochrome c reductase core protein II 0.756596 0.79963 
1371.  UQCRFS1 
"ubiquinol-cytochrome c reductase, Rieske iron-sulfur 
polypeptide 1" 
0.673997 0.820654 
1372.  UQCRH ubiquinol-cytochrome c reductase hinge protein 0.730635 0.787734 
1373.  UQCRQ ubiquinol-cytochrome c reductase complex III subunit VII 0.655835 0.735397 
1374.  URB1-AS1 URB1 antisense RNA 1 (head to head) 0.768621 1.27432 
1375.  URM1 ubiquitin related modifier 1 0.777266 0.915202 
1376.  UROD uroporphyrinogen decarboxylase 0.562775 0.612601 
1377.  USP38 ubiquitin specific peptidase 38 0.48234 0.389678 
1378.  UTP18 "UTP18, small subunit processome component" 0.537868 0.60794 
1379.  UTP3 "UTP3, small subunit processome component homolog  0.539582 0.683986 
1380.  UTP6 "UTP6, small subunit processome component" 0.626186 0.711473 
1381.  VCPKMT valosin containing protein lysine methyltransferase 0.605394 0.87448 
1382.  VDAC3 voltage dependent anion channel 3 0.599311 0.583252 
1383.  VIPR1 vasoactive intestinal peptide receptor 1 0.945101 0.763107 
1384.  VPS25 vacuolar protein sorting 25 homolog 1.09281 1.16585 
1385.  VSTM2L V-set and transmembrane domain containing 2 like 2.51467 2.41676 
1386.  VTA1 vesicle trafficking 1 1.32726 1.38368 
1387.  VTCN1 V-set domain containing T cell activation inhibitor 1 1.77544 1.75288 
1388.  VWC2L von Willebrand factor C domain containing protein 2-like 3.02552 2.7854 
1389.  WASF1 WAS protein family member 1 1.0033 0.791938 
1390.  WBP1 WW domain binding protein 1 0.580605 0.575147 
1391.  WBSCR22 Williams-Beuren syndrome chromosome region 22 0.693725 0.809007 
1392.  WDR12 WD repeat domain 12 0.631358 0.671058 
1393.  WDR18 WD repeat domain 18 0.938405 1.11267 
1394.  WDR41 WD repeat domain 41 0.607608 0.536312 
1395.  WDR5 WD repeat domain 5 0.458789 0.498514 
1396.  WDR61 WD repeat domain 61 0.783432 0.865257 
1397.  WDR72 WD repeat domain 72 0.705664 0.610389 
1398.  WDR75 WD repeat domain 75 0.497876 0.500219 
1399.  WDR82 WD repeat domain 82 0.498426 0.52336 
1400.  WISP2 WNT1 inducible signaling pathway protein 2 2.80975 2.83438 
1401.  WNT10B Wnt family member 10B 0.553471 1.08361 
1402.  WNT6 Wnt family member 6 0.563029 1.08002 
1403.  WNT8B Wnt family member 8B 1.5311 2.08131 
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1404.  WRNIP1 Werner helicase interacting protein 1 0.463639 0.461986 
1405.  XRCC2 X-ray repair cross complementing 2 0.497408 0.37365 
1406.  YAE1D1 Yae1 domain containing 1 0.528961 0.833542 
1407.  YBX1 Y-box binding protein 1 0.608175 0.510208 
1408.  YBX3 Y-box binding protein 3 1.38701 1.41547 
1409.  YEATS4 YEATS domain containing 4 0.743376 0.965598 
1410.  YIF1B 
"Yip1 interacting factor homolog B, membrane trafficking 
protein" 
0.721536 0.907742 
1411.  YRDC yrdC N6-threonylcarbamoyltransferase domain containing 0.756552 0.92334 
1412.  YWHAE 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein epsilon 
0.487217 0.457738 
1413.  YWHAG 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein gamma 
0.868706 0.950922 
1414.  YY1 YY1 transcription factor 0.656623 0.652961 
1415.  ZBTB5 zinc finger and BTB domain containing 5 0.434602 0.518307 
1416.  ZCCHC10 zinc finger CCHC-type containing 10 0.96443 1.18733 
1417.  ZDHHC12 zinc finger DHHC-type containing 12 0.720658 1.1442 
1418.  ZFP91 ZFP91 zinc finger protein 0.636921 0.52485 
1419.  ZIC5 Zic family member 5 0.519752 0.454947 
1420.  ZKSCAN4 zinc finger with KRAB and SCAN domains 4 0.541057 0.569274 
1421.  ZMAT4 zinc finger matrin-type 4 1.53596 1.73342 
1422.  ZMYM5 zinc finger MYM-type containing 5 0.458967 0.56089 
1423.  ZMYND19 zinc finger MYND-type containing 19 1.05418 1.24949 
1424.  ZNF132 zinc finger protein 132 0.974712 0.960395 
1425.  ZNF212 zinc finger protein 212 0.573246 0.799225 
1426.  ZNF22 zinc finger protein 22 1.10956 1.22216 
1427.  ZNF286A zinc finger protein 286A 0.765241 0.59238 
1428.  ZNF32 zinc finger protein 32 0.790834 0.846533 
1429.  ZNF346 zinc finger protein 346 1.50192 1.26861 
1430.  ZNF519 zinc finger protein 519 0.57224 0.698319 
1431.  ZNF584 zinc finger protein 584 0.928914 0.934971 
1432.  ZNF674-AS1 ZNF674 antisense RNA 1 (head to head) 0.734379 1.08159 
1433.  ZNF711 zinc finger protein 711 0.597437 0.462778 
1434.  ZNF77 zinc finger protein 77 0.396748 0.416536 
1435.  ZNRD1 zinc ribbon domain containing 1 0.479523 0.696981 
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